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Summary 
Mechanisms underlying the biological effects of coffee and its constituents are incompletely 
understood. Many effects have been attributed solely to caffeine, neglecting that coffee is a 
mixture of many chemical substances. Some authors suggest that the main mechanism of 
action of caffeine is to antagonize adenosine receptors (AR); a second effect is the inhibition 
of phosphodiesterases with the subsequent accumulation of cAMP and an intensification of 
the effects of catecholamines. Although the inhibition of phosphodiesterases may contribute 
to the actions of caffeine, there is growing evidence that most pharmacological effects of this 
xanthine result from antagonism of AR. 
One of the main objectives of this work was to investigate whether substances other than 
caffeine in coffee may influence the homeostasis of intracellular cyclic nucleotides in vitro 
and in vivo. The influence of selected coffee compounds, extracts and brews on key 
elements involved in the adenosine receptor-mediated signaling pathway have been 
investigated. 
A further aim of this work was also to determine if coffee or some coffee constituents may 
have a stimulatory effect on the cellular heme oxygenase activity (HO-activity). Two coffee 
extracts, a slightly (AB1) and an intensively roasted coffee (AB2), were studied along with 
selected individual compounds.  Caffeine and low substituted pyrazines showed no effect on 
the HO-activity, while NMP, pyrazines with a greater substitution pattern such as 
Tetramethylpyrazine (TMP) and 2-Ethyl-3,5(6)-dimethylpyrazine (2-E-3,5-DMP) and both 
coffee extracts significantly induced the HO-activity in liver hepatocellular carcinoma 
(HepG2), intestinal colo-rectal adenocarcinoma (Caco-2) and in some instances in monocytic 
leukemia (MM6) cells. 
It was found that caffeine, theophylline, coffee extracts from conventional or functional 
coffees, pyrazines (2,3-DE-6-MP, 2-Isobutyl-3-methoxyP), 5-CQA and caffeic acid all 
significantly inhibited the basal cytoplasmatic PDE activity in lysates of lung tumour xenograft 
cells (LXFL529L) and human platelets. To a somewhat lesser extent, PDE inhibition was also 
found in experiments performed with paraxanthine and other pyrazines (2-E-3,5-DMP, TMP 
and 2-E-5-MP). Thus the degree of roasting has a considerable impact on constituents of 
influence for PDE activity. Caffeine, coffee polyphenols and some pyrazines and further, as 
yet unknown roasting products appear to represent the main modulating constituents. 
In two coffee intervention studies, a short-term (8 weeks) and a long-term study (24 weeks), 
comprising 8 and 84 healthy volunteers respectively, we examined extracellular key 
elements of the adenosine pathway including plasma adenosine levels and adenosine 
deaminase activity. Additionally, we studied the intracellular cAMP concentration and the 
PDE activity in platelets as surrogate biomarkers of adipocytes. 
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Results of in vitro experiments had suggested that the concentrations of caffeine and coffee 
extracts required to obtain a half maximal inhibition were in the upper range of physiological 
conditions. Yet, it was demonstrated for the first time in vivo that moderate consumption of 
coffee can modulate the activity of platelet phosphodiesterases in humans in long and short 
term. In both studies, the first exposure to coffee showed a strong inhibition (p<0.001) of the 
PDE activity in the platelet lysates of the participants while the second coffee phase showed 
no or a slight effect when compared with the first coffee intervention.  
In both studies a significant increase (p<0.001) in intraplatelet cAMP concentrations during 
the wash-out phase (after the first coffee phase) was observed. This response could be due 
to inhibition of the PDE activity in the previously phase extending in to the wash out phase. 
However, the behavior of cAMP in the following study phases cannot be easily explained. It 
may be hypothesized that this effect is attributable to adaptive effects to allow PDE inhibition. 
One possibility is the modulation of the expression of membrane-bound adenosine receptors 
in platelet precursors, which still have a nucleus. This may potentially influence adenylate 
cyclase activity in mature platelets. For the observed effects, in addition to caffeine other 
ingredients of coffee appear to play a role. The findings suggest that monitoring of cAMP 
homeostasis in platelets is not a useful surrogate biomarker for effects in other tissues. 
Neither the activity of adenosine deaminase nor the adenosine concentrations in plasma 
were markedly modulated by the coffee consumption in both trials. This may reflect the fact 
that adenosine is subject to quick and effective enzymatic turnover by phosphorylation 
(adenosine kinase) or deamination (adenosine deaminase) allowing keep its concentration 
within a well balanced homeostasis. However, it is also well known, that considerable 
variability exists in the responses to coffee drinking. In part, such variability is due to caffeine 
tolerance, but there is also evidence for a genetic background.  
Altogether the data reported here provide further evidence for the perception that coffee 
consumption is associated with beneficial health effects demonstrated for the cAMP 
enhancement in platelets, known to counteract platelet aggregation. The effects observed for 
the influence of cellular heme oxygenase (HO) are in line with the well documented 
antioxidative activity of coffee and its constituents. 
 
 
Introduction  1 
 
                          
1 Introduction 
 
Coffee is one of the most widely consumed beverages in the world and has been linked with 
both beneficial and harmful biological effects. Epidemiological evidence suggests coffee 
consumption to be associated with prevention or delay of degenerative diseases including 
diabetes mellitus type 2 (T2D), parkinson´s, alzheimer´s, cardiovascular disease (CVD) and 
cancer [Deutscher-Kaffeeverband, 2011; Ranheim and Halvorsen, 2005; Zhang et al., 2009]. 
These beneficial effects have been partly attributed in part to the antioxidant activity of coffee 
[Bakuradze et al., 2011a; Bakuradze et al., 2010; Hoelzl et al., 2010]. Additionally, moderate 
reduction in body weight was reported to correlate with regular coffee consumption [Thom, 
2007; Tunnicliffe and Shearer, 2008]. Some harmful substances in coffee, like the 
carcinogens acrylamide and furan are of major interest concerning consumer health effects 
and have been studied extensively on the last few years [Berger et al., 2011; Mills et al., 
2008; Stadler and Lineback, 2009]. 
Coffee beans contain thousands of constituents, including lipids, proteins, carbohydrates, 
vitamins, and minerals. The precise mechanisms underlying the actions of coffee are 
incompletely understood. Most of the effects have been attributed to caffeine, although 
coffee is a mixture of many biological active compounds [Ferruzzi, 2010; Ranheim and 
Halvorsen, 2005]. More recently, the acknowledgement that coffee and caffeine are not 
physiologically equivalent has increased the exploration of other coffee constituents [Boettler 
et al., 2011b; Farah et al., 2006; Johnston et al., 2003; Tunnicliffe and Shearer, 2008]. 
Average caffeine consumption by adult humans varies among different cultures and nations 
from 80 to 400 mg per person per day. Caffeine elicits a diverse number of pharmacological 
responses, including increased vigilance, decreased psychomotor reaction time, increased 
sleep latency and waking time and may also influence intellectual performance. Moreover, 
caffeine causes relaxation of smooth muscles, enhances the secretion of gastric acid, the 
release of catecholamines, and increases metabolic activity [Varani et al., 2000]. Some 
authors suggest that the main mechanism of action of caffeine is to antagonize adenosine 
receptors; a secondary effect is the inhibition of phosphodiesterases [Ribeiro and Sebastiao, 
2010], with the subsequent accumulation of cAMP and an intensification of the effects of 
catecholamines [Renda et al., 2012]. However, at blood concentrations resulting from normal 
coffee consumption, caffeine acts mainly as an adenosine receptor antagonist, while the 
main caffeine metabolite, paraxanthine, has been shown to inhibit the effect of endogenous 
adenosine on a variety of physiological processes [Fredholm et al., 1999; Varani et al., 
2000].  
Adenosine receptors are associated with intracellular pathways that influence cAMP 
production, phospholipase C activity, and the mitogen-activated protein kinase (MAPK) 
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[Schulte and Fredholm, 2003]. Thus, any tissue that expresses such receptors could respond 
to caffeine. However, there are several subtypes of adenosine receptors and they are found 
in most tissues. This results in a vast array of possible primary and secondary responses 
[Beaudoin and Graham, 2011]. 
One hypothesis explaining how coffee alters T2D involves weight management and body 
composition. Individuals who consume coffee on a regular basis would be expected to have 
a lower body mass, a factor that would lower T2D risk [Tunnicliffe and Shearer, 2008]. 
Caffeine from coffee consumption has been shown to induce thermogenesis, lipolysis, fat 
oxidation, and insulin secretion in both nonobese and obese individuals [Acheson et al., 
2004; Dallas et al., 2008; Greenberg et al., 2006].  This could be a significant contribution to 
the overall energy balance, if it was maintained over decades of caffeine/coffee ingestion. 
There is little evidence that coffee consumption promotes significant weight loss or causes 
alterations in body composition. This appears to be due to habituation to caffeine-induced 
catecholamine responses and lipolysis with prolonged use [Dekker et al., 2007].  
It is also well know that the administration of caffeine to fasted humans also causes an 
increase in FFA mobilization. Adipocytes express adenosine A1 receptors and these are 
tonically active, inhibiting adenylate cyclase and reducing both the level of cAMP and 
lipolysis [Liang et al., 2002]. The proposed mechanism of action of caffeine for the increased 
lipolysis is blockage of adenosine receptors [Greenberg et al., 2006]. It has also been shown 
that it takes much more caffeine to cause fat mobilization in vitro than in vivo [Winder, 1986], 
suggesting that may be an active metabolite is needed (together with caffeine) to bring about 
the increase in lipolysis.  
A large prospective study reported that increased caffeine intake correlated with reduced 
weight gain [Lopez-Garcia et al., 2006a]. A similar effect was seen in decaffeinated coffee 
consumers. Finally, an intervention study comprising 33 healthy volunteers showed that daily 
consumption of 3–4 cups of a special Arabica coffee brew exerts beneficial health effects, 
such as reduced oxidative damage, body fat mass and energy uptake [Bakuradze et al., 
2011a]. 
The mode of action of coffee compounds and their metabolites still is not fully understood.  
Additional studies are needed to clarify if moderate coffee consumption may influence the 
homeostasis of intracellular cyclic nucleotides and to elucidate a pattern of compounds 
responsible for such effects. 
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2 State of the Art 
2.1 Coffee general aspects 
“Coffee (coffee beans) includes the seeds of crimson fruits from which the outer pericarp is 
completely removed and the silverskin (spermoderm) is occasionally removed. The seeds 
may be raw or roasted, whole or ground, and should be from the botanical genus Coffea. 
The drink prepared from such seeds is also called coffee” cited from Belitz et al. [Belitz et al., 
2009]. The name coffee is derived from the name of the province Keffa where shepherds 
from Abyssinia (Ethiopia) discovered the coffee beans in the 6th century. Two hundred years 
later coffee was sold in Europe, thus introducing the new beverage into Western life. But it 
was the Dutch who first started the spreading of the coffee plant in Central and South 
America, where today it reigns supreme as the main continental cash crop. Coffee first 
arrived in the Dutch colony of Surinam in 1718, to be followed by plantations in French 
Guyana and the first of many in Brazil in the state of Pará [ICO, 2011; Yanagimoto et al., 
2004].  
World coffee consumption is estimated at 134 million bags (1 bag ≈ 60 kg) in calendar year 
2010 compared to 131.3 million bags in 2009, an increase of 2.1%. The world coffe 
consumption for exporting countries (Brazil, Colombia, Ethiopia, Indonesia, Mexico, and 
Guatemala etc.) is 30% whereas importing countries represent around 70%. The European 
Union, USA and Japan consume 30.5%, 16.3% and 5.4 % respectively.  Within Europe, 
coffee is most popular in Germany (6.9%), France (4.4%) and Italy (4.3%) according to the 
International Coffee Organization [ICO, 2011; ICO and International-Coffee-Organization, 
2011]. The German coffee market has gone through important changes in 2011. Even 
though the consumption of coffee per capita remained high at 150 liters per year, the trend 
towards freshly brewed coffee for immediate consumption is getting stronger. This reflects 
clearly on the higher demand for espresso as well as coffee capsules and pads. At the same 
time, 75% of German consumers prepare their coffee with roasted grains [Federal Ministry of 
Economics and Technology, 2011] 
The coffee tree or shrub belongs to the family Rubiaceae which has some 500 genera and 
over 6,000 species. The economically two most important species of coffee are Coffea 
arabica (Arabica coffee) - which accounts for over 60 percent of world production - and 
Coffea canephora (Robusta coffee). Two other species, the Coffea liberica (Liberica coffee) 
and Coffea dewevrei (Excelsa coffee), are grown on a much smaller scale. 
The coffe bean (see Figure 2-1) has a green outer skin (exocarp) that turns deep red when 
ripe, and encloses the pulp (mesocarp) and the stone-fruit bean which consists of two 
elliptical hemispheres with flattened adjacent sides. The spermoderm (silverskin) covers 
each hemisphere. “Covering both hemispheres and separating them from each other is the 
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strong fibrous endocarp, called the “parchment”. When the fruit is ripe a thin, slimy layer of 
mucilage surrounds the parchment. Occasionally, 10–15% of the coffee fruits consist of only 
one spherical bean (“peaberry” or “caracol”), which often brings a premium price” cited from 
Belitz et al. [Belitz et al., 2009]. 
 
Figure 2-1: Longitudinal section of a coffee fruit. Modified from Belitz et al. [Belitz et al., 2009]. 
 
Before roasting, coffee beans must be removed from the other fruit parts and dried; this can 
be done in two ways, known as dry and wet method. When the process is complete the 
unroasted coffee beans are called as green coffee [ICO, 2011]. 
In wet processing, ripe coffee cherries are mechanically depulped and the mucilaginous 
residues of the pulp are degraded by fermentation. The resulting beans are still covered by 
the parchment, which subsequently must be dried, conditioned and hulled. This method 
requires the use of specific equipment and substantial quantities of water but ensures that 
the intrinsic qualities of the coffee beans are better preserved. Coffee produced by this 
method is generally considered to be from a better quality and commands higher prices. By 
contrast, during the dry processing entire coffee fruits are dried without removal of the pulp 
and then are hulled mechanically [Selmar et al., 2008]. 
The chemical composition of the green coffee beans differs significantly depending on the 
processing method applied. Quantitative analyses of low molecular sugars in green coffees 
that were processed in parallel either by the traditional wet or the traditional dry method, 
revealed a close correlation between the kind of post-harvest treatment and the contents of 
fructose and glucose. While in washed coffee beans (wet processing) only low amounts of 
both hexoses were present, concentrations in unwashed coffees (dry processing) were 
significantly higher. However, sucrose, the major low molecular sugar in green coffee beans, 
is not significantly affected by coffee processing [Knopp et al., 2006; Selmar and Bytof, 
2008]. 
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2.2 From the raw bean to the roasted coffee  
The desired flavour of coffee is produced during roasting; green coffee has no desirable 
flavour. Chlorogenic acids contribute to body and astringency; sucrose contributes to the 
color, aroma, bitterness and sourness, and proteins remain perfectly stable, but minor protein 
components such as free amino acids, are highly reactive. Trigonelline generates pyridine 
and may consequently be responsible for some objectionable flavours. Caffeine has no 
function other than a contribution to the bitterness [Flament and Bessiere-Thomas, 2002].  
Comparing the content of amino acids (after hydrolysis) in roasted coffee with their content in 
green coffee serine, cystine and lysine are clearly reduced arginine disappears. Glutamic 
acid, the most abundant of the amino acids, proportionally increases (see Table 2-3). It has 
been observed too a partial destruction of the polysaccharides, except cellulose, during 
roasting. Oligosaccharides and arabinans disappear nearly totally, galactans are strongly 
degraded, but mannans remain particularly resistant. Monosaccharides, together with with 
amino acids and amines, are responsible of the formation of melanoidins, pyrazines and 
other nitrogen-containing heterocycles, resulting mainly from the Strecker and Maillard 
reactions.  
Ho and coworkers [Ho et al., 1993] suggested that deamidation of glutamine and asparagine 
give more pyrazines than the corresponding acids when heated with reducing sugars. The 
majority of the volatiles identified in roasted coffee are formed by Maillard reactions, 
however, sensory-specific investigations have shown that many odorants with a strong 
flavour impact are also generated by other formation pathways besides the Maillard reaction 
[Flament and Bessiere-Thomas, 2002; Holscher and Steinhart, 1994]. 
The volatile fraction of roasted coffee has a very complex composition. Dilution analyses 
have shown that of the 850 volatile compounds identified only 4.7% contribute to the aroma. 
Indeed, 28 aroma substances in the concentrations present in a medium roasted Arabica 
coffee drink (see  
Table 2-1 ) can largely approximate its aroma.  The aroma profile of coffee is composed of 
the following notes: sweet/caramel-like, earthy, sulfurous/roasty and smoky/phenolic [Belitz 
et al., 2009]. 
On roasting, the formation of furfurylthiol is promoted by the water content and the slightly 
acidic pH value of the beans because under these conditions, the precursor arabinose in the 
polysaccharides is released by partial hydrolysis. 
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Table 2-1 Concentrations of potent odorants in medium roast Arabica 
coffee from Colombia [Belitz et al., 2009] 
Group/odorant Concentration  
(mg/kg)a  
Sweet/caramel-like group 
 Methylpropanal  
 2-Methylbutanal  
 3-Methylbutanal  
 2,3-Butandione  
 2,3-Pentandione  
 4-Hydroxy-2,5-dimethyl- 3(2H)-furanone  
 5-Ethyl-4-hydroxy-2-methyl- 3(2H) furanone (EHM3F) 
  Vanillin  
Earthy group 
 2-Ethyl-3,5-dimethylpyrazine  
 2-Ethenyl-3,5-dimethylpyrazine  
 2,3-Diethyl-5-methylpyrazine  
 2-Ethenyl-3-ethyl- 5-methylpyrazine 
 3-Isobutyl-2-methoxy- pyrazine 
Sulfurous/roasty group 
 2-Furfurylthiol  
 2-Methyl-3-furanthiol  
 Methional  
 3-Mercapto-3-methylbutyl- formiate 
 3-Methyl-2-butene-1-thiol 
 Methanethiol  
 Dimethyltrisulfide  
Smoky/phenolic group 
 Guaiacol  
 4-Ethylguaiacol  
 4-Vinylguaiacol  
Fruity group 
 Acetaldehyde  
 Propanal  
 (E)-β-Damascenone  
Spicy group 
 3-Hydroxy-4,5-dimethyl- 3(5H)-furanone 
 5-Ethyl-3-hydroxy-4- methyl-2(5H)-furanone 
 
28.2 
23.4 
17.8 
49.4 
36.2 
120 
16.7 
4.1 
 
 
0.326 
0.053 
0.090 
0.017 
0.087 
 
1.70 
0.064 
0.239 
0.112 
0.0099 
4.55 
0.028 
 
3.2 
1.6 
55 
 
130 
17.4 
0.226 
 
 
1.58 
0.132 
a 
Beverage prepared by percolation of coffee powder (54 g) with water (ca. 90 °C) 
 
Robusta coffees contain significantly higher concentrations of alkylpyrazines than Arabica. 
Arabica coffees are usually richer in the odorants of the sweet/caramel-like group. The 
aroma note of raw coffee is produced by 3-alkyl-2-methoxypyrazines, 3-isobutyl-2-
methoxypyrazine having the highest aroma value. Being very stable compounds, they easily 
survive the roasting process. However, this process yields very intensively smelling odorants 
so that the odor of the methoxypyrazines is largely suppressed. The aroma of coffee is not 
stable; the fresh note is rapidly lost. The aroma profile changes because the slow-
evaporating furanones remain. As a result, the aroma balance can be destroyed by the spicy 
odor [Belitz et al., 2009]. 
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Volatile aldehydes that play an important role in coffee aroma are formed partially by 
Strecker degradation of amino acids. Aldehydes are formed by the oxidative degradation of 
amino acids during their interaction with sugars at high temperatures and during the 
interaction of amino acids and polyphenols in the presence of polyphenol oxidase at normal 
temperatures. The formation of various aldehydes and ketones by autoxidation of 
unsaturated fatty acids via breakdown of hydroperoxide intermediates is well established in 
the literature. Therefore their presence is not surprising considering that green coffee beans 
contain lipids and proteins. Hexanal, formed at least partially by oxidation of lipids, was 
identified by Cantergiani et al. [Cantergiani et al., 2001] in a green Mexican arabica (0.24 % 
of the volatiles) and by Czerny and Grosch [Czerny and Grosch, 2000]. 
2.3 Coffee constituents, metabolism and physiological effects 
 
Coffee beans contain thousands of constituents, including lipids, proteins, carbohydrates, 
vitamins, and minerals. In fact, isolating specific compounds responsible for the positive 
effects of coffee is quite difficult. To date, the majority of research on the biological activity of 
coffee has mainly been focused on caffeine. More recently, the understanding that coffee 
and caffeine are not physiologically equivalent has increased the exploration of other coffee 
constituents [Boettler et al., 2011b; Farah et al., 2006; Johnston et al., 2003; Tunnicliffe and 
Shearer, 2008]. 
Green coffee beans smell green-earthy and are further heat treated in a roasting process, 
generating the typical, characteristic flavour and aroma of coffee. The beans are heated 
between 180 ºC and 240 ºC for 8 to 15 min, depending on the degree of roast required. The 
beans increase in volume (50–80%) and change their structure and color. During the 
roasting process green beans turn brown and a 11–20 % loss in weight occurs.  As moisture 
is lost, the bean "pops" audibly rather like popcorn and a chemical reaction called pyrolysis 
takes place: starches are converted into sugar, proteins are broken down and the entire 
cellular structure of the bean is altered. As shown in Table 2-2, the content of proteins, lipids, 
trigonelline, caffeine and minerals only slightly changed by the roasting process, whereas 
chlorogenic acids dramatically decreased and substances such melanoidins are formed. Is 
important to note that the composition of roasted coffee varies greatly, depending on coffee 
variety and extent of roasting [Belitz et al., 2009]. 
2.3.1 Proteins and free amino acids  
Protein is subjected to extensive changes when heated in the presence of carbohydrates, 
resulting in a different amino acid composition of coffee protein acid hydrolysates before and 
after bean roasting (Table 2-3). The total amino acid content of the hydrolysate drops by 
about 30% because of considerable degradation 
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Table 2-2 Compositions of green and roasted coffee (medium degree of roasting) 
 [Belitz et al., 2009] 
Component 
Green coffee Roasted coffee 
Arabica (%)* Robusta (%)* Arabica (%)* Robusta (%)* 
 
Carbohydrates 
 
55-65.5 
 
40-55.5 
 
38.0 
 
41.5 
 
Protein 
 
8.5-12 
 
10 
 
Chlorogenic acids 
 
6.7-9.2 
 
7.1-12.1 
 
2.7 
 
3.1 
 
Lipids 
 
15-18 
 
8-12 
 
17.0 
 
11.0 
 
Trigonelline (niacin) 
 
0.6-1.2 
 
0.3-0.9 
 
1.0 
 
0.7 
 
Caffeine 
 
0.8-1.4 
 
1,7-4 
 
1.3 
 
2.4 
 
Minerals 
 
3-5.4 
 
4.6 
 
Melanoidins 
   
23.0 
*Values in % of solids 
“Arginine, aspartic acid, cystine, histidine, lysine, serine, threonine and methionine, being 
especially reactive amino acids, are somewhat decreased in roasted coffee, while the stable 
amino acids, particularly alanine, glutamic acid and leucine, are relatively increased. Free 
amino acids occur only in traces in roasted coffee” cited from Belitz et al.  [Belitz et al., 2009]. 
Table 2-3 Amino acid composition of the acid hydrolysate of Colombia coffee beans 
prior to and after roasting [Belitz et al., 2009] 
Amino acid Green coffee 
(%) 
Roasted coffee 
(%)* 
Alanine 
Arginine 
Aspartic acid 
Cystine  
Glutamic acid  
Glycine  
Histidine  
Isoleucine  
Leucine  
Lysine   
Methionine  
Phenylalanine  
Proline  
Serine  
Threonine  
Tyrosine  
Valine  
4.75 
3.61 
10.63 
2.89 
19.80 
6.40 
2.79 
4.64 
8.77 
6.81 
1.44 
5.78  
6.60  
5.88  
3.82 
3.61 
8.05  
5.52 
0 
7.13 
0.69 
23.22 
6.78 
1.61 
4.60 
10.34 
2.76 
1.26 
6.32 
7.01 
0.80 
1.38 
4.35 
8.05 
          * Loss due to roasting amounts to 17.6%. 
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2.3.2 Carbohydrates 
Carbohydrates are essential for the formation of aroma compounds, mainly by 
caramelization of the low-molecular-weight sugars and by Maillard reactions with amino 
acids. When green coffee beans are roasted, 98% of their sucrose undergoes hydrolysis and 
further degradation reactions occur. Thus, less than 30% of the total carbohydrates in coffee 
beans are found in brewed coffee. The polysaccharides found in brewed coffee are reported 
to act as prebiotics and dietary fiber and, as such, may reduce the risk of colon cancer [Arya 
and Rao, 2007]. Instant or soluble coffee has an amount of soluble dietary fiber (SDF) of 
aprox. 9 g/L. Mannose and galactose are the main monosaccharides found in these 
beverages suggesting that arabinogalactan and mannans are most important SDF 
components [Diaz-Rubio and Saura-Calixto, 2011]. Soluble dietary fiber also plays a role in 
the antioxidant activity of coffee by binding and enabling passage of phenols to the brewed 
beverage [Diaz-Rubio and Saura-Calixto, 2007]. Decaffeinated coffee may have slightly 
lower levels of carbohydrates than regular coffee, depending on the method used in the 
decaffeination process [Ramalakshmi and Raghavan, 1999]. 
Brewed coffee contains a significantly higher amount of soluble dietary fiber (0.47-0.75 g/100 
mL of coffee) more than other common beverages. As aforementioned, coffee dietary fiber 
contains a large amount of associated antioxidant phenolics (8.7-10.5 mg/100 mL of brewed 
coffee) [Diaz-Rubio and Saura-Calixto, 2007]. Díaz-Rubio et al. shown that galactose (156-
422 mg/100 mL) and mannose (395-246 mg/100 mL) are the major constituents in all 
infusions, suggesting that galactomannans are the main component of SDF in brewed 
coffee.  
2.3.3 Lipids 
The two most important coffee species, Coffea Arabica and Coffea canephora var. Robusta, 
contain between 7 and 17% fat. The lipid content of green Arabica coffee beans averages 
some 15%, whilst Robusta coffees contain much less, namely around 10%. Most of the 
lipids, the coffee oil, are located in the endosperm of green coffee beans [Wilson et al., 
1997]; only a small amount, the coffee wax, is located on the outer layer of the bean. 
The lipid fraction of coffee is very stable and the roasting process produces only minor 
changes. The composition of lipids of green coffe is shown in Table 2-4. Linoleic acid is the 
predominant fatty acid, followed by palmitic acid. The raw coffee waxes, together with 
hydroxytryptamide esters of various fatty acids originate from the fruit epicarp. These 
compounds are 0.06–0.1% of normally roasted coffee beans [Belitz et al., 2009]. 
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Table 2-4 Composition of lipids of green coffee  [Maier, 1981] 
Compounds  (%)  dry matter 
Triacylglycerols 
Esters of diterpene alcohols and fatty acids 
Diterpene alcohols  
Esters of sterols and fatty acids  
Sterols  
Tocopherols  
Phosphatides  
Tryptamine derivatives  
75.2 
18.5 
0.4 
3.2 
2.2 
0.04 - 0.06 
0.1 - 0.5 
0.6 - 1.0 
 
The diterpenes present are cafestol, 16-O-methylcafestol (found only in Robusta coffee), and 
kahweol see Figure 2-2. Cafestol and kahweol are partly degraded by the roasting process. 
They are natural constituents of coffee beans and are released from roast and ground coffee 
beans by hot water, but are largely trapped by the use of a paper filter in coffee preparation. 
These components have been identified as hypercholesterolemic, but although the 
diterpenes are retained in the filter, there is some evidence that consumption of filtered 
coffee may be  associated with a risk of cardiovascular disease [Ranheim and Halvorsen, 
2005]. 
 
 
 
 
                                  Cafestol                                                                 Kahweol                                                       
 
Figure 2-2: Chemical structures of cafestol and kahweol. 
 
Cafestol and kahweol show cholesterol raising potential on one hand and on the other hand 
chemopreventive potential is reported [Pardo Lozano et al., 2007]. In the first case there is 
still some confusion, as to whether these components are involved in the deposition of LDL 
cholesterol but the oxidation of this lipid fraction is not reported to occur, indicating that the 
potential negative effects of coffee are not as high as hypothesized in the literature [Suzuki et 
al., 2008].  
A number of studies have examined the association between boiled coffee consumption and 
cardiovascular disease. There is good evidence that nonfiltered, boiled coffee such as 
Scandinavian-type boiled coffee, cafetière (or French-press) coffee, and Turkish coffee 
increase serum cholesterol levels. Elevated concentrations of plasma triacylglycerol and LDL 
cholesterol are important risk factors for the development of cardiovascular disease. In 
contrast to boiled coffee, consumption of filtered coffee was found to have little or no 
association with serum concentration of cholesterol [Pietinen et al., 1990; Ranheim and 
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Halvorsen, 2005]. Unfiltered coffee brews contain 3–6 mg of cafestol per cup.  Filtered coffee 
does not contain cafestol because the diterpene is retained by paper filters [de Roos et al., 
2001]. 
In humans, most triacylglycerol is transported in VLDL (Very Low Density Lipoprotein) 
particles. VLDL can be further fractionated into two metabolically discrete components: 
VLDL1 and VLDL2. Compared with VLDL1, VLDL2  particles are smaller, enriched in 
cholesteryl ester, depleted in triacylglycerol, and have a lower ratio of apolipopotein (apo) E 
and apo C to apo B. VLDL1 carries almost one-half of the total amount of triacylglycerol in the 
circulation, whereas VLDL2 carries only about one-fifth.  High concentrations of 
triacylglycerol-rich VLDL1 have been suggested to give rise to a preponderance of small, 
dense LDL (low density lipoprotein). Small LDL particles appear to be a higher risk factor for 
the development of cardiovascular disease than the larger. Cafestol raises plasma 
triacylglycerol predominantly through an increased production rate of VLDL1 apo B after 2 wk 
of consumption. [de Roos et al., 2001]. In addition, in vitro studies suggest that cafestol 
elevates plasma LDL-cholesterol concentrations at least in part by down-regulation of the 
LDL receptor. Down-regulation of the LDL receptor appears to be initiated by suppression of 
bile acid synthesis [van Dam and Feskens, 2002]. 
Huber et al. further suggested that coffee consumers are at lower risk of colon cancer and 
attributed reduction to high content of the diterpenes, kahweol and cafestol, and their ability 
to inhibit the CYP450 and SULT (sulfotransferase) enzymes involved in the metabolic 
activation of carcinogens [Huber et al., 2008]. 
Kahweol and cafestol are effective too in ameliorating H2O2-induced oxidative stress and 
DNA damage, probably via scavenging ROS in mouse embryo fibroblast (NIH3T3) cell line 
[Lee and Jeong, 2007]. 
2.3.4 Alkaloids 
Coffee contains two different kinds of alkaloid delivered from nucleotides (see Figure 2-3). 
One type are purine alkaloids, such as caffeine (1,3,7-trimethylxanthine) and theobromine 
(3,7-dimethylxanthine); while trigonelline (1-methylnicotinic acid) represents pyridine alkaloid, 
[Ashihara, 2006]. 
 
 
 
 
 
              Caffeine                                    Theobromine                              Trigonelline                            
Figure 2-3: Chemical structures of caffeine, theobromine and trigonelline 
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2.3.4.1 Purine alkaloids (caffeine) 
Caffeine is the most common purine alkaloid in coffee. A large amount of caffeine is found in 
coffee seeds (mainly in endosperms), but also is found in the pericarp of fruits and leaves of 
coffee plants [Zheng and Ashihara, 2004]. It has been proposed that caffeine is sequestered 
in the vacuoles of coffee leaves as a chlorogenic acid complex, in a coffee drink, 10% of the 
caffeine and about 6% of the chlorogenic acid present occur in this form [Aerts and 
Baumann, 1994]. 
Caffeine crystallizes with one molecule of water into silky, white needles, which melt at 
236.5 °C and sublime without decomposition at 178 °C. This alkaloid is mildly bitter in taste 
and has a threshold value in water of 0.8–1.2 mmol/L. The caffeine content of raw green 
Arabica coffee is 0.9–1.4 %, and 1.5–2.6 % in Robusta. Other purine alkaloids found in 
coffee are theobromine (Arabica: 36–40 mg/kg, Robusta: 26–82 mg/kg)  and theophylline 
(Arabica: 7–23 μg/kg, Robusta: 86–344 μg/kg) which represent demethylated caffeine 
derivates [Belitz et al., 2009]. 
The caffeine content of coffee beans is only slightly decreased during roasting. The loss is 
limited by the increase of the sublimation point of caffeine during roasting by increase of the 
pressure within the bean and by a poor rate of diffusion through the outer layers. The 
solubility of caffeine increases more than 10 times from room temperature to 80 °C and can 
thereby easily be extracted from the coffee beans and grounded coffee. Caffeine is odorless 
and has a bitter taste. It contributes only to about 10% of the perceived bitterness of brewed 
coffee beverages. This sensory characteristic is difficult to distinguish, even by a trained 
panel of assessors, from the astringency caused simultaneously by phenolic compounds 
[Lee et al., 1992]. 
For the production of decaffeinated products, decaffeination is performed prior to the roasting 
process. The most common and least costly caffeine extraction methods use organic 
solvents such as dichloromethane or ethyl acetate, associated with the use of water/vapor 
prior to and after extraction. Beans are then dried until they reach a moisture level similar to 
that prior to processing. Water alone has alternatively been used to replace organic solvents 
in the process. At the end of the process, caffeine content is usually reduced to 0.02-0.3% 
[Farah et al., 2006]. Another possibility for the decaffeination is the carbon dioxide method 
(supercritical fluid extraction), where the caffeine is dissolved from the beans by carbon 
dioxide in the supercritical fluid state at high pressure. Under certain conditions it allows for a 
selective caffeine extraction and leaves most of the other coffee bean constituents unaltered. 
This process has the advantage that it avoids the use of potentially harmful substances [ICO, 
2011]. 
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2.3.4.1.1 Caffeine metabolism 
Following ingestion, caffeine is rapidly and completely absorbed from the gastrointestinal 
tract and maximum caffeine concentrations in blood are reached within 1–1.5 h. Absorbed 
caffeine is readily distributed throughout the entire body. It is lipophilic and penetrates all 
biologic membranes, passes across the blood–brain barrier, through the placenta into 
amniotic fluid and the foetus, and into breast milk [Eteng et al., 1997; Heckman et al., 2010; 
Nawrot et al., 2003]. 
Caffeine is almost completely metabolized in the liver by CYP1A2 (cytochrome P450 1A2) 
exclusively to its principal metabolite paraxanthine (1,7-methylxanthine). The metabolic 
profile of the biotransformation by CYP1A2 averaged 81.5% for paraxanthine, 10.8% for 
theobromine and 5.4% for theophylline. Formation of the primary metabolites, theophylline 
and theobromine, is mediated by CYP2E1 and CYP1A2. The main metabolic routes of 
caffeine are illustrated in Figure 2-4. In the complex metabolism of caffeine, CYP1A2 is solely 
responsible for the caffeine 3-demethylation to paraxanthine and mainly for the 
7-demethylation of 1,7-dimethylxanthine. Thus, paraxanthine is both a product and a 
substrate of CYP1A2. Paraxanthine further undergoes two reactions, one of which is 
8-hydroxylation by CYP2A6 and also CYP1A2. The other reaction, 7-demethylation via 
CYP1A2, leads to an unstable intermediate (UI). This ringopened compound gives two 
competing products: 1-methylxanthine and the acetylated product 
5-acetylamino-6-formylamino-3-methyluracil (AFMU). 1-methylxanthine undergoes 
8-hydroxylation to 1-methyluric acid, mediated by xanthine oxidase with a little contribution of 
CYP1A2. The polymorphic N-acetyltransferase NAT2 mediates the step toward AFMU. 
CYP1A2 and CYP2E1 catalyze the N-demethylation of caffeine at N1 and N7 to produce 
theobromine and theophylline, respectively. Various intermediates of the pathway have been 
isolated from the urine of humans and experimental animals fed caffeine rich diets [Eteng et 
al., 1997; Heckman et al., 2010; Sinues et al., 1999].  Caffeine pharmacokinetics show dose-
dependency with greater maximal concentrations, longer half-lives, and lower clearances at 
higher doses. Longer half-lifes are seen in patients with chronic liver disease whereas 
shorter half-lifes are observed in smokers [Chou, 1992; Gu et al., 1992; Kaplan et al., 1997]. 
Caffeine clearance and the paraxanthine/caffeine AUC0–24 (area under the curve from 0 time 
to 24 h) metabolic ratio in plasma are regarded as the ‘gold standard’ measurements for 
CYP1A2 activity, but the paraxanthine-to caffeine concentration ratio at one time point 
(usually 4 h) has also shown a high correlation with caffeine clearance as estimated from 
plasma, saliva and serum samples [Gu et al., 1992; Perera et al., 2010]. 
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Figure 2-4: Pathways of caffeine metabolism [Eteng et al., 1997; Heckman et al., 2010; Sinues et 
al., 1999]. CYP 450= cytochrome P450; CYP1A2=cytochrome P450 1A2A; AFMU= 
5-acetylamino-6-formylamino-3-methyluracil; NAT2= N-acetyltransferase; XO=Xanthine oxidase 
2.3.4.1.2 Biofunctional effects of caffeine 
Caffeine has been widely studied in a variety of areas regarding human health effects.  Many 
studies substantiate caffeine’s ability to elicit a diverse number of pharmacological 
responses, including increased vigilance, decreased psychomotor reaction time, increased 
sleep latency and waking time and may also influence intellectual performance. Moreover, 
caffeine causes relaxation of smooth muscles, enhances the secretion of gastric acid and the 
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release of catecholamines, and increases metabolic activity. The precise mechanism(s) 
underlying the actions of caffeine remain poorly understood. The biological activity of caffeine 
could at least in part be based on its structural similarity to biologically important compounds 
such as adenine, guanine, adenosine, xanthine, and uric acid. A first hypothesis was that 
caffeine and other methylxanthines primarily acted as inhibitors of phosphodiesterases 
(PDEs). Although the inhibition of PDEs may contribute to the actions of caffeine, there is 
growing evidence that most pharmacological effects result from antagonism of adenosine 
receptors. At blood concentrations resulting from normal coffee consumption, caffeine acts 
mainly as an adenosine receptor antagonist, while the main caffeine metabolite, 
paraxanthine, has been shown to inhibit the effect of endogenous adenosine on a variety of 
physiological processes [Fredholm et al., 1999; Heckman et al., 2010; Varani et al., 2000]. 
The topic about adenosine and adenosine receptors will be discussed in detail in chapter No 
2.5.2.1 and 2.5.2.2. 
Epidemiologic studies have shown some evidence that caffeine/coffee could be an effective 
therapeutic against Alzheimer’s (AD) and Parkinson’s disease (PD). Cross-sectional human 
studies have reported that caffeine consumption in both young and aged normal adults is 
associated with better cognitive performance [Arendash and Cao, 2010; Hameleers et al., 
2000; Jarvis, 1993]. Maia and de Mendonca [Maia and de Mendonca, 2002] reported that AD 
patients consumed markedly less caffeine during the 20 years preceding diagnosis of AD, 
compared with age-matched individuals without AD.  
Caffeine may play a positive role is in the prevention of sunlight-induced skin cancer. The 
main mutagenic effect of UV radiation is DNA damage in which research suggests caffeine 
has a protective role in both mice and humans [Kerzendorfer and O'Driscoll, 2009]. 
T2D is a global health concern estimated to have affected 346 million people worldwide in 
2004, approximately 3.4 million people died in the same year from consequences of high 
blood sugar. WHO projects that related diabetes deaths will double between 2005 and 2030 
[WHO, 2011]. There are several studies that have investigated the association between 
caffeine, particularly caffeine from coffee consumption, and the relative risk for developing 
type 2 DM. A long-term study [Salazar-Martinez et al., 2004] (in the framework of the The 
Nurses' Health Study and Health Professionals' Follow-up Study) on consumption of regular 
coffee, decaffeinated coffee, and other caffeinated beverages, showed an inverse 
relationship between intakes of caffeine and regular coffee and incidence of DM in both men 
and women. This relationship was stronger in women than in men. The researchers did not 
find a relationship between decaffeinated coffee intake and T2D. Rosengren and coworkers 
[Rosengren et al., 2004] reported that more than two cups of coffee per day had potentially 
beneficial effects and protected from the development of diabetes in Swedish women. The 
data indicated that some components in coffee may have a protective effect with respect to 
State of the art  16 
 
                          
the development of diabetes in women, and this supports the findings of the large-scale, 
prospective cohorts of van Dam [van Dam et al., 2004], Tuomilehto [Tuomilehto et al., 2004], 
and Salzar-Martinez [Salazar-Martinez et al., 2004]. In contrast, short-term metabolic studies 
have shown that caffeine ingestion can acutely decrease insulin sensitivity and glucose 
disposal [Greer et al., 2001; Keijzers et al., 2002]. Van Dam et al. examined the effects of 
coffee and caffeine on fasting blood glucose and insulin over 2–4 weeks in healthy subjects. 
They reported that high coffee consumption for 4 weeks increased fasting insulin 
concentrations compared to no coffee intake, while no such effect was seen with “weaker 
coffee”. The authors suggested that the increased fasting insulin concentrations reflected 
decreased insulin sensitivity. No effect on fasting glucose concentrations was observed 
[Ranheim and Halvorsen, 2005; van Dam et al., 2004]. While  the role of caffeine in lowering 
the risk of type 2 DM is not totally clear, it is evident that the consumption of caffeinated 
beverages is not associated with increasing the risk for type 2 DM [Pereira et al., 2006]. 
One hypothesis explaining how coffee alters type 2 DM risk involves weight management 
and body composition. There is evidence of the association between caffeine intake and 
weight reduction. Caffeine supplementation has also been recently considered as an 
effective means of weight management. This alkaloid has been shown to induce 
thermogenesis, lipolysis, fat oxidation, and insulin secretion in both nonobese and obese 
individuals [Dulloo et al., 1999; Greenberg et al., 2006; Kovacs et al., 2004]. Individuals who 
consume coffee on a regular basis would be expected to have a lower body mass, a factor 
that would lower type 2 DM risk. There is little evidence that coffee consumption promotes 
significant weight loss or causes alterations in body composition. This appears to be due to 
habituation to caffeine induced catecholamine responses and lipolysis with prolonged use 
[Dekker et al., 2007].  
A large prospective study reported that increased caffeine intake correlated with lower weight 
gain [Lopez-Garcia et al., 2006a]. However, the amount was only ~0.5 kg over a 12 year 
period. A similar effect was seen in decaffeinated coffee consumers. 
In addition, caffeine has been shown to exhibit several biological effects, such as increased 
fat oxidation and mobilization of glycogen in muscle, increased lipolysis, and decreased body 
fat [Astrup et al., 1990; Ranheim and Halvorsen, 2005; Spriet et al., 1992] and also 
paraxanthine may play a role in increased lipolysis after caffeine administration in humans 
[Hetzler et al., 1990]. 
2.3.4.1.3 Caffeine/coffee safety and adverse effects 
Caffeine induced pharmacological and toxicological effects in adults can present a spectrum 
of clinical symptoms, ranging from nervousness, irritability and insomnia to sensory 
disturbances, diuresis, arrhythmia, tachycardia, elevated respiration and gastrointestinal 
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disturbances. Caffeine toxicity in children is manifested by severe emesis, tachycardia, 
central nervous system agitation and diuresis. Chronic exposure to caffeine has been 
implicated in a range of dysfunctions involving the gastrointestinal system, liver, renal system 
and musculature. The acute lethal dose in adult humans has been estimated to be 10 
g/person. Death has been reported after ingestion of 6.5 g caffeine, but survival of a patient 
who allegedly ingested 24 g caffeine was also reported [James, 1991]. 
Dependency on caffeine is characterized by the development of tolerance, as reflected by 
increases in dose size with time, persistent desire, and withdrawal symptoms. Withdrawal 
symptoms include headaches, irritability, anxiety, depression, drowsiness, and fatigue 
[Greenberg et al., 2006]. 
Many diseases have been associated with caffeine and coffee consumption. Caffeine and 
coffee intake have often been associated with hypertension. Blood pressure, as discussed 
earlier, changes initially but shows little abnormality in the long term. The acute effect of 
caffeine on blood pressure (BP) is well documented, with increases in the range of 5 to 
10 mmHg. Despite the popular belief that tolerance occurs with habitual consumption, it has 
been demonstrated that tolerance to caffeine related blood pressure effects is incomplete 
following daily structured intake. However it has been shown that caffeine resulted in an 
increase in BP in healthy, normotensive, young and older men and women, but the effects of 
caffeine still not well understood in specific subgroups [Farag et al., 2010]. 
In summary, the data currently available indicate that moderate caffeine intake (four or fewer 
cups of coffee per day, or ≤400mg caffeine/day) does not adversely affect cardiovascular 
health. There are insufficient epidemiological data to draw any conclusions about the risk for 
coronary heart disease or mortality associated with consumption of 10 or more cups of coffee 
per day (≥1000 mg caffeine/day) [Nawrot et al., 2003]. 
Caffeine is globally approved by numerous regulatory authorities as a safe dietary ingredient 
for use mainly in carbonatedbeverages and dietary supplements. The evaluation and 
approval process that caffeine underwent has been based on scientific evidence that 
supported its safety. In 1959, the U.S. Food and Drug Administration (FDA) classified the 
caffeine in cola drinks to be generally recognized as safe (GRAS, code #21CFR). Since then, 
the FDA continuosly reevaluates caffeine’s safety as a food ingredient. The latest FDA 
evaluation stated that there was no evidence to show that the use of caffeine would cause 
any negative health effects; therefore, caffeine continues to have GRAS status [FDA, 2011]. 
After reviewing over 200 scientific studies focused on the reproductive effects of caffeine 
Christian and coworkers [Christian and Brent, 2001] concluded that woman who consumed 
moderate amounts of caffeine, less than 5 to 6 mg/kg bw/d, do not have an increase in 
reproductive risks. In 2002, the International Life Sciences Institute (ILSI) assembled another 
expert panel, to focus on recent caffeine-related research in the area of behavior and 
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development in children and adults, withdrawal and related issues, bone, and calcium 
physiology, and reproductive risks in women [Mandel, 2002]. The weight of evidence 
supported the conclusion that a moderate intake of caffeine does not elevate the risks for 
adverse effects. 
Additionally, caffeine is not present in the category of substances classified as causing 
“substance dependence” by the American Psychiatric Association, nor is considered a 
prohibited substance by the World Anti-Doping Agency (WADA) [WADA, 2011]. 
Recent evidence suggests that there is no overall association between moderate coffee 
intake and coronary heart disease (CHD). Cardiovascular disease (CVD) is a multi-factorial 
condition with a wide variety of risk factors, such as high blood pressure, DM, smoking and 
high serum cholesterol. Heredity plays a role in coronary heart disease and stroke, but both 
are largely influenced by lifestyle factors such as diet, physical activity and smoking. A large 
meta-analysis of 21 studies on coffee consumption and coronary heart disease risk found a 
large variation between the individual results of the studies reviewed. Overall, it did not find a 
statistically significant association between coffee drinking and long-term risk of coronary 
heart disease. In fact, habitual moderate coffee consumption was shown to be associated 
with a lower risk of heart disease in women [Wu et al., 2009]. A prospective cohort study 
found no association between caffeine and CHD [Lopez-Garcia et al., 2006b] .  
Elevated plasma homocysteine (Hcy) concentrations are associated with an increased risk of 
vascular disease and foetal birth defects. Coffee consumption positively correlates with 
plasma Hcy concentration [Stolzenberg-Solomon et al., 1999]. Filtered [Urgert et al., 2000] 
and unfiltered [Grubben et al., 2000] coffee increase plasma Hcy concentration by 
approximately 10%, while abstention from filtered coffee reduces plasma Hcy [Christensen et 
al., 2001]. The effect of Hcy can not solely be attributed to caffeine [Verhoef et al., 2002], 
other components of coffee like chlorogenic acid is shown to inhibit the methylation of Hcy by 
betaine, catalysed by betaine-homocysteine methyltransferase (see Chapter 2.3.4.2 and 
2.3.5). 
2.3.4.2 Pyridine alkaloids (trigonelline)  
Trigonelline (see Figure 2-3) was first isolated from fenugreek (Trigonella foenum-graecum) 
and is found in various plants and in some animal species including sea urchins and jellyfish. 
It also appears in mammalian urine after administration of nicotinic acid. Trigonelline in raw 
coffee materials (‘green beans’) is thermally converted to nicotinic acid and to certain flavour 
compounds during roasting [Mazzafera, 1991]. 
Dry coffee contains 0.6–1.3% trigonelline. When the green beans are roasted, the nicotinic 
acid increased to a level of 3.6 – 53.4 mg/100 g because of a progressive demethylation of 
trigonelline and decarboxylation of quinolic acid [Casal et al., 2000; Minamisawa et al., 2004]. 
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A single cup of coffee contains 24–86.2 mg of trigonelline, depending on the origin of the 
beans and degree of roast [Minamisawa et al., 2004]. 
In fact, trigonelline decomposes via two major routes under typical temperatures as used 
during coffee roasting, that is, (1) decarboxylation and methyl rearrangement to form 
pyridines and (2) N-demethylation to give nicotinic acid. Depending on the nature of the 
trigonelline salt in the coffee bean, the degradation route may indeed favor the formation of 
1-methylpyridinium (see 2.3.4.3), which will have a direct and indirect impact on other 
physicochemical properties such as flavour and aroma [Stadler et al., 2002a]. Trigonelline 
has little influence on the quality of coffee brew. Its bitter taste is approximately a quarter of 
that of caffeine, but its thermal degradation products have more sensory and nutritional 
importance e.g. consumption of 3.5 standard cups of coffee per day contributes up to one-
third of the minimum dietary requirement for an adult of nicotinic acid [Flament and Bessiere-
Thomas, 2002]. 
Trigonelline is believed to have anti-migraine, anti-carcinogenic, antiseptic, antioxidative 
[Hirakawa et al., 2005], hypoglycemic [Farah et al., 2006; van Dam, 2006] and 
hypocholesterolemic activities [Zhou et al., 2011]. It may also act as a stimulant and 
sedative. There are no regulations in place regarding the production or use of trigonelline. 
There is no evidence that human exposure to trigonelline causes any level of toxicity. Also, 
no severe side effects of trigonelline have been noted so far. 
In 1997 Wu et al. detected mutagenic activity with metabolic activation of heated trigonelline 
samples; however, higher mutagenic activity was found for trigonelline and its combinations 
without metabolic activation, which suggests that other types of mutagens (direct-acting) 
were predominant [Wu et al., 1997]. 
As previously mentioned, coffee consumption correlates with plasma Hcy concentration, 
some components of coffee could inhibit the methylation of Hcy by betaine, catalysed by 
betaine-homocysteine methyltransferase (BHMT). Although trigonelline is an analogue of 
glycine betaine that may competitively inhibit BHMT, is not responsible for the increase in 
Hcy after coffee consumption, this effect is mainly attributable to caffeine and chlorogenic 
acid (see 2.3.4.1.3 and 2.3.5) [Slow et al., 2004]. 
2.3.4.3 N-methylpyridinium (NMP) 
The quaternary base N-methylpyridinium (see Figure 2-5) is a major reaction product of 
trigonelline subjected to pyrolytic conditions. This quaternary base is formed by 
decarboxylation and represents an important stable intermediate in the thermal reaction 
pathways of trigonelline. As mentioned earlier, two major parameters have a pronounced 
impact on the degradation route and formation of N-methylpyridinium: the temperature and 
the nature of the trigonelline salt [Stadler et al., 2002a]. 
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Figure 2-5: Chemical structure of N-methylpyridinium (NMP). 
 
N-methylpyridinium per se may further react with nucleophiles present in the reaction 
mixture, e.g. substituted pyridines, and forms alkylpyridiniums such as 1,2-, 1,3-, and/or 
1,4-dimethylpyridinium. Thermally induced methyl rearrangements of quaternary salts such 
as 1-methylpyridine can procure a range of volatile products in the presence of a nucleophile 
such as pyridine, in particular good yields of 2- and 4-methylpyridine (30.1 and 34.6%, 
respectively), and minor formation of 3-methylpyridine (5.8%) and ethylpyridines (1.4%) were 
observed. Alkylpyridines thus act as nucleophiles and participate in methyl displacement 
reactions with 1-methylpyridinium to afford pyridine and the new disubstituted 
dialkypyridinium products (see Figure 2-6) [Stadler et al., 2002a]. 
 
 
 
Figure 2-6: Reaction pathways leading to the formation of alkylpiridiniums [Stadler et al., 
2002a]. 
 
The levels of NMP in roasted coffee are positively correlated to the degree of roasting. As 
already mentioned, NMP is not present in raw coffee beans but it is formed during the 
roasting process from its chemical precursor, trigonelline. The degradation is about 50% of 
the trigonelline content and the concentration of N-methylpyridinium in roasted coffee is up to 
0.25% on a dry weight basis [Stadler et al., 2002b]. 
Additionally, NMP has been identified as a suitable dietary biomarker for coffee consumption 
[Lang et al., 2011]. The reported method allows the precise quantitative analysis of NMP 
besides trigonelline and creatinine and can be considered a non-invasive, high-throughput 
technology enabling the rapid and accurate analysis of NMP as a coffee-specific candidate 
biomarker.  
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NMP has been shown to have a chemopreventive activity in vitro and in vivo. Evidence is 
supported by the shown induction of chemopreventive phase II enzymes by dietary coffee 
beverages containing N-methylpyridinium [Somoza et al., 2003]. The molecular mechanism 
for this induction is hypothesized to be based on kinase-mediated reactions rather than 
binding to the arylhydrocarbon receptor (AhR) which is the main receptor involved in the 
phase I/II enzyme induction [Iba et al., 2002]. 
2.3.5 Chlorogenic acids 
In coffee, chlorogenic acids (CGA) are the major antioxidants. They are a family of esters 
formed between transcinnamic acids, mainly caffeic or ferulic acid, and quinic acid. CGA can 
be ester-linked of several positions, and there can be one or two phenolic acids per quinic 
acid moiety, resulting in a complex pattern. The main nine isomers in green coffee beans 
are: 5-CQA (5-caffeoylquinic acid), 4-CQA, 3-CQA, 3,5-diCQA, 4,5-diCQA, 3,4-diCQA, 5-
FQA (5-feruloyl quinic acid), 4-FQA and 3-FQA (see Figure 2-7) which depends on variety, 
location, roasting and processing [Clifford, 2000; Williamson et al., 2011]. 
 
              A) 
 
 
 
 
                             Ferulic acid           p-Coumaric acid           Caffeic Acid 
 
B)                                                                       C) 
 
 
 
 
 
R = OH      5-CQA   R1= CA, R2=CA, R3=H   3,4-diCQA 
R= OCH3   5-FQA   R1= CA, R2=H, R3=CA   3,5-diCQA 
R= H         5-pCoQA   R1= H, R2=CA, R3=CA   4,5-diCQA 
 
Figure 2-7: Chemical structures of monomeric hydroxycinnamates (A). Main chlorogenic acid 
monoesters (B) and diesters (C) of quinic acid (QA). Esterification also occurs in carbons 3 and 4 
of the quinic acid. CA=caffeic acid, FA= ferulic acid, pCoA= coumaric acid, CQA= caffeoylquinic acid, 
FQA= feruloylquinic acid, diCQA= dicaffeoylquinic, p-couma-roylquinic acids (p-CQA).  
 
Coffee roasting causes a progressive destruction and transformation of CGA with some 
8±10% being lost for every 1% loss of dry matter. During the early stages, CGA 
isomerisation occurs accompanied by partial hydrolysis yielding quinic acid and the various 
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cinnamic acids. The released cinnamates may be decarboxylated, degraded to a range of 
simple phenols and further transformed. CGA in which position 5 is not substituted may 
lactonise forming caffeoyl and feruloyl-1,5-γ-quinides referred to collectively as chlorogenic 
lactones (CGL) [Clifford, 2000]. 
The CGA content in brewed coffee is influenced by the used coffee beans. Arabica beans 
contain less CGA than Robusta varieties. The roasting method also plays an important role 
in the CGA content of the final coffee product. For example, the light medium roasting 
condition was found to result in the highest amount of transformation from CGA to the 
corresponding lactones, suggesting that this process reduced the amount of CGA in coffee 
[Farah et al., 2005]. 
During the decaffeination process, losses of key flavour components of coffee generally 
occur, especially when solvents that lack specificity, such as water are used. Among the 
compounds lost may be the chlorogenic acids (CGA) and their related compounds [Farah et 
al., 2006]. 
When consumed by healthy volunteers, phenolic acids from coffee are absorbed and 
metabolized by complex pathways involving reduction, hydrolysis, methylation, sulfation and 
glucuronidation. Phenolic acids are partially absorbed in the small intestine, but mostly after 
microbial catabolism in the colon. More studies on chlorogenic acid bioavailability are needed 
on healthy humans after consumption of coffee, including dose–response studies [Del Rio et 
al., 2010; Williamson et al., 2011]. 
Ferulic acid and p-coumaric acid are often ester-linked to plant cell wall polymers and cannot 
be absorbed in this complex form. Enzymes able to break the ester bonds and release free 
phenolic acids are therefore required as the first step in the uptake and metabolism of dietary 
hydroxycinnamates. The presence of such esterase activity has been demonstrated in the 
large intestine (microflora enzymes) of rats and humans. The esterase(s) are able to 
hydrolyze and release the hydroxycinnamates ferulate and p-coumarate, which then were 
available for absorption into the circulatory system [Andreasen et al., 2001]. An esterase 
activity able to hydrolyze chlorogenic acid has been demonstrated in human colonic 
microflora [Plumb et al., 1999]. Chlorogenic and caffeic acid can also be absorbed from the 
small intestine into the circulatory system of humans [Olthof et al., 2001a]. 
A series of health benefits have been associated with the consumption of CGA and their 
lactones, such as reduction of the relative risk of cardiovascular disease, T2D, and 
Alzheimer’s disease [Ranheim and Halvorsen, 2005]. Even antibacterial and 
antiinflammatory activities were reported [Almeida et al., 2006; dos Santos et al., 2006].  
Different studies have shown the antioxidant activity of CGA and caffeic acid, mainly by using 
in vitro studies but also as a result of in vivo and ex vivo investigations [Bakuradze et al., 
2010; Gomez-Ruiz et al., 2007; Nenadis et al., 2004]. 
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Since only one-third of ingested CGA is absorbed in the small intestine, large amounts reach 
the colon, where it is hydrolyzed by the microflora to caffeic acid and quinic acid [Olthof et al., 
2001a]. These compounds are extensively metabolized to a range of products including m-
coumaric, dihydroferulic, 3-hydroxyphenylpropionic, and hippuric acids [Olthof et al., 2003]. 
Some authors attribute the antioxidant activity especially to these phenolic compounds 
generated from CGA by microbial metabolism [Gomez-Ruiz et al., 2007; Nenadis et al., 
2004], other to the presence of original constituents particularly 5-CQAs and its isomers 3- 
and 4-CQA [Bakuradze et al., 2010]. Some authors point out that CGA represents a potent 
activator of Nrf2 translocation in different cell lines [Boettler et al., 2011a; Feng et al., 2005]. 
Johnston et al.[Johnston et al., 2003] reported that the ingestion of either caffeinated or 
decaffeinated coffee containing equal amounts of chlorogenic acid and glucose caused acute 
changes in gastrointestinal hormone concentrations. They concluded that chlorogenic acid 
attenuated the rate of glucose uptake in the proximal small intestine and moved it to more 
distal regions of the small intestine. Their findings suggest that chlorogenic acid or some 
other noncaffeine coffee constituents antagonizes caffeine’s stimulation of glucose uptake in 
the small intestine. Additionally, Nieuwenhoven et al [Van Nieuwenhoven et al., 2000] using 
a sugar absorption test of intestinal permeability shown that the addition of caffeine to a 
sports drink expedited glucose uptake in the small bowel in 10 athletes. The implication is 
that chlorogenic acid slows the absorption of glucose from the gut, whereas caffeine 
accelerates it. However, 3 wk of intravenous infusion of chlorogenic acid significantly lowered 
the postprandial peak response to a glucose challenge in insulin-resistant Zucker rats 
[Rodriguez de Sotillo and Hadley, 2002]. Several mechanisms have been suggested for the 
effects of chlorogenic acid on glucose metabolism including decrease of glucose output in 
the liver, helping preserve β-cell function by promoting the synthesis of the homeodomain 
transcription factor IDX-1 (which helps beta cells respond to increases in plasma glucose) 
[Greenberg et al., 2006; McCarty, 2005], inhibition of glucosidase and glucose-6-
phosphatase (suggesting that it may delay intestinal glucose uptake and also reduce hepatic 
glucose output) and a stimulatory effect on the incretin hormones glucagon-like peptide 1 
(GLP-1) and glucose-dependent insulinotropic peptide (GIP) [Olthof et al., 2011]. Manzano 
and Williamson [Manzano and Williamson, 2010] showed that polyphenols, phenolic acids 
and tannins-rich extracts from strawberry and apple were able to influence glucose uptake 
into the cells and transport to the basolateral side by inhibiting activities of the glucose 
transporters (GLUT2 >SGLT1). 
Chlorogenic acid is marketed under the tradename Svetol® in Norway and the United 
Kingdom as a food active ingredient used in coffee, chewing gum, and mints to promote 
weight reduction. There is evidence that Svetol® significantly inhibited glucose-6-phosphate 
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hydrolysis in intact human liver microsomes in a competitive manner [Henry-Vitrac et al., 
2010]. 
A correlation between chlorogenic acids and stomach discomfort after ingestion of coffee 
brew has been described [Weiss et al., 2010]. Moreover there is some evidence that CGA 
raise total Hcy concentrations in plasma and could be partly responsible for the higher 
homocysteine concentrations observed in coffee drinkers [Olthof et al., 2001b]. 
2.3.6 Pyrazines 
Pyrazines are monocyclic heteroaromatic substances containing nitrogen atoms in the 1- and 
4-position of the aromatic ring (see Figure 2-8). Many substituted pyrazines occur naturally. 
These pyrazines carry substituents at one or more of the four ring carbon atoms. 
Alkylpyrazines contain only carbon and hydrogen substituents. From these alkylpyrazines 
alone, 70 different compounds have been identified in nature. Other substituents include 
oxygenated functional groups like alkoxy groups and acyl groups or sulphur containing thiol 
or sulphide groups [Adams et al., 2002; Wagner et al., 1999]. 
 
 
 
 
Figure 2-8: General structure of pyrazines. 
 
Many of these compounds have intensive smells and very low odour threshold values. 
Therefore, these compounds contribute to many aromas and flavours.  In coffee, a number of 
methyl-, dimethyl-, ethyl-, diethyl- and mixed ethyl–methyl pyrazines have been detected and 
are considered to be important for flavour and aroma [Adams et al., 2002; Czerny et al., 
1999; Muller and Rappert, 2010; Richling et al., 2005]. In 2000, Czerny and Grosch [Czerny 
and Grosch, 2000] demonstrated that the aroma of raw coffee is primarily caused by 
3-isobutyl-2-methoxypyrazine (3-Isobutyl-2-methoxyP). Parallel, 2-methoxy-3,5 
dimethylpyrazine (2-Methoxy-3,5-DMP) was identified as an additional aroma-active 
compound of raw as well as roasted coffee. During roasting, the concentrations of other 
aroma compounds (like methional and phenols) increase drastically and mask, together with 
other odorants that are exclusively formed by the roasting process, the peasy odor of 3-
isobutyl-2-methoxypyrazine. 
From aroma-extract dilution analysis,  2,3-diethyl-5-methylpyrazine (2,3-DE-5-MP) was found 
to be the dominant component of the aroma of a medium roasted Arabica coffee sample 
[Grosch, 2001]. On the other hand, our research group identified 2-methylpyrazine (2-MP), 
2,5-dimethylpyrazine (2,5-DMP) and 2,6-dimethylpirazine (2,6-DMP) as the most abundant 
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pyrazines in coffee brews [Pickard et al., 2011]. Some of the pyrazines found in coffee are 
illustrated in Figure 2-9. 
                    
                               
2,3,5,6-Tetramethylpyrazine (TMP)       2-Ethyl-3,5(6)-Dimethylpyrazine (2-E-3,5-DMP)        2-Methylpyrazine (2-MP) 
 
 
                                                       
 2,3,5-Trimethylpyrazine (2,3,5-TriMP)                2,3-Dimethylpyrazine (2,3-DMP)                  2,5-Dimethylpyrazine (2,5-DMP) 
                
                                               
 2,3-Diethyl-5-methylpyrazine (2,3-DE-5-MP)                            Pyridin                                   2-Ethyl-5-Methylpyrazine (3-E-5-MP) 
 
                                                           
 2,6-Dimethylpyrazine (2,6- DMP)   2-Isobutyl-3-Methoxypyrazine (2-Isobutyl-3-methoxyP)  2-Ethyl-3-Methylpyrazine (2-E-3-MP) 
Figure 2-9: Chemical structure of some pyrazines present in coffee [Czerny and Grosch, 2000; 
Grosch, 1996, 2001; Richling et al., 2005]. 
   
Pyrazines may also be formed by heating of food in the Maillard reaction [Amrani-Hemaimi et 
al., 1995; Low et al., 2007]. The greatest amounts of pyrazines are formed at temperatures 
between 120 and 150 °C, but pyrazine formation has also been observed at 70 °C. The 
nitrogen atoms are derived from amino acids and the carbon atoms from sugars. Amino 
acids influence the substitution patterns of the pyrazines formed and fructose yields more 
pyrazines than glucose. Low et al. showed [Low et al., 2007] that the formation of 
alkylpyrazines depends on the amino acid composition. 
Several routes have been published for the chemical synthesis of pyrazines. The total annual 
volume of use of pyrazine and quinoxaline derivatives as flavouring ingredients has been 
estimated to be 2135 kg in the USA. The production in 2002 was 347 kg of 2,3,5-TriMP, 144 
kg of TMP and 923 kg of acetylpyrazine. The daily uptake of pyrazines added as flavouring 
agents has been estimated to be 3 μg/kg body weight [Adams et al., 2002]. 
Pyrazines are important contributors to the flavour of various roasted, toasted, or similarly 
heated foods. They are thought to arise primarily from a heat-induced condensation between 
amino acids and sugars (α-dicarbonyl compounds) through the Strecker degradation. Their 
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concentrations in foods are in the range from approximately 0.001 to 40 ppm [CIVO-TNO, 
1999]. 
Formed usually at temperatures above 100 °C, alkylpyrazines are important products of the 
Maillard reaction, or nonenzymatic browning. This reaction, initiated with the condensation of 
a reducing carbohydrate with an amino compound, is mostly responsible for the formation of 
flavour and color in processed food products. On the sugar side, the reactants are mainly 
glucose, fructose, maltose, lactose and, to a smaller extent, reducing pentoses, e. g., ribose 
“On the side of the amino component, amino acids with a primary amino group are more 
important than those with a secondary because their concentration in foods is usually higher. 
The reactive carbonyl group of the sugar reacts with the nucleophilic amino group of the 
amino acid, and forms a complex mixture of molecules responsible for a range of odors and 
flavours. This process is accelerated in an alkaline environment, as the amino groups are 
deprotonated and, hence, have an increased nucleophilicity. The type of the amino acid 
determines the resulting flavour” cited from Belitz et al.  [Belitz et al., 2009]. 
The most accepted mechanism for pyrazine formation involves the condensation reaction of 
two α-aminocarbonyl compounds with the formation of a dihydropyrazine, which oxidizes 
spontaneously to the corresponding pyrazines [Adams et al., 2008].  
Nucleophilic compounds like amino acids or amines easily add to the carbonyl function of 
reducing carbohydrates and form imines (Schiff bases). The rearrangement of the imines 
leads to an aminoketose called Amadori compound (1-amino-1-deoxyketose). Amadori 
products are only intermediates formed in the course of the Maillard reaction. In spite of their 
limited stability, these products can be used under certain conditions as an analytical 
indicator of the extent of the heat treatment of food. Amadori compounds are degraded to 1-, 
3-, and 4-deoxydicarbonyl compounds (deoxyosones) in the pH range 4–7 (see Figure 2-10). 
“The concentrations of Amadori and deoxyosones compounds vary, depending on the 
reaction conditions (pH value, temperature, time, type and concentration of the educts). As a 
result, there is a change in the product spectrum and, consequently, in the color, taste, odor, 
and other properties of the food in each case” cited from Belitz et al. [Belitz et al., 2009]. 
 
 
 
 
 
 
 
 
 
Figure 2-10: Formation of deoxyosones [Belitz et al., 2009] 
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The reactions between α-dicarbonyl compounds, like the deoxyosones obtained in the 
Maillard reaction, and amino acids are classed under the term Strecker reaction (see Figure 
2-11). This reaction leads to the formation of aldehydes (Strecker aldehydes), CO2 and α-
aminoketones on oxidative decarboxylation of the α-amino acids [Adams et al., 2008]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-11: Strecker reaction and formation of α-aminoketones. 
 
The condensation of two α-aminoketones and subsequent oxidation to dihydropyrazine 
results in the formation of pyrazines (see Figure 2-12). When the intermediate 
dihydropyrazine reacts with a carbonyl compound, an alkylpyrazine with an additional 
substituent is formed and the oxidation step is not necessary [Shibamoto et al., 1979]. The 
many studies performed so far show that there is more than one chemical pathway involved 
in pyrazines formation in complex Maillard systems. Even a very simple model system 
produces a large number and variety of alkylpyrazines. The availability of various precursors 
will determine which route predominates [Adams et al., 2008]. 
 
 
 
 
 
 
Figure 2-12: Alkylpyrazines formation from α-aminoketones [Shibamoto et al., 1979]. 
 
In humans and laboratory rodents, orally administered substituted pyrazines are rapidly 
absorbed from the gastrointestinal tract and excreted. Approximately 90% of the dose (100 
mg/kg) of 2-MP, 2,5-DMP, 2,6-DMP or methoxypyrazine administered to male Wistar rats by 
a gastric feeding tube was excreted in the urine as polar metabolites within 24 h. More than 
α 
 
α 
 
α 
 
α 
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50% of the administered dose (100 mg/kg) of 2,3-DMP was recovered in the urine within 24 
h [Hawksworth and Scheline, 1975]. 
In humans and animals, two basic reactions for the conversion of pyrazines have been 
described. Either an alkyl group is oxidized by P450 type enzymes to form the corresponding 
alcohols or carboxylic acids or the ring is hydroxylated by molybdenum-containing oxidases 
of the xanthin oxidase type [Hawksworth and Scheline, 1975]. Carboxylic acids and the 
hydroxylated pyrazines can then be excreted directly or conjugated with glucuronic acid or 
glutathione via the kidney [Adams et al., 2002]. There are no reports describing the 
degradation of the pyrazine ring itself in higher organisms [Muller and Rappert, 2010]. 
The acute toxicity of the pyrazines that are used as flavouring additives has been found to be 
very low. The oral LD50 in rats ranged from 158 mg/kg for 2-pyrazinethanthiol to more than 
4,000 mg/kg for 2-isobutyl-3-methoxypyrazine. In short- and long-term subacute chronic 
studies, no adverse effects were found, and in in vitro and in in vivo carcinogenicity, 
mutagenicity and genotoxicity tests, the influence of pyrazines was also negative. Based on 
all these findings, the pyrazines have received the GRAS (generally regarded as safe) status 
by The Flavor and Extract Manufacturers Association for the use as flavouring agents in food  
[Adams et al., 2002]. 
Some substituted pyrazines, especially  tetramethylpyrazine (TMP) an active ingredient of a 
commonly used Chinese herb named “Chung Chong” (Ligusticam Wallichii Franch), have 
been found to have pharmacological effects, such as diuretic [Jones et al., 1967], 
hepatoprotective [Chen et al., 2011; Kim et al., 1997], antithrombogenic [Sheu et al., 1997; 
Wang et al., 2008], and tuberculostatic effects [Abdel-Aziz and Abdel-Rahman, 2010; 
Milczarska et al., 1999]. There is some evidence that TMP scavenges superoxide anions 
dose-dependently, and decreases the production of nitric oxide significantly [Zhang et al., 
2003], has antiinflammatory properties and regulates inflammatory responses at 
atherosclerotic lesions [Li et al., 2009] and possess anti-apoptotic and neuroprotective 
effects [Fan et al., 2006].  
In 2006, Chen et al. [Chen et al., 2006] showed that TMP suppresses ischemia-induced 
ventricular arrhythmias and reduces the infarct size resulting from ischemia/reperfusion injury 
in vivo. They associated the cardioprotective activity of TMP with its antioxidant activity via 
induction of HO-1 and with its capacity for neutrophil inhibition (see Chapter 2.4.4). 
Methylpyrazines and their metabolites (pyrazinoic acids) exhibited blood lipid-lowering effects 
in rats [Kagami et al., 2008]. 
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2.3.7 Coffee compounds with undesirable effects  
2.3.7.1 Polycyclic aromatic hydrocarbons (PAHs) 
Roasting is a crucial step for the production of coffee, as it enables the development of color, 
aroma, and flavour, which are essential for the characterization of the coffee quality. At the 
same time, roasting may lead to the formation of not desirable compounds, such as 
polycyclic aromatic hydrocarbons (PAHs) [Oosterveld et al., 2003; Orecchio et al., 2009].  
PAHs are a group of chemicals that are formed by the incomplete combustion of organic 
matter and are thus generated whenever fossil fuels or vegetation is burned, and they are 
one of several classes of carcinogenic chemicals present in tobacco smoke. PAHs are also 
ubiquitous environmental contaminants [Rey-Salgueiro et al., 2008 ].  Benzo[a]pyrene, a five-
ring PAH (see Figure 2-13) whose metabolites are mutagenic and highly carcinogenic, 
usually serves as a lead compound [Eisenbrand and Schreier, 2006]. 
 
 
 
 
 
Figure 2-13: Chemical structure of Benzo[a]pyrene. 
 
The presence of polycyclic aromatic hydrocarbons (PAHs) in coffee samples has also been 
reported and may be attributed to either contamination of the initial green beans [Houessou 
et al., 2006; Houessou et al., 2007] or formation of these compounds during the roasting step 
[Rey-Salgueiro et al., 2008 ]. Formation of phenanthrene, anthracene and benzo[a] 
anthracene in coffee beans was observed at temperatures above 220 °C, whereas formation 
of pyrene and chrysene required 260 °C. The PAH transfer to the infusion was quite 
moderate (<35%), with a slightly lower extractability for dark-roasted coffee as compared to 
light-roasted coffee [Houessou et al., 2007].  
In 2009, Orecchio et al. [Orecchio et al., 2009] have shown that coffee contributes with very 
insignificant quantities to the daily human intake of carcinogenic PAHs and that the PAHs 
identified in most of the coffee samples originate from high temperature processes. 
2.3.7.2 Furan 
Furan is an organic compound with high volatility and lipophilicity. It is formed during 
commercial or domestic thermal treatment of food. In 2009, European authorities revealed 
the presence of relatively high furan levels in coffee (see Table 2-5) [EFSA, 2009]. The furan 
concentration in coffee drink depends on the content of the coffee powder used for brewing, 
as well as on the type of the brewing procedure. Coffee brews from espresso-type machines 
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have considerably higher amounts of furan than others, reaching concentrations of 88 µg/L 
[Kuballa et al., 2005]. According to US-FDA data, an average furan concentration of 52 µg/kg 
was found in ground coffee, brewed using automatic drip coffee makers [Morehouse et al., 
2008] 
 
Table 2-5 Coffee powder furan levels [EFSA, 2009] 
Type of roasted coffee Furan (µg/kg) 
Average Maximum 
Beans or ground 
Beans 
Ground 
Instant (powder) 
1691 
2271 
1112 
588 
6500 
4895 
5749 
2200 
           
Furan induces hepatocellular tumors in rats and mice and cholangiocarcinomas in rats with a 
high incidence. It is assumed that cis-2-butene-1,4-dial, the reactive metabolite of furan, is 
the causative agent leading to toxicity and carcinogenicity. Based on this data, furan is 
classified as a possible human carcinogen. The initial exposure estimates revealed a 
relatively small margin between human exposure and those furan doses, which induce liver 
tumors in experimental animals.  
The liver possess high capacity to eliminate furan from the bloodstream by first-pass 
metabolism.  Furan is rapidly metabolized by cytochrome P450 (CYP) enzymes to the 
α,β-unsaturated dialdehyde, cis-2-butene-1,4-dial, identified as the major primary metabolite 
(see Figure 2-14) [Bakhiya and Appel, 2010]. Cis-2-butene-1,4-dial is a highly reactive 
compound and is considered to be the ultimate (geno)toxic intermediate in furan-treated 
animals. It can bind covalently to cellular proteins and nucleosides. The biotransformation of 
furan to a protein-binding intermediate was observed in earlier studies both in vivo and in 
vitro [Parmar and Burka, 1993]. 
 
 
 
 
Figure 2-14: Bioactivation of furan to cis-2-butene-1,4-dial. 
 
The margin of exposure (MOEs) for furan was calculated at dietary exposures of 0.001 
mg/kg body weight per day, to represent the average dietary exposure to furan for the 
general population, and 0.002 mg/kg bw per day, to represent the dietary exposure to furan 
for consumers with high exposure. This estimate will also cover dietary exposure of children. 
Comparison of these dietary exposures with the lower limit on the benchmark dose for a 10% 
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induction of hepatocellular adenomas and carcinomas in female mice (BMDL10) of 0.96 
mg/kg bw per day, gives MOEs of 960 and 480 for average and high dietary exposures, 
respectively. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) considered 
that these MOEs indicate a human health concern for a carcinogenic compound that might 
act via a DNA-reactive genotoxic metabolite. The furan levels can be reduced in some foods 
through volatilization (e.g. by heating and stirring canned or jarred foods in an open 
saucepan). However, there is currently a lack of quantitative data for all foods, and no 
information is available on other mitigation methods [JECFA, 2010] 
2.3.7.3 Acrylamide 
Acrylamide (2-propenamide) is by room temperature (RT) a white odourless crystalline solid, 
soluble in water, ethanol, ether, and chloroform. Due to its α,β-unsaturated carbonyl structure 
tends acrylamide for polymerization and 1,4-Michael-like additions to nucleophiles 
[Eisenbrand and Schreier, 2006]. 
 
 
 
Figure 2-15: Chemical structure of acrylamide (AA). 
 
The main route for the formation of acrylamide in coffee (as in most other concerned foods) 
is the Maillard reaction, initiated by the condensation of asparagine and reducing 
carbohydrates, such as fructose or glucose, or, alternatively, reactive carbonyls (including 
dicarbonyls, n-aldehydes, 2-oxo acids). However, coffee beans are subject to relatively 
higher temperatures than other foods because of the roasting at 220–250 °C. Under such 
conditions, more than one pathway, beyond the commonly accepted asparagine/sugar (or 
carbonyl) condensation, may be expected to furnish acrylamide via the Maillard reaction 
[Guenther et al., 2007]. 
Several thermally reactions for the formation of acrylamide are feasible and the salient 
intermediates are acrolein, acrylic acid and 3-aminopropionamide. Acrolein can be formed by 
different pathways, including the oxidative degradation of lipids, and could react further via 
acrylic acid to form acrylamide lipids, and could react further via acrylic acid to form 
acrylamide. Under certain conditions, acrolein together with asparagine may generate 
appreciable amounts of acrylamide [Yasuhara et al., 2003]. Acrylic acid can also react with 
ammonia (released during the thermolysis of amino acids) to furnish acrylamide by 
aminodehydroxylation, which is a well-known reaction of acids leading to amides [Stadler et 
al., 2002b; Yaylayan and Stadler, 2005]. 
Levels of reducing sugars [Guenther et al., 2007] and moisture [Lantz et al., 2006] in green 
coffees showed no correlation with acrylamide levels after roasting. A factor that could 
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contribute to relatively higher acrylamide levels is the number of immature beans used in 
production. Such beans, are characterized by significantly higher amounts of free 
asparagines (>2-fold) versus mature beans [Mazzafera, 1999]. 
Studies in rats indicate that AA orally administered via drinking water is rapidly and 
extensively absorbed from the gastrointestinal tract. AA and AA-related metabolites are 
widely distributed among tissues with no evidence for accumulation [Doerge et al., 2005]. 
Acrylamide is in part biotransformed to the epoxide glycidamide (GA). GA is considered to be 
responsible metabolite for the genotoxic and carcinogenic effect of AA [Doroshyenko et al., 
2009]. In mice and humans, the conversion of AA to GA is mediated by cytochrome P450 
2E1 (CYP2E1) [Settels et al., 2008; Sumner et al., 1999]. 
AA and GA are conjugated to glutathione, which is the main pathway of AA metabolism in 
both rodents and humans [Bjellaas et al., 2007]. Glutathione adducts are converted to the 
respective mercapturic acid (MA) metabolites N-acetyl-S-(2-carbamoylethyl)-cysteine 
(AAMA); N-acetyl-S-(2-carbamoylethyl)-cysteine-S-oxide; N-(R,S)-acetyl-S-(2-hydroxy-2-
carbamoylethyl)-cysteine (glycidamide mercapturic acid -GAMA-); and N-acetyl-S-(1-
carbamoyl-2-hydroxyethyl)-cysteine to be excreted in the urine. Of these, AAMA and GAMA 
have been unequivocally confirmed in humans [Fuhr et al., 2006; Watzek et al., 2012]. 
Acrylamide and glycidamide have the capability to bind covalently to nucleophilic sites of 
proteins and nucleic acids [Ghanayem et al., 2005]. AA has been classified as class 2A 
carcinogen (probably carcinogenic to humans) by IARC [IARC, 1994.]. Foods found to 
contain substantial amounts of AA are potato products, such as fried potatoes or French fries 
(median content 240 µg AA/kg), gingerbread (300 µg AA/kg) and bread (15 µg AA/kg); where 
the main part of AA is located in the crust [Boon et al., 2005]. 
Another mode of interaction with biomolecules concerns binding of AA and GA to 
nucleophilic regions in proteins and peptides, such as amino and sulfhydryl groups. 
Hemoglobin (Hb) adducts are often used as validated biomarkers to monitor internal 
exposure to electrophilic xenobiotics [Ehrenberg and Tornqvist, 1991].  
AA is presumed to exert its genotoxic activity via metabolic transformation into the genotoxic 
metabolite GA which is known to be mutagenic in bacteria and mammalian cells [Baum et al., 
2005; Berger et al., 2011], without metabolic activation AA has not been found to be 
mutagenic or genotoxic at biologically relevant concentrations [Hashimoto and Tanii, 1985].  
Carcinogenicity studies in rats indicate that chronic AA exposure increased the incidence of 
various tumor types from the dose of 0.5 mg/kg/d, which would correspond to a human 
equivalent dose of 7.6 µg/kg/d [Tyla et al., 2000]. 
In humans, there is some evidence about the relationship between dietary AA and cancer 
incidence/mortality in epidemiologic studies [Hogervorst et al., 2007, 2008]. Olesen et al. 
showed a statistically significant correlation between levels of AA adduct to Hb and breast 
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cancer with an estimated incidence rate ratio of 2.7 (95% confidence interval) per 10-fold 
increase in adduct level [Olesen et al., 2008].  
2.4 Antioxidant activity of coffee  
Antioxidant activity of foods and beverages is one of the properties that has generated much 
interest within the scientific community. Coffee brew, a complex mixture of numerous 
bioactive compounds, is known to exhibit distinct antioxidant activity [del Castillo et al., 2005].  
As mentioned before, antioxidative activity in coffee is generally associated with its content of 
phenolic compounds as well as Maillard reaction products [Bakuradze et al., 2010; Gomez-
Ruiz et al., 2007; Nenadis et al., 2004]. 
 
2.4.1 Oxidative stress 
Oxidative stress is a disturbance in the oxidant-antioxidant balance leading to potential 
cellular damage. The imbalance can result from a lack of antioxidant capacity caused or by 
an overabundance of reactive oxygen species (ROS). ROS are potential carcinogens 
because of their roles in mutagenesis, tumor promotion, and progression [Droge, 2003]. 
If not regulated properly, the excess ROS can damage lipids, proteins or DNA, impeding their 
normal function. ROS alterations in different signaling pathways may modulate gene 
expression, cell adhesion, cell metabolism, cell cycle and cell death. These events may 
induce oxidative DNA damage, which in turn increases chromosomal aberrations associated 
with cell transformation. ROS may also lead to activation of cellular signal pathways, such as 
those mediated by mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB), 
phosphatidylinositol 3-kinase (PI3K), p53, β-catenin/Wnt and pathways associated with 
angiogenesis [Ha et al., 2010; Martindale and Holbrook, 2002]. 
2.4.2 Reactive oxygen species (ROS)  
Free radicals can be defined as molecules or molecular fragments containing one or more 
unpaired electrons in atomic or molecular orbitals. This unpaired electron(s) usually gives a 
considerable degree of reactivity to the free radical. Radicals derived from oxygen represent 
the most important class of radical species generated in living systems (see Table 2-6). 
Molecular oxygen (dioxygen) has a unique electronic configuration and is itself a radical 
[Halliwell and Gutteridge, 1999].  
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Table 2-6 Radical and non-radical reactive oxygen species [Halliwell and Gutteridge, 
1999] 
Radicals Non-radicals 
Superoxide, O2
- 
Hydroxyl, OH 
Peroxyl, RO2
 
Alkoxyl, RO 
Hydroperoxyl, HO2
 
Hydrogen peroxide, H2O2 
Hypochlorous acid, HOCl 
Ozone, O3 
Singlet oxygen, 1O2 
Peroxynitrite, ONOO 
 
Several basic cellular processes lead to the production of ROS within a cell. The 
mitochondrial electron transport chain is the main source of ATP in the mammalian cells. 
Cellular respiration involves the reduction of molecular oxygen (O2) to water in the electron 
transport chain. This reduction occurs through four one-electron reductions (see below) 
resulting in the formation of reactive, partially reduced intermediates such as the superoxide 
anion radical, hydrogen peroxide, and the hydroxyl radical that may act as prooxidants [Kelly 
et al., 1998]. 
 
(1)  O2   e    →  O2   
(2)  O2    e      
+  →  H2O2  
(3)  H2O2  e     
+  → OH + H2O  
(4)  OH + e     +  →  H2O 
 
The addition of one electron to dioxygen forms the superoxide radical anion (O2
-). 
Superoxide anion, arising either through metabolic processes or following oxygen “activation” 
by physical irradiation, is considered the “primary” ROS, and can further interact with other 
molecules to generate “secondary” ROS, either directly or prevalently through enzyme- or 
metal-catalysed processes [Valko et al., 2007]. Once produced, ROS as O2
- and OH  (two 
of the most studied ROS) may damage cellular components and tissues. Superoxide 
oxidizes catecholamines, tocopherols, ascorbate, and thiols. It can also inactivate enzymes 
such as catalase and peroxidases. 
The hydroxyl radical is highly reactive, making it a very dangerous radical with a very short in 
vivo half-life of approx. 10−9 s. Thus, when produced in vivo •OH reacts close to its site of 
formation [Pastor et al., 2000]. 
The redox state of the cell is largely linked to an iron (and copper) redox couple and is 
maintained within strict physiological limits. It has been suggested that iron regulation 
ensures that there is no free intracellular iron; however, in vivo, under stress conditions, an 
excess of superoxide releases “free iron” from iron-containing molecules. The released Fe2+ 
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can participate in the Fenton reaction (5), generating highly reactive hydroxyl radicals [Valko 
et al., 2007]. 
(5) Fe2+ +H2O2 → Fe
3+ + •OH +OH− 
 
Under stress conditions, O2
- acts as an oxidant of [4Fe–4S] cluster-containing enzymes 
(dehydratase-lyase family enzymes) and facilitates •OH production from H2O2 by making Fe
2+ 
available for the Fenton reaction. The superoxide radical participates in the Haber–Weiss 
reaction (6) which combines a Fenton reaction and the reduction of Fe3+ by superoxide, 
yielding Fe2+ and oxygen [Halliwell and Gutteridge, 1999]. 
 
(6) Fe3+ +O2    →  Fe
2+ + O2 
 
Fenton chemistry is known to occur in vitro, but its significance under physiological 
conditions is not clear, under non physiological conditions e.g. hemochromatosis, 
β-thalassemia, or hemodialysis, higher amounts of “free available iron” can have deleterious 
effects. “Free-iron” is transported into an intermediate, labile iron pool (LIP), which represents 
a steady state exchangeable, and readily chelatable iron compartment [Kakhlon and 
Cabantchik, 2002]. 
 
2.4.3 Antioxidant defenses 
Exposure to free radicals from a variety of sources has led organisms to develop a series of 
defense mechanisms. Defense mechanisms against free radical-induced oxidative stress 
involve preventative mechanisms, repair mechanisms, physical defenses, and antioxidant 
defenses. The composition of antioxidant defenses differs from tissue and cell-type to cell 
type. Extracellular fluids have different protective mechanisms from the intracellular 
environment. In general, antioxidant defenses comprise: agents that catalytically remove free 
radicals and other “reactive species” (e.g. antioxidative enzymes like superoxide dismutase, 
glutathione peroxidase, catalase); proteins that minimize the availability of pro-oxidants such 
as iron, copper ions and haem (e.g. transferrins, metallothionein, ceruloplasmin); proteins 
that protect biomolecules against damage (e.g. heat shock proteins) and low-molecular-mass 
agents or  non-enzymatic antioxidants that scavenge ROS and reactive nitrogen species 
(RNS) represented by ascorbic acid (Vitamin C), α-tocopherol (Vitamin E), glutathione 
(GSH), uric acid, bilirubin, carotenoids, flavonoids, and other antioxidants. Under normal 
conditions, there is a balance between both the activities and the intracellular levels of these 
antioxidants. This balance is essential for the survival of organisms and their health [Halliwell 
and Gutteridge, 1999]. 
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One of the best studied models of redox regulation in mammalian cells is the redox control of 
HO-1. HO-1 induction in skin fibroblasts may serve as an inducible defense pathway to 
remove heme liberated by oxidants. The mRNA and HO-1 protein are strongly induced by 
ROS, UVA irradiation and various stressors; thus the inducibility of HO-1 mRNA in many 
tissues and various mammalian species has rendered HO-1 mRNA a useful marker for 
cellular oxidative stress at the mRNA level [Keyse and Tyrrell, 1989]. 
 
2.4.4 Heme oxygenase (HO) 
Heme oxygenases (HOs) are the rate-limiting enzymes in catabolism of heme, converting it 
to carbon monoxide (CO), biliverdin (BV), and ferrous iron [Maines, 1997]. The HOs play 
critical roles in physiological iron homeostasis, antioxidant defense and in signaling pathways 
that employ CO as a messenger. Three mammalian isoforms of HO have been identified: 
HO-1, an inducible enzyme that is most highly concentrated in tissues that are involved in the 
catabolism of heme proteins; HO-2, a non-inducible isoform that is present in highest 
concentrations in the brain and testes and is thought to be particularly involved in signaling 
pathways; and HO-3, an isoform with low catalytic activity and uncertain physiological role. 
HO isoforms are also found in plants and most other species, including bacteria [Montellano, 
2000; Ravanelli and Branco, 2008; Was et al., 2011]. 
HO-1 is a member of the heat shock protein family (HSP-32), and its expression is triggered 
by diverse stress-inducing stimuli including hypoxia, heavy metals, UV irradiation, ROS and 
reactive nitrogen species (RNS). It is believed that induction of HO-1 protects cells from 
these toxic stimuli by multiple mechanisms: a) decreasing the prooxidant level (heme); b) 
increasing the antioxidant level (bilirubin); c) producing the antiapoptotic molecule CO; d) 
inducing ferritin, which removes and detoxifies free ferric ion; and e) preventing 
overstimulation of the immune response [Fang et al., 2004]. 
HO catalyzes the first and rate-limiting step in the oxidative degradation of heme b (Fe-
protoporphyrin-IX) to form the open-chain tetrapyrrole biliverdin-IXα (see Figure 2-16). The 
HO reaction displays regiospecificity for the heme molecule, such that only the α-isomer of 
biliverdins produced. Biliverdin-IXα (BV) is subsequently converted to bilirubin-IXα (BR) by 
an NAD(P)H-dependent reductase. HO catalyzed heme cleavage releases the heme iron in 
the ferrous form Fe (II) and eliminates the α-methene bridge carbon of the heme as CO. The 
HO enzymatic activity requires three moles of molecular oxygen (O2) per heme molecule 
oxidized, and reducing equivalents (seven electrons) from NADPH-cytochrome-P450-
reductase [Ryter et al., 2006a]. 
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Figure 2-16: Ring opening of heme to give four isomeric biliverdins (IXα, IXβ, IXγ and IXδ) and 
reduction of the IXα and IXβ isomers to the corresponding bilirubins. Modified from McDonagh 
[McDonagh, 2001].  
 
In more detail, the heme is first oxidized to α-meso-hydroxyheme, which in the deprotonated 
state has free radical character and reacts with oxygen to produce verdoheme and CO (see 
Figure 2-17). No exogenous reduction equivalents are required for this reaction. The 
verdoheme is subsequently converted to BV and free iron in a reaction that requires 
NADPH–cytochrome-P450-reductase and O2 [Montellano, 2000]. A recent single-turnover 
kinetic analysis, in which the rate constants for the various catalytic steps were determined, 
has shown that product release involves sequential reduction of the ferric to the ferrous BV 
complex, release of the ferrous iron, and finally dissociation of the biliverdin from the protein 
[Liu and Ortiz de Montellano, 2000]. The slow step in the single-turnover sequence is BV 
release. However, BV release is accelerated in the presence of biliverdin reductase, the 
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enzyme that converts BV to BR, and reduction of ferric to ferrous verdoheme becomes rate-
limiting.  
Given the established reaction intermediates, the results of the kinetic analysis, and the fact 
that the oxygens in BV are derived from different molecules of oxygen, hypothetical 
mechanisms have been formulated for the conversion of α-meso-hydroxyheme to 
verdoheme and verdoheme to BV [Montellano, 2000; Unno et al., 2007; Wilks, 2002].  
 
 
 
Figure 2-17: Schematic of HO catalytic intermediates [Unno et al., 2007]. 
 
The inducible form of HO, HO-1, occurs at a high level of expression in the spleen and other 
tissues that degrade senescent red blood cells, including specialized reticuloendothelial cells 
of the liver and bone marrow [Tenhunen et al., 1969]. HO is present in: 
 hematopoietic stem cells of the bone marrow, where it may inhibit cellular 
differentiation by lowering the intracellular concentration of heme, a differentiation 
factor for these cells [Abraham, 1991] 
  liver parenchyma, which is the site of uptake and degradation of plasma heme, 
hemoglobin, and methemalbumin. Under conditions of hemolysis, HO-activity 
dramatically increases in liver parenchyma, kidney, and macrophages a result of 
increased levels of circulating hemoglobin [Tenhunen et al., 1970] 
 most other tissues not directly involved in erythrocyte or hemoglobin metabolism, HO-
1 typically occurs at low to undetectable levels under basal conditions, but responds 
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to rapid transcriptional activation by diverse chemical and physical stimuli [Ryter et 
al., 2006a]. 
Highest expression of HO-2, the constitutively expressed isozyme, occurs in the testes, but 
the protein is also found abundantly and ubiquitously in other systemic tissues including, 
brain and central nervous system, vasculature, liver, kidney, and gut. In rats, HO-2 does not 
respond to transcriptional activation by environmental stress but may respond to 
developmental regulation by adrenal glucocorticoids in the brain [Raju et al., 1997]. 
There is some evidence about HO-1 gene expression and total HO-activity modulation in 
some cultured cells like liver carcinoma (HepG2) [Ghattas et al., 2002; Lavrovsky et al., 
2000; Takahashi et al., 1999], and colo-rectal adenocarcinoma (Caco-2) [Follett et al., 2002; 
Uc and Britigan, 2003] and HT29 cell lines [Lee et al., 2007; Paul et al., 2005]. 
In the cell, HO-1 enzymes have been characterized as endoplasmic reticulum (ER) 
associated proteins, due to the abundant detection of HO-activity in microsomal (104,000 g) 
fractions. Both HO-1 and HO-2 contain a COOH-terminal hydrophobic domain segment that 
suggests a general membrane compartmentalization. Kim et al. described a functional 
association of HO-1 with plasma membrane caveolae, small invaginations of the plasma 
membrane, in endothelial cells [Kim et al., 2004].  
HO-1 activity has been measured using several techniques. Although BV is a primary 
metabolite of the HO-1/heme reaction, it is rarely used as an indicator because of poor 
spectral properties, extinction coefficient (Ɛ) of only 8 to 10 mM-1 cm-1[Kutty and Maines, 
1981]. Thus, one of the most common HO-1 activity assays relies on the reduction of 
biliverdin to bilirubin, as originally described by the group of Tenhunen [Tenhunen et al., 
1969]. In this method, BR formation is monitored spectrophotometrically by the increase in 
absorbance at 468 nm (Ɛ468= 43.5 mM
-1 cm-1), which is approximately 5-fold higher than that 
of BV  [Huber et al., 2009]. Thus, HO-1 activity is measured by monitoring BR formation 
using the diference in absorbance at 464 to 530 nm [McNally et al., 2004; Motterlini et al., 
1995; Tenhunen et al., 1970]. 
HO-1 gene is commonly induced by agents and chemicals that produce an oxidative cellular 
stress involving ROS generation. Known examples of ROS generating systems that activate 
the expression of the ho-1 gene include hydrogen peroxide (H2O2), quinines (e.g, 
menadione) which generate O2
-  and/or H2O2  through redox cycling process, 
photosensitizers and UVA radiation [Gong et al., 2003].   
Heavy metals (cadmium, cobalt, zinc, tin, lead and mercury) potently activate the ho-1 gene 
in cell culture systems and produce tissue-specific effects in vivo depending on the 
compound and route of administration [Ryter et al., 2006a]. Heavy metals form complexes 
with thiols, such as reduced glutathione (GSH). In vivo, heavy metals cause a characteristic 
depletion of hepatic GSH followed by a rebound increase from de novo synthesis.  
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The complexation of metals with protoporphyrin IX (PPIX), the natural precursor of heme, 
generates metalloporphyrins. Several metals such as cobalt, zinc, copper and iron can serve 
as substrates for ferrochelatase, the enzyme that incorporates iron into PPIX in the final step 
of heme synthesis. The substrate and catalytic cofactor of HO-1, heme (iron-protoporphyrin-
IX), acts as an inducer of ho-1 gene expression and activity [Tenhunen et al., 1970]. Several 
metalloporphyrins, including SnPPIX, CoPPIX and ZnPPIX, induce HO-1 transcription but 
also act as competitive inhibitors of HO-activity both in vitro and in vivo [Sardana and 
Kappas, 1987]. 
Many phenolic compounds activate ho-1 through the Nrf-2/Keap1 pathway, which plays a 
major role in the transcriptional activation of the ho-1 gene by electrophilic compounds. A 
broad class of antioxidants, has recently been identified as potent ho-1 inducing agents, 
including caffeic acid phenethyl ester [Scapagnini et al., 2002], carnosol [Martin et al., 2004], 
curcumin [Balogun et al., 2003b; Motterlini et al., 2000; Scapagnini et al., 2002], resveratrol 
[Juan et al., 2005], chalcones, rosolic acid [Foresti et al., 2005] and garlic organosulfur 
compounds [Chen et al., 2004a].  
In 2008, Cavin et al. reported a significant induction of HO-1 mRNA expression in rat liver 
and primary hepatocytes treated with 800 µg/mL of standard instant coffee for 24 h [Cavin et 
al., 2008]. It is worth noting that HO-1-transcription in vitro was increased by 100 mg/mL 
coffee extract of a low-roast coffee rich in CGA (see chapter 2.3.5), while in vivo, only the 
extract of a strongly roasted coffee,  low in CGA but containing high levels of NMP, increased 
HO-1-transcript levels [Boettler et al., 2011b]. 
The functional consequences of HO-activity are related to the three principle reaction 
products: BR, iron, and carbon monoxide (CO) see Figure 2-18. Iron released from HO-
activity triggers pathways involving the activation of the iron regulatory protein (IRP), leading 
to its sequestration and recycling. Competing pathways involve its extracellular efflux and its 
potential participation in deleterious cellular reactions. BV and BR have been well 
documented as an initial defense mechanism against cellular oxidative stress and tissue 
inflammation in response to multiple stimuli. The third metabolite, CO, is known to act as a 
potent vasodilator and anti-inflammatory molecule via cellular signaling cascades like NO 
[Huber et al., 2009].  
The iron released from heme by HO-activity potentially enters a pool of “labile” or 
“chelatable” iron, where it may be available for cellular iron depending processes included 
the promotion of intracellular ROS production (see Haber–Weiss reaction, Chapter 2.4.2). 
Free heme is also a potentially dangerous pro-oxidant compound, which may promote 
membrane lipid peroxidation [Ryter et al., 2002]. 
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Figure 2-18: Functional consequences of the three principle reaction products of HO-activity: 
bilirubin, iron, and carbon monoxide (CO) [Ryter et al., 2006a]. 
 
The antioxidative protection afforded by HO-activity cannot be explained alone by the 
conversion of heme in exchange for increased intracellular iron. The antioxidant protection of 
HO with respect to iron metabolism, is facilitated by further coupling with proteins that either 
promote the sequestration or export of the liberated iron e.g. IRPs and ferritin. Ferritin has 
been implicated as a cytoprotective molecule in in vitro models [Balla et al., 1992; Lin and 
Girotti, 1998]. 
BR and BV are water-insoluble pigments derived in vertebrates from heme catabolism. In 
mammals and some other vertebrates BV is reduced promptly to BR by NADPH/biliverdin 
reductase (BVR). Only trace amounts of BV are detectable in vivo during normal human 
heme metabolism, demonstrating that the reduction is quantitative and rapid. Although green 
pigments, thought to be BV, have been observed under pathological conditions, there is no 
physiological evidence for accumulation of BV during normal human heme metabolism 
[McDonagh, 2010a].  
Once formed, BR is transported in bloodstream in a reversible complex with serum albumin 
and absorbed into the liver where it is transformed into three different glucuronide derivatives 
by a specific glucuronosyl transferase enzyme, UGT1A1 [Blake et al., 2005]. The polar 
glucuronide derivatives are secreted into bile by the canalicular ATP-dependent transport 
protein MRP2 (multidrug resistanceassociated protein 2, ABCC2). Unlike BV, bilirubin needs 
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to be glucorodidated for efficient excretion and prevention of its intestinal reuptake. 
Conjugated BR is secreted by bile into the small intestine during the passage of the large 
intestine in to the feces, where it is further degraded to urobilinogens by the reductive 
processes of intestinal microorganisms. When glucoronidation is deficient, as in neonates or 
people with the Gilbert syndrome, unconjugated bilirubin accumulates in the circulation and 
extravascular tissue. Why humans and many other vertebrates reduce biliverdin to bilirubin, 
which is toxic and requires further energy-requiring steps to be eliminated, is not known 
[McDonagh, 2010b]. 
The reason why BR requires glucuronidation for elimination, whereas BV and BR conjugates 
do not, is that BV and BR are both flexible molecules that can assume many different 
conformations in solution. BV but not BR, this allows formation of particular conformations 
(stereoisomers) in which the acidic carboxyl side-chains are internalized by hydrogen 
bonding to other groups in the molecule (see Figure 2-19). This has the effect of ‘neutralizing’ 
the polar groups and accounts for the surprising lipophilicity of bilirubin [McDonagh, 2002]. 
Structure and solubility of BR in membranes and aqueous environments are still poorly 
characterised, as is the structure of the crucially important bilirubin–albumin complex that 
transports bilirubin in the circulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-19: Constitutional structure and preferred conformation of bilirubin (BR). Striped 
bonds represent intramolecular hydrogen bonds [McDonagh, 2010b]. 
 
Physiological antioxidant benefit of the metabolic conversion of heme to the elimination 
product BR has been suggested to occur in the circulating plasma, which is supported by 
oxidative stress resistance of hyperbilirubinemic rats [Dennery et al., 1995]. Despite its 
elimination from cells and tissues, current evidence supports a beneficial role for 
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endogenously produced BR at a cellular level. This mechanism may underlie, the 
cytoprotective properties of HO-1 in certain models [Clark et al., 2000; Motterlini et al., 2000]. 
Currently, BV and BR remain viable experimental therapeutic agents for the treatment of 
several inflammatory disease states including transplant-associated ischemia/reperfusion 
(I/R) injury, i.e. tissue damage caused when blood supply returns to the tissue after a period 
of ischemia or lack of oxygen, and vascular injury [Adin et al., 2005; Fondevila et al., 2004]. 
CO has effects on intracellular signaling processes, which culminate in anti-inflammatory, 
antiproliferative, antiapoptotic, and anticoagulative effects. The physiological effects of CO 
have been related to its endogenous production from basal and inducible HO-activity.  The 
physiological signaling effects of CO known to date involve relatively few defined 
mechanisms; the modulation of soluble guanylate cyclases (sGC) activity and subsequent 
stimulation of cGMP production are the most commonly observed. Like NO, CO binds 
directly to the heme iron of sGC, leading to stimulation of enzymatic activity. The stimulation 
of sGC and subsequent elevation of cGMP levels confers to CO its vasoactive properties 
[Furchgott and Jothianandan, 1991]. CO exerts a variable and multimodal effect on 
vasodilation, which involves several mechanisms. The dilatory effects of CO are attributed to 
direct endothelium-independent effects on vascular smooth muscle cells (SMC), including 
the modulation of cGMP and K+ channel activity in the same model, and indirect effects on 
the expression of endothelial-derived vasoconstrictors and myogenic factors [Ryter et al., 
2002]. 
CO exerts also potent anti-inflammatory effects and mediates much of the anti-inflammatory 
effects seen with HO-1. CO selectively inhibits the expression of the pro-inflammatory 
cytokines like tumor necrosis factor alpha (TNFα), IL-1βand MIP-1β and increases 
production of the anti-inflammatory cytokine IL-10. There is evidence that CO mediates these 
anti-inflammatory effects specifically through MAP kinases [Otterbein et al., 2000]. 
Furthermore, increasing evidence suggests possible roles for HO-derived CO as a signaling 
intermediate in the brain and central nervous system (CNS) in a number of neurological 
processes that include olfactory signal transduction, long-term potentiation (LTP), 
nonadrenergic noncholinergic (NANC)-dependent relaxation, cholinergic regulation of 
circadian rhythms, the autonomic regulation of cardiovascular function, and oxygen-sensing 
processes [Artinian et al., 2001; Stevens and Wang, 1993; Williams et al., 2004]. 
HO-1 has been implicated in the pathologies of a number of diseases associated with 
oxidative stress including Alzheimer’s disease [Schipper, 2011], DM [Turkseven et al., 2005] 
and atherosclerosis [Ishikawa et al., 2001]. On the other hand, it should be noted that 
expression of HO-1 is usually higher in cancer cells than in surrounding healthy tissues, as 
shown for lymphosarcoma, prostate cancers, brain tumors, adenocarcinoma, hepatoma, 
squamous carcinoma, glioblastoma, melanoma, Kaposi sarcoma, or pancreatic carcinoma 
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[Doi et al., 1999; Goodman et al., 1997; Hara et al., 1996; Maines and Abrahamsson, 1996; 
McAllister et al., 2004; Torisu-Itakura et al., 2000; Was et al., 2010].  
Expression of HO-1 in tumors can be further elevated in response to chemo-, radio-, or 
photodynamic therapies, possibly as a result of oxidative stress. There are several lines of 
evidence showing that HO-1 exerts potent and comprehensive protumoral effects in growing 
tumors [Was et al., 2011]. Its upregulation improves the survival of various tumor cell lines 
exposed to stressful agents both in vitro [Busserolles et al., 2006; Chen et al., 2004b; Liu et 
al., 2004] and in vivo [Hirai et al., 2007]. Downregulation of HO-1 has been shown to inhibit 
the growth of a pancreatic tumor cell line [Berberat et al., 2005], whereas overexpression of 
HO-1 in human and murine melanoma cells increased significantly their proliferation [Was et 
al., 2006]. These effects seem to be strongly cell-type-dependent, as HO-1 activity exhibited 
antiproliferative actions in human and rat breast cancer cell lines [Hill et al., 2005]. HO-1 can 
also promote tumor angiogenesis and metastasis as demonstrated in humans and in animal 
models. Its overexpression in melanoma cells and pancreatic cancer cells increased 
colonization of lungs, whereas inhibition of HO-activity completely inhibited formation of 
pulmonary metastases [Sunamura et al., 2003; Was et al., 2011]. 
2.5 The cAMP-Pathway 
Despite the large number of known hormones that stimulate second-messenger formation, 
the most important second messengers belong only to three distinct groups: cyclic 
nucleotide monophosphates such adenosine 3',5'-cyclic monophosphate (cAMP) and the 
guanosine 3',5'-cyclic monophosphate (cGMP); inositol phospholipids such inositol 
trisphosphate (IP3) and diacylglycerol (DAG) and Ca
2+ ions (see Figure 2-20). 
Binding of an external signal (first messenger) to a specific receptor from the outer surface of 
the target cell membrane activates a transducer protein that carries the signal through the 
membrane. The transducer protein then activates an amplifier that catalyzes the formation of 
a second messenger. The second messenger binds to an internal regulator that controls 
various effectors, leading to a cellular response(s) [Randall et al., 1997]. 
The hydrolysis of ATP into cAMP by adenylate cyclase requires Mg2+ and a trace amount of 
Ca2+. As cAMP is produced, it binds to an inhibitory regulatory subunit of protein kinase A 
(PKA), causing the subunit to dissociate from the catalytic subunit of PKA. This free and 
active catalytic subunit can phosphorylate effectors proteins using ATP. Phosphorylation of 
these effector proteins may either increase or inhibit their activity, thereby inducing cellular 
response(s). Some effector proteins are enzymes, catalyze further chemical reactions; others 
are nonenzymatic proteins such as membrane channels, structural proteins, or regulatory 
proteins. 
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The cAMP-dependent pathway, also known as the adenylate cyclase pathway, is a G 
protein-coupled receptor-triggered signaling cascade used in cell communication. A central 
element of this signaling cascade is the second messenger cAMP (3',5'-cyclic adenosine 
monophosphate) that activates PKA [Alberts et al., 2004]. 
 
Figure 2-20: Chemical structures of second messengers. 
 
Many different cell responses are mediated by cAMP. These include increase in heart rate, 
cortisol secretion, and breakdown of glycogen and fat. This pathway can activate enzymes 
and regulate gene expression. The activation of preexisting enzymes is a fast process, 
whereas effects of the regulation of gene expression can take up to hours. The cAMP 
pathway was studied through loss of function (inhibition) and gain of function (increase) of 
cAMP [Devlin, 2002]. 
Signaling pathways employing cAMP or cGMP play a critical role controlling many processes 
across a broad spectrum of organisms. The actions of many physiological signals (see Table 
2-7) are mediated by very specific and highly controlled changes in the cellular levels of 
these second messengers. These changes in either global cyclic nucleotide content or that 
constrained to specific cellular compartments within the cell are essential for a wide range of 
physiological processes like vision, olfaction, synaptic function, muscle contraction, water 
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and electrolyte homeostasis, immune responses, hemostasis, carbohydrate and lipid 
metabolism. The amplitude and duration of the cyclic nucleotide responses are determined 
by the balance between their rates of synthesis (by adenylate or guanylate cyclases) and 
degradation (by cyclic nucleotide phosphodiesterases). The key to the specificity of hormonal 
effects lies in the tissue distribution of effector proteins that that can be phosphorylated by 
cAMP dependent PKA [Beavo et al., 2007]. 
 
Table 2-7 Hormone-induced responses mediated by cAMP pathway* [Alberts et al., 
2004; Berridge, 1985; Randall et al., 1997] 
Signal Tissue Cell response 
Stimulatory 
Epinephrine (β-receptors) 
(+ ACTH and glucagon) 
 
 
 
Thyroid-stimulating hormone 
(TSH) 
 
Vasopressin 
Glucagon 
Serotonin 
 
Prostaglandin I1 
 
Inhibitory 
Epinephrine 
(α2receptors) 
 
 
Adenosine 
 
Skeletal muscle  
Fat cells 
Heart 
 Intestine 
 Smooth muscle  
 
Thyroid gland  
 
 
Kidney  
Liver  
Salivary gland 
(blowfly) 
Blood platelets 
 
 
Blood platelets 
 
Fat cells 
 
Fat cells 
 
Breakdown of glycogen 
Increased breakdown of lipids 
Increased heart rate and force of contraction 
Fluid secretion 
Relaxation 
 
Thyroxine secretion 
 
 
Resorption of water  
Breakdown of glycogen 
Fluid secretion 
 
Inhibition of aggregation and secretion 
 
 
Stimulation of aggregation and secretion 
 
Decreased lipid breakdown 
 
Decreased lipid breakdown 
ACTH (Adrenocorticotropic hormone) 
*. Some responses to local mediators and to neurotransmitters are also mediated by cAMP 
 
2.5.1 The cAMP signalling cascade 
cAMP is involved in a multitude of cellular processes including cell proliferation and 
differentiation. The second messenger cAMP mediates the transcriptional regulation of 
various genes and activates target enzymes, especially PKA. cAMP homeostasis is primarily 
regulated by its formation through adenylate cyclases (AC) and by its degradation by 
phosphodiesterases (PDE).  
The pathway employing cAMP as the second messenger has a stimulatory receptor (Rs) and 
an inhibitory one (Ri), which both communicate with the amplifier AC by way of transducer G 
proteins; stimulatory G protein (Gs) and inhibitory G protein (Gi) see Figure 2-21. 
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Figure 2-21: The cAMP pathway. Hormone-stimulated regulation of AC within the membrane leads 
to an increase or decrease in cytosolic cAMP level. Binding of hormones or other ligands to their 
stimulatory or inhibitory receptors (Rs and Ri respectively) induce binding of GTP to the 
respective transducer proteins, Gs and Gi. The GTP-activated G proteins are then able to either 
activate or inhibit the AC until the GTP is hydrolysed to guanosine diphosphate (GDP). Activated AC 
catalyzes the conversion of ATP to cAMP, which binds to the regulatory subunit of protein kinase A 
(PKA). The catalytic subunit can phosphorylate various intracellular effector proteins, yielding 
activated phosphoproteins that mediate cellular responses. In time, cAMP is degraded to AMP by a 
phosphodiesterase (PDE), and the phosphorylated effector proteins often are dephosphorylated to 
their inactive forms. Both of these mechanisms reduce or terminate the effects of the external signal. 
Adapted from Randall et al. [Randall et al., 1997]. 
 
G proteins are composed of three protein subunits (α, β and γ) two of which are bound to 
plasma membrane by short lipid tails. In the unstimulated state, the α-subunit has GDP 
bound to it, and the G protein is idle. When an extracellular ligand binds to its receptor, the 
altered receptor activates a G protein by causing the α-subunit to lose some of its affinity for 
GDP, and recruits a molecule of GTP. This activation breaks up the G protein subunits: the 
"switched-on" α subunit, clutching its GTP, detaches from the βγ complex, giving rise to two 
separate molecules that now roam independently along the plasma membrane. The two 
activated parts of a G protein (the α-subunit and the βγ complex) can both interact directly 
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with target proteins located in the plasma membrane, which in turn may relay the signal to 
yet other destinations. The longer these target proteins have an α or a βγ subunit bound to 
them, the stronger and more prolonged the relayed signal will be (see Figure 2-22). The 
amount of time that the α- and βγ-subunits remain dissociated (and hence available to relay 
signals) is limited by the behavior of the α-subunit. The α-subunit has an intrinsic GTP-
hydrolyzing (GTPase) activity, and it eventually hydrolyzes its bound GTP to GDP; the α-
subunit then reassociates with a βγ complex and the signal is shut off. This reunion generally 
occurs within seconds after the G protein has been activated. The reconstituted G protein is 
now ready to be reactivated by another activated receptor [Alberts et al., 2004] .  
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-22: Stimulated G-
protein-linked receptors 
activate G-protein subunits. 
From Alberts et al. [Alberts 
et al., 2004]. 
 
 
2.5.2 Adenosine and its receptors 
2.5.2.1 Adenosine 
Adenosine, a purine nucleoside (see Figure 2-23) generated extracellularly from adenine 
nucleotides, is produced by cells and tissues in response to a variety of physical and 
metabolic conditions and mediates physiological activities that include sedation, inhibition of 
platelet aggregation and vasodilatation [Ralevic and Burnstock, 1998]. As aforementioned, 
the effects of adenosine are mediated by a family of four G protein-coupled receptors, A1, 
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A2A, A2B and A3. Engagement of the adenosine A2A receptor promotes the resolution of 
inflammation [Chan and Cronstein, 2002], which accounts for at least some of the anti-
inflammatory actions of many commonly used drugs, including salicylates, methotrexate and 
sulfasalazine [Chan et al., 2006]. Adenosine A2A receptors also promote tissue repair, wound 
healing and matrix production [Montesinos et al., 2002; Victor-Vega et al., 2002]. 
Subsequently, adenosine and its receptors have also been found to promote fibrosis (excess 
matrix production) in the skin, lungs, and liver [Chan et al., 2006]. 
 
Figure 2-23: Chemical structure of adenosine (ADO). 
 
Since many of the functions of adenosine are homeostatic and protective in nature, and in 
principle, equalize local energy requirements with energy supply, it has also been proposed 
to be a “retaliatory metabolite” [Spychala, 2000]. 
There are several independent sources of adenosine, including cell death and nucleotide 
degradation, ischemia and ATP breakdown, ATP/ADP/AMP release and subsequent 
dephosphorylation, and S-adenosylhomocysteine hydrolysis. Extracellular nucleotides may 
also originate from cytosolic sources by vesicular release exocytosis, passage through 
channels, and cell lysis, which would individually or in combination provide a steady-state or 
acute supply of adenosine. This constant release of adenosine is counteracted by its 
metabolism, which may proceed either by phosphorylation to form AMP, catalyzed by 
adenosine kinase (AK), or by deamination to inosine, catalyzed by adenosine deaminase 
(ADA). AK, due to its low Km (40 nM), phosphorylates adenosine at physiological 
concentrations. ADA has a Km value 3 orders of magnitude higher (70 mM) and specific 
activity 10-fold higher than AK, and in most tissues, functions as a high volume/low affinity 
system that turns on when available adenosine concentrations increase above a certain 
level. However, since AK and ADA have vastly different kinetic properties, the fate of 
adenosine is largely determined by its local concentration. At physiological levels of 
adenosine (below 1.0 mM), phosphorylation is the predominant route of its metabolism 
[Snyder and Lukey, 1982]. Overall, under normal conditions of low adenosine levels, AK is 
the major physiological regulator of adenosine concentrations [Lloyd and Fredholm, 1995] 
and characteristically, its Km of 40 nM is physiologically positioned between the high-affinity 
binding of adenosine to A1 (3–30 nM), intermediate-affinity binding to A2A (20- 200 nM), and 
low-affinity binding to A2B (5 mM) adenosine receptors [Spychala, 2000].  
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Under normal conditions, adenosine is continuously formed intracellularly as well as 
extracellularly. Adenosine is produced mainly by dephosphorylation of AMP catalyzed by 5´-
nucleotidase (5´-NT) see Figure 2-24. Several forms of this enzyme have been described, 
but only two of them (cytosolic 5´-NT-I [cN-I] and ecto-5´-NT) seem to participate in the 
regulation of the adenosine homeostasis. In the heart, adenosine may be generated by AMP-
selective (cN-I) 5´-NT, which is restricted to cardiac and breast muscle and, to some extent, 
brain tissue. This cytosolic enzyme produces adenosine that must be released from the cell 
to have pharmacological effects [Sala-Newby et al., 1999].  
 
 
Figure 2-24: Interconversion of extracellular and intracellular adenine nucleotides and 
adenosine. Adenosine is formed both intracellularly and extracellularly from adenine nucleotides, 
which are sequentially dephosphorylated to adenosine. Intracellular adenosine may be transported 
into the extracellular space via facilitated transport by ENT1. Extracellular adenosine is also taken up 
by cells through the same transporter. Two cell surface molecules, CD39 and CD73, catalyze the 
dephosphorylation of adenine nucleotides to adenosine in the extracellular space. Adapted from 
Cronstein [Cronstein, 2011]. ENT1: equilibrative nucleoside transporter 1; CD39: nucleoside 
triphosphate phosphohydrolase; CD73: ecto-50-nucleotidase. 
 
There is good evidence that intracellular formation of adenosine is at least as important as 
adenosine formation from breakdown of extracellular ATP. Intracellular formation 
predominantly occurs as a consequence of activity of intracellular 5´-nucleotidases, of which 
two forms, cN-I and cN-II, have been reported. These two enzymes may play different roles, 
cN-I breaking down AMP to adenosine and cN-II breaking down IMP and GMP to inosine 
and guanosine, respectively [Sala-Newby et al., 1999]. Adenosine generated intracellularly is 
transported into the extracellular space mainly via specific bi-directional transporters through 
facilitated diffusion that efficiently evens out the intra- and extracellular levels of adenosine 
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(see Figure 2-24). These transport proteins were termed ENT1 and ENT2 (for the 
equilibrative transport proteins) and CNT1 and CNT2 (for the concentrative types). When the 
activity of transporters is decreased, e.g., by drugs or by reducing temperature, extracellular 
biologically active levels of adenosine increase [Fredholm et al., 2001].  
The dephosphorylation of extracellular AMP to adenosine is mediated by ecto-5´-
nucleotidase, also known as CD73 [Zimmermann, 1992]. This is a ubiquitous enzyme 
expressed in many tissues at variable levels, ranging from very high in fibroblasts and some 
carcinomas to very low or absent in cells of hematopoietic origin. Ecto-5´-nucleotidase is 
linked to the plasma membrane by glycosyl phosphatidylinositol, and produces adenosine 
from AMP, which may be actively released from some cells or from adenine nucleotides that 
accumulate extracellularly as a consequence of either active release or passive efflux 
secondary to ischemia and necrosis in solid tumors [Spychala, 2000].  
Overexpression of CD73 has been proposed to protect organs under stress by the formation 
of cytoprotective adenosine [Beldi et al., 2008]. As mentioned earlier, the adenosine 
produced extracellularly is also subject to metabolic breakdown by adenosine deaminase to 
produce inosine or (re)phosphorylation by adenosine kinase to produce AMP. Therefore, 
when an organ is under stress there is a highly complex and time-dependent interplay of the 
activation of many receptors in the same vicinity. In addition to the direct activation of ARs by 
selective agonists or their blockade by selective antagonists, inhibition of the metabolic or 
transport pathways surrounding adenosine is also being explored for therapeutic purposes 
[Wilson and Mustafa, 2009]. 
Most tissues in the body and cells in culture release adenosine to the extracellular medium, 
from where it can feed back and act as an autocoid on the ARs present locally. The basal 
levels of extracellular adenosine have been estimated near to 100 nM in the heart and  20 
nM in the brain [Fredholm et al., 2005] whereas in human plasma concentrations ranging 
from 10 to 70 nM under normal physiological conditions (normoxia) and depending on the 
sampling site (radial artery, median cubital vein and internal jugular vein) have been found 
[Dolezalova et al., 2005; Saito et al., 1999]. 
In the case of severe ischemic stress, levels of adenosine can rapidly rise to the micromolar 
range, which would cause a more intense and generalized activation of the four subtypes of 
ARs. Nevertheless, it is thought that the exogenous administration of highly potent and 
selective AR agonists in such cases of severe ischemic challenge might still provide 
additional benefit beyond that offered by the endogenous adenosine generated [Wilson and 
Mustafa, 2009]. 
Ethanol, one of the most important causes of hepatic fibrosis/cirrhosis in the Western world, 
stimulates increased extracellular adenosine levels in vitro through its action on the 
nucleoside transporter and ethanol ingestion increases purine release into the bloodstream 
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and urine in normal volunteers. The released adenosine binds to its receptors in the liver to 
promote fibrosis, a form of sustained wound healing in response to injury [Chan et al., 2006]. 
There is some evidence that caffeine blocks the development of hepatic fibrosis, an effect 
that could explain the epidemiologic finding that coffee drinking reduces the likelihood of 
death from liver disease in a dose-dependent manner [Chan et al., 2006]. 
A number of observations strongly suggest that adenosine may have similar functions in 
cancer. Due to rapid growth, large solid tumors routinely experience severe hypoxia and 
necrosis, which causes adenine nucleotide degradation and adenosine release. The 
released adenosine would then exert a broad range of effects that benefit malignancy by 
providing a supportive environment for the accelerated growth. This supportive environment 
may include protection against ischemia, stimulation of growth and angiogenesis, and 
suppression of immune responses [Spychala, 2000].  
The alkylxanthines caffeine and theophylline are the prototypical antagonists of adenosine 
receptors (ARs), and their stimulant actions are produced primarily through blocking the 
depressant actions of the adenosine through the A1 and A2A ARs. The stimulant actions of 
the alkylxanthines were thought to occur as a result of inhibition of phosphodiesterases. 
Although this inhibition may contribute to the actions of caffeine, there is growing evidence 
that most pharmacological effects of this xanthine result from antagonism of adenosine 
receptor [Varani et al., 2000] and these non-AR-mediated actions require higher 
concentrations of caffeine than are typically ingested in the human diet [Fredholm and 
Jacobson, 2009; Stanley et al., 1989; Wilson and Mustafa, 2009]. 
Conlay et al. [Conlay et al., 1997] showed that adenosine antagonists such as caffeine 
influences rat plasma adenosine concentrations, by an unknown mechanism, at caffeine 
doses approximating those provided to humans by 3–6 cups of coffee per day.  
2.5.2.2  Adenosine receptors (ARs) 
Extracellular adenosine acts on a family of cell surface receptors termed adenosine 
receptors (ARs). To date four subtypes of ARs are known: A1, A2A, A2B, and A3 (see Table 
2-8). The ARs are G protein-coupled receptors (GPCRs) and consist of a single polypeptide 
chain with the N terminus located at the extracellular side and seven transmembrane helices. 
The A1 and A3 receptors preferentially couple to Gi protein to inhibit AC and consequently the 
production of cAMP, whereas the A2A and A2B subtypes stimulate the production of cAMP by 
coupling to Gs or Go proteins [Muller and Jacobson, 2011a]. Nevertheless, the receptors can 
couple also to other G protein pathways, especially when over expressed. The natural ligand 
is adenosine, but at A1 and A3 receptors inosine can also act as a partial agonist [Fredholm et 
al., 2001]. Furthermore, the A2B subtype, which has the lowest affinity (Ki > 1µM) of all the 
subtypes for native adenosine, is also coupled to Gq (subunit that activates phospholipase 
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C). Adenosine has the highest affinity at the A1 and A2A ARs (Ki values of 10-30nM), and the 
affinity of adenosine at the A3 receptors is intermediate (approx. 1 µM for the rat A3 AR) 
[Wilson and Mustafa, 2009].  
 
Table 2-8 Expression, G protein-coupling and major functions of adenosine receptors 
[Fredholm et al., 2001] 
Tissue 
distribution/ 
function 
Receptor 
A1  A2A A2B A3 
Hight 
expression 
Brain, spinal cord, 
eye, adrenal gland 
and atria 
Spleen, thymus, 
leukocytes 
(lymphocytes and 
granulocytes),blood 
platelets.GABA-ergic 
neurons, 
olfactory bulb 
Cecum, colon, 
bladder 
Testis (rat), mast 
cells (rat). 
Intermediate 
levels 
Skeletal muscle, 
liver, 
kidney, adipose 
tissue, 
salivary glands, 
esophagus, colon, 
antrum and testis 
Heart, lung, blood 
vessels 
Lung, blood 
vessels, eye, 
and mast cells 
Cerebellum, 
hippocampus, lung, 
spleen (sheep), 
pineal 
Low levels Lung (but probably 
higher 
In bronchi), 
pancreas 
Other brain regions Adipose 
tissue, 
adrenal gland, 
brain, kidney, 
liver, ovary, 
pituitary gland 
Thyroid, adrenal 
gland, spleen, liver, 
kidney, heart, 
intestine, testis 
Fuctions Bradycardia; 
inhibition of 
lipolysis; reduced 
glomerular 
filtration, 
antinociception; 
reduction of 
sympathetic and 
parasympathetic 
activity; 
presynaptic 
inhibition; neuronal 
hyperpolarization; 
ischemic 
preconditioning 
Regulation of 
sensorimotor 
integration in basal 
ganglia; 
inhibition of platelet 
aggregation and 
polymorphonuclear 
leukocytes; 
vasodilatation, 
protection 
against ischemic 
damage, stimulation of 
sensory nerve activity 
 
Relaxation of 
smooth 
muscle in 
vasculature 
and intestine; 
inhibition of 
monocyte and 
macrophage 
function, 
stimulation of 
mast cell 
mediator 
release 
Enhancement of 
mediator release 
from mast cells 
preconditioning 
 
G Protein 
coupling* 
Gi1/2/3 
 
Go 
Gs 
Golf 
G15/16 
Gs 
Gq/11 
Gi2,3 
Gq/11 
Effects of G 
Protein 
coupling 
↓ cAMP 
↑ IP3/DAG 
↑ cAMP 
↑ IP3 
↑ cAMP 
↑ IP3/DAG  
↓ cAMP 
↑ IP3/DAG  
*The Gα subunits Gs, Gi, G12/13, and Gq11 regulate various enzymes. For example, Gs stimulates, 
whereas Gi inhibits AC to increase or decrease cAMP. Gq/11 activates phospholipase Cp (PLCP) to 
generate inositol trisphosphate (IP3), which mobilizes Ca
2+
, and diacylglycerol (DAG), which activates 
protein kinase C (PKC).  
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ARs are well conserved and widely expressed. The endogenous agonist, adenosine, has a 
minimal concentration that is sufficient to slightly activate the receptors where they are very 
highly expressed as in the basal ganglia, on fat cells and in the kidney. Adenosine has an 
important physiological role in these tissues and here antagonists such as caffeine may exert 
effects in healthy individuals. Adenosine levels rise in stress and distress (up to 30 µM in 
ischemia) and tend to minimize the risk for adverse outcomes by increasing energy supply 
and decreasing cellular work, by stimulating angiogenesis, mediating preconditioning and 
having multiple effects on immune competent cells [Fredholm, 2010; Fredholm et al., 2001]. 
When given in very high amounts, adenosine can affect intracellular nucleotide pools and 
even provide a source of metabolizable energy. In addition, it was reported that the human 
growth hormone secretagogue receptor (GHS-R) could also be activated by adenosine and 
not only by the endogenous agonist ghrelin [Tullin et al., 2000]. However, most effects of 
adenosine are due to activation of adenosine receptors. 
The effects of ARs activation tend to be cytoprotective in many organs and tissues under a 
wide variety of physiological conditions. The increase of extracellular adenosine in response 
to stress (e.g. hypoxia) and the resulting activation of ARs are supposed to be a stress 
adaptation mechanism [Muller and Jacobson, 2011b] . These protective responses may take 
the form of decreased energy demand (e.g. bradycardia), increased energy supply (e.g. 
vasodilation or angiogenesis), ischemic preconditioning (e.g. in the heart or brain), inhibition 
of the release of excitotoxic neurotransmitters, suppression of cytokine-induced apoptosis, or 
reduced inflammatory response [Fredholm et al., 2001]. 
The half-life of adenosine in circulation is very short, due to its rapid conversion to inosine 
(adenosine deaminase) or phosporylation to 5′-AMP (adenosine kinase), or its uptake 
through nucleoside transporters (such as the equilibrative transporter ENT1). Therefore, 
analogues of adenosine for selective activation of ARs tend to prevent these processes and 
thereby lengthen the half-life. For example, the A3-selective agonist IB-MECA has a half-life 
of 8–9 h in man [van Troostenburg et al., 2004].  
Similar to the function and regulation of other GPCRs, both activation and desensitization of 
the ARs occur after agonist binding. Interaction of the activated ARs with G protein-coupled 
receptor kinases leads to their phosphorylation. AR responses desensitize rapidly, and this 
phenomenon is associated with receptor downregulation, internalization and degradation. 
The most rapid downregulation among the AR subtypes is generally seen with the A3 AR 
(often a matter of few minutes), due to phosphorylation by GRKs. The A2A AR is only slowly 
(shorter than 1 h) desensitized and internalized as a result of agonist activation, whereas A1 
AR shows a typical half-life of several hours [Klaasse et al., 2008; Wilson and Mustafa, 
2009]. 
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Synthetic adenosine antagonists have also been explored for potential therapeutic 
applications. Various early analogues of the xanthines, which greatly increased the AR 
subtype-selectivity over the naturally occurring alkylxanthines, tended to be hydrophobic and 
poorly water-soluble and consequently of low bioavailability. Recently introduced AR 
antagonists and prodrug approaches have overcome some of these issues [Muller and 
Jacobson, 2011a; Vollmann et al., 2008]. 
The structure–activity relationship of adenosine derivatives as AR agonists has been 
exhaustively studied. Nearly all of the known AR agonists are derivatives of purine 
nucleosides, either adenosine or xanthosine [Muller and Jacobson, 2011a]. The prototypical 
AR antagonists are alkylxanthine derivatives. The natural plant alkaloids caffeine and 
theophylline were the first adenosine receptor (AR) antagonists described in the literature. 
They exhibit micromolar affinities and are non-selective. A large number of derivatives and 
analogues were subsequently synthesized and evaluated as AR antagonists. Very potent 
antagonists have thus been developed with selectivity for each of the four AR subtypes 
[Muller and Jacobson, 2011b]. 
The major caffeine and theophylline metabolites in humans, paraxanthine and 1-methyl 
xanthine, are as potent as their parent compounds and therefore may contribute to the 
observed effects on ARs. These simple alkylxanthines show affinity to the ARs at nanomolar 
concentrations with slight variations between different species (see Table 2-9).  
 
Table 2-9 Adenosine receptor affinities of natural xanthine derivatives 
[Muller and Jacobson, 2011b] 
Xanthine Ki (nM) 
A1  A2A A2B A3 
Caffeine 10.7 – 44.9 (h) 
41.0 – 44.0 (r) 
47.0 (gp) 
9.56 – 23.4 (h) 
32.5 – 48.0 (r) 
10.4 – 33.8(h) 
30.0 (r)  
13.0 (m) 
13.3(h) 
>100.0 (r)  
 
Theophylline 6.7 (h) 
8.74 – 14.0 (r) 
7.06 (gp) 
4.71 (rb) 
6.3 (c) 
1.7 – 6.7 (h) 
22.0 – 25.3 (r) 
6.07 – 74 (h) 
15.1 (r) 
5.63 (m) 
11.0 (gp) 
17.7 (rb) 
37.8 (d) 
22.3 – 86.4 (h) 
85.0 – >100.0 (r) 
>100.0 (d) 
Theobromine 83.4 – 105.0 (r) >250.0 (r) 130.0 (h) >100.0 (r) 
Paraxanthine 21.0 (r) 32.0 (r) 4.5 (h) >100.0 (r) 
Human (h), cow (c), dog (d), guinea pig (gp), mouse (m), rat (r), rabbit (rb). 
 
The present work mainly focuses on effects on platelets and adipose tissue, both expressing 
mainly A1 and A2A AR. Therefore, these two receptor subgroups and their physiological 
function will be discussed in more detail. 
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2.5.2.3 Adenosine A1 receptor 
The A1 R is coupled to the inhibitory Gi and Go proteins and stimulation of the receptor can 
therefore result in inhibition of AC, activation of several types of K+ channels, inactivation of 
Ca2+ channels and activation of phospholipase Cβ [Fredholm et al., 2001]. Previous studies, 
where pharmacological tools have been utilized for the evaluation of metabolic roles of 
adenosine, have proposed that the A1 R is of major importance [Dong et al., 2001].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-25: Summary of possible intracellular signalling pathways involved in the regulation 
of lipolysis in adipocytes. AC, adenylate cyclase; ATGL, adipose triglyceride lipase; ATP, adenosine 
triphosphate; cAMP, cyclic adenosine monophosphate; CGI-58, comparative gene identification-58; 
cGMP, cyclic guanosine monophosphate; DAG, diacylglycerol FAs, fatty acids; FoxO1, forkhead box 
class O 1; GC, guanylate cyclase; GTP, guanosine triphosphate; HSL, hormone-sensitive lipase; 
iNOS, inducible nitric oxide; IP3, inositol triphosphate; IRS-1, insulin receptor substrate 1; JAK, Janus 
kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MAG, 
monoacylglycerol; MGL, monoacylglycerol lipase; NO, nitric oxide; PDE, phosphodiesterase; PDK, 
phosphoinositide-dependent kinase; PKA, cAMP-dependent protein kinase; PKB, protein kinase B; 
PKC, protein kinase C; PKG, cGMPdependent protein kinase; PLC, phospholipase C; PLIN, perilipin; 
STAT, signal transducers and activators of transcription; TAG, triacylglycerol. Modified from Chaves et 
al [Chaves et al., 2011]. 
 
There is evidence that adenosine can regulate several aspects of adipose tissue function 
including lipolysis. Adipose tissue is the only tissue capable of hydrolyzing its stores of 
triacylglycerol (TAG) and of mobilizing fatty acids and glycerol in the bloodstream so that 
they can be used by other tissues. The full hydrolysis of TAG depends on the activity of three 
enzymes, adipose triglyceride lipase (ATGL), hormonesensitive lipase (HSL) and 
monoacylglycerol lipase, each of which possesses a distinct regulatory mechanism [Chaves 
et al., 2011]. It has recently been shown that HLS and ATGL, together responsible for 
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approx. 95% of TAG hydrolase activity in adipocytes, can be activated simultaneously 
[Schweiger et al., 2006].  
The main pathway leading to lipolysis is the cAMP-dependent proteinkinase (PKA) pathway 
(see Figure 2-25). The production of cAMP is modulated by G-protein-coupled receptors of 
the Gs/Gi family and cAMP degradation is regulated by PDE. Activation of AC in adipocytes 
subsequently increases intracellular cAMP levels leading to the activation of PKA, resulting in 
phosphorylation and translocation of HSL to fat droplets.  However, other pathways that 
activate TAG hydrolysis are under investigation. Lipolysis can also be started by G-protein-
coupled receptors of the Gq family, through molecular mechanisms that involve 
phospholipase C, calmodulin and protein kinase C. There is also evidence that increased 
lipolytic activity in adipocytes occurs after stimulation of the mitogen-activated protein kinase 
(MAPK) pathway or after cGMP accumulation and activation of protein kinase G [Greenberg 
et al., 2001]. Several agents, such as adenosine, atrial natriuretic peptide, β-hydroxybutyrate, 
catecholamines, endothelin-1, insulin, glucocorticoids, growth hormone, lactate, leptin, 
melanocortins, neuropeptide Y, peptide YY, prostaglandin E2, thyroidstimulating hormone 
and TNFα, contribute to the control of lipolysis in adipocytes by modulating the activity of 
HSL and ATGL. However, some agents stimulate more than one intracellular transduction 
pathway [Chaves et al., 2011]. 
Secreted adenosine by adipocytes binds to the G-protein coupled adenosine A1 receptor and 
reduces AC activity and induces the inhibition of lipolysis in adipose tissue [Dhalla et al., 
2009]. Insulin also reduces lipolysis and intracellular cAMP levels, and both adenosine and 
insulin mediate additive antilipolytic effects in mouse adipocytes; however, the mechanisms 
of action are different, and the effects are not synergistic [Johansson et al., 2008]. Increases 
in cAMP accumulation and lipolysis in adipose tissue have been observed when adenosine 
deaminase is added to degrade endogenous adenosine or after treatment with adenosine 
receptor antagonists. Recently, it was shown that removal of endogenous adenosine with 
adenosine deaminase causes lipolysis in adenosine A1 receptor (+/+) but not in adenosine A1 
receptor (-/-) adipocytes [Johansson et al., 2008] and that incubation of isolated rat 
adipocytes with an adenosine A1 receptor antagonist induces an increase in lipolytic activity. 
Moreover, the adenosine A1 receptor antagonist enhances the lipolytic response to 
epinephrine and increases cAMP levels in adipocytes. These findings provide strong 
evidence that the antilipolytic effect of adenosine involves impairment of PKA activation 
[Szkudelski et al., 2009]. 
The possibility that adenosine and insulin interact with each other in adipose tissue has 
potential clinical relevance in view of the growing concern for T2D secondary to obesity [Wild 
et al., 2004]. There is also considerable evidence that long-term coffee consumption is 
associated with a decreased risk for T2D, possibly via antagonistic actions of caffeine on 
adenosine A1 receptors [van Dam and Hu, 2005]. 
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2.5.2.4  Adenosine A2A/A2B receptors 
The A2A R are mainly coupled to stimulatory G proteins (Gs and Golf) but can also couple to 
G15/16 [Kull et al., 2000; Offermanns and Simon, 1995] are present in the central nervous 
system as well as in peripheral organs (see Table 2-8) It has been shown that A2A R 
antagonists can be of therapeutic value for the treatment of Parkinson's disease 
[Schwarzschild et al., 2006]. This receptor family is also involved in sleep regulation, shown 
by using A2A R knock out mice where caffeine induced wakefulness [Huang et al., 2005]. 
Furthermore, A2A R are important for regulating of blood pressure, vasodilation, ischemic 
damage, platelet aggregation, inflammation and pain [Fredholm, 2010; Jacobson and Gao, 
2006]. 
Platelets are small anuclear circulating cell fragments which are critical for the process of 
thrombosis and the formation of hemostatic plugs [Watson, 2009]. Platelets are formed from 
the cytoplasm of large bone marrow megakaryocytes (Mks) by a process called 
megakaryocytopoiesis. A normal platelet count ranges between 150,000 and 350,000 per µL 
blood. The formed platelets are all of different shapes, have different compositions, and are 
all different sized. Despite lacking a nucleus, platelets are still highly active ‘cells’ retaining 
many intracellular organelles including mitochondria, an extensive cytoskeletal and tubule 
system, and specific alpha and dense granules which store platelet-specific proteins and 
coagulation factors which are released upon platelet activation, and enzymes such as cyclo-
oxygenase and phospholipase A2 which is activated in a Ca
2+ dependent manner. Although 
they contain no nucleus, since platelets are formed from Mks, newly formed platelets contain 
small amounts of mRNA and mRNA processing enzymes [Kaushansky, 2008]. The platelet 
has a lifespan in the circulation of 7–10 days and the Mks-derived mRNA disappears from 
platelets over the first 24 h, therefore platelets containing mRNA (called reticulated platelets) 
only account for 5–15% of the total platelet population [Bishop-Bailey, 2010; Michelson, 
2007]. Platelets function by adhering to the walls of injured blood vessels. They clump 
together or aggregate to form platelet plugs necessary for coagulation.  
Atherothrombosis is a leading cause of mortality in the Western world. Platelet accumulation 
at sites of vascular injury is the primary event in arterial thrombosis, and the activation of 
platelets is a critical component of atherothrombosis [Ruggeri, 2002]. After the initial 
adhesion of platelets to extracellular matrix, such as to collagen at sites of vascular injury, 
autocrine and paracrine factors, including ADP, thrombin, epinephrine, and thromboxane A2, 
amplify and sustain the initial platelet response, and recruit circulating platelets to form a 
hemostatic plug. Many agonists, such as ADP, thrombin, and epinephrine, directly activate 
platelet Gi receptors and decrease the cAMP level. Other agonists, including collagen and 
thrombin, also indirectly decrease their cAMP level by release of ADP [Davi and Patrono, 
2007; Yang et al., 2010b; Yang et al., 2002]. 
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It is well established that cAMP is a critical cytosolic regulator of platelet aggregation. cAMP 
inhibits platelets by activating PKA, which phosphorylates several substrates, such as inositol 
trisphosphate receptors, contributing to inhibition of cytoskeletal reorganization, integrin 
activation, and granule secretion [Sim et al., 2004]. 
Adenosine is released from vascular wall cells and platelets into the extracellular space as a 
breakdown product of ATP. Adenosine, acting through adenosine receptors, stimulates G-
protein coupled AC in platelets and increases intracellular levels of cAMP, resulting in 
inhibiton of platelet activation [Yang et al., 2010b]. Platelets are rich in A2A adenosine 
receptors and, it has been speculated that the A2A AR is the only adenosine receptor that 
significantly affects platelet activation in response to adenosine [Varani et al., 1999]. A2A AR 
knockout (KO) mice show higher platelet aggregation activity in response to ADP [Ledent et 
al., 1997].  
 
Figure 2-26: Regulation and action of cAMP in human platelets. PDE, phosphodiesterase; TXA2, 
thromboxane A2; GP, glycoprotein; PLC, phospholipase C; TP, thromboxane/prostanoid receptors; 
vWf, von Willebrand factor, MK, megakaryocyte; ATP, adenosine triphosphate; ADP, adenosine 
diphosphate; cAMP, cyclic adenosine monophosphate; 5´AMP, Adenosin-5'-monophosphat; A2A, 
Adenosine A2A receptor; A2B, Adenosine A2B receptor; P2Y1, P2Y purinoceptor 1; P2Y12, P2Y 
purinoceptor 12. Adapted from Jackson and Schoenwaelder [Jackson and Schoenwaelder, 2003]. 
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Amisten et al. [Amisten et al., 2008] recently showed that mRNA of the A2B AR is expressed 
in human platelets at similar levels to A2A AR mRNA. A2B AR display a higher aggregation 
response controlling the expression of ADP receptors and ADP-induced platelet aggregation, 
where cAMP downregulates P2Y1R expression in megakaryocyte (MKs). It is, then, 
conceivable that the lifelong lower basal cAMP level in A2B AR KO platelets could contribute 
to greater basal expression of ADP receptors, which would induce higher aggregation activity 
[Yang et al., 2010b]. 
There is evidence that repeated intake of caffeine alters the response of platelets to 
adenosine. After chronic caffeine consumption, platelet aggregability may be reduced due to 
upregulation of A2A receptors present on the platelet surface. The antiaggregatory effects are 
associated with a rise in intracellular cAMP levels due to activation, by a selective A2A 
agonist, of AC [Varani et al., 1999]. Caffeine acts most potently at A2A receptors, followed 
closely by A1 receptors, then A2B receptors, and as a weak antagonist at human A3 receptors 
[Klotz et al., 1998]. Blockade of ARs by caffeine, namely the A1 and the A2A receptor types, 
inhibits the action of endogenous adenosine in a variety of physiological processes. Under 
normal conditions, blood levels of adenosine appear to be sufficient to tonically activate A2A 
receptors in platelets. It is therefore conceivable that caffeine could block these tonically 
activated A2A receptors in platelets and alter their functions modulated by adenosine [Varani 
et al., 2000]. Biaggioni et al. [Biaggioni et al., 1991] found that a repeated dosing regimen of 
caffeine leads to significant changes in human platelets in the functional responses to the 
adenosine receptor agonist 5´-N-ethylcarboxamidoadenosine (NECA). Caffeine withdrawal 
produced a significant leftward shift of the NECA-induced inhibition of aggregation. 
Repeated administration of caffeine (750 mg/d for 1 week) to human volunteers revealed an 
increase in A2A receptor density in platelets, accompanied by sensitization of platelet 
responses, such as an increase in cAMP accumulation and decrease in platelet aggregation 
[Varani et al., 1999]. The treatment with 400 mg/d caffeine for 1 week did not modify A2A 
receptor binding and functional parameters. However, treatment with 400 mg/d for 2 weeks 
or 600 mg/d for 1 week resulted in a significant increase of adenosine A2A binding sites, a rise 
in cAMP accumulation, an increase of antiaggregatory effects, and  a decrease in calcium 
levels elicited by the A2A receptor agonist 2-hexynyl-5´-N-ethylcarboxamidoadenosine (HE-
NECA) [Varani et al., 2000]. 
The upregulation of A2A receptors can probably be ascribed to the synthesis of new receptors 
during differentiation of precursor cells (MKs). The increase of adenosine A2A receptors found 
at 1 hour after the last dose of caffeine treatment was similar to that obtained at 12 or 60 
hours after caffeine withdrawal, showing that the withdrawal was not necessary for the 
upregulation of A2A receptors. This study also found that platelet aggregation was associated 
State of the art  61 
 
                          
with activation of AC and with a rise in intracellular calcium concentrations [Varani et al., 
2000].  
2.5.3 Cyclic nucleotide phosphodiesterase superfamily (PDEs) 
PDEs comprise a group of enzymes that degrade the phosphodiester bond in the second 
messenger molecules cAMP and cGMP thereby hydrolyzing the 3´ bond of either cAMP or 
cGMP and converting it to its 5' counterpart (see Figure 2-27). While both cyclic nucleotides 
can be transported out of the cell at a low rate, evidence indicates that the catalytic action of 
PDEs provides the major pathway to rapidly lower cellular cyclic nucleotide content [Beavo et 
al., 2007]. 
 
Figure 2-27: Degradation of cAMP to 5`-AMP by phosphodiesterases (PDEs).  
 
As the cyclic phosphate structure is strained, this reaction is highly exothermic (>10 
kcal/mol), making it essentially irreversible in the cell. This rapid and essentially irreversible 
reaction provides an effective mechanism for the control of a high-affinity second messenger, 
particularly, when levels of the messenger must oscillate rapidly [Greengar et al., 1969].  
Two classes of PDEs (class I and class II) that can hydrolyze cAMP and cGMP are known. In 
mammals and flies, only class I enzymes have been identified whereas yeast and 
protozoans contain both class I and class II PDEs. It is interesting to note that multiple genes 
encoding cyclic nucleotide PDEs are present in nearly all eukaryotic species. However, in 
general, the complexity and number of different gene products increase as the complexity of 
the species increases [Bender and Beavo, 2006]. 
Class I PDEs are the most extensively studied groups of PDEs. In mammalian tissues, three 
of the eleven PDE families selectively hydrolyze cAMP, three families selectively hydrolyze 
cGMP and five families hydrolyze both cyclic nucleotides with varying efficacies (Table 2-10).  
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Table 2-10 PDE Isoenzyme Families [Bender and Beavo, 2006; Dousa, 1999; Francis, 
2005; Jeon et al., 2005; Marko et al., 2000] 
Enzyme family Properties Inhibitory compounds 
PDE1 
 
Ca
2+
/calmodulin-stimulated, hydrolyzes cAMP and 
cGMP  
Vinpocetine, 8-MeoM-IBMX, 
IC224, SCH51866 
PDE2 cGMP-stimulated, hydrolyzes cAMP and cGMP  EHNA, PDP, IC933 
PDE3 
 
cGMP-inhibited, hydrolyzes cAMP and cGMP  
 
Milrinone, Cilostamide, 
Trequinsin, Cilastazol,   
PDE4 
 
cAMP-specific, rolipram-sensitive 
 
Rolipram, Ro-20-1724, 
Roflumilast, Cilomilat, Denbufyllin 
PDE5 
 
cGMP-specific, zaprinast-sensitive 
 
Zaprinast, Dipyridamole, 
Sildenafil, Vardenafil, Tadalafil 
PDE6 cGMP-specific, PDE of the photoreceptor  Zaprinast, Dipyridamole  
PDE7 cAMP-specific, rolipram-insensitive IC242, BRL 50481 
PDE8 cAMP-specific, IBMX-insensitive  Dipyridamole  
PDE9 cGMP-specific, IBMX-insensitive  SCH 51866, Zaprinast  
PDE10 
 
cAMP-inhibited, IBMX-sensitive,  hydrolyzes cGMP 
and cAMP 
Zaprinast, Dipyridamole 
 
PDE11 hydrolyzes cAMP and cGMP  Tadalafil, Zaprinast, Dipyridamole 
 
Is worth noting that the general structures for cyclic nucleotides and the derivatized 
alkylxanthine inhibitors, which are competitive inhibitors, are similar (see Figure 2-28).  
 
 
 
 
 
 
    
                  cAMP                                               Caffeine                                     IBMX 
Figure 2-28: Chemical structures of cAMP, caffeine and 3-isobutyl-1-methylxanthine (IBMX) a 
synthetic alkylxanthine nonspecific inhibitor of PDEs. 
 
The heterocyclic ring of these inhibitors, which mimics the purine of cyclic nucleotides, 
comprises a six-membered pyrimidine ring conjoined with a five-membered ring containing 
two or more nitrogens. The affinity of a particular PDE for the various inhibitors is dictated by 
(1) the chemical characteristics of the particular heterocyclic ring, (2) groups appended to the 
ring, (3) differences in the distribution of electrons within the ring, and (4) structural 
restrictions of PDE catalytic sites for entry and binding of derivatized alkylxanthines with 
particular molecular structures. Substituents appended to the ring can impact affinity for the 
various PDE catalytic sites by forming new contacts with regions in and around the catalytic 
sites of PDEs or by interference with these regions. The distribution and number of carbons 
and nitrogens within the ring system can alter the electron distribution, thereby impacting the 
strength of the interactions [Beavo et al., 2007; Corbin et al., 2006; Francis et al., 2011]. 
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The present work was focused on the study about the role of PDE3 and PDE4 isoenzymes in 
adipocytes and platelets as surrogate biomarker. For a better understanding of the problem, 
additional information about these isoenzymes will be described in more detail in the 
following chapters. 
2.5.3.1 Phosphodiesterase 3 (PDE3) 
The PDE3 has been extensively studied, especially in regard to its usefulness as drug 
targets. One unique feature of the PDE3 family is their ability to hydrolyze both cAMP and 
cGMP, but in a manner suggesting that in vivo the hydrolysis of cAMP is inhibited by cGMP. 
Thus, they have earned the title “the cGMP-inhibited PDE”. They also are characterized by 
their ability to be activated by several phosphorylation pathways including the PKA and 
PI3K/PKB pathways. Two PDE3 genes, PDE3A and PDE3B, have been identified, but 
splice/start variants have been conclusively demonstrated only for the PDE3A isoform 
[Bender and Beavo, 2006]. 
PDE3s were initially purified and described as enzymes that hydrolyze both cAMP and 
cGMP with relatively high affinities (Km(cAMP) <0.4 µM; Km(cGMP) <0.3 µM). However, the Vmax for 
hydrolysis of cAMP is nearly 10-fold higher than the Vmax for cGMP. Therefore, in vitro cGMP 
can act as an inhibitor of cAMP hydrolysis with an apparent Ki of 0.6 µM. This inhibition also 
occurs in platelets [Maurice and Haslam, 1990]. 
The PDE3A and PDE3B isoforms have a high degree of amino acid identity (>80% of the 
catalytic region) and very similar kinetic properties. The activity of both isoforms in several 
cell types is regulated by phosphorylation (e.g. by PKA) in response to hormonal stimulation. 
In platelets prostaglandins and epinephrine showed a feedback response through PKA to 
activate PDE3A [Shakur et al., 2001]. Similarly, first-messenger signals such as insulin, 
insulin-like growth factor 1 (IGF1), and leptin acting through the PI3K/PKB pathway can 
induce a phosphorylation of PDE3B and probably also PDE3A to stimulate their activity. It is 
thought that these phosphorylation events are important to many of the physiological 
processes controlled by these hormones [Bender and Beavo, 2006].  
PDE3A and PDE3B are expressed in a variety of tissues and have distinct but overlapping 
localizations [Bender and Beavo, 2006] (see Table 2-11). PDE3B is a major PDE in adipose 
tissue, liver, and pancreas, as well as in several cardiovascular tissues [Shakur et al., 2001]. 
In contrast, PDE3A is distinctly expressed in platelets and oocytes, whereas PDE3B is 
unique to T lymphocytes, macrophages, β-cells, and adipocytes. In tissues, PDE3B is almost 
always found to be membrane bound, whereas PDE3A has been found to be both cytosolic 
and membrane bound [Shakur et al., 2001]. 
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Table 2-11 PDE3 isoform localization and function [Beavo et al., 2007; Bender and 
Beavo, 2006; Shakur et al., 2001] 
Isoform Localization Function 
Tissue/Cellular Intracellular 
PDE3A 
 
 
 
 
Heart, vascular smooth 
muscle, platelets, oocyte, 
kidney; PDE3A variants have 
differential expression in 
cardiovascular tissues 
Can be either membrane 
associated or cytosolic, 
depending on the variant and 
the cell type 
Regulates cardiac 
contractility, platelet 
aggregation, vascular smooth 
muscle contraction, oocyte 
maturation and regulation of 
renin release 
PDE3B 
 
Vascular smooth muscle, 
adipocytes, hepatocytes, 
kidney, β-cells, developing 
sperm, T lymphocytes, 
macrophages 
 
Predominantly membrane 
associated; Localized to 
endoplasmic reticulum and 
microsomal fractions 
Mediates insulin signaling, 
especially its antilipolytic 
effects. Regulates cell cycle/ 
proliferation and mediates 
the inhibitory effects of leptin 
and other signals on insulin 
secretion and renin release 
 
Selective PDE3 inhibitors include amrinone, milrinone, cilostamide, and cilostazol. The most 
potent is trequinsin. Amrinone was the first recognized but possesses only modest affinity 
and selectivity [Bender and Beavo, 2006]. To date there have been no inhibitors described 
that clearly distinguish between PDE3A and PDE3B, although OPC-33450 has been 
reported to show some selectivity [Sudo et al., 2000].  
PDE3 inhibitors antagonize platelet aggregation, block oocyte maturation, increase 
myocardial contractility, and enhance vascular and airway smooth muscle relaxation. In 
platelets, aggregation is highly regulated by cyclic nucleotides. PDE3A is a regulator of this 
process and PDE3 inhibitors effectively prevent platelet aggregation [Shakur et al., 2001]. In 
fact one drug, cilastazol (Pletal®), is approved for treatment of intermittent claudication. Its 
mechanism of action is thought to involve inhibition of platelet aggregation along with 
inhibition of smooth muscle proliferation and vasodilation. There is also evidence that cGMP, 
acting as a competitive inhibitor of PDE3A, exerts most of its antiplatelet effects by 
increasing cAMP via inhibition of PDE3A [Maurice and Haslam, 1990]. 
PDE3 enzymes are also involved in regulation of cardiac contractility and vascular smooth 
muscle. Interestingly, both PDE3A and PDE3B are expressed in vascular smooth muscle 
cells and are likely to modulate contraction. Their expression in vascular smooth muscle cells 
is altered under several conditions such as elevated cAMP, the switch from contractile to 
proliferative phenotype, and hypoxia [Maurice et al., 2003]. 
One of the most intensely studied roles for PDE3B have been in the areas of insulin, IGF1, 
and leptin signaling. Activation of PDE3B is thought to be important for the antilipolytic and 
antiglycogenolytic actions of insulin [Shakur et al., 2001], as well as for IGF1 and leptin 
inhibition of glucagon-like peptide-1 (GLP-1)-stimulated insulin release from pancreatic islets. 
This idea has now been expanded to include at least part of the effects of leptin on food 
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intake and body weight [Zhao et al., 2002]. At the molecular level it is thought that leptin, 
IGF1, and insulin activation of phosphatidylinositol 3-kinase (PI3K) in turn stimulates PKB 
phosphorylation of PDE3B triggering activation of the enzyme. In pancreatic β-cells, leptin 
causes the activation of PDE3B, which leads to marked inhibition of GLP-1-stimulated insulin 
secretion. The effect of leptin is abolished when insulin secretion is induced with cAMP 
analogues that cannot be hydrolyzed by PDE3B. Selective inhibitors of PDE3B and PI3K 
completely prevent the leptin effect on insulin secretion and cAMP accumulation [Zhao et al., 
1998]. The involvement of PDE3B in regulation of these important metabolic pathways has 
encouraged researchers to begin exploring the possible roles of this enzyme in disorders 
such as obesity and DM [Bender and Beavo, 2006]. 
2.5.3.2  Phosphodiesterase 4 
PDE4 has been one of the most studied PDEs, and there is a large body of literature on its 
biochemistry, genetics, and physiological function. It is now recognized that there are four 
genes (PDE4A–PDE4D) that make up this family. Moreover, each gene has multiple variants 
(>20 have been described). PDE4 is expressed in a multitude of tissues and cell types and 
plays a role in a large number of physiological processes (see Table 2-12) [Beavo et al., 
2007; Bender and Beavo, 2006]. 
The PDE4 enzymes are universally selective for cAMP with Km values typically between 1 
and 10µM. Vmax values of the PDE4 enzymes for cAMP, although lower than those for PDE1s 
and PDE2s, are comparable with those for most other PDEs [Beavo et al., 2007]. 
Several recent studies have shown links between PDE4 expression and disease conditions. 
For example, one region of the PDE4D gene was found to confer increased risk of ischemic 
stroke [Gretarsdottir et al., 2003] as well as a link between the PDE4D gene and bone 
density was found [Reneland et al., 2005].  
This family of PDEs has been the most widely studied regarding its subcellular distribution 
and how this distribution is important to cellular functions and targets.  
Many tumor cells exhibit significantly decreased cAMP levels as a consequence of 
overexpression of cyclic nucleotide phosphodiesterases. Marko et al. [Marko et al., 2000] 
found that in the solid large cell lung carcinoma LXFL529, both cytosolic and particulate PDE 
activities were much higher than in the respective cell lines. Furthermore, in both the tumor 
tissue and cell lines, Rolipram-sensitive PDE4 was found to represent the highest cAMP 
hydrolyzing activity [Marko et al., 2002]. 
The long forms of each PDE4 subtype can be phosphorylated by PKA. Phosphorylation of a 
site on the upstream conserved region 1 (UCR1) module causes a conformation change and 
a ~60 to 250% increase in activity of the catalytic domain. Functionally, phosphorylation also 
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leads to an increased sensitivity to Mg2+, increased affinity for Rolipram, and an altered effect 
of extracellular signal-regulated kinase (ERK) phosphorylation [Sette and Conti, 1996]. 
Physiologically, it is thought that activation of the mitogen activated protein kinase (MAPK) 
pathway will initially lead to local increases in cAMP. This increase in turn will activate PDE4 
phosphorylation by PKA that will cause a return of cAMP to a lower level [Houslay and 
Adams, 2003]. 
Nearly all of the PDE4 isozymes show both low (micromolar)- and high (nanomolar)-affinity 
Rolipram binding sites. These two different types of sites represent two or more different 
“states” of the catalytic domain of the PDEs. At least part of the high-affinity state seems to 
involve the bivalent metal ion sites in the catalytic domain [Bender and Beavo, 2006]. 
 
Table 2-12 PDE4 isoform localization and function [Beavo et al., 2007; Bender and 
Beavo, 2006; Shakur et al., 2001] 
 
Isoform Localization Function 
Tissue/Cellular Intracellular 
PDE4A  
 
Widely expressed with mRNA 
found in many tissues; 
olfactory system, immune 
cells, and testis; high levels of 
several variants in the brain 
PDE4A5 is localized to membrane 
ruffles through its Src 
homology domain; the supershort 
variant PDE4A1 is 
entirely membrane-associated; 
PDE4A4 associates with 
Src family kinases; PDE4A5 is 
localized by AKAP binding; 
PDE4A is recruited to a lipid raft 
fraction in activated T cells 
At least one form is 
expressed in most cells, 
and PDE4s play roles in a 
wide array of processes, 
including brain function, 
monocyte and macrophage 
activation, neutrophil 
infiltration, vascular smooth 
muscle proliferation, fertility, 
vasodilation, and cardiac 
contractility PDE4B  
 
 
High levels of mRNA detected 
in a variety of tissues; notable 
expression in immune cells 
and the brain 
PDE4s can be recruited to 
interact with β-arrestin; is 
recruited to a lipid raft fraction in 
activated T cells 
PDE4C  
 
More restricted expression 
compared with other PDE4 
isoforms; mRNA found in lung, 
testis, and several cell lines 
mainly of neuronal origin 
Predominantly cytosolic; PDE4s 
can be recruited to interact with  
β -arrestin 
 
PDE4D  
 
mRNA widely distributed and 
found in a variety of tissues; 
high protein levels in the brain; 
expression of variants seems 
to be localized to specific 
tissues and regions; variants 
are found in many commonly 
used cell lines (HEK293, COS) 
and in inflammatory cells 
Variants can be found in cytosolic 
or particulate fractions; PDE4D3 
is localized by binding to mAKAP 
and AKAP450; PDE4D3 is a part 
of the cardiac RyR2 channel 
complex; PDE4D5 interacts 
with RACK1; can be recruited to 
interact with β-arrestin 
mRNA (messenger RNA); RACK1, (receptor for activated C-kinase 1); AKAP (A-kinase anchoring 
proteins), RyR2 (ryanodine receptor 2), Src (Proto-oncogene tyrosine-protein kinase); mAKAP(muscle 
specific A-kinase anchoring protein). 
 
A significant number of PDE4 inhibitors have been developed, and a great deal of 
investigation is ongoing to explore their use as therapeutic agents. The prototypical PDE4 
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inhibitor is Rolipram, which was originally developed as a possible antidepressant agent. 
This compound and now many others (see Table 2-10) can have >100-fold selectivity for 
inhibition of PDE4 versus other PDE family members. One problem with PDE4 inhibitors as 
therapeutic agents has been their propensity to promote emesis. It is thought that most of 
these effects are mediated, at least in part, via actions in the CNS, and so far it has been 
difficult to separate the effects on emesis from more desirable effects. Recently it has been 
suggested that inhibition of PDE4D in the brain is responsible for the emetic side effects of 
PDE4 inhibitors [Lipworth, 2005]. Thus, development of PDE4B specific inhibitors is being 
undertaken as a possible means of maintaining anti-inflammatory activity without causing the 
emetic side effect of nonspecific PDE4 inhibition. 
In addition to chronic obstructive pulmonary disease, other inflammatory diseases for which 
PDE4 inhibitors currently being developed include use as drugs against asthma, arthritis and 
psoriasis. It is well established that PDE4 inhibitors can effectively suppress release of 
inflammatory mediators and immune cell infiltration [Castro et al., 2005]. Major dampening 
effects have been seen on neutrophil, monocyte, and T-lymphocyte function. However, 
PDE4 is a major cAMP hydrolyzing activity in a large number of proinflammatory and 
inflammatory cells, and PDE4 inhibitors probably target multiple cell types [Abrahamsen et 
al., 2004].  
Finally, in animal models, treatment with rolipram or other PDE4 inhibitors seems to enhance 
several models of learning and memory [Siuciak, 2008; Zhang et al., 2005]. 
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3 Aims 
This work was conceived as part of the project “Identifizierung, Prüfung und Optimierung der 
gewichtsreduzierenden Eigenschaften von Kaffee“ (Identification, analysis and optimization 
of coffee weight-reducing properties) as a follow-up project to Coffee Prevention (grant No. 
0313843) within the initiative "Funktionelle Ernährungsforschung” (functional nutrition 
research) of the BMBF (German Federal Ministry of Education and Research). The principal 
aim of this research project was to provide the scientific basis for the development and 
reproducible production of a functional coffee beverage with specific weight-regulating effect, 
providing scientific evidence for the functionality of the product in biological systems. The 
project was carried out with the following research groups: workgroup (WG) Marko, 
Department of Food Chemistry and Toxicology, University of Vienna, Austria; WG Hofmann, 
Food Chemistry and Molecular Sensory Science at the Technical University of Munich, 
Germany; WG Somoza, Department of Nutritional and Physiological Chemistry, University of 
Vienna, Austria and WG Eisenbrand/Richling, Department of Food Chemistry and 
Toxicology/Molecular Nutrition, Technical University of Kaiserslautern, Germany. 
Earlier studies have shown that compounds generated during the so called Maillard reaction 
are potent inhibitors of cAMP phosphodiesterases. This applies, e.g. for TMP, which is found 
in trace amounts in roasted coffee along with other pyrazines. TMP exhibited a strong 
relaxation endothelium-independent effect in rat aorta, TMP causes cAMP accumulation and 
blockade of the release of calcium from internal stores. Moreover, summation of the 
vasodilatation was found when TMP was combined with theophylline, suggesting that the 
elevation of cAMP by TMP was similar to that caused by theophylline, a known inhibitor of 
phosphodiesterase. Thus, an increase in cAMP level may be responsible for the vasodilator 
effect of TMP on rat aorta. Additionally, release of calcium from internal stores can also play 
an important role [Wu et al., 1989]. Similar mechanisms have also been attributed to the 
demonstrated inhibitory effect on platelet function. TMP inhibits platelet aggregation by 
blocking intracellular Ca2+ mobilization, inhibiting PDE, and preventing exposure of GP IIb/IIIa 
receptors to the outer surface of platelets following activation [Liu and Sylvester, 1994].  A 
further effect of TMP that may have health significance is its ability to induce antioxidant 
enzymes such as HO-1 [Chen et al., 2006]. The consumption of coffee has previously been 
shown by our group to reduce oxidative damage in lymphocytes [Bakuradze et al., 2011a]. 
Therefore, the effect of coffee consumption on HO-1 activity should be investigated as a part 
of planned human intervention study within the BMBF research project. 
The main objective of this doctoral thesis was to investigate whether substances other than 
caffeine in coffee may influence the homeostasis of intracellular cyclic nucleotides in vitro 
and in vivo. The interest was focused not only on the substances present in coffee before 
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roasting but also in those compounds generated during the roasting process which are found 
in brewed coffee.   
Whithin this thesis, one goal was to evaluate the effect of coffee extracts and isolated coffee 
compounds on the enzymes involved in the cAMP signaling cascades and therewith the 
intracellular cAMP concentrations. The use of biomarkers and surrogate endpoints (blood 
cells) was necessary because they were easier, earlier, cheaper or more ethical to obtain, 
achieve or monitor than clinical endpoints (adipocytes). Therefore, potential target cells in 
blood allowing to estimate the effect of coffee consumption on nucleotide homeostasis in 
humans were evaluated.  
The present work was divided into an in vitro part, where the effect of coffee compounds, and 
in some experiments coffee extracts, on the HO-1 activity, PDE activity and cAMP 
concentration were comparatively investigated; and a second in vivo part, which included two 
human studies: a short term study to test and choose the appropriate biomarkers to be 
employed in the following cross over designed long term study where the effect of activity-
optimized coffee drinks on the previously selected biomarkers should be determined. 
 The aims of the in vitro experiments were (1) to determine if coffee or some coffee 
constituents may have a stimulatory effect on the HO-activity of intestinal colorectal 
adenocarcinoma (Caco-2), liver hepatocellular carcinoma (HepG2) and monocytic 
leukemia (Mono Mac 6/ MM6) cell lines, (2) to investigate whether substances other 
than caffeine in coffee may influence the homeostasis of intracellular cyclic 
nucleotides in a known cell model: the large cell lung tumour xenograft (LXFL529L) 
cells, (3) find an appropiate surrogate biomarker of adipocytes and characterize the 
effect of the previously mentioned coffee compounds and coffee extracts on its 
intracellular cyclic nucleotides homeostasis and (4) to evaluate the potential of 
preadipocytes (SGBS) cells, as a model for adipocyte differentiation, respect to these 
biomarkers. 
 Furthermore, the aims of the in vivo experiments were (1) to find appropiate 
biomarkers for the modulation of the cAMP pathway, (2) to assess whether moderate 
consumption of regular coffee, caffeine reduced coffee and/or functional coffee can 
modulate the selected biomarkers, (3) to identify and characterize specific changes in 
circulating nucleosides (adenosine) and enzymes (adenosine deaminase) following 
exposure to coffee and (4) to attempt to interpret these changes in term of metabolic 
pathways.
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4 Material and methods 
4.1 Cell culture  
To culture cells is a complex process by which cells are grown and maintained under 
controlled conditions. These conditions are appropriate temperature, air humidity and gas 
mixture (typically, 37 °C, 5% CO2 for mammalian cells) in a cell incubator. Culture conditions 
may vary according to the cell type and variation of conditions for a particular cell type can 
result in different phenotypes being expressed. 
The most commonly varied factor in culture systems is the growth medium. Recipes for 
growth media vary e.g. in pH, glucose concentration, growth factors, and the presence of 
other nutrients. The growth factors used to supplement media are often derived from animal 
blood, such as calf serum.  
Cells can be grown in suspensions or adherent cultures. Some cells need to be cultured in 
suspension without being attached to a surface, such as cells that naturally exist in the 
bloodstream (e.g. lymphocytes, monocytes etc). On the other hand, adherent cells require a 
surface, such as tissue culture plastic, which may be coated with extracellular matrix 
components to increase adhesion properties and provide other signals needed for growth 
and differentiation. Most cells derived from solid tissues are adherent.  
4.1.1 Cell lines  
HEK-293 cell line  
HEK-293 cells also commonly known as 293 are fibroblastoid semi-adherent human primary 
embryonal kidney cells that grow as a monolayer with a doubling time of 20-24 h. They were 
established in 1977 from a human primary embryonal kidney and transformed using the 
adenovirus type 5. They are rated “risk category 1” by the German Central Commission for 
Biological Safety [DSMZ, 2004]. 
HEK-293 cells were grown in Dulbecco's Modified Eagle Medium (with 4500 mg/l Glucose, 
and pyridoxin HCl, without Natrium-Pyruvat) containing 1% (v/v) penicillin/streptomycin 
(10,000 units/10,000μg per ml) and 10% (v/v) heat-inactivated fetal calf serum (FCS) in a 
humidified incubator. HEK-293 cells were purchased from the German Collection of 
Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH –DSMZ). 
HT29 cell line 
HT29 cells are epithelial-like adherent cells that grow as monolayer in large colonies with a 
doubling time of 40-60h. They were first established in 1964, originally from a primary colonic 
tumour of a 44-year old Caucasian female. They form a well-differentiated adenocarcinoma 
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consistent with colony primary grade I and possess a hyper-triploid karyotype with a 17.5% 
polyploidy  [DSMZ, 2004]. 
HT29 cells were cultured in Dulbecco's Modified Eagle Medium (with 4500 mg/l Glucose, and 
pyridoxin HCl, without sodium pyruvate) containing 1% (v/v) penicillin/streptomycin (10,000 
units/10,000μg per ml) and 10% (v/v) heat-inactivated FCS in a humidified incubator. HT29 
cells were purchased from the German Collection of Microorganisms and Cell Cultures 
(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH –DSMZ). 
HepG2 cell line  
HepG2 cells are human hepatoma cancer cells which were established from the tumour of a 
15 year old Argentinian harboring a hyperploid kayrotype [DSMZ, 2004]. They are adherent 
cells which grow in a monolayer.  
HepG2cells were cultured in RPMI 1640 medium containing L-glutamine, 1% (v/v) 
penicillin/streptomycin (10,000 units/10,000 μg per ml) and 10% (v/v) heat-inactivated FCS in 
a humidified incubator. Cells were kindly provided by Prof. Dr. Dr. med. D. Schrenk 
(University of Kaiserslautern, Germany). 
Caco-2 cell line 
The Caco-2 cell line is a continuous human epithelial colorectal adenocarcinoma cell line, 
established from the primary colon tumor (adenocarcinoma) of a 72-year-old Caucasian man 
in 1974 [DSMZ, 2004]. Although derived from a colon (large intestine) carcinoma, when 
cultured under specific conditions the cells become differentiated and polarized such that 
their phenotype, morphologically and functionally, resembles the enterocytes lining the small 
intestine.  
Caco-2 cells were cultured in Dulbecco's Modified Eagle Medium, 1% (v/v) 
penicillin/streptomycin (10,000 units/10,000μg per ml) and 20% (v/v) heat-inactivated FCS in 
a humidified incubator. Caco-2 cells were purchased from the German Collection of 
Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH –DSMZ). 
 
MonoMac 6 cell line (MM6) 
The MonoMac cell line is a human acute monocytic leukemia cell line established from the 
peripheral blood of a 64-year-old man with relapsed acute monocytic leukemia in 1985 
following myeloid metaplasia.  
MonoMac 6 cells were grown in RPMI 1640 containing L-glutamine, 1% (v/v) 
penicillin/streptomycin (10,000 units/10,000 μg per ml),10% (v/v) heat-inactivated FCS and 
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25 mM HEPES in a humidified incubator [DSMZ, 2004; Ziegler-Heitbrock, 2006]. Cells were 
kindly provided by Prof. Dr. Dr. med. D. Schrenk (University of Kaiserslautern, Germany). 
LXFL 529L 
The large cell lung tumour xenograft LXFL 529L was established in serial passage onto nude 
mice, NMRI genetic background (from which a permanent cell line was developed [Berger et 
al., 1992]. This cell line was cultured at 37 °C (5% CO2 and 95% humidity) in RMPI 1640 
medium with addition of 1% penicillin/streptomycin and 10% fetal calf serum (FCS).  
In general, cells were subcultured once or twice weekly and were routinely tested for the 
absence of mycoplasm contamination. Cells were kindly provided by Prof. Dr. H. H. 
Fiebig(University of Freiburg, Germany). 
SGBS Cells 
The human Simpson-Golabi-Behmel syndrome (SGBS) preadipocyte cell strain originates 
from an adipose tissue specimen of a patient with SGBS. They are neither transformed nor 
immortalized, and provide an almost unlimited source due to their ability to proliferate for up 
to 50 generations with retained capacity for adipogenic differentiation [Fischer-Posovszky et 
al., 2008]. Cells were kindly provided by Prof. Dr. M. Wabitsch (University of Ulm, Germany) 
[Wabitsch et al., 2001]. 
Adipogenic differentiation of SGBS cells 
The optimized differentiation scheme is depicted in Figure 4-1. The cells were grown in 
plates for 3 days to near confluence in DMEM (Dulbecco's  Modified Eagle Medium)/F12 
containing 10% fetal calf serum (FCS). Differentiation is started  by washing cells 3 times 
with phosphate buffered saline (PBS) and then changing to a serum- and albumin-free 
differentiation medium (DMEM/F12 supplemented with 2 μmol/l Rosiglitazone, 25 nmol/l 
Dexamethasone, 0.5 mmol/l methylisobuthylxantine, 0.1 μmol/l cortisol, 0.01 mg/ml 
transferrin, 0.2nmol/l triiodotyronin, and 20 nmol/l human insulin). After 4 days, medium is 
changed, and cells are further cultured in DMEM/F12 supplemented with 0.1 μmol/L cortisol, 
0.01 mg/ml transferrin, 0.2 nmol/l triiodotyronin, and 20 nmol/lL human insulin [Wabitsch et 
al., 2001]. Within a few days, the cells start to accumulate lipids,and small lipid droplets are 
visible after approximately 1 week [Fischer-Posovszky et al., 2008], for functional cAMP 
studies the cells were differentiated until day 17 and for lipolysis assays until day 20. 
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Figure 4-1. Optimal differentiation protocol for human SGBS cells [Fischer-Posovszky et al., 
2008] 
4.1.2  Changing Cell Medium  
The culture medium is the most important component of the culture environment, because it 
provides the necessary nutrients and growth factors for cell growth, as well as regulating the 
pH and the osmotic pressure of the culture. 
The medium in which cells are grown not only provides essential nutrients for cell growth, but 
also collects excretory products of cell metabolism. Increasing accumulation of cellular 
metabolic products as protons, leads to an increasing acidity of the growth medium, which 
can be monitored by the gradual change in the colour (from red to yellow) of the phenol red 
indicator contained in most growth medium. 
To change the growth medium, old medium was removed and the cells were rinsed once 
with PBS (37°C) to wash out dead cells. Subsequently, pre-warmed (37°C) adequate growth 
medium was added and the flask is placed in the humidified incubator (37°C, 5% CO2, 95% 
moisture).  
Table 4-1: PBS Composition (1x) 
Reagent Final concentration (mM) 
NaCl 171.0 
Na2HPO4 10 
KCl 3.4 
KH2PO4 1.8 
                           pH 7.4, autoclaving. 
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4.1.3 Subculture of Cells  
Subculturing, also referred as passaging, is the removal of the medium and transfer of a 
fraction of cells from a previous culture into fresh medium, a procedure that enables further 
propagation of the cell line or cell strain. 
Many adherent cell lines grow optimally as monolayer in cell culture flasks. On attaining a 
confluent population, some cell lines transcend to multilayer growth by adding multiple layers 
over the first, resulting in suppressed cell growth (contact inhibition) and a change in 
metabolism. To maintain monolayer cell growth, cells were passaged when they had reached 
a semi-confluent population.  
The growth medium was aspirated and the cells were rinsed with pre-warmed and sterile 
PBS to remove dead cells and residual growth medium (that might inactivate trypsin/EDTA 
and hinder cell detachment). Then pre-warmed (37 °C) trypsin/EDTA was added and the 
culture was placed in a humidified incubator (HT29 and SGBS: 3 min, HEK-293: 10 s, 
Caco-2: 5 min). The culture flask was gently clapped to detach the cells. Pre-warmed (37 °C) 
serum-supplemented medium was added (inhibits the lysing activity of trypsin/EDTA) and the 
cells were re-suspended by pipetting up and down. The required volume of the cell 
suspension was transferred to a new culture flask, pre-warmed serum and antibiotic 
supplemented medium was added, and the cells were further cultivated under normal 
conditions.  
For suspension cells like MonoMac6, an aliquot of the cell suspension with uniformly 
dispersed free cells and cell aggregates was transferred to a new flask with fresh medium.  
Table 4-2: Trypsin-EDTA solution composition 
Reagent Amounts 
Trypsin 500 mg 
EDTA 250 mg 
PBS (10x) 100 ml 
Stirred overnight on ice, set to pH 7-7.4 and filled to 1000 ml with re-distilled water, steril 
filtered (0.2 µm) and aliquoted à 5 ml and stored at -20 °C. 
 
4.1.4 Cell quantification 
Measuring total cell numbers (by haemocytometer counts of whole cells) is easily achieved. 
The counting chamber consists of nine squares, each of these squares have a defined area 
of 1 mm2 and a depth of 0.1 mm. Thus arises a volume of 0.1 µl per square. Shortly before 
the cells are passaged, the counting chamber was prepared: the cover was cleaned with 
70% Ethanol and lightly moistened, then was gently slid onto the counting chamber .The 
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formation of Newton rings between the external support and the cover glass indicates correct 
positioning of the cover glass.  
For cell counting, an aliquot of cell suspension (see 4.1.3) was diluted 1:1 with trypan blue. 
This dye stains dead cells due to their membrane permeability to blue. These blue-stained 
cells were not taken into account during subsequent counting. A defined part of the stained 
cell suspension was then pipetted under the coverslip by capillary action of the 
hemocytometer. Only living cells in the four corner squares of the chamber were counted. 
The mean of the cell number was multiplied by the dilution factor of 2 and 104 to obtain the 
number of cells per milliliter [Lindl, 2000]. 
4.1.5 Mycoplasma detection 
Cultures can become infected by mycoplasma from media, sera, trypsin or the operator. 
They are not visible to the naked eye, and, while they can affect cell growth, their presence is 
often not obvious.  It is important to test for the absence of mycoplasma at regular intervals 
(every 1-3 months) as they cab seriously affect cellular biochemistry, antigenicity and growth 
characteristics [Freshney, 1994]. 
To test for mycoplasma infection, cells were plated on a glass slide and allowed 24 h for 
regeneration and growth. Thereafter, medium was washed off the slide with cold methanol (-
20°C) and the slide was placed in methanol (-20 °C) for at least 15 min to affix the cells. 
Subsequently, the cells were stained with DAPI/SR101 solution (4’-6-diamidino-2-
phenylindol-di-hydrochloride/sulforhodamine 101) and scrutinized under a fluorescence 
microscope (excitation wavelength of 450 - 490 nm). Nucleic acid appears blue (DAPI) and 
plasma proteins appear red (SR101). Scattered small bluish dots seen over the red regions 
of the plasma are a positive sign for mycoplasma infection [Lindl, 2000]. 
 
4.1.6 Storage of Cells  
Cellular damage induced by freezing and thawing is generally believed to be caused by 
intracellular ice crystals and osmotic effects.  The addition of a cryoprotective agent, such as 
DMSO or glycerol, and the selection of suitable freezing and thawing rates, minimizes 
cellular injury [Freshney, 1994]. 
The cells were trypsinized as described in Section 6.1.1.4. Trypsin was inactivated by 
addition of 8 ml of fresh serum-containing medium. The cell suspension was divided into 1 ml 
aliquots and mixed with 100 µl DMSO. The cells are then frozen at -20 °C and further stored 
at -80 °C in the biofreezer. Long-term storage takes place in liquid nitrogen. About 1x106 
SGBS cells were suspended per freezing vial and then placed in a freezing container filled 
with isopropanol and stored at -80 °C overnight.  Next day cells were placed in liquid nitrogen 
storage tank.  
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4.1.7 Re-culturing Cells  
During cell culture, it is of utmost importance to be mindful because some cell lines, while in 
culture, change their physiological properties with increasing passage number. It is therefore 
necessary to replace old cells from stocks to maintain reproducible results (Lindl 2000).  
The frozen cell suspension was thawed quickly in a water bath at 37 °C, rapidly taken up with  
10 ml medium (10 % FCS, v/v) and centrifuged at room temperature at 200g for 4 min. The 
supernatant was discarded and the cell pellet was re-suspended in 5ml medium (20%, FCS 
v/v). Finally, the entire cell suspension is transferred to a small tissue culture flask (25 cm2) 
and incubated at 37° C, 5% CO2 and 95% humidity. Upon achieving high confluency, the 
cells are passaged into a medium culture flask (80 cm2). Cells were maintained for at least 
two weeks in culture before attaining experimental competence [Lindl, 2000]. 
 
4.1.8 Trypan blue viability test 
The dye exclusion test is used to determine the number of viable cells present in a cell 
suspension. It is based on the principle that live cells possess intact cell membranes that 
exclude certain dyes, such as trypan blue, whereas dead cells do not. In this test, a cell 
suspension is simply mixed with dye and then visually examined to determine whether cells 
take up or exclude dye. A viable cell will have a clear cytoplasm whereas a nonviable cell will 
have a blue cytoplasm [Strober, 1997]. 
The mix of cell suspension and trypan blue was made as previously described, unstained 
(viable) and stained (nonviable) cells were count separately in the hemacytometer. To obtain 
the total number of viable cells per ml of aliquot, the total number of viable cells was 
multiplied by 2 (the dilution factor for trypan blue). Calculations of the percentage of viable 
cells were made as follows: 
 
Viable cells (%) =    Total number of viable cells per ml of aliquot  x 100 
                    Total number of cells per ml of aliquot 
 
4.1.9 Cell culture materials 
Equipment 
 
Analytical balance  
Autoclave-steam sterilizer 
Biofreezers 
 
Sartorius  
Tuttnauer Systec, 5075 EL  
Heraeus, Herafreeze 
Angelantoni Industrie, Irilab 800 
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Centrifuges 
 
CO2  incubators 
 
Counting chamber 
Drying cabinet  
Electronic single-channel pipette 
Fluorescence microscope  
Graduated and pasteur pipettes 
Laminar flow cabinets 
  
Microscope 
Multichannel pipettes 
 
Multipette 
NALGENE® freezing container  
pH meter 
Pipetus® (pipetting aid) 
Thermomixer 
Ultrasonic bath 
Water Bath 
Vortex Genie 2TM  
Heraeus Instruments Multifuge 1 L-R 
Eppendorf, Centrifuge 5417R 
Binder, Tuttlingen  
wtbBinder, Tuttlingen 
Marienfeld, Neubauer-improved 
Heraeus, KTG 800  
Research® pro, Eppendorf 
Axioscop2 (HB 50/AC), Zeiss 
Hirschmann Laborgeräte 
Heraeus Instruments Laminair HLB 2448 GS 
       Kojair, BIOWIZARD Golden Line 
Leitz Labovert inverted microscope 090-122.01  
Abimed HT 
Research® pro Electronic Pipette, Eppendorf 
Eppendorf, Abimed  
Thermo Fisher Scientific  
Hanna Instruments HI2210 
Hirschmann Laborgeräte  
Eppendorf  
Bandelin, Sonorex RK 106  
Julabo SW-20C 
Bender & Hobein AG  
 
Chemicals and culture media 
Apo-transferrin  
Biotin  
DAPI/SR101 solution 
Dexamethasone  
DMEM/F-12 
DMSO for UV-spektroskopie 
Dulbecco´s MEM/Nutrient-Mix F12 (DM) 
Dulbecco´s Modified Eagle Medium (DMEM) 
EDTA 
Ethanol, p.A. 
Fetal calf serum (FCS)  
Glukose 
HBSS 
Sigma-Aldrich 
Sigma-Aldrich 
Partec 
Sigma-Aldrich   
Gibco/Invitrogen  
Fluka 
Gibco/Invitrogen  
Gibco/Invitrogen  
Merck 
Merck 
Gibco/Invitrogen  
Merck 
Gibco/Invitrogen  
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Consumables  
Cell culture dishes (35, 60 94mm) 
Cell scrapers 
Centrifuge tubes (Falcon tubes) 
Cryogenic storage vials (1ml) 
Microplates (6,12, 24, 48, 96 well formats) 
Pipette tips  
Reaction tubes (1,5 and 2 ml) 
Sterile filters (0,2µm, cellulose acetate, PVDF) 
Suspension culture flasks (25cm2, 75cm2, 175cm2) 
Syringes and needle  
Tissue culture flasks (25 cm2, 75 cm2, 175 cm2) 
Greiner 
Greiner 
Greiner 
Greiner 
Greiner 
Greiner 
Greiner 
Sartorius, Roth  
Greiner 
Braun  
Greiner, Nunc, BD Falcon  
HEPES 
Hydrocortisone  
IBMX  
Insulin 
KH2PO4 
KCl 
MgSO
4 
* 7 H
2
O  
Methanol 
NaHCO
3 
Na2HPO4 
NaCl  
NaOH  
Pantothenic acid  
Penicillin-Streptomycin 
2-Propanol
 
RPMI 1640 
Rosiglitazone 
Triiodo-L-thyronine  
Trypan Blue solution (0.4%) 
 
Trypsin, 3,5 U/mg  
Versene 
Merck 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Merck 
Merck 
Merck 
Merck 
Merck 
Merck 
Merck 
Merck 
Sigma-Aldrich 
Gibco, Invitrogen  
Merck 
Gibco, Invitrogen  
Sigma-Aldrich  
Sigma-Aldrich 
Sigma-Aldrich 
   
    Serva 
Gibco, Invitrogen  
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4.2 Heme oxygenase assay (HO-assay) 
4.2.1 Principles of the assay 
The assay for determination of total HO-activity is based on the enzymatic conversion of 
heme to bilirubin via biliverdin (see Figure 4-2). Heme is oxidatively metabolized to biliverdin, 
which dissociates from the HO-1 and is rapidly converted to the hydrophobic molecule, 
bilirubin, in an NADPH-dependent reaction catalyzed by cytosolic biliverdin (BVR). Liver 
cytosol has been used as a source of BVR. This method has been described by Tenhunen et 
al. [Tenhunen et al., 1970] and modified by Motterlini et al. [Motterlini et al., 1995] and 
recently by McNally et al. [McNally et al., 2004]. 
HO-activity was assessed in the cell lysate by measuring formation of the HO metabolite 
bilirubin. Therefore cells were disrupted after incubation to achieve a complete release of the 
HO enzyme. Hemin converted by HO to bilirubin was extracted with chloroform. The amount 
of extracted, yellow-colored bilirubin is determined with a UV spectrometer and correlated 
with the enzymatic activity of HO. 
 
 
Figure 4-2: Pathway of heme metabolism. HO enzymes catalyze the rate-limiting step in heme 
metabolism. Both HO isoenzymes (HO-1 and HO-2) oxidize heme to the bile pigment biliverdin-IXα. 
The reaction requires 3 mol of molecular oxygen and NADPH as well as cytochrome P-450 reductase 
as a source of electrons. The cleavage of the heme ring releases the coordinated iron, as well as the 
α-methene bridge carbon as carbon monoxide (CO). The principal HO reaction product, biliverdin-IXα, 
is further metabolized to bilirubin-IXα by NAD(P)H and biliverdin reductase. Modified from Ryter et al. 
[Ryter et al., 2006b]. 
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4.2.2 Cell lysate and sample preparation 
3x106 HepG2, Caco2 cells or 1x106 MonoMac6 cells were seeded in Petri dishes (∅ 92 mm) 
or in small tissue culture flask. Confluent cells were then incubated with the test substance 
for 24h in medium without FCS under normal growth conditions (37 °C, 5% CO2 and 95% 
humidity). 
Briefly, after the incubation, cells were washed twice with cold PBS, gently scraped off the 
dish, and centrifuged (1000g for 10 minutes at 4°C). The cell pellet was suspended in 500 µl 
buffer (2 mM MgCl2 and 100 mM KH2PO4, pH 7.4), frozen in liquid nitrogen and thawed for 3 
times, and finally sonicated on ice before centrifugation at 18 000g for 10 minutes at 4 °C. 
400 µL of the supernatant was added to 200 µl NADPH-test system (see Table 4-3). 
The reaction was conducted for 1 hour at 37 °C in the dark and terminated by the addition of 
800 µl chloroform. The extracted bilirubin was calculated by the difference in absorption 
between 464 and 530 nm with use of a quartz ultra microcuvette (extinction coefficient, 40 
mM-1 cm-1 for bilirubin). HO-activity was expressed as picomoles of bilirubin formed per 
milligram protein per hour [Foresti et al., 1997; Polte et al., 2000] 
 
Table 4-3: NADPH-test system Composition 
Reagent Concentration 
ß-NADPH 0.8 mM 
Glucose-6-phosphate 2 mM 
Glucose-6-phosphate dehydrogenase 0.2 U 
Hemin 50 µM 
Rat liver cytosol (see 6.3) 500 µg Protein 
        Final volume: 200 µl 
. 
4.2.3 HO assay materials 
Equipment (see 4.1.9 Cell culture) 
Precision ultra micro Cell 
Ultrasonic homogenisor  
UV-VIS spectrophotometer 
Hellma 
Braun, Labsonic 2000 
Shimadzu, UVmini-1240 
Chemicals (see 4.1.9 cell culture) 
Ammonium pyrrolidinedithiocarbamate 
Chloroform p.A 
D-Glucose 6- phosphate  
Glucose-6-phosphat-dehydrogenase (S. cerevisiae) 
Sigma-Aldrich 
Fisher Scientific 
Sigma-Aldrich 
Sigma-Aldrich 
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Hemin 
KH2PO4 
MgCl2 
-NADPH  
Sigma-Aldrich 
Merck 
Merck 
Sigma-Aldrich 
 
Consumables (see 4.1.9 Cell culture) 
4.3 Rat liver cytosol preparation 
4.3.1 Rat liver cytosol preparation Method  
The livers of three albino rats (120-180 g body wt.) were used for the preparation of the 
cytosol. Animals were starved for 24 h before being killed by decapitation.  
4.3.1.1 Preparation of homogenate 
After decapitation of rats, livers were dissected out rapidly and placed on ice in a beaker 
glass. The livers were washed three times with MIC-I-Buffer (see Table 4-4). The washed 
livers were blotted dry with filter paper and broken up by mincing. Portions of the mince were 
transferred with 9 ml of MIC-I-Buffer into a glass homogenizer (Potter-Elvehjem Tissue 
Grinder) and homogenized with 5 passes of a PTFE-pestle. 
Table 4-4: MIC-I-Buffer Composition 
Reagent Concentration 
Sucrose 0.25 M 
EDTA 5.5 mM 
Tris 0.2 M 
        pH: 7.5 
4.3.1.2  Isolation of cytosol.  
The homogenate was centrifuged at 100 g for 10min at 4 °C, the supernatant then 
centrifuged at 9000 g for 10 min at 4 °C. The resulting supernatant was ultracentrifuged at 
105000 g for 1h at 4 °C to obtain the cytosolic fraction (supernatant) and a microsome pellet. 
The cytosolic fraction was aliquoted, frozen in liquid nitrogen and then stored at -80 °C. 
 
4.3.2  Rat liver cytosol preparation materials 
Equipment 
Potter-Elvehjem tissue grinders 
PTFE pestles 
Tissue homogenizer 
Ultracentrifuge 
Wheaton Industries Inc 
Wheaton Industries Inc  
Heidolph-Laboratory RZR-2100 
Beckman, OptimaTM TL 
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Chemicals 
EDTA 
HCl 
Sucrose 
Tris  
Consumables (see 4.1.9 Cell culture) 
Serva 
Roth 
Fluka 
Roth 
   
4.4 Protein determination by Bradford 
The Bradford assay is a colorimetric protein assay based on an absorbance shift of the dye 
Coomassie® Brilliant Blue G-250 in which under acidic conditions the red form of the dye is 
converted into its blue form that binds to protein. The binding of the dye to protein causes a 
shift in the absorption maximum of the dye from 365 to 595 nm and it is the increase in 
absorption at 595 nm which is monitored.  The amount of the complex present in solution is a 
measure for the protein concentration and can be estimated by use of an absorbance 
reading [Bradford, 1976]. 
4.4.1 Procedure 
A sequential standard row from 0.1-1.0 mg/ml protein was prepared with bovine serum 
albumin (BSA, Fraktion V, 2 mg/ml, Bio-Rad). If required, the samples were diluted with re-
distilled water. 10μl of each probe, blank (re-distilled water or buffer in which the sample was 
processed) and standard was pipetted in triplicates into a 96-well microplate on ice. Then 
190 µl of Bradford solution was added to each well and after 5 min incubation at RT, the 
plate was measured at λ = 595 nm in a microplate reader. The standard curve was used to 
determine the protein concentration for each unknown sample. 
4.4.2 Protein determination by Bradford Materials  
Equipment 
Multidetection microplate reader BioTek, SynergyTM 2 
 
Chemicals 
Bradford reagent 
Bovine serum albumine (2 mg/ml) 
Bio-Rad 
  Bio-Rad 
Consumables 
96-well microplates (F-bottom, PS) 
Pipette tips 
Reaction tubes 
Greiner 
Greiner 
Greiner 
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4.5 Phosphodiesterase (PDE) activity determination 
4.5.1 PDE assay method 
PDE activity was determined according to the method of Pöch [Poch, 1971] with slight 
modifications. It is used to determine the turnover of cAMP (cGMP) to 5'AMP (5'GMP) by 
phosphodiesterases. A definite amount of tritiated cyclic nucleotide was added to the cell 
lysate and depending on its PDE activity cAMP (cGMP) will be converted at different rates to 
the corresponding 5'-nucleotide.  This will be precipitated after a definite period of incubation 
(≈ 20% conversion of cAMP to 5´AMP). The remaining radioactive cAMP (cGMP) in the 
supernatant was measured using a scintillation counter, its value is inversely proportional to 
cAMP (cGMP) concentration in the sample. 
4.5.1.1 Preparation of the cell lysates (in vitro assay) 
The cells were trypsinized and counted as described in 6.1.1.4 and 6.1.1.5. Per cell line, 
three petri dishes (∅ 92 mm) with 1x106 cells (LXFL or SGBS) were seeded. 
After 24h of incubation (cells should have 60-80% confluency) the cells were processed, 
medium was removed and the cell layer rinsed twice with 1-2 ml ice-cold PBS (see Table 
4-1). Thereafter, the cells were scraped in 2 × 150 µL RunIII buffer (Table 4-5) per petri dish 
and then the cell suspension was homogenized using a Wheaton glass tissue grinder („tight“ 
Pistill, 40 strokes). The supernatant of a first centrifugation (100 000 g, 4 °C, 40 min) 
corresponds to the so-called cytosolic fraction. All of the above steps were performed with 
cool solutions and over ice. The RunIII buffer was freshly prepared just before testing. 
 
Table 4-5.  RunIII Buffer Composition 
Reagent Final concentration 
Tris/HCl pH 7.4 50 mM 
MgCl2 × 6 H2O 10 mM 
EDTA 0.1 mM 
Benzamidine 5 mM 
Pepstatine A 1 μM 
Leupeptine 1 μM 
Soybean trypsin inhibitor  0.5 μM 
PMSF 0.5 mM 
β-Mercaptoethanol 0.5 mM 
Addition of Triton
®  
X-100 (final concentration 0.5%, v/v) in the RunIII/Triton buffer for the 
membran fraction test. 
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4.5.1.2 Preparation of platelet suspensions (in vivo) 
Preparation of platelet-rich plasma (PRP) 
The preparation of PRP from whole blood was achieved by centrifugation by 800 g for 5 min 
at RT. Three distinct phases were seen: 
a) Packed red cells 
b) Buffy coat (thin band of white blood cells) 
c) Straw-coloured PRP. 
The PRP was aspirated taking care not to disturb either the buffy coat or red cells to prevent 
contamination of the platelet preparation and was then transferred to a fresh eppendorf tube. 
Platelet counts in PRP are normally 350 000 to 500 000 platelets/µl [Watson and Authi, 
1996]. 
4.5.1.3 Isolation of platelets from PRP 
Platelets were isolated from PRP by centrifugation at 800 g for 15 min at room temperature 
to yield a platelet pellet.  Then the supernatant (Platelet poor plasma) was aspirated and 
stored for the ADA experiments and the pellet was gently resuspended in buffer (for the PDE 
assay in Run III buffer und for cAMP assay in Stimulation buffer). The presence of platelet 
clumps at this stage represents a large degree of platelet activation and, if present, the 
preparation should be discarded. The platelet suspensions were stored at -80°C and before 
the test thawed and sonicated on ice. 
4.5.1.4 Isolation of platelets from platelet concentrate (in vitro) 
Plateletconcetrates were obtained from the DRK-Blutspendedienst (Red Cross Blood 
Transfusion Service) Baden Württemberg-Hessen in Mannheim. Each platelet concentrate 
was a suspension of human platelets (pooled from four donors) in 255 ml of a platelet 
additive solution and CPD (citrate-phosphate-dextrose) plasma, containing approximately 
2.0-4.5 x 1011 thrombocytes/preparation. 
Concentrates were stored for max. 5 days at 25 °C under constant agitation. To isolate the 
platelets from the concentrate, 50 ml of this suspension were decanted in 50 ml tubes, then 
EDTA was added to a final concentration of 5 mM, mixed thoroughly and centrifuged at 1500 
g for 15 min at room temperature. The supernatant was discarded (taking into account that 
this is potentially biohazardous) and the pellet was resuspended in RunIII buffer at a volume 
equivalent to that of the original concentrate. 
4.5.2 cAMP-PDE assay 
Using the cAMP-PDE assay, the cAMP to 5´AMP hydrolyzing activity of PDE isoenzymes 
(cellular fraction) can be measured. In particular enzyme activities of the isoforms that work 
best with substrate concentrations of 1 µM in the assay are determined. Furthermore, 
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influence of different modulators on the PDE activity can be tested by partial replacement of 
buffer with the appropriate test compound (see Table 4-7). All solutions were stored on ice 
and the assay was pipetted and stopped in an ice bath. 
4.5.2.1 Procedure 
The cAMP [3H]-mix was prepared by addition of 13 µl of tritiated cAMP[3H] (≈13 µCi) to 5 ml 
cAMP-mix (see cAMP-mix composition) which is then mixed thoroughly.  
 
Table 4-6: cAMP-mix composition 
Reagent Final concentration 
Tris/HCl (pH 7.4) 30 mM 
MgCl2 × 6 H2O 9 mM 
5’AMP 3 mM 
cAMP 3 μM 
Aliquot of 5 ml were stored at -20 °C. Just before starting the test: addition of 13 µl cAMP [
3
H] 
(≡ 13 µCi) per 5 ml → cAMP [
3
H]-mix. 
 
Assay tubes were prepared according to the following pipetting scheme.  PDE activity of 
each sample was always performed in triplicate. 
 
Table 4-7: Pipetting scheme for PDE assay 
 Components 
Blank 100 μl RunIII-Buffer 
50 μl cAMP[3H]-mix 
Basal activity 50 μl RunIII-Buffer 
50 μl cell lysate 
50 μl cAMP[3H]-mix 
Modulator 50 μl Modulator 
50 μl cell lysate 
50 μl cAMP[3H]-mix 
 
After the addition of cAMP [3H] samples were mixed using a vortex mixer. The reaction 
started by incubating the tubes in a water bath at 37 °C temperature. The incubation period 
depends on the cAMP turnover which should not exceed about 20%, so the enzyme kinetics 
is guaranteed to be in a steady state. The corresponding incubation period was determined 
by a pre-test at different incubation times.  The reaction was stopped by adding 250 µL 
0.266 M ZnSO4 on ice. The 5´AMP[
3H] was precipitated by addition of 250 µL 0.266 M 
Ba(OH)2 and separated by centrifugation at 20 000 g for 5 min.  From the supernatant, which 
contains the nonhydrolyzed cAMP [3H], 450 µL were transferred into a tube containing 4.5 ml 
scintillation cocktail and after vortex, the samples were measured for 2 min in a scintillation 
counter. 
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4.5.2.2 Results interpretation 
The measured [3H]-cAMP activity is proportional to the remaining cAMP[3H]-concentration, 
i.e. the turnover corresponds to the difference between the original and remaining [3H] 
activity. To compare data the PDE activity was normalized to protein content. The 
determination of protein content was performed according to Bradford [Bradford, 1976]. The 
PDE activity is given in (cAMP pmol / min × mg protein). 
4.5.2.3  PDE assay materials  
4.5.2.4 Equipment 
Ultrasonic Homogenisor  
Incubator shaker 
Liquid Scintillation Counter 
Microcentrifuge 
Braun, Labsonic 2000 
Edmund Bühler, Hood TH 15 
Beckman, LS-5801 
Eppendorf, 5417R 
 
Chemicals 
Adenosine 5′-monophosphate 
Adenosine 3′,5′-cyclic monophosphate 
Adenosine 3,5,cyclic phosphate ammoniumsalt (2,8-3H) 
Ba(OH)2 
Benzamidine 
Caffeine 
EDTA 
Hydrochloric acid (37%) 
IBMX 
Leupeptin 
β-Mercaptoethanol 
MgCl2 x 6H2O 
Paraxanthine 
Pepstatin A 
PMSF 
Pyrazines 
Pyridine  
Rolipram 
Scintillation Cocktail  
Soybean trypsin inhibitor 
Tris/HCl 
Triton® X-100 
Zaprinast 
ZnSO4 
Alexis, Sigma 
Sigma 
Hartmann Analytik, 250 µCi/ml 
Merck 
Sigma-Aldrich 
Sigma-Aldrich 
Serva 
J.T. Baker  
Calbiochem 
Alexis 
Fluka 
Merck 
Sigma-Aldrich 
Alexis 
Alexis 
Aldrich, SAFC 
Merck 
Calbiochem  
Roth, Rotiszint eco plus  
Roche 
Roth  
Serva 
Calbiochem 
VWR-prolabo 
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Consumables (see 4.1.9 cell culture) 
Measuring vials for scintillation counter Roth   
4.6  Blood adenosine quantification  
4.6.1 Samples preparation 
The adenosine quantification in blood was performed by HPLC-ESI-MS/MS as described 
previously by Doležalová et al. [Dolezalova et al., 2005] with some modifications. For this 
purpose, the venous blood samples were deproteinized immediately after collection with an 
equal volume of 1 M perchloric acid (PCA) to prevent potential enzymatic degradation or 
production of adenosine. The samples were cooled in ice-water and centrifuged at 4 000 g 
for 5 min at 4 °C. 300 µl of the clear supernatant was transferred to a test tube and 20 µl of 
internal standard containing 1.6 µM [1´,2´,3´,4´,5´-13C5]-Adenosine (Omicron, USA) was 
added. The solution was neutralized by addition of 20 µl buffer containing 2.5 M K3PO4 and 
1.3 M KOH. After a short centrifugation step (4 000 g, 5 s) the potassium perchlorate 
precipitate was removed and the supernatant was diluted with 250 µl of re-destilled water 
and applied on a preconditioned StrataX 33u Polymeric Reversed Phase-solid-phase 
extraction (SPE) column (30 mg/ml, Phenomenex).  After the sample had passed through the 
column, the column was rinsed with 1.5 ml of re-destilled water. Adenosine was eluted with 
1000 µl (2 times 500 μl) of methanol [Dolezalova et al., 2005]. 
The eluate was concentrated to a volume of about 100 µl using a vacuum centrifuge, then 
1:4 diluted with 0.02 % acetic acid. Aliquots (10 µl) were measured using HPLC-ESI-MS/MS. 
The chromatographic separation of adenosine was performed with an Aqua C18 column 
(250 × 4.6 mm, 5 u, Phenomenex) using an isocratic solvent system of 0.1% formic acid in 
water (v / v) and methanol (85:15; v / v) at a flow rate of 0.5 ml / min. 
The detection of the analyte and the internal standard was performed using a triple-
quadrupole tandem mass spectrometer API 3200™ (Applied Biosystems, Darmstadt, 
Germany) with positive electrospray ionization (ESIpos). The quantification of adenosine was 
performed by determining the ratio of the peak area of adenosine with the peak area of 
isotope-labeled standard. 
4.6.2 Tuning and calibration of the mass spectrometer 
In a mass spectrometer, the ion source, mass filter, and detector operational parameters 
influence the produced mass spectra. The ion source parameters affect how many ions are 
produced, how many ions are directed toward the mass filter, and the relative amount of a 
given mass ion that is directed into the mass filter. The mass filter parameters in a 
quadrupole instrument affect the peak widths, mass assignments, mass resolution, and 
sensitivity and the detector parameters the magnitude of the signal and the sensitivity of the 
Materials and methods                                                                                        89 
 
                          
system. All of the tuning parameters influence the quality of the mass spectra and the ability 
of a given mass spectrum to be matched with a spectral data base. 
 
Tuning and calibration of the instrument ensures the best results of the experiments. Tuning 
is performed to check the mass spectrometer or to ensure that the spectra produced 
resemble a previously determined standard. On the other hand, calibration is the process of 
calibrating the mass scale using a compound or mixture that showed peaks with accurately 
known masses. Tuning and calibration of the mass spectrometer were carried out with 
polypropylene (PPG) 1:10 standards for ESIpos polarization as indicated by Applied 
Biosystems  [Applied-Biosystems, 2008].ESI positiv ESI negati 
4.6.3 Optimization of the substance and source specific parameters 
The mass spectrometer has several parameters (source and substance-specific parameters) 
that can be specifically optimized for each analyte to achieve a high sensitivity of the device 
(see Figure 4-3) 
 
 
Figure 4-3: Schematic structure of a triple quadrupole mass spectrometer. Source-specific 
parameters, substance-specific parameters, CUR: Curtain Gas, DP: Declustering Potential, EP: 
Entrance Potential, CEP: Collision Cell Entrance Potential, CE: Collision Energy, CAD: Collision 
Activated Dissociation, CXP: Collision Cell Exit Potential [Applied-Biosystems, 2008]. 
 
The source-specific parameters include ion spray voltage, nebulizer gas, turbo gas, 
temperature and curtain gas. Their function is explained in Table 4-8. 
 
Table 4-8: Source-specific parameters of a Triple quadrupole mass spectrometer 
Parameter Abbreviation Function 
Ion Spray Voltage IS Voltage applied between the needle and orifice plate that 
“ionizes” and nebulizes the liquid flow. Polarity determines 
what  type of ions will reach MS. In positive mode typically 
4000 and 5500V; In negative mode –3000 to –4000V 
Nebulizer Gas (N2) GS1 Facilitates droplet formation. Higher flow, higher GS1 
Turbo Gas (N2) GS2 Aids in solvent evaporation, increasing ion efficiency. 
Heated gas stream intersects nebulized liquid stream at 
about 90o right in front of the curtain plate 
Materials and methods                                                                                        90 
 
                          
Temperatur TEM Temperature of GS2: Promotes desolvation, thereby 
forming Analyte ions in the gas phase 
Curtain Gas CUR High purity N2 that flows between the orifice and the 
curtain plate. It repulses large droplets and neutrals 
keeping the Q0 clean 
 
To optimize the source-specific parameters, first the composition of the mobile phase and the 
retention time of the analyte were determined. This was then adjusted with the corresponding 
isocratic flow rate of the HPLC. Then the analyte was injected by loop injection (no column 
separation) under changing source parameters with the help of the FIA (Flow Injection 
Analysis) tools of the Analyst 1.4.2 Software. 
The substance-specific parameters include declustering potential, entrance potential, 
collision cell entrance potential, collision energy, CAD gas and collision cell exit potential. 
These parameters were optimized using a syringe pump (flow: 10 µl/min) and the 
"Quantitative Optimization" tool of the Analyst 1.4.2 software. In Table 4-9 the substance 
specific parameters to be optimized and their functions are listed. 
 
Table 4-9: Substance-specific parameters of a Triple quadrupole mass spectrometer 
Parameter Abbreviation Function 
Declustering Potential DP Potential difference between the skimmer and the Orifice: 
minimizes the formation of solvent cluster ions, reduces 
chemical noise. 
Entrance Potential EP The voltage between the skimmer (ground) and the 
entrance to Q0. Focusing of the ions in Q0 
Collision Cell Entrance Potential CEP Potential difference between Q0 and the entrance to Q2. 
Facilitates ion transmission to the collision cell. Is the 
most mass dependent parameter 
Collision Energy CE Potential difference between the Q0 and Q2. Determines 
the degree of fragmentation in Q2  
Collisionally Activated Dissociation 
gas 
CAD-gas Pressure of the collision gas (N2) in Q2 
Collision Cell Exit Potential CXP Potential difference between Q2 and IQ3. Always 4V 
 
 
4.6.4 Quantification by stable isotope dilution analysis (SIDA) 
The adenosine quantification in blood was carried by stable isotope dilution analysis (SIDA). 
A stable isotope [1´,2´,3´,4´,5´-13C5] (100nM)-Adenosine was used as internal standard. This 
method has the advantage that the isotope standard can already be added before sample 
preparation and treated analogously to the analyte. Due to the structural similarity of the 
analyte with the internal standard, its physical and chemical properties are almost identical. 
For the sample preparation, chromatography, ionization and detection can be assumed that 
the analyte and the internal standard behave similar. As shown in Figure 4-4, the internal 
standard (IS) also showed the same retention time as the analyte. 
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 +MS2 (273.07) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of Adenosine 13C_InitProduct_Pos.wiff (Turbo Spray) Max. 2.1e6 cps.
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Figure 4-4: HPLC-MS/MS chromatogram of the analyte Adenosine (100 nM) (A) and the internal 
standard [1´,2´,3´,4´,5´-
13
C5]-Adenosine (100 nM) (B) performed with an Aqua C18 column (250 × 
4.6 mm, 5 u, Phenomenex) under isocratic conditions (0.1% formic acid in water (v/v) and 
methanol (85:15; v/v) 0.5 ml / min). 
 
4.6.5 Adenosine quantification by mass spectrometry 
The detection of adenosine was performed by HPLC-ESI-MS/MS (API 3200) by positive 
ionization (electrospray ionization, ESI) in multiple reaction monitoring (MRM) mode. The 
transition of protonated [1´,2´,3´,4´,5´-13C5]-adenosine (m/z 273) and adenosine (m/z 268) to 
fragment m/z 136, which corresponds to the mass protonated adenine, were monitored (see 
Figure 4-5 and 4-6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5: Mass scan in positive mode of [1´,2´,3´,4´,5´-
13
C5]-adenosine at Q1(m/z 100-300) 
A 
B 
Adenosine 
[1´,2´,3´,4´,5´-13C5]-Adenosine  
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 +MS2 (268.08) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of Adenosine _InitProduct_Pos.wiff (Turbo Spray) Max. 1.3e6 cps.
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Figure 4-6: Mass scan in positive mode of [1´,2´,3´,4´,5´-
13
C5]-adenosine at Q1(m/z 100-300) 
 
In Table 4-10, the calculated mass-specific parameters used for the measurement of 
adenosine are listed. Due to the strong structural similarity of the analyte and the internal 
standard no differences in the optimized parameters were determined. 
 
Table 4-10: Mass-specific parameters for adenosine quantification 
Parameter Adenosin [1´,2´,3´,4´,5´-13C5]-adenosine 
Q1 [amu] 268 273 
Q3 [amu] 136 136 
Dwell time 
[ms] 
150 150 
Source specific parameters 
CUR [psi] 10 10 
CAD [psi] 5 5 
IS [kV] 5500 5500 
TEM [°C] 390 390 
GS 1 [psi] 40 40 
GS 2 [psi] 80 80 
Substance-specific parameters 
DP 36 41 
EP 3 4.5 
CEP 25 25 
CXP 4 4 
 
CUR: curtain gas, CAD: Collisionally Acivated Dissociation Gas, IS: Ion Spray Voltage, TEM: 
Temperatur, GS 1: Nebulizer Gas, GS 2: Turbo Gas, DP: Declustering Potential, EP: Entrance 
Potential, CEP: Collision Cell Entrance Potential, CXP: Collision Cell Exit Potential 
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4.6.6 Chromatography 
The chromatographic separation of adenosine was carried out with an Aqua C18 column 
(250 × 4.6 mm, 5 u, Phenomenex) at a flow of 0.5 ml /min.  The elution was achieved using 
an isocratic solvent system of 0.1% formic acid in water (v/v) and methanol (85:15; v/v) see 
Table. 4-11, at 8.5 min. A fully automated software controlled the Valco two position valve to 
divert the eluent fractions that contain the analyte in to the mass spectrometer.  The early 
eluting components (before the first 4 minutes) as well as the components after 15 min were 
deviant to waste, thereby reducing contamination of the ion source. 10 µl of sample were 
injected for each measurement. 
Table 4-11: Solvent composition for gradient elution of adenosine 
Time (min) Flow Rate 
(%) 
Eluent A 
(%) 
Eluent B 
(%) 
0.05 0.5 85 15 
11.5 0.5 85 15 
11.7 0.8 1 99 
15.7 0.8 1 99 
16 0.5 85 15 
20 0.5 85 15 
Eluent A: 0.1% formic acid in water (v/v), Eluent B: methanol 
 
4.6.7 Calibration curve for the quantitative analysis of adenosine  
The standard addition method (often referred to as "spiking" the sample) is commonly used 
to determine the concentration of an analyte in a complex matrix such as biological fluids.  
The idea is to add analyte to the sample ("spike" the sample) and monitor the change in 
instrument response [Harris, 1991]. For this purpose (100 nM -final concentration-) of the 
[1´,2´,3´,4´,5´-13C5]-adenosine and known quantities (0, 50, 100, 150 and 200 nM –final 
concentration-) of the analyte were added to the plasma samples (300 µl each sample). 
Thereafter the samples preparation was performed as described in 4.7.1. The instrument 
response was measured for samples (each concentration in triplicate) and data were plotted 
as seen in Figure 4-6. The recovery rate for the analyte in spiked plasma was 102.7±12.8% 
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Figure 4-7: HPLC-ESI-MS/MS Calibration curve (Adenosine 0 – 200 nM). Internal Standard (IS) 
1´,2´,3´,4´,5´-
13
C5]-Adenosin(100 nM). Concentrations are given in nM and the Areas in cps/min.  
 
4.6.8 Detection and quantification limits 
The limit of detection (LOD) expressed as the concentration of a compound is derived from 
the smallest measure that can be detected with reasonable certainty for a given analytical 
procedure based on a signal/ noise ratio of 3:1 [IUPAC, 1997]. 
The limit of quantification (LOQ) is usually defined as twice the limit of detection and gives 
the lowest value that can be quantified reproducibly. The determination of detection and 
quantification limits for adenosine was based on a calibration curve where the peak height 
versus concentration was plotted.  
Based on a background noise of 35 cps the calculated the LOD was 30.6 fmol and the LOQ 
was 61.1 fmol (absolute amount). 
 
4.6.9 Day-to-day variability 
As previously described by Doležalová et al. adenosine concentrations in deproteinized 
blood samples are not stable [Dolezalova et al., 2005]. The inter-assay (between-day) 
variation was determined by replicate analyses of the same sample on three separate days. 
For this purpose, deproteinized blood samples were extracted within 6 h of collection and 
analyzed on HPLC-ESI-MS/MS immediately and after storage at −80°C for 1, 2, 4 and 6 
days. Results are shown in results and discussion section. 
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4.6.10  Blood adenosine quantification materials 
Equipment 
Aqua C18 column (250 × 4.6 mm, 5 u) 
Binary HPLC-Pump  
 
Interface 
Phenomenex 
PU-2080 Plus Intelligent HPLC Pump (Jasco, Groß 
Umstadt) 
LC-Net II/ADC (Jasco, Groß-Umstadt) 
Mass spectrometer with valco valve 
 
Oil rotary vacuum pump 
API 3200 Triple Quadropole (Applied Biosystems, 
Darmstadt) 
Univac (Uniequip) 
Sampler AS-2057 Plus Intelligent Sampler (Jasco, Groß 
Umstadt), 4 °C 
Software 
Vacuum Concentrator Centrifuge 
Analyst 1.4.2 (Jasco, Groß-Umstadt) 
UniVapo 150H (Uniequip) 
 
Chemicals 
[1´,2´,3´,4´,5´-13C5]-adenosine 
Acetic Acid p.a.  
Formic Acid  
K3PO4 
KOH 
MeOH (HPLC grade) 
Perchloric Acid p.a. 
 
Omicron Biochemicals, Inc. 
Roth 
Chemsolute  
Sigma-Aldrich 
Sigma-Aldrich 
J.T. Baker 
Fluka 
 
Consumables 
HPLC-Vials  
Inserts for Vials 
Strata-X 33u polymeric reversed phase 
SPE Tubes (30 mg/ml) 
Pipette tips 
Reaction tubes 
 
Buddeberg  
Wagner & Munz  
Phenomenex 
 
Greiner  
Greiner 
4.7 Intracellular cAMP quantification 
cAMP is one of the most important second messengers, mediating diverse physiological 
responses of neurotransmitters, hormones and drugs.  Intracellular concentration of cAMP is 
tightly regulated by two membrane-bound enzymes, AC and PDE. AC activity promotes the 
synthesis of cAMP from ATP while PDE degrades cAMP to 5´-AMP. The measurement of 
Materials and methods                                                                                        96 
 
                          
intracellular cAMP could be used as a marker for measuring the effect of test compounds on 
AC activation or inhibition. Measurement of intracellular cAMP concentration was carried out 
using the PerkinElmer´s LANCE® Kit. This kit is intended for the quantitative determination of 
adenosine 3',5'-cyclic monophosphate (cAMP) in cell culture and cell membrane samples 
[PerkinElmer and Inc., 2007]. 
4.7.1  Principles of the assay 
The LANCE cAMP assay is a homogeneous time-resolved fluorescence resonance energy 
transfer (TR-FRET) immunoassay designed to measure cAMP produced upon modulation of 
AC activity by G protein-coupled receptors (GPCRs). The assay is based on the competition 
between an europium-labeled cAMP tracer complex and sample cAMP for binding sites of 
cAMP-specific antibodies labeled with the Alexa Fluor®647 dye. The europium-labeled cAMP 
tracer complex is formed by the tight interaction between Biotin-cAMP (b-cAMP) and 
streptavidin labeled with Europium-W8044 chelate (Eu-SA). 
When antibodies are bound to the Eu-SA/b-cAMP tracer, a light pulse at 340 nm excites the 
Eu-chelate molecules of the tracer. The energy emitted by the Eu-chelate is transferred to an 
Alexa molecule on the antibody, which in turn emits light at 665 nm (see figure 4-6). The 
fluorescence intensity measured at 665 nm will decrease in the presence of cAMP from test 
samples and resulting signals are inversely proportional to the cAMP concentration of a 
sample [PerkinElmer and Inc., 2007]. 
 
Figure 4-8:  LANCE cAMP assay principle. From PerkinElmer  [PerkinElmer and Inc., 2007] 
 
4.7.2 Standard curve assay protocol 
The standard curve was carried out according to the manual of PerkinElmer in a final assay 
volume of 24 µl [PerkinElmer and Inc., 2007]. 
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a. 6 μL of each cAMP Standard dilution was added in a well of the half-area Platte 
(measurements were performed in triplicate). The preparation of the standard serial 
dilutions was made according to the Table 4-12. 
 
Table 4-12: Preparation of cAMP Standard serial dilutions 
Dilution 
number 
Final concentration in 
the assay (M) 
Volume of dilution Volume of 
stimulation buffer 
1 1x10-6 8 µL of cAMP 
Standard 
92 µL 
2 3x10-7 30 µL of dil. 1 70 µL 
3 1x10-7 30 µL of dil. 2 60 µL 
4 3x10-8 30 µL of dil. 3 70 µL 
5 1x10-8 30 µL of dil. 4 60 µL 
6 3x10-9 30 µL of dil. 5 70 µL 
7 1x10-9 30 µL of dil. 6 60 µL 
8 3x10-10 30 µL of dil. 7 70 µL 
9 1x10-10 30 µL of dil. 8 60 µL 
10 3x10-11 30 µL of dil. 9 70 µL 
11 1x10-11 30 µL of dil. 10 60 µL 
12 0 0 70 µL 
The dilutions were prepared in stimulation buffer 1X HBSS containing 5 mM HEPES, 0.1% BSA 
and 0.5 mM IBMX at pH 7.4. 
 
b. then 6 μL of antibody solution (1/100 dilution of the Alexa Fluor®647-anti cAMP 
antibody solution in stimulation buffer) were added 
c. Incubation for 60 min at room temperature 
d. addition of 12 μL of detection mix (Eu-W8044 labeled streptavidin plus Biotin-cAMP in 
detection buffer) 
e. coverage of microplate with TopSeal-A film and incubation for 60 min at room 
temperature 
f. read on a TRF detection instrument.  
 
A representative cAMP standard curve is presented in Figure 4-8.  The EC50 was 3.76 nM ± 
0.71 for all repetitions with a detection limit of 1 fmol/well approximately. 
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Figure 4-9: Example of a typical Lance cAMP standard curve measured on EnVision instrument 
after 1 hour incubation in a half-area microplate. 
 
4.7.3 Cell based assay 
4.7.3.1  Cell preparation (in vitro) 
It was necessary to generate Forskolin dose-response curves in order to establish the 
optimal cell number per well.  The optimal cell number was the one for wich the Forskolin 
dose-response curves fits most of the linear region of a cAMP standard curve (see results 
and discussion chapter). For this purpose HEK-293 and SGBS cells (from day 1 to 7 after 
differentiation) were cultured as indicated and then harvested with versene, a non enzymatic 
cell dissociation solution.  Thereafter cells were washed with 1x HBSS and resuspended in 
stimulation buffer at a concentration of 2x106 cells per ml (12000 cells per 6 µl) and further 
diluted to obtain the needed cell number. It is recommended to test 12000, 6000, 3000 and 
1000 cells per 6 µl [PerkinElmer and Inc., 2007].  A “no cell” control and a cAMP Standard 
curve were always run in parallel. The Alexa Fluor 647-labeled antibodies were added to 
the final cell suspension by making a 1/100 dilution of the stock solution in the cell 
suspension. 
The assay was performed in white half-area microplates in a final assay volume of 24 µl, 
following the same protocol as the standard curve.  The preparation of the Forskolin serial 
dilutions was made using a stock solution 500 µM Forskolin according to the Table 4-13. 
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Table 4-13:  Preparation of Forskolin serial dilutions 
Dilution 
number 
 
Forskolin 
(M) 
Final 
concentration in  
12 µl reaction (M) 
Volume of dilution Volume of 
stimulation 
buffer 
1 2x10-4 1x10-4 120 µl of Stock 
solution 
180 µl 
2 6x10-5 3x10-5 30 µL of dil. 1 70 µL 
3 2x10-5 1x10-5 30 µL of dil. 2 60 µL 
4 6x10-6 3x10-6 30 µL of dil. 3 70 µL 
5 2x10-6 1x10-6 30 µL of dil. 4 60 µL 
6 6x10-7 3x10-7 30 µL of dil. 5 70 µL 
7 2x10-7 1x10-7 30 µL of dil. 6 60 µL 
8 6x10-8 3x10-8 30 µL of dil. 7 70 µL 
9 2x10-8 1x10-8 30 µL of dil. 8 60 µL 
10 6x10-9 3x10-9 30 µL of dil. 9 70 µL 
11 2x10-9 1x10-9 30 µL of dil. 10 60 µL 
12 0 0 0 70 µL 
The dilutions were prepared in stimulation buffer 1X HBSS containing 5 mM HEPES, 0.1 % BSA 
and 0.5 mM IBMX at pH 7.4. 
 
To determine the EC50, the Forskolin signal inhibition curve should be transformed to a cAMP 
production curve, using the cAMP standard curve that was measured in parallel.  
 
Agonist concentration 
The presence of an agonist is required to produce Gs alpha (Gαs) and Gi alpha subunit (Gαi) 
antagonist dose-response curves. To determine the optimal concentration of the agonist, two 
agonists dose-response curves were generated: one in the absence of antagonist and the 
other with excess (10µM) of a reference antagonist. The curves were plotted in the same 
graph. The agonist concentration at wich the difference between the two curves is the largest 
was selected. DMSO at concentrations up 2% during cell stimulation does not affected assay 
performance [PerkinElmer and Inc., 2007]. 
 
4.7.3.2 Platelet suspensions preparation (in vivo) 
Platelets suspensions were prepared as described in 6.5.1.2, concentrations were measured 
and data were normalized to protein concentrations. The determination of protein 
concentration was performed according to Bradford [Bradford, 1976]. The cAMP content is 
given in [cAMP nM × mg protein]. 
 
Materials and methods                                                                                       100 
 
                          
4.7.4 Intracellular cAMP quantification materials 
Equipment 
EnVision® multilabel reader 
Optical filters 665 and 615nm 
PerkinElmer 
PerkinElmer 
 
Chemicals 
BSA 
Caffeine 
DMSO 
Forskolin 
HBSS 
Hepes 
IBMX  
Lance® cAMP 384 Kit  
Paraxanthine 
Pyrazines 
Versene  
 
Sigma Aldrich 
Sigma-Aldrich 
Fluka  
Sigma-Aldrich 
Invitrogen 
Roth 
Sigma Aldrich 
PerkinElmer, Massachusetts, USA 
Sigma Aldrich 
Aldrich, SAFC 
Invitrogen 
 
Consumables 
Pipette tips  
Reaction tubes  
Top Seal-A 384 
White, Half-area 96-well microplates 
 
Greiner  
Greiner 
PerkinElmer 
PerkinElmer 
 
4.8 Adenosine deaminase measurements (in vivo) 
Adenosine deaminase (ADA) levels in the plasmas of subjects were measured using a 
commercially available assay kit from Diazyme Laboratories. The ADA assay (see figure 4-8) 
is based on the enzymatic deamination of adenosine to inosine which is converted to 
hypoxanthine by purine nucleoside phosphorylase (PNP). Hypoxanthine is then converted to 
uric acid and hydrogen peroxide (H2O2) by xanthine oxidase (XOD). H2O2 further reacted with 
N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline (EHSPT) and 4-aminoantipyrine (4-AA) 
in the presence of peroxidase (POD) to generate a quinone dye which is monitored in a 
kinetic manner [Diazyme and Laboratories, 2010].  
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Figure 4-10. Adenosine deaminase assay principle. Adenosine deaminase (ADA), purine 
nucleoside phosphorylase (PNP), hydrogen peroxide (H2O2), xanthine oxidase (XOD), N-Ethyl-N-(2-
hydroxy-3-sulfopropyl)-3-methylaniline (EHSPT), 4-aminoantipyrine (4-AA), peroxidase (POD) 
[Diazyme and Laboratories, 2010]. 
 
4.8.1  Plasma collection and handling 
Plasma from venous blood was assayed.  After the obtention of the platelets pellet, the PPP 
(platelet poor plasma) was stored at -80°C. 
 
4.8.2 Assay procedure 
The assay was performed in 96 well non-sterile microplates in a final assay volume of 275 µl, 
following the indications of the protocol [Diazyme and Laboratories, 2010].                          
a) 180 µl of the Reagent 1 (see composition in Table 4-14) and 5 µl of Sample where 
added in the microplate 
b) After three minutes at RT in a dark place, 90 µl of Reagent 2 (see composition in 
Table 4-14) were added and the microplate was incubated at 37 °C within the 
microplate reader 
c) Finally, the absorbance at 550 nm was measured after five and eight minutes 
consecutively 
 
Table 4-14: Reagent composition  of the ADA asay kit  [Diazyme and Laboratories, 2010] 
Reagent Concentration 
Reagent 1 pH 8.0 
Tris HCl 50mM 
4-AA 2mM 
PNP 0.1U/ml 
XOD 0.2U/ml 
Peroxidase 0.6U/ml 
Stabilizers  
Reagent 2 pH 4.0 
Tris HCl 50mM 
Adenosine  10mM 
EHSPT 2mM 
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4.8.3 Calibration and results interpretation 
To calibrate the procedure two standard ADA controls (adenosine deaminase from bovine 
liver and BSA) 10.3 and 47.2 U/L from Diazyme were used along with 0.9% saline as zero 
reference. 
To calculate the ADA activity in Plasma, first the average rate of the absorbance change 
ΔA/min was estimated. Then ADA activity (U/L) in the plasma sample were calculated by 
using the following  formula:  
 
ADA (U/L)= ΔA/min * Tv  /  ε x Sv x L 
 
ε: μmolar extinction coefficient of quinone dye (ε = 32.2 x 10
-3 
μM-1cm
-1
)  
Tv: Total reaction volume (ml)  
Sv: Sample volume (ml)  
L: Cuvette light path length (1.0cm) 
 
4.8.4 Adenosine deaminase materials 
Equipment 
Multidetection microplate reader BioTek, SynergyTM 2 
 
Chemicals 
Adenosine deaminase assay kit 
NaCl 
Diazyme Laboratories, Poway CA, USA 
Merck 
 
Consumables 
96-well microplates (F-bottom, PS) 
Pipette tips 
Reaction tubes 
Greiner 
Greiner 
Greiner 
 
  
 
 
4.9 Statistical analysis 
The results are expressed as arithmetic mean ± standard deviation of mean (SD) or median 
and interquartile range (IQR: from lower quartile, Q1 to upper quartile, Q3). The Anderson 
Darling test was used to verify whether the data were normally distributed. 
The significance of differences was determined with ANOVA for repeated measures followed 
by either the paired Student’s t-test for parametric data. Differences without normal 
distribution were analyzed by the two-sided paired Wilcoxon test or by the unpaired Mann-
Whitney test. 
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5 Results and Discussion  
The present work investigated the question if coffee or coffee constituents may have a 
stimulatory effect on HO-activity in different cell lines such as liver hepatocellular carcinoma 
(HepG2), intestinal colorectal adenocarcinoma (Caco-2) and the monocytic leukemia (MM6) 
cells. Here previously published data showed effects depending on the degree of roasting. 
Therefore two coffee extracts, a slightly (K2) and an intensively roasted coffee (K5), as well 
as the coffee constituents: caffeine, NMP and several alkyl-pyrazines were studied. The 
present work was performed within the project „Coffee Prevention: Charakterisierung, 
Optimierung und Prüfung antioxidativer Effektivität” (Health and Coffee: Characterization, 
optimization and testing of antioxidant effectiveness) funded by the German Federal Ministry 
of Education and Research (BMBF) grant No. 0313843. 
In a follow up project entitled „Slim Down Coffee“: Identifizierung, Prüfung und Optimierung 
der gewichtsreduzierenden Eigenschaften von Kaffee (Identification, analysis and 
optimization of the weight-reducing properties of coffee) the aim was to determine whether 
substances other than caffeine in coffee may influence the homeostasis of intracellular cyclic 
nucleotides in vitro and in vivo. The study was also focused on substances present in coffee 
before roasting but also compounds generated during the roast process which are found in 
brewed coffee were of interest.   
5.1 HO-activity 
Mammalian cells have developed several protective mechanisms to prevent ROS formation 
or to detoxify ROS. These mechanisms involve both antioxidants and protective enzymes. 
Among the various cytoprotective enzymes, the protective functions of HO-1 are described in 
chapter No 2.4.4.  
As increasing evidence indicates that HO-1 provides protection, modulation of HO-1 
expression may represent a novel target for therapeutic intervention. In particular, a non-
cytotoxic pharmacological inducer of HO-1 may increase the intrinsic antioxidant potential of 
cells.  
One of the goals of this work was to determine if coffee or some coffee constituents may 
have a stimulatory effect on HO-activity in different cell lines like Caco-2, HepG2 or 
MonoMac 6 (MM6). Two coffee extracts, a slightly (AB1) and a intensively roasted coffee 
(AB2), caffeine, NMP and some aroma compounds like pyrazines were investigated.  
 
5.1.1 HO-activity assay optimization and screening of positive controls 
The influence of coffee constituents in the total HO-activity was measured using a method 
first described by Tenhungen et al. [Tenhunen et al., 1970] with modifications described by 
Motterlini et al. [Motterlini et al., 1995] and McNally et al. [McNally et al., 2004]. Here the 
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determination of total HO-activity is based on the enzymatic conversion of heme to bilirubin 
via biliverdin (see chapter 4.2). Heme is oxidatively metabolized to biliverdin, which 
dissociates from the HO-1 and is rapidly converted to the hydrophobic molecule, bilirubin, in 
an NADPH-dependent reaction catalyzed by cytosolic biliverdin (BVR). Liver cytosol has 
been used as a source of BVR. HO-activity was assessed in the cell lysate by measuring 
formation of the HO metabolite bilirubin. The amount of extracted, yellow-colored bilirubin 
was determined with a UV spectrometer and correlated with the enzymatic activity of HO. 
For positive evaluation of the newly established method three compounds previously 
described as HO-1 inducers, namely pyrrolidine dithiocarbamate (PDTC), quercetin and 
curcumin (see Figure 5-1) were tested.  
 
 
 
 
    
           PDTC         Curcumin             Quercetin 
 
Figure 5-1: Chemical structures of HO-1 inducers: pyrrolidine dithiocarbamate (PDTC), 
curcumin und quercetin. 
PDTC is a thiol-containing agent, which mediates a variety of effects on cell physiology. 
There is some evidence that PDTC induces expression of HO-1 in vitro in DLD-1 colon 
carcinoma and endothelial cells [Hellmuth et al., 2002; Stuhlmeier, 2000] and in vivo [Hata et 
al., 2003]. Curcumin a yellow colouring ingredient of the spice turmeric obtained from the 
rhizome of Curcuma longa could induce HO-1 expression in dimethyl nitrosamine injured 
liver of rats [Farombi et al., 2008] and renal ephitelial cells [Balogun et al., 2003a]. 
Furthermore, quercetin, a member of the flavonoid family, has been reported to mediate 
cytoprotection through induction of HO-1 in lung epithelial cells [Hayashi et al., 2011] and 
fibroblasts [Nakamura et al., 2011]. 
Three different human neoplastic cancer cell lines were used for this experiment: human 
hepatoma cancer cells (HepG2), human epithelial colorectal adenocarcinoma cells (Caco-2) 
and human acute monocytic leukemia cells (MonoMac6). To determine if these compounds 
provide a high amount of enzyme activity (positive control) cells were exposed to various 
concentrations of the above mentioned inducers (10–1000µM) for 12, 24 and 48 h.  Results 
are shown in Figure 5-2, 5-3 and 5-5.  
Incubation of the three cell lines for 12 hours with various concentrations of selected 
inductors shows no significant differences (see Figure 5-2), except for 1000 µM PDTC in 
HepG2 cells .The basal total HO-activity for the HepG2 and the Caco-2 cell lines was similar, 
whereas MonoMac 6 cells showed almost three times more background activity. 
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Figure 5-2: Effect of PDTC, curcumin and quercetin on HO-activity in HepG2, Caco-2 and MM6 
cells. Cells were exposed for 12 h to medium or medium supplemented with various concentrations of 
compounds (0-1000 µM). Data are expressed as mean ±SD of four to five independent experiments 
(triplicates); normalized to protein content and expressed as picomoles of bilirubin formed per 
milligram protein per hour. Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; 
***p˂0.001 vs. untreated cells). 
Figure 5-3: Effect of PDTC, curcumin and quercetin on HO-activity in HepG2, Caco-2 and 
MM6cells. Cells were exposed for 24 h to medium or medium supplemented with various 
concentrations of compounds (0-1000 µM). Data are expressed as mean ±SD of four to five 
independent experiments (triplicates); normalized to protein content and expressed as picomoles of 
bilirubin formed per milligram protein per hour. Significances were calculated using Student´s t-test 
(*p˂0.05; **p˂0.01; ***p˂0.001 vs. untreated cells). 
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After 24 hours incubation, HO-activity analysis showed an inhomogeneous and complex 
dose response effect among all cell lines under study. HepG2 and Caco-2 cells showed the 
most potent induction of HO-activity after 24 h upon treatment with PDTC 1000 μM together 
with a high cell viability  90.6% ± 2.2% (HepG2) and 85.4% ± 3.9% (Caco-2) viable cells. HO-
activity induction by 1000 µM PDTC for 24h was about 10-fold in HepG2 cells, 5-fold in 
Caco-2 and only 1.4-fold compared to basal HO-activity (see Figure 5-4 A).  
PDTC and quercetin have shown a dose related effect in HepG2 and Caco-2 cells. PDTC 
and quercetin concentrations (100 μM and 1000 μM) caused a significant induction of the 
HO-activity without a substantial reduction of viable cells compared to control treatment. 
MM6 cell line showed no induction of the HO-activity after 24 h of treatment with curcumin 
and quercetin (see Figure 5-4 B+C). 
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Figure 5-4: Viability of cells exposed to PDTC (A), curcumin (B) and quercetin (C) at 37°C. 
HepG2, Caco-2 and MM6 cells were exposed for 24 and 48 h to medium or medium supplemented 
with various concentrations of compounds (0-1000µM). Cell viability was measured using the trypan 
blue viability test (see Materials and methods). Results represent means ±SD of 6 independent 
experiments (triplicates). Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; 
***p˂0.001 vs. control). 
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Figure 5-5: Effect of PDTC, curcumin and quercetin on HO-activity in HepG2, Caco-2 and MM6 
cells. Cells were exposed for 48 h to medium or medium supplemented with various concentrations of 
compounds (0-1000µM). Data are expressed as mean ±SD of four to five independent experiments 
(triplicates); normalized to protein content and expressed as picomoles of bilirubin formed per 
milligram protein per hour. Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; 
***p˂0.001 vs. untreated cells) 
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Concentration response effects after 48 h were neither straight proportional nor uniform 
among different cell lines (see Figure 5-5). In general a large reduction in cell viability below 
60% for all cell lines of all tested substances was observed from 100 µM (see Figure 5-4). 
Therefore, the following experiments were incubated for 24 h with inducers. 
PDTC 1 mM was selected as positive control due to its ability to induce a large amount of 
HO-activity and its reproducibility, without drastically affecting the cell viability in comparison 
to curcumin and quercetin. 
Artifactual H2O2 formation in DMEM (Dulbecco's Modified Eagle Medium) media has been 
previously reported [Bellion et al., 2009; Long et al., 2007]. From the cell lines under study, 
only Caco-2 cells were incubated in DMEM media, where sodium bicarbonate (a constituent 
of DMEM cell culture media) was identified as a strong generator of H2O2 in cell culture 
[Bellion et al., 2009]. Considering the evidence that artifactual H2O2 formation potentially 
influences in vitro antioxidant biomarkers and that quercetin acts as a moderate H2O2 
generator [Bellion et al., 2009], control incubations were performed in presence or absence 
of 100 U/mL catalase, results are shown in Figure 5-6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-6: Modulation of HO activity in HepG2, Caco-2 and MM6 cells after 24 h incubation 
with PDTC (0 –1000 µM with/without catalase 100 U/mL). Data are expressed as mean ±SD of 3 - 5 
independent experiments (triplicates); normalized to protein content and expressed as picomoles of 
bilirubin formed per milligram protein per hour. Significances of untreated vs. catalase-treated cells 
were calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001). 
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The results show almost no difference between the HO-activities in HepG2 and MM6 cells 
incubated with or without catalase.  Furthermore, HO-activity after incubation of Caco-2 cells 
with catalase at 0, 100 and 1000 µM PDTC was slight but significantly lower compared to 
cells incubated without catalase. Evidence shows that H2O2 decreased cell viability but 
increased HO-1 expression in a concentration- and time-dependent manner in human pulp 
cells [Min et al., 2008] and that upregulation of HO-1 protects PC12 (rat adrenal medulla) and  
L02 (normal human hepatic) cells against H2O2 induced cell damage via induction of Nrf2 
pathway [Chen et al., 2005; Chen et al., 2010]. 
 
5.1.2 Influence of coffee constituents on the total HO-activity 
As already mentioned, coffee is a complex mixture consisting of several compounds. 
Recently, kahweol was reported as upregulator of the expression and activity of HO-1 in 
human neuroblastoma SH-SY5Y cells [Hwang and Jeong, 2008]. Likewise, Cavin et al. 
reported a marked induction of mRNA expression of HO-1 in rat liver and primary 
hepatocytes treated with 800 µg/mL of standard instant coffee for 24 h [Cavin et al., 2008]. 
Boettler et al. reported that 100 µg/mL of an extract from NMP enriched coffee elevated the 
HO-1 gene expression in human PBL (peripheral blood leukocytes) after 3 h incubation and 
in HT29 cells after 3 h and 24 h incubation with 100 µg/mL of the same coffee extract. In 
parallel, a pilot intervention trial with 27 healthy moderate coffee drinkers showed an 
increase of HO-1 gene expression after consumption of (500 mL/day) dark roast coffee for 4 
weeks [Boettler et al., 2011b]. 
The effect of various concentrations (1µM – 1mM) of NMP, caffeine, TMP, 2E-3,5 DMP, 2-E-
3-MP, 2MP and two coffee extracts (K2 and K5) on HO-activity of HepG2, Caco2 and MM6 
cells were tested. For each independent experiment the positive control (PDTC 1mM) and 
the negative control (water or DMSO) were run in parallel. Results are shown in Figure 5-7 to 
Figure 5-11 
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Figure 5-7: Effect of NMP (N-methylpyridinium) on HO-activities in HepG2, Caco-2 and MM6 
cells. Cells were exposed for 24h to medium or medium supplemented with various concentrations of 
NMP (0-1000µM). Data are expressed as mean ±SD of five independent experiments (triplicates); 
normalized to protein content and expressed as picomoles of bilirubin formed per milligram protein per 
hour. Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. control). 
 
Results about the NMP induction of the HO-activity in HepG2 (from 0.3 µM) and Caco-2 cells 
(from 10 µM) were consistent with the potential of this coffee compound to elevate HO-1 
gene expression [Boettler et al., 2011b]. It is worth noting that Hwang et al. estimated a 
positive correlation between time-dependent increases in HO-1 mRNA, protein expression 
and enhancement of HO-1 activity in human neuroblastoma cells treated with kahweol 
[Hwang and Jeong, 2008]. This might suggest that a part of the protective effects of NMP 
may be due its potential to stimulate gene and protein expression resulting in increased HO-
1 activity. 
Caffeine, along with its catabolic products theobromine and xanthine, is a key component of 
coffee. Caffeine and its metabolites may also contribute to the overall antioxidant and 
chemopreventive properties of caffeine-containing beverages, such as coffee [Azam et al., 
2003]. The determination of the influence of caffeine on the HO-activity in HepG2 cells were 
performed in the working group as part of a four-weeks training in research work by Y. 
Diener. Results are shown in the Figure 5-8. 
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Figure 5-8: Effect of caffeine on HO-activities in HepG2 cells. Cells were exposed for 24 h to 
medium or medium supplemented with various concentrations of caffeine (0-100µM). Data are 
expressed as mean ±SD of three independent experiments (triplicates); normalized to protein content 
and expressed as picomoles of bilirubin formed per milligram protein per hour. Significances were 
calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. control). 
 
As shown in Fig. 5-8 caffeine up to 1000 µM exhibited no inductive effect on HO-activity of 
HepG2 cells. In fact, Takakusa et al. [Takakusa et al., 2008] reported that HO-1 levels in 
human hepatocytes exposed for 24h to increasing concentrations of caffeine (30, 100, and 
300 µM) were not different from those of the control.  
Tetramethylpyrazine (TMP), an active ingredient of a traditional Chinese herb (Ligusticum 
wallichii Franch) has been widely used especially in the treatment of patients with cerebral 
and cardiac ischemic diseases. In 2006, Chen et al. showed in a rat model of myocardial 
ischemia/reperfusion injury that TMP suppresses ischemia-induced ventricular arrhythmias 
and reduces the infarct size resulting from ischemia/reperfusion (I/R) injury in vivo [Chen et 
al., 2006]. They associated the cardioprotective activity of TMP with its antioxidant activity via 
induction of HO-1 and its capacity to inhibit neutrophils. The authors showed that treatment 
with TMP (10 mg/kg) in non-ischemic myocardium for 2 h strongly induced HO-1 expression. 
The level of HO-1 protein in the control group was quite low, whereas pretreatment with TMP 
5 and 10 mg/kg significantly increased HO-1 protein expression in ischemic. 
To determine if TMP and other alkyl pyrazines with different substitution patterns like 
2E-3,5-DMP, 2E-3-MP and 2-MP have any effect on HO-activity in our model, cells were 
treated for 24 h with various concentrations of pyrazines (0-1000 µM). Incubations with 
2-E-3-MP were performed by the student M. Hiery as part of a four-weeks training research 
work. 
Results and Discussion                                                                                      112 
 
                          
A 
0
5
10
15
20
25
30
35
40
45
50 control PDTC 1mM TMP
*** ***
0.1 0.3  1.0  3.0  10  100 1000  µM 0.1 0.3  1.0  3.0  10  100 1000  µM 0.1 0.3  1.0  3.0  10  100 1000  µM
HepG2 Caco-2 MM6
***
*** ***
*****
***
***
***
*
*
***
***
**
**
H
O
 a
c
ti
v
it
y
 [
 p
m
o
l/
m
g
 p
ro
t/
h
]
 
B 
0
5
10
15
20
25
30
35
40
45
50
control PDTC 1mM 2-E-3,5-DMP
*** ***
0.1 0.3  1.0  3.0  10  100 1000  µM 0.1 0.3  1.0  3.0  10  100 1000  µM 0.1 0.3  1.0  3.0  10  100 1000  µM
HepG2 Caco-2 MM6
**
*** ***
****
***
***
***
***
***
H
O
 a
c
ti
v
it
y
 [
 p
m
o
l/
m
g
 p
ro
t/
h
]
 
Figure 5-9: Effect of TMP (A) and 2-E-3,5-DMP on HO-activities in HepG2, Caco-2 and MM6 
cells. Cells were exposed for 24 h to medium or medium supplemented with various concentrations of 
TMP or 2-E-3,5-DMP (0-100µM). Data are expressed as mean ±SD of five independent experiments 
(triplicates); normalized to protein content and expressed as picomoles of bilirubin formed per 
milligram protein per hour. Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; 
***p˂0.001 vs. control). 
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Figure 5-10: Effect of 2-E-3-MP (A) and 2-MP (B) on HO-activities in HepG2 cells. Cells were 
exposed for 24 h to medium or medium supplemented with various concentrations of 2-E-3-MP or 
2MP (0-100µM). Data are expressed as mean ±SD of three independent experiments (triplicates); 
normalized to protein content and expressed as picomoles of bilirubin formed per milligram protein per 
hour. Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. control). 
 
In general, after 24 hours incubation the effects of the studied pyrazines show a 
nonhomogeneous and complex dose response effects among the studied cell lines. It is 
important to note that highly substituted pyrazines, like TMP and 2-E-3,5-DMP, significantly 
induced the HO-activity in HepG2 and Caco-2 cells at concentrations >1 µM but without a 
clear dose-response relationship. In contrast, 2-E-3-MP and 2-MP showed no effect. 
To achieve an estimation of the potential of coffee as inducer of HO-activity two coffee 
extracts prepared from coffee beans, derived from the same batch of green coffee beans 
(Arabica Brazil, Santos, unwashed) which were roasted in a fluidized bed roaster (RFB 
Neuhaus Neotec) at the Institute of Thermal Separation Processes (Technische Universität 
Hamburg-Harburg) were tested by D. Liesenfeld in his training research. The resulting 
coffees were: a light roast (AB1; 2 min of roasting time) comprising a high CGA content 
(819.2 mg/L) and a dark roast (AB2; 5 min of roasting time) that was extremely high in NMP 
(73.7 mg/L) compared to standard coffees [Bakuradze et al., 2011a; Boettler et al., 2011b]. 
Coffee brews were produced from ground coffee beans as described by Lang et al. [Lang et 
al., 2008]. Briefly, 48 g of coffee powder was placed onto the filter of a conventional coffee 
machine and extracted with 900 mL of (boiling) water; the resulting coffee brews were 
immediately cooled (ice bath) and lyophilized. NMP and CGA were quantified as described 
by Lang et al. and Weiss et al. [Lang et al., 2006; Lang et al., 2008; Weiss et al., 2010]. 
For HO-activity experiments, coffee extracts were dissolved in double distilled water; results 
are shown in Figure 5-11. 
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Figure 5-11: Effects of coffee extracts from a light (AB1) and a dark (AB2) roasted coffee on 
HO-activity in HepG2 cells. Cells were exposed for 24 h to medium or medium supplemented with 
various concentrations of AB1 or AB2 coffee extracts (0.001–100 mg/L) w/o catalase. Data are 
expressed as mean ±SD of five independent experiments (triplicates); normalized to protein content 
and expressed as picomoles of bilirubin formed per milligram protein per hour. Significances were 
calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. control).  
 
Coffee extracts showed a significant induction of HO-activity at high concentrations (from 10 
mg/L for AB1 and 1 mg/mL for AB2). Is worth noting that 100 mg/L AB1 showed similar 
increase in HO-activity as 1 mg/L AB2 extract.  These results indicate that the degree of 
roasting and thereby the composition of the coffee have a major influence on HO-activity 
stimulation. 
The stimulatory effect of NMP and substituted pyrazines on the HO-activity in HepG2 and 
Caco-2 cells has been previously shown (see Figure 5-7 and Figure 5-9) correlates with the 
observed effect of the coffee extract AB2 containing high concentrations of NMP. 
Furthermore, the results obtained by Bottler at al. [Boettler et al., 2011b] where NMP was 
identified as a strong modulator of ARE-dependent gene transcription in vitro, HO-1 gene 
expression ex vivo and in vivo, are in agreement with the findings presented in this work. 
The possibility that other coffee constituents may also play a role for the HO-stimulation must 
be considered, e.g. caffeic acid esters have alredy been described to activate HO-1 gene 
expression in mouse macrophage cells [Suzuki et al., 2006]. Although kahweol was reported 
as upregulator of the expression and activity of HO-1 [Hwang and Jeong, 2008] it is 
important to take into account that this natural component in coffee is degraded by the 
roasting process and largely trapped by the use of a paper filter in coffee preparation.  Until 
now CGA have not shown HO-1 gene expression in vitro and ex vivo [Boettler et al., 2011b; 
Suzuki et al., 2006]. 
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5.2 PDE activity 
Cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the 
phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate 
the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular 
domains. PDEs are therefore important regulators of signal transduction mediated by these 
second messenger molecules [Randall et al., 1997]. While both cyclic nucleotides can be 
transported out of the cell at a low rate, evidence indicates that, quantitatively, the catalytic 
action of PDEs provides the only pathway to rapidly lower cellular cyclic nucleotide content at 
least in the majority of cell types [Beavo et al., 2007].  
The isoenzyme PDE3 has been shown to participate in a complex interplay between insulin 
and cAMP signalling networks, important for the regulation of insulin-induced glucose uptake 
and lipogenesis as well as insulin-induced inhibition of lipolysis in adipocytes [Beavo et al., 
2007].  
The stimulatory actions of the alkylxanthines were thought to occur as a result of inhibition of 
phosphodiesterases. Although this inhibition may contribute to the actions of caffeine (e.g. 
influence on thermogenesis, lipolysis, fat oxidation and insulin secretion) there is growing 
evidence that most pharmacological effects result from antagonism of adenosine receptors 
[Stanley et al., 1989; Varani et al., 2000] and these non-AR-mediated actions require higher 
concentrations of caffeine than those typically ingested with the human diet [Fredholm and 
Jacobson, 2009; Stanley et al., 1989; Wilson and Mustafa, 2009]. 
An  intervention study comprising 33 healthy volunteers showed that daily consumption of 3–
4 cups of a special Arabica coffee brew exerts health beneficial effects, such as reduced 
oxidative damage, body fat mass and energy uptake [Bakuradze et al., 2011a]. 
One of the main objectives of the present work was to investigate whether substances other 
than caffeine in coffee may influence the homeostasis of intracellular cyclic nucleotides in 
vitro and to determine whether it is possible to modulate the phosphodiesterase activity 
through coffee consumption in potential human target cells (in vivo). The interest was 
focused not only on substances present in coffee before roasting but also in those 
compounds generated during roasting which are found in coffee brews. 
 
5.2.1 PDE activity in vitro 
5.2.1.1 PDE experiments in LXFL529L cell lysates 
The assay to measure cAMP-phosphodiesterase activity was performed using lysates of 
large cell lung tumor xenograft cell line LXFL529L [Fiebig et al., 1992]. Previous studies in 
our department showed that Rolipram-sensitive PDE4 isoenzyme represent the highest 
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cAMP hydrolysing activity in this cell line, and 85% of the total activity was localized in the 
cytosol [Kunz, 2000; Marko et al., 2002; Marko et al., 2000]. 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-12: Modulation of cAMP-phosphodiesterase activity by coffee constituents and 
caffeine metabolites in LXFL529L cell lysates. Lysates were directly incubated with various 
concentrations of NMP, caffeine, theophylline or paraxanthine (0.1–5 mM). Data are expressed as 
mean ±SD of four to five independent experiments (triplicates); normalized to protein content and 
expressed as a percentage of the NC. Significances were calculated using Student´s t-test (*p˂0.05; 
**p˂0.01; ***p˂0.001 vs. NC). Positive control: Rolipram (10µM); negative control (NC): 1% DMSO. 
IC50 (half maximal inhibitory concentration) were determined as the mean of the IC50 values of the 
different experiments, each calculated by linear regression. 
 
NMP shows no inhibition of cAMP-hydrolysis in LXFL529L cells. Nevertheless, caffeine, 
paraxanthine (the principal metabolite of caffeine) and theophylline showed a half maximal 
inhibitory concentration (IC50) of 4.8, 1.9 and 0.5 mM respectively. 
Alredy in 1962, Butcher and Sutherland  [Butcher and Sutherland, 1962] demonstrated that 
theophylline and theobromine inhibit PDE. Inhibitory potencies of caffeine and theobromine 
were comparable, whereas theophylline was approximately six-fold more potent. Similarly, 
theophylline showed a stronger inhibitory effect on cAMP hydrolysis of LXFL529L cells 
(approx. 9 times higher compared to caffeine) in our test system. 
An important object of this study was to determine whether some aroma compounds 
generated during the roasting process, show effects on the activity of PDEs. Therefore, a 
total of 12 pyrazines with different substitution patterns, all present in coffee were studied 
(see Figure 5-13). 
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Figure 5-13: Modulation of cAMP-phosphodiesterase activities by twelve pyrazines in 
LXFL529L cell lysates. Lysates were directly incubated with various concentrations of pyrazines 
(0.1–5 mM). Data are expressed as mean ±SD of five independent experiments (triplicates); 
normalized to protein content and expressed expressed as a percentage of the NC. Significances 
were calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. NC). Positive control: 
Rolipram (10µM); negative control (NC): 1% DMSO. IC50 (half maximal inhibitory concentration) were 
determined as the mean of the IC50 values of the different experiments, each calculated by linear 
regression. 
 
Depending on their substitution pattern, pyrazines show either weak or no effect on PDE 
activity. In general, unsubstituted pyrazines and pyrazine derivatives containing only methyl 
group substituents (with the exception of TMP) showed no effect, whereas, pyrazines 
substituted with ethyl groups like 2-E-3,5-DMP, 2-E-5-MP and 2-E-3-MP were able to inhibit 
cAMP-hydrolysis in LXFL529 cell lysates from approx. 1mM. The lowest IC50 values were 
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observed for pyrazine derivatives containing more than one ethyl group like 2-E-3-MP or a 
methoxy functional group as 2-Isobutyl-3-methoxyP (see Figure 5-13). 
To get more profound estimation of the potential of coffee as cAMP hydrolysis inhibitor, six 
coffee extracts were examined. The AB1 and AB2 extracts were previously described in 
chapter 5.1.2. Furthermore, coffees from the human trials (Caffè Crema, reduced caffeine 
coffe, SC and RC) are described in the design of each study.  
Coffee brews were produced from coffee pods (pre-packaged ground coffee beans in their 
individual filter) as indicated to volunteers who participated in the short term study (Cafè 
Crema and caffeine reduced) and in the long term study (reference (RC) and study coffee 
(SC)). From each coffee pod (content 7.8 ± 0.2 g coffee) 110 to 130 mL of coffee were 
brewed, immediately cooled (ice bath) and lyophilized. After lyophilization 14 g/L extract for 
the caffeine reduced coffee, 16 g/L for Caffè Crema and 12 g/L for the RC and SC were 
obtained.  
For PDE activity experiments, coffee extracts were dissolved in double distilled water, results 
are shown in Figure 5-14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-14: Modulation of cAMP-phosphodiesterase activity by different coffee extracts in 
LXFL529L cell lysates. Lysates were directly incubated with various concentrations of coffee extracts 
(0.1–5 µg/mL). Data are expressed as mean ±SD of five independent experiments (triplicates); 
normalized to protein content and expressed expressed as a percentage of the NC. Significances 
were calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. NC). Positive control: 
Rolipram (10µM); negative control (NC): 1% DMSO. IC50 (half maximal inhibitory concentration) were 
determined as the mean of the IC50 values of the different experiments, each calculated by linear 
regression. SCE: study coffee extract; RCE: reference coffee extract. 
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It is well-known from literature that caffeine is a nonselective inhibitor of phosphodiesterases 
[Essayan, 2001]. The observed PDE inhibition effects of coffee extracts AB1 and AB2 (IC50= 
0.42 and and 0.47 mg/mL respectively) can not be attributed solely to caffeine (IC50= 4.8 mM 
≈ 0.9 mg/mL in LXFL529L lysates) see Table 5-1 (see page No. 125). Additionally, the 
inhibitory effect of a extract from a commercial coffee (Caffè Crema), caffeine reduced coffee 
and the coffee extract (SCE) from the SC coffee were similar; with a half maximal inhibitory 
concentration of 2.6, 3.3 and 2.7 mg/mL respectively. For the reference coffee extract (RCE) 
no concentration-response relationship was found. 
In general the coffee extracts AB1 and AB2, rich in pyrazines and NMP, showed potent PDE 
inhibition compared to other investigated coffee extracts samples. 
5.2.1.2 Biomarker evaluation 
The used biomarkers and surrogate endpoints (blood cells) were necessary because they 
were easier, more ethical to obtain and monitored than clinical endpoints (adipocytes). 
Therefore, potential target cells in blood allowing the estimation of the effect of coffee 
consumption on nucleotide homeostasis in humans were preferred. 
It is known from the literature that phosphodiesterase 3 (PDE3) is present in rabbit and 
human erythrocyte membranes and its inhibition by Iloprost induced cAMP [Hanson et al., 
2008]. However phosphodiesterase activity in the particulate fraction of erythrocytes by the 
used method (see Material and Methods chapter) could not be detected. Such results could 
be explained with findings of Nakagawa et al. [Nakagawa et al., 1984], showing that the 
stabilization of PDE during the isolation of erythrocyte membranes is critical to maintain 
enzyme activity, or because,  the major PDE activity present in mammalian (human) 
erythrocytes has been shown to be PDE1 that hydrolyzes cGMP, not cAMP [Petrov et al., 
1998]. 
In contrast, monocytes and lymphocytes isolated following the protocol of Gantner et al. 
[Gantner et al., 1997] showed a robust cAMP hydrolysing activity, both in the particulate 
(45 ± 2 for monocytes and 15 ± 6 pmol/108 cells x min) and in the cytosolic fraction (60 ± 3 
for monocytes and 30 ± 5 pmol/108 cells x min).  Of note, for each experiment 250 mL 
peripheral blood were needed to isolate the required cell number and that  PDE4 was the 
predominant phosphodiesterase in monocytes and lymphocytes (PDE3 is a major PDE in 
adipose tissue). For these reasons these potential target cells were not of use in the long 
term study. 
5.2.1.3 PDE experiments in platelet cell lysates 
cAMP and cGMP are two critical intracellular second messengers with strong inhibitory 
activity on fundamental platelet functions. PDEs, by catalysing the hydrolysis of cAMP and 
cGMP, limit the intracellular levels of cyclic nucleotides, thus regulating platelet function. The 
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inhibition of PDEs may therefore exert a strong platelet inhibitory effect. Platelets possess 
three PDE isoforms, PDE2, PDE3 and PDE5, with different selectivity for cAMP and cGMP 
[Gresele et al., 2011]. 
For the in vitro experiments corresponding to cAMP hydrolysing activity, platelets were 
isolated from PRP plasma (see Material and Methods chapter) or from platelet concentrates. 
Platelet-concentrates were obtained from the DRK-Blutspendedienst (German Red Cross 
Blood Transfusion Service) Baden Württemberg-Hessen in Mannheim. Each platelet 
concentrate was a suspension of human platelets (pooled from four donors) in 255 ml of a 
platelet additive solution and CPD (citrate-phosphate-dextrose) plasma, containing 
approximately 2.0-4.5 x 1011 thrombocytes per preparation.  
A previous characterization of the phosphodiesterases in each batch of platelets was always 
performed using Rolipram (PDE4), Milrinon (PDE3), and Zaprinast (PDE5) as specific 
inhibitors and Ca2+/calmodulin (PDE1) as stimulator. In general, the major effect was shown 
by the selectively PDE3 inhibitor Milrinon (10µM) which inhibited 61.4 ± 2.1% of the total 
PDE activity in platelet lysates (see Figure 5-15). The results are in accordance with previous 
observations of  Sun et al. [Sun et al., 2007], showing that PDE3 is the main PDE expressed 
in platelets and cardiac ventricular myocytes, and is responsible for the functional changes 
caused by PDE inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-15: Profiles of phosphodiesterase activities in human platelets lysates. Lysates were 
directly incubated with Rolipram, Milrinone, Ca
+
/CaM and Zaprinast. Data are expressed as mean ±SD 
of eleven independent experiments (triplicates); normalized to protein content and expressed as a 
percentage of the NC. Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; 
***p˂0.001 vs. NC).  
 
As aforementioned naturally occurring methylxanthines were the earliest PDE inhibitors to be 
discovered, and among them, caffeine was the first [Sutherland and Rall, 1958]. Ardlie and 
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co-workers documented inhibition of platelet aggregation by caffeine and theophylline in 
1967 [Ardlie et al., 1967].  In 1971, Mills and Smith [Mills and Smith, 1971] showed that 
adenosine increases cAMP in platelets and that methylxanthines prevent the conversion of 
cAMP to AMP, acting as PDE inhibitors, thus greatly increasing the inhibitory effects of 
adenosine on platelet aggregation. Caffeine and theophylline also act as nonselective 
adenosine receptor antagonists [Beavo et al., 2007; Gresele et al., 2011]. Results about the 
effect of coffee compounds and coffee extracts on the PDE activity of platelet cell lysates are 
shown in Figure 5-16 to 5-20.  
In general, effects in platelet lysates are comparable to those obtained from LXFL529L cell 
lysates. Tested coffee constituents (except NMP) showed various inhibitory effects on PDE 
activity in platelets (see Figure 5-16). The PDE-inhibitory effect of caffeine was more 
pronounced in lysates of platelets (IC50=0.7 mM) than in LXFL529L cell lysates (IC50=4.8 
mM). Paraxanthine, its mammalian metabolite, and theophylline exhibited similar IC50 values 
(see Table 5-1) in platelet and LXFL529L cell lysates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-16: Modulation of cAMP-phosphodiesterase activities by coffee constituents (caffeine, 
theophylline, paraxanthine and NMP) and caffeine metabolites in platelet lysates. Lysates were 
directly incubated with various concentrations of NMP, caffeine, theophylline or paraxanthine (0.1–5 
mM). Data are expressed as mean ±SD of five independent experiments (triplicates); normalized to 
protein content and expressed as a percentage of the NC. Significances were calculated using 
Student´s t-test (*p<0.05; **p<0.01; ***p<0.001 vs. NC). Positive control: Milrinone (10µM); negative 
control (NC): 1% DMSO. IC50 (half maximal inhibitory concentration) were determined as the mean of 
the IC50 values of the different experiments, each calculated by linear regression. 
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Pyrazines showing a good PDE inhibitory effect on LXFL529L cell lysates were chosen to be 
studied for inhibition of PDE activity from platelet lysates. Tested pyrazines showed PDE 
inhibitory effects similar to caffeine (see  
 
 
Figure 5-17) and were partly cell type dependent Table 5-1 shows for comparison the IC50 
PDE inhibition values for pyrazines in LXFL529L and platelet lysates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-17: Modulation of cAMP-phosphodiesterase activities by selected pyrazines 
(2-Isobutyl-3-methoxyP, 2-E-3,5-DMP, 2,3-DE-5-MP, TMP) in platelet lysates. Lysates were directly 
incubated with various concentrations of pyrazines (0.1–5 mM). Data are expressed as mean ±SD of 
five independent experiments (triplicates); normalized to protein content and expressed as a 
percentage of the NC. Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; 
***p˂0.001 vs. NC). Positive control: Milrinone (10µM); negative control (NC): 1% DMSO. IC50 (half 
maximal inhibitory concentration) were determined as the mean of the IC50 values of the different 
experiments, each calculated by linear regression. 
 
The coffee extracts previously studied in LXFL529L cell lysates were used to determine their 
effects on cAMP hydrolysing activity of platelets lysates, results are shown in Figure 5-18.  
In platelets PDE inhibition by coffee extracts was more efficient by intensively roasted coffee, 
the half maximal inhibitory concentrations of AB1 was 0.5 mg/mL and 0.25 mg/mL for AB2. 
Thus AB2 showed in platelets almost twice as much inhibitory activity as the AB1 coffee 
extract. These results indicate that the degree of roasting has a major influence on PDE 
inhibition since both extracts have similar caffeine content.  
Extracts from Caffè Crema and caffeine reduced coffee showed in the investigated 
concentration range (0.1-5 mg/ml) showed a significant inhibitory effect of the platelets PDE 
activity. For the reference coffee extract (RCE) again no concentration-response relationship 
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was found, though it showed a more potent inhibition of PDE activity when compared with 
LXFL529L results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-18: Modulation of cAMP-phosphodiesterase activities by coffee extracts from AB1, 
AB2, Caffè Crema, caffeine reduced, SCE and RCE coffees in platelet lysates. Lysates were 
directly incubated with various concentrations of coffee extracts (0.1–5 µg/mL). Data are expressed as 
mean ±SD of five independent experiments (triplicates); normalized to protein content and expressed 
expressed as a percentage of the NC. Significances were calculated using Student´s t-test (*p˂0.05; 
**p˂0.01; ***p˂0.001 vs. NC). Positive control: Milrinone (10µM); negative control (NC): 1% DMSO. 
IC50 (half maximal inhibitory concentration) were determined as the mean of the IC50 values of the 
different experiments, each calculated by linear regression. SCE: study coffee extract; RCE: reference 
coffee extract. 
 
Platelet lysates were for PDE activity further analyzed to determine whether the PDE activity 
might be affected by other natural substances present in coffee such as polyphenols. 
Preliminary results are shown in Figure 5-19. 
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Figure 5-19: Modulation of cAMP-phosphodiesterase activities by coffee polyphenols in 
platelet lysates (preliminary data). Lysates were directly incubated with various concentrations of 5-
CQA and caffeic acid (0.1–5 mM). Data are expressed as mean ±SD of five independent experiments 
(triplicates); normalized to protein content and expressed expressed as a percentage of the NC. 
Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. NC). Positive 
control: Milrinone (10µM); negative control (NC): 1% DMSO. IC50 (half maximal inhibitory 
concentration) were determined as the mean of the IC50 values of the different experiments, each 
calculated by linear regression. SCE: study coffee extract; RCE: reference coffee extract. 
 
5-CQA and caffeic acid showed IC50 values of 0.49 and 0.48 mM respectively, which are 
comparable to pyrazines. Is worth noting that the pH of these incubation batch could have an 
artifactual inhibitory effect on PDE activity, therefore, it is recommended to verify these data. 
The results show that different coffee constituents, exhibit caffeine-like PDE inhibition in 
human platelet lysates and that caffeine, polyphenols and some pyrazines might represent 
the main modulating constituents. 
 
Table 5-1: IC50 values for coffee constituents and coffee extracts in LXFL529L and 
platelet concentrate lysates 
Tested compound 
or Extract 
IC50 values* 
LXFL529L Platelets concentrate 
Caffeine 4.8 ± 0.6 mM (≈0.9 mg/mL) 0.7 ± 0.003 mM(≈0.14 mg/mL) 
Paraxanthine 1.9 ± 0.8 mM (≈0.4 mg/mL) 8.5 ± 1.3 mM (≈1.5 mg/mL) 
Theophylline 0.5 ± 0.07 mM (≈0.09 mg/mL) 0.9± 0.06 mM (≈0.  mg/mL) 
AB1 Extract 0.42 ± 0.04 mg/mL 0.5 ± 0.03mg/mL 
AB2 Extract 0.47 ± 0.06mg/mL 0.25± 0.09 mg/mL 
Caffè Crema Extract 3.3 ± 0.8 mg/mL 4.1 ± 0.5 mg/mL 
Caffeine reduced coffee 2.6 ± 0.5 mg/mL 4.2± 1.6 mg/mL 
SCE** 2.7 ± 0.3 mg/mL 3.2± 1.5. mg/mL 
2-E-3,5 DMP 2.0± 0.2 mM (≈0.3 mg/mL) 1.0 ± 0.3mM (≈0.1 mg/mL) 
TMP 1.4± 0.1 mM (≈0.2 mg/mL) 1.6 ± 0.05 mM (≈0.2 mg/mL) 
2,3-DE-6-MP 0.3± 0.02 mM (≈0.1 mg/mL) 0.4± 0.03mM (≈0.1 mg/mL) 
2-E-5-MP 1.7 ± 0.2mM (≈0.2 mg/mL) nd*** 
2-Isobutyl-3-methoxyP 0.6 ± 0.01 mM (≈0.1 mg/mL) 1.0± 0.005 mM (≈0.2 mg/mL) 
5-CQA nd*** 0.49 ± 0.01 mM (≈0.17 mg/mL)
a
 
Caffeic acid nd*** 0.48 ± 0.09 mM (≈0.09 mg/mL)
a
 
 
* IC50 (half maximal inhibitory concentration) values were determined as the mean of the IC50 values of 
the different experiments, each calculated by linear or sigmoidal regression. 
** SCE: study coffee extract 
*** nd: no determined 
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It is known from the literature that caffeine inhibition of PDEs requires high levels (100 –1000 
µM in mouse and pigs cerebral cortex slices) than for interaction with adenosine receptors 
(10 – 100 µM), but the potencies of the metabolites paraxanthine and theobromine respect to 
inhibition of most known PDEs have not been studied [Francis et al., 2011]. Depending on 
the serving size, the caffeine content of beverages and/or food, and the variation in 
clearance times, it is plausible that plasma and cellular caffeine levels could be within the 
range for pharmacological actions on PDEs [Chou and Bell, 2007]. It is also well established 
that the intracellular concentration/action of a PDE inhibitor cannot be confidently predicted 
strictly on the basis of its extracellular concentration [Francis et al., 2011; Thompson, 1991]. 
5.2.1.4  PDE experiments in SGBS cell lysates 
As aforementioned, the clinical endpoint in focus of this work are adipocytes, where the 
production of cAMP is modulated by G-protein-coupled receptors of the Gs/Gi family and 
cAMP degradation is regulated by PDEs. The activation of AC and the subsequent increase 
in intracellular cAMP levels leads to the activation of PKA and the phosphorylation and 
translocation of HSL to fat droplets, thus activating lipolysis. 
As shown in LXFL529L and platelet lysates, caffeine and theophylline weakly inhibit cyclic 
nucleotide PDEs, and additionally show little selectivity among PDE families. However, there 
is evidence that very modest (less than 20%) inhibition of crude PDE activity by 
alkylxanthines resulted in a significant increase in lipolysis [Beavo et al., 2007; Beavo et al., 
1970]. 
For the experiments with adipocytes, the human Simpson-Golabi-Behmel syndrome (SGBS) 
preadipocyte cell strain was used. Cells were obtained from Prof. Dr. M. Wabitsch (University 
of Ulm, Germany) [Wabitsch et al., 2001]. SGBS preadipocytes were seeded at a 
concentration of 5 × 105 cells/petri dishes (in ∅ 92 mm) and cultured until 80 to 90% 
confluence in 10% FBS-containing DMEM/F12 medium supplemented with biotin, 
pantothenic acid and penicillin/streptomycin antibiotics. Every 2 to 3 days cells were washed 
with PBS buffer and the medium was changed (see Material and Methods chapter).  
To induce differentiation, confluent preadipocytes were incubated in DMEM/F12 medium 
containing human transferrin, insulin, cortisol and triiodothyronine, IBMX, Dexamethasone 
and Rosiglitazone for the first 96 h. Subsequently, cells were further differentiated in serum 
free DMEM/F12 medium containing human transferrin, insulin, cortisol and triiodothyronine. 
Every 2 to 3 days the medium was refreshed without washing the cells. After 12 days 
65−85% of the preadipocytes were differentiated into mature adipocytes. The number of 
adipocytes per Petri dish was 1.57 ± 0.56 × 106 (mean ± SD, n = 9). Small lipid droplets were 
visible after approximately 1 week (see Figure 5-20). 
For PDE activity experiments, cells were tested at different stages of differentiation. 
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Preadipocytes (before differentiation)  Preadipocytes (before differentiation) 
Adipocytes (day 10) Adipocytes (day 20) 
Adipocytes (day 27) Adipocytes (day 35) 
 
Figure 5-20: Adipogenic differentiation of SGBS cells. Microphotographs of SGBS cells during 
adipose differentiation cultured acocording to the differentiation protocol [Fischer-Posovszky et al., 
2008]. Cells were viewed under phase contrast using a Zeiss Axiovert 25 inverted microscope and 
images captured using a mounted Canon EOS 33 camera. Intracellular lipid droplets were visible on 
culture day 7 (magnification x 80). On culture day 20 (magnification x 80), the cells are filled with high 
amounts of intracellular lipids and after 35 days aprox. 100% of the preadipocytes were differentiated 
into mature adipocytes (magnification x 25). 
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Very low levels of PDE activity was found in adipocytes during differentiation < 2 pmol cAMP 
(3H)/min*mg protein (see Figure 1-22) compared to e.g. ≈ 200 pmol cAMP (3H)/min*mg 
protein in platelet lysates. It must be noted that elevation of cellular cAMP concentrations is a 
crucial event in the adipocytes differentiation and that factors increasing cellular cAMP, such 
as IBMX or Forskolin, strongly accelerate the initiation of the differentiation program. Thus, it 
was observed that the use of a nonspecific inhibitor of PDEs (IBMX) during the first 4 days of 
differentiation dramatically affected the cAMP-hydrolysis capacity in SGBS cells. Though the 
unspecific PDE inhibitor IBMX is removed after day 4 of differentiation, the cAMP hydrolyzing 
activity in adipocytes, up to day 30, still remains at very low level. 
Additionally, IBMX withdrawal or the use of dibutyryl cAMP (a cell permeable cAMP analog 
which mimics the action of endogenous cAMP) in µM concentrations did not induce 
adipocyte differentiation. 
Likewise, a weak PDE activity was detected in SGBS adipocytes and adipocytes from 
epididymal fat pads isolated according to protocol of Rodbell [Rodbell, 1964] (see Figure 
5-21), that could be significantly inhibited by the PDE3 inhibitor Milrinone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-21: cAMP hydrolysis activity of rat adipocytes and SGBS cells. Lysates were directly 
incubated with Rolipram and Milrinone (10 and 50 µM). Data are expressed as mean ±SD of five 
independent experiments (triplicates); normalized to protein content. Significances were calculated 
using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. untreated cells).  
 
5.2.2 PDE activity in vivo 
5.2.2.1  Short term study with human volunteers 
Ten male and female healthy probands were recruited within the University of Kaiserslautern. 
The inclusion criteria were as follows: age 20–44 years, no known active ongoing disease 
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(apparent good health), nonsmoking status (to avoid contributory effects of nicotine or other 
tobacco alkaloids to caffeine effects or tolerance), average coffee consumers. The exclusion 
criteria were as follows: treatment with any drug (to avoid any interference with the 
autonomic nervous system or with the effects of caffeine; this included therapy with 
sympathomimetic drugs, α- or β-adrenergic receptor blockers, theophylline, and any 
antihypertensive therapy), high performance athletes, existing metabolic disorders/diseases 
and a BMI (in kg/m2) ≥ 30. From 10 volunteers, 2 left the study left the study for private 
reasons. 
This short term intervention was a seven-week human study divided into five phases (see 
Scheme 1). Throughout the study, the volunteers were asked to completely refrain from 
consuming coffee, tea, cola drinks, energy drinks, and other caffeine containing drinks or 
medicaments. A written list of such drinks was provided to the candidates at the time of 
screening.  Written informed consent was obtained from each volunteer. On October 12th 
2010, the short term study was approved by the local Ethics Committee of the Medical 
Association of Rhineland-Palatinate, Germany. 
In this short term study, two different coffees were used. Café Crema coffee consisted in a 
commercial blend of 100% Arabica coffees from Brazil and Peru. The degree of roasting was 
60 SKT for the Brazilian coffee in the Agtron scale (most coffee is roasted between scores of 
25 and 75, with commercial scores primarily between 55 and 75) and 64 SKT for the Peru 
coffee. The degree of roasting of the blend was slightly above 60 SKT, this small difference 
with the caffeine reduced coffee were negligible. The caffeine reduced coffee was a mixture 
of Arabica Brazil (75% decaffeinated with 25% non-decaffeinated coffee), the specified 
degree of roasting for this coffee was 60 SKT. 
 
Table 5-2: Caffeine concentration in coffees of the short term study 
Content  Caffè Crema 
 
Caffeine reduced 
coffee 
Caffeine (% dry matter) 1.23 0.27 
Moisture (%) 4.5 3.8 
 
The 7-week intervention study was designed as follows:  
 week 1, 1st wash-out 
 weeks 2 & 3, coffee uptake (Caffè Crema) 
 week 4, 2nd wash-out 
 weeks 5 & 6, coffee uptake (caffeine reduced coffee) 
 week 7, 3rd wash-out.  
 
 
Probands daily consumed 750 ml of freshly brewed coffee (8 coffee pods, with/without sugar 
in three equal portions: morning, noontime, afternoon). In the wash-out phases, the coffee 
brew was replaced by equal volumes of water (750 ml). Anthropometric measurements were 
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    1 Week                          2 Weeks                      1 Week                      2 Weeks                         1 Week 
1. wash-out                    Caffè Crema             2. wash-out        Caffeine reduced coffee     3. wash-out 
(750 ml Water)               (750 ml daily)             (750 ml Water)          (750 ml daily)               (750 ml Water) 
    
1.BC                    2.BC             3.BC             4.BC                  5.BC            6.BC             7.BC            8.BC 
    
AM                       AM                                     AM                     AM                                   AM               AM 
 
 
 
 
 
performed in fasting during the morning at the beginning and at end of each study phase of 
the study (see Scheme 1). In addition blood sanples were collected each week throughout 
the study (1.BC to 8. BC).  
 
Scheme 1: Study design of the short term human intervention. Blood samples were collected at 8 
time points (red arrows). Caffè Crema coffee or the caffeine reduced coffee were administered 
alternatively on the first or second intervention phase of the study. BC: Blood collection; AM: 
Anthropometric measurements. 
 
Additionally, body weight of subjects was assessed by a medical scales (Seca delta 707, 
Seca, Hamburg, Germany) and body height with a Seca 206 (Seca, Hamburg, Germany) 
measuring tape. The body composition of subjects was determined by a bioimpedance 
analyzer (Maltron-BF-906, Maltron International, UK) and skinfold measurements using a 
SlimGuide skinfold caliper (Creative health products, Michigan, USA) using the 7-folds 
formula of Jackson Pollock [Jackson et al., 1980]. 
The PDEs activities of platelets of volunteers were evaluated in the short term study. For this, 
platelets were isolated from the peripheral venous blood PRP of probands as described in 
the materials and methods chapter. Results of cAMP hydrolyzing activity in platelets of the 8 
volunteers are shown Figure 1-23. The PDE activity significantly increases after the first 
wash-out phase. During the subsequent two-weeks intervention with coffee (Caffè Crema) a 
highly significant inhibition of PDE activity could be observed. This effect was even 
maintained until the next week wash-out phase (2nd wash-out, 5.BC), but returned to the level 
of the 1st wash-out phase (2. BC) during the two-weeks intervention with caffeine reduced 
coffee. A further slight increase in PDE activity was observed in the 2 study weeks with 
caffeine reduced coffee and the last wash-out phase (BC. 6 – 8). 
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Figure 5-22: Modulation of cAMP-phosphodiesterase activities by coffee consumption in 
platelets of volunteers during the course of the short term trial. The data (Box diagrams) are 
normalized to protein content and expressed as PDE activity (cAMP pmol/min x mg protein). 
Significances were calculated using F-test followed by Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 
vs. 1
st
 wash-out).Yellow background: 2 weeks Caffè Crema intervention, green background: 2 weeks 
caffeine reduced coffee intervention.(n=8) 
 
It is possible that results during the coffee intervention may be attributed to a caffeine 
concentration-dependent effect on the platelets PDE activity. As mentioned above, caffeine 
is known as a nonselective inhibitor of phosphodiesterases and the intervention coffees have 
different concentrations of caffeine: Caffè crema (91.6 mg/pod) and caffeine reduced coffee 
(20.8 mg/pod). Furthermore, the possibility of the existence of an adaptative response of the 
platelet PDE to increased levels of intracellular cAMP as previously shown by Huang et al. in 
transgenic mice [Huang et al., 2002] could not be excluded. Nonetheless, in the present 
study we were able to show for the first time that moderate consumption of coffee can 
modulate the activity of platelet phosphodiesterases in vivo. 
5.2.2.2  Long term study 
Subjects 
90 healthy volunteers (42 women and 48 men) were recruited within the University of 
Kaiserslautern, Germany. The inclusion criteria were: age 19–44 years, no known active 
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ongoing disease (apparent good health), BMI between 19-26 (kg/m2), nonsmoking status, 
average daily coffee intake (1 to 3 cups/d). 
The exclusion criteria were as follows: treatment with any medicament, smokers, high 
performance athletes, existing metabolic disorders/diseases, existing irregularity of the 
menstrual cycle, pregnancy, and  BMI (in kg/m2) ≤ 19 or ≥ 26. 
The volunteers were asked to completely refrain from consuming additional caffeinated 
beverages such as coffee, tea, cola drinks, energy drinks, or other caffeine containing drinks 
or medicaments, dietary supplements as well as dark chocolate. A written list of products 
was provided to the candidates at the time of screening. Otherwise, subjects were asked to 
maintain their usual diet. 
Candidates were invited to an information event where detailed information on study design, 
stage and duration of the study was provided. According to the vote of ethics, subjects 
underwent a medical examination to ensure that the health status met the predefined criteria.  
92 study participants were selected on the basis of the medical examination. Written 
informed consent was obtained from each volunteer. 
On December 14th 2010, the protocol was approved by the Ethics Committee of the Medical 
Association of Rhineland-Palatinate, Mainz (Germany). On January 8th 2011 the study was 
started in the Department of Food Chemistry and Toxicology of the University of 
Kaiserslautern with 90 participants who were randomly divided into two groups (A and B). 
From 90 volunteers, 6 did not complete the requirements in the second phase of the trial, 
which resulted in a total of 84 subjects. 
 
Study design 
This was a prospective, double-blind, randomized study with crossover design (see Scheme 
2). The principal investigators and the study participants were kept unaware of which coffee 
group A and B were drinking. 
The long term study comprised 5 phases each of 4 weeks duration (see Scheme 2). In the 
first phase (1st wash-out) both groups consumed at least 750 mL of water distributed through 
out the day. During the first 4 weeks coffee intervention phase, group A consumed the 
reference coffee (RC) while the group B consumed the study coffee (SC). After a further four-
week "2nd wash-out phase” the RC and SC groups were switched (i.e. group A received SC 
and group B RC). The study was completed with a third phase of wash-out for 4 weeks.  
At the beginning of each phase 40 mL of peripheral venous blood was collected from each 
volunteer by medical personnel from the Westpfalz-Klinikum, Kaiserslautern, as approved by 
the ethics committee. Additionally 50 mL urine was collected in a total of 6 sampling 
appointments.  
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Scheme 2: Crossover design used in the long term study.  Blood and urine collection (BC) time 
points are indicated by red arrows. Reference coffee or the study coffee were provided alternatively on 
the first or second intervention phase of the study. Blood samples were collected before and after 
each phase. The 2.BC represents the baseline. 
 
Coffee administration 
In the four-week intervention phase, subjects consumed a total of 750 mL coffee (study or 
reference coffee) throughout the day (6 coffee cups/day, 125 mL each one). Subjects brewed 
their coffee themselves. Therefore, study participants were provided with an automatic pod 
coffee machine (from Tchibo Company). They also received the study or reference coffee 
pods (for 28 days) and instructions for preparing the coffee beverage. For each portion a 
coffee pod (approx. 7.2 g) was brewed with 130 mL of tap water. Finally, approx. 125 ml of 
coffee brew was consumed (without milk and optional addition of sugar). In the wash-out 
phases coffee was replaced by equal volumes of water.  
The optimized study coffee (SC, 3012, 60 SKT) was produced by selection of four individual 
batches from eight industrially roasted coffees. Furthermore, the reference coffee (RC, 2601, 
74SKT) was established from a blend of equal representation the five top-selling ground 
coffees of the German market. It is worth noting that the NMP concentration in the SC was 
more than twice as RC. Composition of the coffees is presented in Table 5-3. 
 
Table 5-3 Concentration of selected constituents of coffees of the long term study 
(4thInterim report/Juli 2011/BMBF: Slim Down Coffee) 
Content  Coffee powder /  Coffee brews 
Reference coffee (RC) Study coffee (SC) 
Caffeine (mg/L)  12.4 / 743.7 13.1 / 769.7 
CQA (mg/L) 19.3/ 1185.8 10.2 / 600.5 
NMP (mg/L)  0.4 / 23.6 1.5 / 72.8 
Trigonelline (mg/L)  6.3 / 379.9 4.1 / 193.6 
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Volunteers filled out daily food intake records for one week prior each blood collection time 
point. Dietary protocols were analyzed using the PRODI® 5 Expert software package (Nutri-
Science GmbH, Freiburg, Germany). 
Additionally, at each visit, body weight of subjects was assessed by a medical scales (Seca 
delta 707, Seca, Hamburg, Germany) and body height with a Seca 206 (Seca, Hamburg, 
Germany) measuring tape. The body composition of subjects was determined by a 
bioimpedance analyzer BIA 101 (SMT medical GmbH, Würzburg) and skinfold 
measurements in a subpopulation (10 volunteers per group) were performed using a 
SlimGuide skinfold caliper (Creative health products, Michigan, USA)  using the 7-folds 
formula of Jackson Pollock [Jackson et al., 1980]. 
The hydrolytic activity of PDEs in platelet lysates of volunteers from the long term study was 
also estimated by the Pöch method [Poch, 1971] (see Material and methods chapter). 
Platelets were isolated from EDTA-anticoagulated blood as previously described and then 
lysed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-23: Modulation of cAMP-phosphodiesterase activities by coffee consumption in 
platelets of volunteers during the course of the long term trial. The data (Box diagrams) are 
normalized to protein content and expressed as PDE activity (cAMP pmol/min x mg protein). The 
Anderson Darling test was used for the analysis of normal distribution. Significances between time 
points were calculated using two-sided, paired Wilcoxon test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. the 
preceding phase) and the analysis of differences between groups using the two-sided, unpaired 
Mann-Whitney test (*p˂0.05; **p˂0.01; ***p˂0.001 A vs.B). Silver background: 4 weeks reference 
coffee intervention, red background: 4 weeks study coffee consumption (n=84). Solid black trendline: 
group A, dash red trendline: group B. In blue: significances between groups. 
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In general, statistically significant differences were observed between the standard treatment 
(reference coffee) and the study coffee, where the study coffee inhibited more effectively the 
PDE activity in the platelets of probands. These results were noteworthy because in the in 
vitro experiments NMP showed no effect on phosphodiesterases activity, but one of the most 
important differences in the composition of the coffees lies in the NMP concentration (SC 
was more than twice as RC, see table 5-3). Remarkably, as indicated in  Figure 5-23, the 
different responses between the first and the second exposure to coffee intervention, where 
the first showed a strong loss of the PDE activity in the platelet lysates of the participants 
while the second coffee phase showed no effect (for the group B). Coffee withdrawals (wash-
out phases) were similar over the study. 
It should be noted that the variability of responses of volunteers to coffee consumption may 
be due to genetic factors [Renda et al., 2012], making it plausible that the obtained results in 
the second coffee phase exposure might be related to an adaptive response of the PDEs to 
the cAMP levels in the platelets as discussed earlier. There is evidence in the literature 
demonstrating that elevating intracellular cAMP levels can provoke increases in PDEs that 
metabolize the cyclic nucleotide, as dampening effect [Huang et al., 2002]. Therefore it was 
of interest to know the intracellular cAMP concentrations in platelets after coffee 
consumption. The data will be presented and discussed in the following chapter. 
 
5.3 Determination of cellular cAMP (3',5'-cyclic adenosine monophosphate) levels 
cAMP is one of the most important second messengers, mediating diverse physiological 
responses of neurotransmitters, hormones, and drugs. Intracellular concentration of cAMP is 
tightly regulated by two membrane bound enzymes, AC and PDE. AC activity promotes the 
synthesis of cAMP from ATP while PDE degrades cAMP to AMP.  
The measurement of intracellular cAMP is thus an ideal method for measuring the effect of 
test compounds on GPCR-mediated AC activation or inhibition that should be accompanied 
by determining effects on the cAMP hydrolytic activity of PDEs. 
The alkylxanthines caffeine and theophylline are the prototypical antagonists of adenosine 
receptors (ARs) which are linked to GPCRs, and their stimulant actions are produced 
primarily through blocking the depressant actions of the adenosine through the A1 and A2A 
ARs. There is growing evidence that most pharmacological effects of xanthines result from 
antagonism of AR. Additionally, the activity of PDE is slowed by methyl xanthines, caffeine, 
or theophylline; thus increasing the intracellular concentration of cAMP. Varani et al. [Varani 
et al., 2000] have shown that treatment with caffeine for 2 weeks with 400 mg/d or 600 mg/d 
for 1 week resulted in  a significant increase (upregulation) of adenosine A2A binding sites, a 
rise in cAMP accumulation, an increase of antiaggregatory effects, and a decrease in 
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calcium levels elicited by the A2A receptor agonist 2-hexynyl-5´-N-
ethylcarboxamidoadenosine (HE-NECA). 
Measurement of intracellular cAMP concentration was carried out using the PerkinElmer 
LANCE® Kit (see Principles of the assay in the Material and methods chapter). This kit is 
intended for the quantitative determination of cAMP in cell culture and cell samples 
[PerkinElmer and Inc., 2007]. 
To study the effects of coffee and its components on the intracellular concentrations of 
cAMP, the assay was performed in vitro using HEK293 and SGBS cells (at different stages 
of differentiation) and in vivo using platelets from the short term and the long term studies. 
 
5.3.1 cAMP in vitro experiments 
Using Forskolin (an AC activator) dose-response curves were generated in order to establish 
the optimal cell number per well.  The optimal cell number was the one for which the 
Forskolin dose-response curves fitted most of the linear region of a cAMP standard curve 
(see Figure 5-24). For this purpose HEK-293 (cell model suggested by the assay producer, 
and therefore taken as reference for the experiments in this work) and SGBS cells (from day 
1 to 20 after differentiation) were cultured, harvested and prepared for the assay as indicated 
in the material and methods chapter.  A “no cell” control and a cAMP standard curve were 
always run in parallel. To determine the half maximal effective concentration (EC50), the 
Forskolin signal inhibition curve was transformed to a cAMP production curve, using the 
cAMP standard curve that was measured in parallel. Cells were incubated parallel with IBMX 
to prevent enzymatic degradation of cAMP by PDEs.   
 
 A                                                                B 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-24: Determination of the optimal HEK-293 cell number. (A) Typical LANCE cAMP 
standard curve, (B) Forskolin dose-response curves for HEK-293 cells; blue curve with 1000 cells/well, 
red 3000 cells/well and green 6000 cells/well. EC50 for Forskolin in 3000 cells/well = 2.25 ± 0.7 µM. 
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The obtained forskolin dose-response with 3000 HEK293 cells/well provides a response that 
falls within the linear region of the cAMP curve and is in good accordance with data 
presented in the assay protocol. Similar experiments were conducted with SGBS cells at 
different time points of the adipose differentiation process. The Forskolin dose-responses for 
6000 cells/well preadipocytes and adipocytes in the 17th day of differentiation are shown in 
the Figure 5-25. 
 
A                                                                      B 
 
 
 
 
 
 
 
 
 
Figure 5-25: Forskolin dose-response of SGBS preadipocytes (A) and adipocytes at the 17
th
 
day of differentiation (B). 6000 cells/well were stimulated with various concentrations of Forskolin (0 
– 0.1mM) for 1h in a 96 half-Area well plates (n=3). 
 
Factors that increase cellular cAMP, such as IBMX or Forskolin, lead to the initiation of the 
differentiation program. There is some evidence that cAMP concentration in adipocytes is 
pivotal during the early stages of adipocyte differentiation [Petersen et al., 2008]. As shown 
observed in Figure 5-25, the Forskolin dose-responses for the SGBS cells at different time 
points of differentiation are diverse. Preadipocytes have an  EC50 of 0.063 ± 0.01 µM while 
adipocytes on day 17 of differentiation have an  EC50 of 19.9 ± 0.2 µM which is 316 times 
higher. It would mean that the stimulatory capacity of the potent activator of AC, Forskolin, 
may exert less stimulatory effect on adipocytes in advanced stages of differentiation. 
These data show that the SGBS cell system is not stable, thus it was necessary to estimate 
the reproducibility of the assay at different stages of differentiation before performing the 
experiments with coffee and coffee compounds. The results showed that adipocytes on day 
17th of differentiation showed similar Forskolin dose-response curves which EC50 between 
10.7 - 20.1 µM (n=7). 
It is well know that the administration of caffeine to fasted humans also causes an increase in 
FFA mobilization. It has been proposed that the mechanism of action of caffeine for the 
increased lipolysis is blockage of adenosine receptors. It has also been shown that it takes 
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much more caffeine to cause fat mobilization in vitro than in vivo [Winder, 1986], which 
suggests that there may be an active metabolite working with caffeine to bring about the 
increase in lipolysis. There is also evidence that the caffeine metabolite paraxanthine might 
play a role in increased lipolysis after caffeine administration to humans [Hetzler et al., 1990].  
The effect of some coffee compounds like caffeine, NMP, chlorogenic acid and trigonellien 
on the cAMP concentration in the SGBS cell model at day 17th of differentiation was 
investigated. For each compound the signal inhibition curve was transformed to a cAMP 
production curve, using the cAMP standard curve that was run in parallel in the same plate. 
Additionally, cells were incubated parallel with IBMX to prevent enzymatic degradation of 
cAMP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-26: Modulation of the cAMP concentration in SGBS cells by caffeine, NMP, 
chlorogenic acid and trigonelline in concentrations between 1 µM and 1 mM. Cells were 
incubated with IBMX, Forskolin (EC50 concentration) and the respective substance in 96 half-area 
plate. Data are expressed as mean ±SD of five independent experiments (triplicates) and normalized 
to protein content. Significances were calculated using Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 
vs. untreated cells). 
 
As shown in Figure 5-26, caffeine significantly increased cAMP concentration in SGBS 
adipocytes at concentrations ≥ 3 µM. A concentration of 6.5 µM caffeine is needed for 
doubling the initial cAMP content in the SGBS cells. Surprisingly, other substances present in 
coffee such as chlorogenic acid and trigonelline were also able to increase the cAMP 
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concentrations in the model with doubling effective concentrations of 0.15 and 0.4 mM 
respectively.  
On the other hand, pyrazines (data not shown) and NMP did not show any effect up to 1mM. 
It is also important to note that the determination of the effect of coffee extracts was not 
possible due to interferences caused by the color of the extracts with the fluorescent signal of 
the immunoassay emitting at 665 nm. 
In vitro experiments on the lipolysis in SGBS cells according to the protocol of Hellmer et al. 
and Lundin et al. [Hellmer et al., 1989; Lundin et al., 1989] were not successful because the 
luciferase enzyme was inactivated by the used microplate, generating a higher decay rate in 
the control experiment. 
5.3.1.1 cAMP platelet concentrations in the short term study  
cAMP concentration in platelets of participants in the short term study was also evaluated. As 
aforementioned, platelets were isolated of probands and data were normalized to protein 
concentrations. cAMP content is given in (cAMP nM per mg protein). 
After the first wash-out phase a decrease of cAMP level in platelets was observed (see 
Figure 5-27). During the subsequent intervention with coffee the cAMP levels increased. A 
further increase was observed after the 2nd wash-out phase (4th week), which is in line with 
data from Borea et al. describing similar increases in cAMP concentrations during caffeine 
withdrawal [Borea et al., 1999]. After the next 1 week coffee intervention (6th BC), with 
caffeine reduced coffee, the cAMP levels decreased almost to the starting point (1st BC) and 
a week later (7. BC) increased again and remained at a similar level over the last wash-out 
period to the end of the study (8.BC). 
As previously mentioned, intracellular concentration of cAMP is tightly regulated by two 
enzymes, AC and PDE. AC activity promotes the synthesis of cAMP from ATP while PDE 
degrades cAMP to AMP.  Even though concentrations of cAMP in the platelets of subjects 
correlate with the PDE activities until the 6.BC (see), the observed phenomenon in the last 
two blood sampling points might be explained with the AC role in the intacellular cAMP 
synthesis. AC can be activated or inhibited by G proteins, which are coupled to membrane 
receptors.  
Platelet maturation and development involve the expression of many receptors on the 
platelet cell surface. Of particular physiological relevance to platelet cAMP concentration are 
the adenosine receptors (A2A and A2B) and the prostacyclin receptors, mainly coupled to 
stimulatory G proteins; the P2Y nucleotide ADP receptors (P2Y12 and P2Y1), and thrombin 
receptors (PAR1), coupled to inhibitory G proteins [Yang et al., 2010b].  
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Figure 5-27: Modulation of cAMP concentration by coffee consumption in platelets of 
volunteers during the course of the trial. The data (Box diagrams) are normalized to protein content 
and expressed as cAMP concentration (nM/mg protein). Significances were calculated using F-test 
followed by Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. 1
st
 wash-out). Yellow background: 2 
weeks Caffè Crema intervention, green background: 2 weeks caffeine reduced coffee intervention 
(n=8). 
 
There is only evidence about the effect of caffeine on adenosine receptors. Varani et al.  
[Varani et al., 2000] published that caffeine consumption (600 mg/d for 1 week or 400 mg/d 
for 2 weeks), upregulated platelet adenosine A2A receptors, which was highly correlated with 
antiaggregatory effects, a rise in cAMP concentration and a decrease in intracellular calcium 
levels. In fact, the upregulation of adenosine A2A receptors caused by intake of caffeine could 
be interpreted to indicate that endogenous adenosine has a tonic influence on human 
platelets, and the presence of the antagonist is counterbalanced by the upregulation of A2A 
receptors [Varani et al., 2000].  
It is important to mention that, although human platelets are anucleate fragments of 
megakaryocytes, they retain cytoplasmic mRNA that could be translated to proteins 
[Gnatenko et al., 2003; Williams et al., 2010]. 
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5.3.1.2 cAMP platelet concentrations in the long term study  
In order to evaluate the long-term effects of coffee consumption on cAMP, platelets of the 
participants in the long term study were isolated and analyzed using a time-resolved 
fluorescence immunoassay [PerkinElmer and Inc., 2007] as described in the Material and 
methods section. Results of the cAMP platelet concentration in the long term study are 
shown in the Figure 5-28. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-28: Modulation of the cAMP concentrations in platelets of volunteers during the 
course of the long term trial. The data (Box diagrams) are normalized to protein content and 
expressed as cAMP concentration (nM/mg protein). The Anderson Darling test was used for the 
analysis of normal distribution Significances between time points were calculated using two-sided, 
paired Wilcoxon test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. the preceding phase) and the analysis of 
differences between groups using the two-sided, unpaired Mann-Whitney test (*p˂0.05; **p˂0.01; 
***p˂0.001 A vs.B). Silver background: 4 weeks reference coffee intervention, red background: 4 
weeks study coffee intervention (n=84). Solid black trendline: group A, dash red trendline: group B. In 
blue: significances between groups. 
 
No changes in the cAMP concentrations of platelets were observed between the 1.BC and 
the 2.BC time points for the group A, while group B experimented first a decrease of the 
cAMP concentrations during the first wash-out phase followed by a significant increase in the 
first coffee phase. In common a significant cAMP increase after the first coffee phase (coffee 
withdrawal, 4.BC) for both groups was shown, despite that the activity of PDE increased 
considerably in this same phase of the study. This observation may be due to an effect 
mediated by platelet surface receptors as previously described in chapter No.2.5.24 . Then 
from 5.BC (second coffee intervention) the values trend to return to the initial cAMP 
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concentrations, phenomenon that correlates with the activity of enzymes phosphodiesterases 
in 5.BC. According to the PDE results, the group B which showed more PDE activity in this 
intervention point showed a stronger decrease of cAMP levels as group A. 
It is important to emphasize, that despite both groups (A and B) behaved similarly over the 
course of the study, but significant differences during the coffee intervention and the first 
wash-out phase were observed. Group B showed a greater response to coffee intervention, 
regardless of whether it was SC or RC, suggesting a greater sensitivity of this group to the 
coffee.  Variability in the physiologic responses to coffee is well documented, with subjects 
totally indifferent to even a large amount of coffee ingestion, and subjects deriving e.g. 
profound cardiovascular and neuropsychological consequences to coffee drinking. Renda et 
al. suggested that part of this variability may be explained by genetic factors [Renda et al., 
2012]. 
Comparing the long and short-term effects of coffee consumption on the cAMP levels in 
platelets of volunteers from both studies, it can be stated that the first phase of coffee 
withdrawal led to an increase in the cAMP concentrations, as also previously described by 
Varani et al. [Varani et al., 2000; Varani et al., 1999]; this effect trends to be regulated rapidly 
by compensatory mechanisms, such as increased activity of PDEs, so that no apparent 
differences were observed within the long term study. 
5.4 Adenosine 
Adenosine is a key endogenous molecule that regulates tissue function by activating four G-
protein-coupled adenosine receptors: A1, A2A, A2B and A3. Since many of the functions of 
adenosine are homeostatic and protective in nature, and in principle, equalize local energy 
requirements with energy supply. The organ- and cytoprotective functions of adenosine also 
include stimulation of angiogenesis and inhibition of inflammatory reactions at the site of 
injury [Spychala, 2000].  
Adenosine quantification in blood was performed by HPLC-ESI-MS/MS as described 
previously by Doležalová et al. [Dolezalova et al., 2005] with some modifications (see 
Material and Methods chapter). As described by these authors, concentrations of adenosine 
in deproteinized blood samples wer not stable. Our interassay (between-day) variation was 
established by replicate analyses of the same sample on three separate days. For this 
purpose, deproteinized blood samples were extracted within 6 h of collection and analyzed 
on LC-MS/MS immediately and after storage at −80°C for 2, 4 and 6 days. 
Intra- (within-day) and inter-assay (between-day) experiments revealed that adenosine 
concentrations in deproteinized blood samples were not stable at RT, with a significant 
elevation of 20 ± 3.6% for the control, same sample after solid-phase extraction (SPE) and 
analyzed immediately on LC-MS/MS (see Figure 5-29). After solid-phase extraction of the 
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deproteinated samples elevated adenosine levels in samples stored at -80 °C for longer than 
2 days (5 ± 4.5%), 4 days (13 ± 2.2%) and 6 days (27 ± 1.1%) were observed. Adenosine 
concentrations remained constant in the extracts stored at room temperature or -80 °C for up 
24h.  In the present work, deproteinized blood samples were extracted within 4h of collection 
and analyzed on LC-MS/MS immediately in order to avoid such quantification artefacts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-29: Intra-assay (within-day) and inter-assay (between-day) variations of the adenosine 
quantification in plasma samples by HPLC-ESI-MS/MS as described in the material and 
methods chapter. % of variation of the method was established by replicate of of three independent 
experiments (triplicates) vs. a deproteinized control blood sample wich was extracted (SPE) and 
immediately analyzed on LC-MS/MS. Samples were also analyzed after 1, 2, 4 and 6 days of storage 
at -80 ° C. Data are expressed as % of the control (mean ±SD). Significances were calculated using 
Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. control). 
 
5.4.1 Effect of coffee consumption on adenosine (ADO) plasma 
concentrations in the platelets of participants in the short term study. 
In 1997 Conlay et al. [Conlay et al., 1997] reported that caffeine, particularly after prolonged 
administration, increases dramatically the levels of adenosine in plasma in rats. They found 
an increase in adenosine concentration after antagonist administration and its reduction after 
antagonist withdrawal, suggesting a receptor-mediated regulation of the plasma adenosine 
(ADO) concentration. As suggested by Fredholm et al. [Fredholm et al., 1999], this finding 
clearly needs to be reproduced, especially in humans. 
Taking into account the stimulatory effect of adenosine on its receptors in platelets, and 
understanding that this effect may affect the homeostasis of intracellular cAMP, the effect of 
coffee consumption on ADO plasma concentrations were determined following the protocol 
previously described in the material and methods chapter. For this purpose EDTA-
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anticoagulated blood samples were deproteinized, extracted and analyzed immediately after 
collection.   
Under normal physiological conditions, human plasma concentrations of ADO in the radial 
artery were 12.0 ± 0.9 nM, in the median cubital vein (17.7 ± 6.5 nM) and in the internal 
jugular vein (14.0 ± 2.8 nM) [Reid et al., 1991; Saito et al., 1999]. Extracellular concentrations 
of ADO are directly linked with the local energy balance. Once the balance between energy 
production (ie. ATP production) and its consumption is disturbed, bidirectional ADO 
transporters pump ADO from the cell. In fact, the level of ADO can increase dramatically to 
10 µM or more following ischemia [Andine et al., 1990; Gunnar, 2010]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-30: Modulation of adenosine (ADO) plasma concentrations by coffee consumption of 
volunteers during the course of the short term trial. The data (Box diagrams) are expressed as 
ADO concentration (nM). Significances were calculated using F-test followed by Student´s t-test 
(*p˂0.05; **p˂0.01; ***p˂0.001 vs. 1
st
 wash-out).Yellow background: 2 weeks Caffè Crema 
intervention, green background: 2 weeks caffeine reduced coffee intervention (n=8). 
 
In contrast to the findings of Conlay et al., adenosine concentrations in plasma of the 
probands, showed no considerable changes during the study. It should be noted that in the 
first wash-out (2.BC) adenosine concentrations in plasma decreased approx. 50% when 
compared to baseline (1. BC), this effect correlates with the decrease in the concentration of 
cAMP in platelets at the same point. During both coffee interventions, values tended to 
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decrease compared with the previous phase wash-out, however, these changes were not 
significant. Additionally, no changes were observed between the responses to both coffees. 
This observation could be supported by Gunnar, who stated that adenosine is subject of a 
quick and effective neutralization by phosphorylation (adenosine kinase) or deamination 
(adenosine deaminase) to keep the concentration of adenosine within a well balanced 
homeostasis [Gunnar, 2010; Spychala, 2000]. 
In order to determine whether changes in adenosine concentrations are detectable in short 
time period after caffeine consumption, as described by Conlay et al. [Conlay et al., 1997], 
sampling was also carried out at 0, 1 and 2 hours after coffee consumption during the first 
phase of intervention. Results are shown in Figure 5-31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-31: Modulation of adenosine plasma concentrations after (0, 1 and 2h) coffee 
consumption. Data (Box diagrams) are expressed as ADO concentration (nM). Significances were 
calculated using ANOVA followed by Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. 0h). (n=8). 
 
Adenosine plasma concentrations of the participants of the short term study after 0, 1 and 2h 
showed no significantly changes. These results shown that short-term adenosine 
homeostasis is not affected by coffee consumption by the used amounts in this work. 
 
5.4.2 Plasma concentrations of ADO in the long term study 
Due to the intricate work methodology, the long-term effect of coffee consumption on plasma 
concentrations of adenosine was estimated in a randomly selected subpopulation of 19 
participants (11 group A and 8 group B) from the long term study. As aforementioned the 
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extracellular concentrations of this purine nucleoside are well regulated by various 
intracellular and extracellular mechanisms. According to data obtained in the short term 
study, no significant changes from the first wash-out phase were observed. Results are 
shown in Figure 5-32. 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-32: Modulation of plasma adenosine concentrations by coffee consum of volunteers 
during the course of the long term trial. The data (Box diagrams) are expressed as plasma ADO 
concentration (nM). The Anderson Darling test was used for the analysis of normal distribution 
Significances between time points were calculated using two-sided, paired Wilcoxon test (*p˂0.05; 
**p˂0.01; ***p˂0.001 vs. the preceding phase) and the analysis of differences between groups using 
the two-sided, unpaired Mann-Whitney test (*p˂0.05; **p˂0.01; ***p˂0.001 A vs.B). Silver background: 
4 weeks reference coffee intervention, red background: 4 weeks study coffee intervention (n=19). 
Solid black trendline: group A, dash red trendline: group B. In blue: significances between groups. 
 
Again a decrease of almost 50% in the first wash-out (2.BC) compared to the 1.BC was 
observed. Then the values remained in the same range of concentration until the end of the 
study, with a slight tendency to return to baseline. In general, no statistically significant 
differences below 1% (p˂0.01) were observed between groups or treatments, considering 
that during the first coffee phase, group B showed a greater increase of the ADO 
concentration in plasma when compared with group A. There is evidence that modifications 
of ADO concentrations are associated with local changes in energy metabolism as indicated 
by increases in levels of pyruvate and lactate and increased phosphorylation of AMP-
activated protein kinase. In fact, adenosine is the end-product of hydrolysis of the universal 
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“energy currency”, ATP, thus energy consumption and adenosine formation are directly 
related [Gunnar, 2010; Porkka-Heiskanen and Kalinchuk, 2011].  
Although volunteers of the short term and the long term studies were asked to maintain their 
usual diet, the possibility cannot be ignore that food consumption records would have been 
useful to show or exclude the participation in a trial, and this may alter the dietary behaviors 
[Kohlmeier, 1994]. Such a change is not very probable given the guidance the participants 
received, but still may have contributed for the dramatic change observed at the time of 
initiating the study (2. BC).  
5.5 Adenosine Deaminase (ADA) 
As mentioned in the state of the art chapter, there are two enzymes that constitute the major 
pathways of adenosine removal: adenosine kinase and adenosine deaminase (ADA). The 
latter enzyme is present mostly intracellularly but is also found in some extracellular 
compartments. The Km for adenosine is well above 5 mM and adenosine deaminase is 
therefore of particular importance when adenosine levels are high [Fredholm et al., 1999]. 
Adenosine kinase, by contrast, has a Km level in the range of physiological intracellular 
adenosine concentrations. Indeed, blockade of adenosine kinase has a much larger effect on 
the rate of adenosine release than the blockade of ADA [Lloyd and Fredholm, 1995]. 
Other possible roles have been proposed for the ecto-ADA (although the location of the 
enzyme is mainly cytosolic, ADA is also found associated to membrane fractions so that its 
active site is available to the exterior environment of the cells), e.g. an interaction between 
adenosine deaminase and A1 adenosine receptors in pig brain cortical membrane [Saura et 
al., 1996] suggesting that A1R could be a second ecto-ADA binding protein and that ADA is 
needed for an effective coupling between A1R and heterotrimeric G proteins [Cristalli et al., 
2001]. 
Many constituents of dietary crude plant material can exert biological effects through ADA 
inhibition (i.e., garlic and onion extracts); among them compounds such as flavonoids and 
sapogenins show interesting biological properties. With respect to coffee compounds, a 
direct inhibitory effect of caffeic and ferulic acid on the enzyme, with IC50 values of 0.06 and 
0.04 mg/mL respectively has been reported [Koch et al., 1992]. 
The effect of coffee consumption on the activity of ADA was determined in plasma samples 
of a human study conducted in 2008 [Bakuradze et al., 2011b]. In this 12-wk intervention 
study, 33 healthy male probands consumed daily 750 mL of freshly brewed black filtered 
coffee (with/without sugar) in three equal portions (morning, noontime, afternoon). In the 
wash-out phases, the coffee brew was replaced by equal volumes of water. The 12-wk 
intervention study was designed as follows: weeks1–4, 1st wash-out; weeks 5–8, coffee 
uptake; and weeks 9–12, 2nd wash-out. Results are shown in Figure 5-33 . 
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ADA levels in the plasmas of subjects were measured as described in the material and 
methods chapter. To calibrate the procedure, two standard ADA controls (adenosine 
deaminase from bovine liver and BSA) 10.3 and 47.2 U/L provided by the manufacturer were 
used along with 0.9% saline as zero reference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-33: Modulation of the adenosine deaminase activity (ADA) by coffee consumption in 
plasma of volunteers during the course of the trial. The data (Box diagrams) are expressed as 
ADA activity (U/L). Significances were calculated using a f-test followed by Student´s t-test (*p˂0.05; 
**p˂0.01; ***p˂0.001 vs. 1
st
 wash-out). Brown box: 4-wk. coffee intervention phase. (n=32). 
 
After the four-week trial intervention ADA significantly increased during the coffee treatment 
compared to the first wash-out phase. Based on these results it was important to clarify, 
whether the observed effect had an influence on the adenosine levels or adenosine 
metabolism.  
For this purpose the short term study was designed to also study effects on ADA. 
Experiments about the ADA activity and uric acid concentrations in plasma were carried out 
by the diplom student Eirich, M.. Results show a significant increase (approx. 30% compared 
to the first wash-out phase) of the ADA enzyme activity during the Caffè Crema intervention 
lasting until the first week of the second coffee intervention with the caffeine reduced coffee. 
Then the activity decreased, returning to baseline levels. Plasmatic uric acid concentrations 
showed no cahnges within the short term study [Eirich, 2011]. 
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5.5.1 Plasma ADA activity in the long term study 
ADA activity in plasma of participants in the long term study was determined. Statistically 
significant differences between groups, from the start of the study and the second wash-out 
phase, and between coffes (SC and RC) in the first coffee intervention phase were observed. 
Results up the first wash-out phase correlate with the observations corresponding to 
adenosine concentrations in plasma (see Figure 5-34).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-34: Modulation of plasma adenosine deaminase activity by coffee consumption of 
volunteers during the course of the long term trial. The data (Box diagrams) are expressed as 
plasma ADA activity (U/L). The Anderson Darling test was used for the analysis of normal distribution 
Significances between time points were calculated using two-sided, paired Wilcoxon test (*p˂0.05; 
**p˂0.01; ***p˂0.001 vs. the preceding phase) and the analysis of differences between groups using 
the two-sided, unpaired Mann-Whitney test (*p˂0.05; **p˂0.01; ***p˂0.001 A vs.B). Silver background: 
4 weeks reference coffee intervention, red background: 4 weeks study coffee intervention (n=84). 
Solid black trendline: group A, dash red trendline: group B. In blue: significances between groups. 
 
Healthy subjects show a plasma ADA activity in the range of 4 – 20 U/L [Diazyme and 
Laboratories, 2010], indicating that the enzymatic activity of ADA in plasma from 98.8% of 
the volunteers was normal. As expected, neither the ADA activity nor the adenosine 
concentrations in plasma were markedly modulated by coffee. This confirms that adenosine 
deaminase acquires particular importance only when adenosine levels are high [Fredholm et 
al., 1999; Gunnar, 2010; Spychala, 2000]. 
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6 General Discussion 
 
Coffee is one of the most widely consumed beverages in the world and has been linked with 
beneficial biological effects. Epidemiological evidence suggests coffee consumption to be 
associated with prevention or delay of degenerative diseases including T2D, Parkinson and 
Alzheimer disease, cardiovascular disease (CVD) and cancer [Deutscher-Kaffeeverband, 
2011; Greenberg et al., 2006; Ranheim and Halvorsen, 2005; Zhang et al., 2009]. Many 
beneficial effects have been attributed to the antioxidant activity of coffee [Bakuradze et al., 
2011a; Bakuradze et al., 2010; Hoelzl et al., 2010]. Additionally, moderate reduction in body 
weight was reported to correlate with regular coffee consumption [Thom, 2007; Tunnicliffe 
and Shearer, 2008]. Coffee beans contain thousands of constituents, including lipids, 
proteins, carbohydrates, vitamins, and minerals. In fact, addressing specific compounds 
responsible for the positive effects of coffee is quite difficult. To date, the majority of research 
on the biological activity of coffee has mainly been focused on caffeine. More recently, the 
acknowledgement that coffee and caffeine are not physiologically equivalent has increased 
the exploration of other coffee constituents [Boettler et al., 2011b; Farah et al., 2006; 
Johnston et al., 2003; Tunnicliffe and Shearer, 2008]. 
The HOs play critical roles in physiological iron homeostasis, antioxidant defense, and, as 
shown from accumulating evidence, in signaling pathways that employ CO as a messenger. 
Particularly, through its enzymatic products HO-1 mediates many cellular functions in 
protecting cells and tissues against inflammation and oxidative stress. Numerous studies 
have indicated the protective function of HO-1 in some diseases, especially in cardiovascular 
conditions [Wu et al., 2011].  
One of the goals of this work was to determine if coffee or some coffee constituents may 
have a stimulatory effect on the HO-activity of intestinal colorectal adenocarcinoma (Caco-2), 
liver hepatocellular carcinoma (HepG2) and monocytic leukemia (Mono Mac 6/ MM6) cell 
lines. Two coffee extracts, a slightly (AB1) and an intensively roasted coffee (AB2), were 
studied along with selected individual compounds (see Table 6-1). 
Caffeine and low substituted pyrazines showed no effect on the HO-actvity of HepG2 cells, 
while NMP and pyrazines with a greater substitution pattern such as TMP and 2-E-3,5-DMP 
significantly induced the HO-activity in HepG2, Caco-2 and in some instances in MM6 cells 
(see Table 6-1). 
NMP, the compound formed during the coffee roasting from trigonelline, showed particularly 
high and reproducible inducing HO-activity in HepG2 and Caco-2 cell lines.  
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Table 6-1: Induction of HO-activity by coffee compounds and coffee extracts in in 
HepG2, Caco-2 and MM6 cells 
Tested compound 
or extract 
Cell line 
HepG2 Caco-2 MM6 
NMP 1 µM* 10 µM* 100µM*** 
Caffeine no effect nd nd 
TMP 1 µM*** 1 µM* 0.1 µM *** 
2-E-3,5-DMP 1 µM* 1 µM* no effect 
2-E-3-MP no effect nd nd 
2-MP no effect nd nd 
AB1 extract 10 mg/L* nd nd 
AB2 extract 1 mg/mL* nd nd 
* lowest concentration showing a significant effect and concentration-response relationship 
** nd: no determined 
*** no concentration-response relationship 
 
The concentration of NMP in both coffee extracts varied considerably (AB1: 9.08 mg/L and 
AB2: 70.53 mg/L) when comparing the lowest effective concentration of both extracts in the 
HepG2 cells (10 mg/L and 1 mg/L respectively) they were in a similar range (0.03 µM and 
0.02 µM) see Table 6-2.  
 
Table 6-2 Lowest concentration of coffee extracts showing a significant effect on the 
HO-activity induction in HepG2 cells and its equivalent content of NMP 
Content  LC* corresponds to  
AB1 10 mg/L 6.3 µg NMP (0.03µM) 
AB2 1 mg/L 4.6 µg NMP (0.02µM) 
* lowest concentration showing a significant effect  
 
An inductive effect of NMP as single compound became measurable from 1 µM in HepG2 
cells. This suggests that in addition to NMP the complex matrix of coffee and presence of 
other substances may play a role. 
Regarding the use of HO as a biomarker in clinical studies, the European Food Safety 
Agency (EFSA) [EFSA, 2011] published an opinion discounting induction of antioxidant 
enzymes (as SOD, catalase glutathione peroxidase and HO) as evidence for claims related 
to the “antioxidant defense system”. Modulation of these enzymes may indicate a biological 
response to oxidative stress of any origin, including diet, and as such is not considered 
specific. May even reflect a pro-oxidant effect of a dietary component. 
The influence of coffee on the HO-1 gene expression has been previously discussed. A 
marked induction of mRNA expression of HO-1 in rat liver and primary hepatocytes treated 
with 800 µg/mL of standard coffee for 24 h was reported by Cavin et al. [Cavin et al., 2008]. 
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Similarly, Boettler et al. reported that an NMP rich-coffee extract elevated the HO-1 gene 
expression in leukocytes and HT29 cells after 3 h and 24 h incubation with 100 µg/mL 
[Boettler et al., 2011b]. The experiments of Boettler et al. were carried out with the same 
coffee extracts i.e. NMP rich coffee extract corresponding to AB2. It may be therefore 
concluded, that considerably more AB2 extract was needed to stimulate gene expression in 
HT29 cells than to achieve the stimulation of HO-1 activity in HepG2 cell line. 
Nrf2/ARE pathway has been proposed as the potential mechanism whereby coffee activates 
phase I and phase II enzyme activity in mice liver [Cavin et al., 2008]. Recently it has been 
shown that 5-CQA and NMP are potent activators of Nrf2-nuclear translocation and 
subsequent ARE-dependent gene transcription in human colon carcinoma cells (HT29) 
[Boettler et al., 2011a].  
Cells have developed defense mechanisms against ROS-induced damage, such as the 
induction of the expression of Phase II detoxifying enzymes [Zhang and Gordon, 2004]. The 
expression of many Phase II detoxifying genes is regulated by the activation of antioxidant or 
electrophile response elements (ARE/EpRE) which are activated via binding of the 
transcription factor Nrf2. Increased nuclear levels of Nrf2 provoke gene transcription of phase 
II detoxifying enzymes. In quiescent cells, Nrf2 is sequestered in the cytoplasm associated 
with Keap1. Activation by ROS or upstream protein kinases induces the translocation of Nrf2 
into the nucleus, its binding to ARE and the onset of the transcription of phase II enzymes 
such HO-1 [Itoh et al., 1997; Thimmulappa et al., 2002]. 
Relatively few studies have implied roles for protein kinases in ho-1 transcriptional regulation. 
In several cell culture models (i.e., primary rat hepatocytes and vascular smooth muscle), 
treatment with dibutylated cAMP and other agonists of protein kinase A (PKA) activated ho-1 
transcription [Durante et al., 1997; Immenschuh et al., 1998; Ryter et al., 2006a]. However, 
this potential interplay between HO-1 and PKA was not evidenced in this work, because 
those substances (such as NMP) that stimulated the HO-1 activity did not show any 
stimulatory effect on intracellular cAMP concentrations and in contrast, those that increased 
intracellular cAMP levels (such as the caffeine) did not affect the activity of HO-1. 
The precise mechanisms underlying the actions of coffee on a reduced risk of several 
chronic and degenerative diseases including cardiovascular disorders, DM, obesity and 
neurodegenerative disorders are incompletely understood. Many effects have been attributed 
to caffeine. However coffee is a mixture of many chemical substances, some of which, such 
as polyphenols, are pharmacologically active [Ferruzzi, 2010]. The main mechanism of 
action of caffeine is to antagonize adenosine receptors; a secondary effect is the inhibition of 
phosphodiesterases [Ribeiro and Sebastiao, 2010], with the subsequent accumulation of 
cyclic AMP and an intensification of the effects of catecholamines [Renda et al., 2012].  
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Although the inhibition of phosphodiesterases may contribute to the actions of caffeine, there 
is growing evidence that most pharmacological effects of this xanthine result from 
antagonism of adenosine receptors.  
One of the main objectives of the doctoral thesis was to investigate whether substances 
other than caffeine in coffee may influence the homeostasis of intracellular cyclic nucleotides 
in vitro and in vivo. The influence of coffee and some coffee compounds on several 
components of the cAMP pathway (see red circles in Figure 6-1) have been investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1: The cAMP Signaling Pathway: investigated parameters in human and partly in cell 
culture studies (in red circles). Adapted from Cronstein [Cronstein, 2011]. and Randall et al. [Randall 
et al., 1997]. 
 
In Table Table 6-3 the results during the coffee phases of two human studies are 
schematically summarized. Results are expressed compared to the first wash-out phase for 
the short term study and the corresponding wash-out phase for the long term study. 
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Table 6-3: Biomarker modulation by coffee consumption during the coffee intervention 
phases in both human studies 
 
 
 
Biomarker 
Short term Study (n=8) Long term study (n=84) 
Caffè Crema 
 
Caffeine reduced 
coffee 
Reference coffee 
(RC) 
Study coffee (SC) 
1
st
 week 2
nd
 week 1
st
 week 2
nd
 week Group A Group B Group A Group B 
PDE activity in 
platelets 
 
p˂0.001 
 
p˂0.001 
   
p˂0.001 
  
p˂0.001 
 
p˂0.001 
cAMP 
concentration in 
platelets 
 
p˂0.01 
 
p˂0.001 
 
p˂0.001 
 
p˂0.001 
 
p˂0.001 
 
p˂0.001 
 
p˂0.001 
 
p˂0.001 
ADO 
concentration in 
plasma 
       
p˂0.01 
 
p˂0.05 
ADA activity in 
Plasma 
* * 
p˂0.001 
* 
p˂0.01 
*     
The Anderson Darling test was used for the analysis of normal distribution. Short term study 
significances were calculated using F-test followed by Student´s t-test (*p˂0.05; **p˂0.01; ***p˂0.001 
vs. 1
st
 wash-out). For the long term study significances between time points were calculated using 
two-sided, paired Wilcoxon test (*p˂0.05; **p˂0.01; ***p˂0.001 vs. the preceding phase) and the 
analysis of differences between groups using the two-sided, unpaired Mann-Whitney test (*p˂0.05; 
**p˂0.01; ***p˂0.001 A vs.B).  
 = No changes; = decrease; = increase  
* Data from [Eirich, 2011] 
 
Caffeine was used for many years to block PDE in biochemical studies until more potent 
(theophylline) and specific (Rolipram) inhibitors became available [Belibi et al., 2002]. There 
is evidence that caffeine inhibition of PDEs in vitro requires higher levels (100 –1000 µM in 
mouse and pigs cerebral cortex slices) than for interaction with adenosine receptors (10 – 
100 µM), but the potencies of its metabolites, paraxanthine and theobromine, for inhibition of 
most known PDEs have not been studied [Francis et al., 2011]. In the current work we found 
that caffeine, theophylline, coffee extracts (AB1 and AB2), volatile pyrazines (2,3-DE-6-MP, 
2-Isobutyl-3-methoxyP), the phenolic compounds 5-CQA and caffeic acid all significantly 
inhibited the basal cytoplasmatic PDE activity in lysates of  LXFL529L cells and platelets. To 
a lesser somewhat extent a PDE inhibition was also found in experiments performed with 
paraxanthine, other coffee extracts (SCE, RCE, Caffè Crema and reduced caffeine coffee), 
and other pyrazines (2-E-3,5-DMP, TMP and 2-E-5-MP (see Table 5-1, results and 
discussion chapter). 
The analysis of interaction of methylxanthines with cAMP homeostasis is complicated by the 
fact that, in addition to inhibiting PDE, they may block A1 and A2 receptors, thereby 
influencing the generation of cAMP [Dousa, 1994]. Binding of adenosine to A1 receptors 
blocks AC, in adipocytes, through the activation of the Gi inhibitory mechanism previously 
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mentioned in the Chapter Nr. 2.5.2.3. By contrast, binding to the A2 subtype, expressed by 
platelets, activates AC through Gs stimulatory protein.  
There is evidence that Rolipram lacks adenosine receptor affinity and primarily blocks PDE 
(as also shown in this work in the LXFL529L cells), elevating basal levels of cAMP, in 
primary polycystic kidney disease cells strongly potentiating the effect of adenosine to 
increase intracellular levels of cAMP [Belibi et al., 2002]. By contrast, caffeine did not 
potentiate the action of adenosine, but at blood concentrations resulting from normal coffee 
consumption acts mainly as an adenosine receptor antagonist. As evidence of antagonism of 
caffeine, the in vitro experiments performed in this work with SGBS adipocytes have shown 
that caffeine at concentrations ≥ 3 µM increased significantly the cAMP levels in a 
concentration dependent manner (see Figure 5-26 in the Results and Discussion chapter). 
Similar effects were also observed with other coffee compounds, such as chlorogenic acid 
and trigonelline at concentrations ≥ 300 µM. NMP showed no effect on cAMP concentrations 
of SGBS cells. 
Moreover, platelets express mainly A2 receptors which are linked to stimulatory G proteins. 
Both in vivo studies (the short term and the long term) showed a significant increase in 
intracellular cAMP levels of platelets in the second phase of coffee withdrawal. This may be 
interpreted, at least in part to reflect the absence of the antagonist caffeine in connection with 
a presumed upregulation of A2A receptors in platelets as a consequence of repeated coffee 
consumption as suggested from data of Varani et al. [Varani et al., 2000; Varani et al., 1999]. 
The latter effect has also been observed in mouse brain [Johansson et al., 1997]. 
Many authors indicate that although human platelets are anucleate fragments of 
megakaryocytes, they retain cytoplasmic mRNA and may translate proteins [Gnatenko et al., 
2003; Williams et al., 2010]. Varani et al. suggested that the observed increase in A2A- 
binding by its selective agonist (HE-NECA), as a response of continuous caffeine treatment 
and that it is unlikely to have been due to the synthesis of new A2A receptors of mature 
platelets. It may more likely occur during differentiation of precursor cells [Varani et al., 
1999]. This would indicate that generation of platelets originating from precursor cells which 
had been exposed to caffeine/coffee may present enhanced adenosine binding density in 
comparison to previously unexposed generations. The same group reported increased 
adenosine A2A receptors alredy at 1 hour after the last dose of caffeine treatment. The effect 
was similar to that obtained at 12 or 60 hours after caffeine withdrawal. Thus suggests that 
the withdrawal was not necessary for the upregulation of A2A receptors [Varani et al., 2000]. 
Taken together, there is evidence that chronic intake of caffeine alters the response of 
platelets to the actions of adenosine and that chronic caffeine consumption may lead to a 
reduction in platelet aggregability as a result of upregulation of adenosine binding sites 
located on the platelet surface. 
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Additionally, cAMP concentrations changed significantly during the first phase of exposure to 
coffee compared with the first wash-out phase (2. BC). This increase is however distinct as 
that observed in the withdrawal phase. It is possible that this phenomenon, could be due to 
the rapid response of PDEs to the effect of the first coffee withdrawal (first wash-out phase/ 
2.BC) as shown in the short term study (short-term effect). Alternatively the study participants 
may not have regularly consumed moderate to high amounts of coffee before entry to the 
study. Based on in vitro studies, many authors have reported that the modulation of the 
enzyme PDE with regular consumption of caffeine and/or coffee is unlikely [Fredholm and 
Jacobson, 2009; Stanley et al., 1989; Wilson and Mustafa, 2009] . Some authors even claim 
that to cause an effective inhibition of PDEs in vivo doses of caffeine near convulsant effects 
are required. Furthermore, they conclude that inhibition of PDEs by caffeine is unlikely to 
significantly contribute to the in vivo pharmacology of moderate doses of caffeine [Tarter et 
al., 1998]. Even though in the in vitro experiments of the present work, the required 
concentrations of caffeine and coffee extracts to obtain a half maximal inhibition were 
unphysiological, it was demonstrated for the first time in vivo that moderate consumption of 
coffee can modulate the activity of platelet phosphodiesterases in humans. 
As aforementioned, in view of the serving size and the variation in clearance times, it cannot 
be excluded that plasma and cellular caffeine levels may come close to the range for 
inhibitory activity on PDEs [Chou and Bell, 2007]. It is also well established that the 
intracellular concentration/action of a PDE inhibitor cannot be confidently predicted strictly on 
the basis of its extracellular concentration [Francis et al., 2011; Thompson, 1991]. It is also 
possible that by inhibiting PDE in conjunction with receptor modulation, moderate 
consumption of coffee/caffeine might affect affect intracellular cAMP concentrations. 
It is worth noting that not only caffeine showed an inhibitory effect in  in vitro experiments. 
Other compounds present in coffee as pyrazines, theophylline, some polyphenols and to a 
lesser extent the major metabolite of caffeine, paraxanthine, also had an inhibitory effect on 
PDE activity of LXFL529L cells and platelets. Thus the degree of roasting has a considerable 
impact on constituents of influence for PDE activity. Out of the compounds under study caffeine, 
coffee polyphenols and some pyrazines represented the main modulating constituents. 
To estimate the interaction of substances in the complex matrix coffee, concentration-
dependent effects on PDE were determined for each compound in combination with fixed 
concentrations of one compound in LXFL529L cells. The interaction of two compounds was 
quantified by determining the combination index (CI), in accordance with the following classic 
isobologram equation [Chou and Talalay, 1984; Tallarida, 2006]. 
 
CI = (D)1/(Dx)1 + (D)2/(Dx)2                               
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Where Dx is the dose of one drug alone required to produce an effect (in this case IC50), and 
(D)1 and (D)2 are the doses of compounds 1 and 2, respectively, in combination that produce 
the same effect. From this analysis, the combined effects of the two coffee compounds can 
be summarized as follows: CI = 1 indicates summation (additive and zero interaction); CI < 1 
indicates synergism; and CI> 1 indicates antagonism 
According with the foregoing the combination of caffeine and paraxanthine with pyrazines 
(2E-3,5-DMP, TMP,  2,3-DE-6-MP, 2-E-5-MP and 2-Isobutyl-3-methoxyP) was not found 
synergistic. Rather the effect found was located in the line of additivity suggesting that each 
constituent contributes to the effect according to its own potency.  
All known PDE catalytic domains interact to some extent with methylxanthines and related 
compounds in a very wide range of affinities. Methylxanthine-related compounds that are 
profoundly potent inhibitors for certain PDEs are ineffective for inhibiting other PDEs [Beavo 
et al., 2007]. Moreover, members of the PDE8 and PDE9 families are not significantly 
inhibited by methylxanthine inhibitors such as IBMX are commonly described as 
“nonspecific”. The affinities of the various PDEs for IBMX vary by more than 100-fold, for 
Zaprinast by more than 1,000-fold, for Sildenafil by more than 7,000-fold, and for Vardenafil 
by more than 300,000- fold [Francis et al., 2011]. In this work, similarly, PDE-inhibitory effect 
were partly cell type/PDE family dependent (PDE4 for LXFL529 and PDE3 the major PDE 
expressed by platelets). Caffeine was seven times more active in platelets than in LXFL529L 
cells, 2-E-3,5-DMP showed a two fold stronger inhibitory activity in platelet concentrates, 
compared to 2-isobutyl-3-methoxyP which was more effective in LXFL529L cells. Thus, 
despite the overall similarities in the catalytic pockets of these enzymes, there are elements 
that strongly discriminate among these compounds. 
As indicated in the chapter Nr. 5.2.2, PDE responses between the first and the second coffee 
intervention phases in both in vivo studies were different. The first exposure to coffee (3.BC) 
showed a strong inhibition of the PDE activity with a simultaneous increase in cAMP 
concentrations in the platelet lysates of the participants (see Table 6-4) while the second 
coffee phase showed no (for group B) or only a slight (for group A) effect when compared 
with the first part of the cross-over intervention. There is ample literature to demonstrate that 
elevating intracellular cAMP levels can provoke increases in PDEs activity, as a so called 
dampening effect [Huang et al., 2002]. In both studies, there was a significant increase in 
intracellular cAMP concentrations during the wash-out phase (4. BC) preceding the second 
coffee phase (see Table 6-4).  
cAMP elevation is known to lead to increased expression and activity of PDEs in other blood 
cells such as monocytes and lymphocytes [Schudt et al., 1996], cultured rat aortic vascular 
smooth muscle cells [Maurice, 1998] and adipocytes from transgenic mice [Huang et al., 
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2002], and this may be the reason of the different responses observed between the first and 
the second coffee phase. 
 
Table 6-4: PDE activity and cAMP modulation by coffee consumption during the long 
term study  
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Silver background: 4 weeks reference coffee intervention red background: 4 weeks study coffee 
intervention (n=84). Data are expressed as mean ±SD. 
 
Conlay et al. [Conlay et al., 1997] reported that adenosine, particularly after prolonged 
administration of caffeine, increases dramatically in rat plasma. They found also an increase 
in adenosine concentration after antagonist administration and its reduction after antagonist 
withdrawal, suggesting a receptor-mediated regulation of the plasma adenosine 
concentration.  
In contrast to the findings of Conlay et al., adenosine concentrations in plasma of the 
probands showed no dramatical changes in both human studies. It should be noted that 
during the first wash-out (2.BC) adenosine concentrations in plasma decreased approx. 50% 
when compared to baseline (1.BC), this effect correlates with the decrease in the 
concentration of cAMP in platelets at the same point. During both coffee interventions, values 
increased (p˂0.05) compared with the previous phase wash-out. Adenosine concentrations 
in plasma of probands showed a significant increase in response to the study coffee 
intervention (p˂0.01 for group A and p˂0.05 for group B). However, in general it can be 
noted that the values remained within a narrow range. This may reflect the fact that 
adenosine is subject of a quick and effective neutralization by phosphorylation (adenosine 
kinase) or deamination (adenosine deaminase) to keep its concentration within a well 
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balanced homeostasis [Gunnar, 2010; Spychala, 2000]. Adenosine plasma concentrations of 
the participants of the short term study after 0, 1 and 2 h showed also no significant changes. 
Taken together, results show that adenosine homeostasis was not considerably affected by 
moderate coffee consumption in both studies. Likewise, adenosine desaminase activity did 
not show large fluctuations in both studies. However, by the long term trial a significant trend 
to decrease after the two coffee intervention phases, especially for group B, was observed.  
As expected, neither the ADA activity nor the adenosine concentrations in plasma were 
markedly modulated by the coffee consumption. Adenosine deaminase acquires particular 
importance only when adenosine levels are high [Fredholm et al., 1999]. 
The precise long term mechanisms underlying the actions of coffee are incompletely 
understood. Many effects have been attributed to caffeine, neglecting that coffee is a mixture 
of many chemical substances, some of which, are pharmacologically active [Ferruzzi, 2010]. 
Some authors suggest that the main mechanism of action of caffeine is to antagonize 
adenosine receptors; a secondary effect is the inhibition of phosphodiesterases [Ribeiro and 
Sebastiao, 2010], with the subsequent accumulation of cAMP and an intensification of the 
effects of catecholamines [Renda et al., 2012]. 
However, it is also well known, that considerable variability exists in the responses to coffee 
drinking. In part, such variability is due to tolerance [Colton et al., 1968], but there is also 
evidence for a genetic background. Individual differences in responses to caffeine may occur 
at the metabolic (pharmacokinetic) or at the drug-receptor level (pharmacodynamic), and 
they can contribute to the quality and magnitude of direct effects as well as to consumption 
[Yang et al., 2010a]. 
Genetic variations which can affect pharmacokinetic and pharmacodynamic responses to 
coffee encompass CYP1A2 gene variants affecting caffeine pharmacokinetics. An A to C 
substitution at position 734 (CYP1A2*1F) decreases enzyme inducibility, which results in 
impaired caffeine metabolism [Renda et al., 2012]. As aforementioned, most pharmacologic 
effects of caffeine result from the antagonism to adenosine, mostly with respect to A2A 
(ADORA2A), receptors [Ongini and Fredholm, 1996]. The C to T genetic variant of the 
ADORA2A gene has been shown to be related to susceptibility to anxiety and sleep changes 
[Renda et al., 2012; Yang et al., 2010a]. Moreover, the 34 C to T genetic mutation of AMP 
deaminase, which catalyzes the deamination of AMP to inositol monophosphate and thus 
reduces enzyme activity, may increase adenosine availability for its receptors [Feldman et 
al., 1999]. Genetic polymorphisms of adrenergic receptors may also contribute to the 
variability in platelets responses to coffee [Beres et al., 2008].  
Altogether the data reported in this work provide evidence that moderate coffee consumption 
positively modulates platelet aggregation, a critical step involved in CVD and thrombosis, by 
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influencing cAMP homeostasis. However, further research and mechanistic in depth studies 
for further substantiation of benefitial health effects of coffee consumption is still needed. 
 
                                                                                                                                160                                                                                            
 
                          
References  161 
 
                          
7.  References  
 
Abdel-Aziz M, Abdel-Rahman HM. 2010. Synthesis and anti-mycobacterial evaluation of some 
pyrazine-2-carboxylic acid hydrazide derivatives. Eur J Med Chem 45:3384-3388. 
Abraham NG. 1991. Molecular regulation--biological role of heme in hematopoiesis. Blood Rev 5:19-
28. 
Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, Mustelin T, Zaccolo M, Houslay M, 
Tasken K. 2004. TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts 
potentiates TCR signaling. J Immunol 173:4847-4858. 
Acheson KJ, Gremaud G, Meirim I, Montigon F, Krebs Y, Fay LB, Gay LJ, Schneiter P, Schindler C, 
Tappy L. 2004. Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am J 
Clin Nutr 79:40-46. 
Adams A, Polizzi V, van Boekel M, De Kimpe N. 2008. Formation of pyrazines and a novel pyrrole in 
Maillard model systems of 1,3-dihydroxyacetone and 2-oxopropanal. J Agric Food Chem 
56:2147-2153. 
Adams TB, Doull J, Feron VJ, Goodman JI, Marnett LJ, Munro IC, Newberne PM, Portoghese PS, 
Smith RL, Waddell WJ, Wagner BM. 2002. The FEMA GRAS assessment of pyrazine 
derivatives used as flavor ingredients. Flavor and Extract Manufacturers Association. Food 
Chem Toxicol 40:429-451. 
Adin CA, Croker BP, Agarwal A. 2005. Protective effects of exogenous bilirubin on ischemia-
reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 288:F778-
784. 
Aerts RJ, Baumann TW. 1994. Distribution and utilization of chlorogenic acid in Coffea seedlings. 
Journal of Experimental Botany 45:497-503. 
Alberts B, Johnson A, Lewis J, Raff M, Bray D, Hopkin K, Roberts K, Walter P. 2004. Essential cell 
biology (2 ed.). New York. 
Almeida AA, Farah A, Silva DA, Nunan EA, Gloria MB. 2006. Antibacterial activity of coffee extracts 
and selected coffee chemical compounds against enterobacteria. J Agric Food Chem 
54:8738-8743. 
Amisten S, Braun OO, Bengtsson A, Erlinge D. 2008. Gene expression profiling for the identification of 
G-protein coupled receptors in human platelets. Thromb Res 122:47-57. 
Amrani-Hemaimi M, Cerny M, Fay LB. 1995. Mechanisms of Formation of Alkylpyrazines in the 
Maillard Reaction. J. Agric. Food Chem. 43:2818-2822. 
References  162 
 
                          
Andine P, Rudolphi KA, Fredholm BB, Hagberg H. 1990. Effect of propentofylline (HWA 285) on 
extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient 
ischaemia. Br J Pharmacol 100:814-818. 
Andreasen MF, Kroon PA, Williamson G, Garcia-Conesa MT. 2001. Esterase activity able to hydrolyze 
dietary antioxidant hydroxycinnamates is distributed along the intestine of mammals. J Agric 
Food Chem 49:5679-5684. 
Applied-Biosystems. 2008. API 3200/4000/5000TM LC-MS/MS System Basic Training. In. 
Ardlie NG, Glew G, Schultz BG, Schwartz CJ. 1967. Inhibition and reversal of platelet aggregation by 
methyl xanthines. Thromb Diath Haemorrh 18:670-673. 
Arendash GW, Cao C. 2010. Caffeine and coffee as therapeutics against Alzheimer's disease. J 
Alzheimers Dis 20 Suppl 1:S117-126. 
Artinian LR, Ding JM, Gillette MU. 2001. Carbon monoxide and nitric oxide: interacting messengers in 
muscarinic signaling to the brain's circadian clock. Exp Neurol 171:293-300. 
Arya M, Rao LJ. 2007. An impression of coffee carbohydrates. Crit Rev Food Sci Nutr 47:51-67. 
Ashihara H. 2006. Metabolism of alkaloids in coffee plants. Braz. J. Plant Physiol 18:1-8. 
Astrup A, Andersen T, Christensen NJ, Bulow J, Madsen J, Breum L, Quaade F. 1990. Impaired 
glucose-induced thermogenesis and arterial norepinephrine response persist after weight 
reduction in obese humans. Am J Clin Nutr 51:331-337. 
Azam S, Hadi N, Khan NU, Hadi SM. 2003. Antioxidant and prooxidant properties of caffeine, 
theobromine and xanthine. Med Sci Monit 9:BR325-330. 
Bakhiya N, Appel KE. 2010. Toxicity and carcinogenicity of furan in human diet. Arch Toxicol 84:563-
578. 
Bakuradze T, Lang R, Hofmann T, Stiebitz H, Bytof G, Lantz I, Baum M, Eisenbrand G, Janzowski C. 
2010. Antioxidant effectiveness of coffee extracts and selected constituents in cell-free 
systems and human colon cell lines. Mol Nutr Food Res 54:1734-1743. 
Bakuradze T, Boehm N, Janzowski C, Lang R, Hofmann T, Stockis JP, Albert FW, Stiebitz H, Bytof G, 
Lantz I, Baum M, Eisenbrand G. 2011a. Antioxidant-rich coffee reduces DNA damage, 
elevates glutathione status and contributes to weight control: Results from an intervention 
study. Mol Nutr Food Res 55:793-797. 
Bakuradze T, Bohm N, Baum M, Eisenbrand G, Janzowski C. 2011b. Investigation on 
preventive/antioxidative effectiveness of coffee in probands. Naunyn-Schmiedebergs Archives 
of Pharmacology 383:80. 
References  163 
 
                          
Balogun E, Foresti R, Green CJ, Motterlini R. 2003a. Changes in temperature modulate heme 
oxygenase-1 induction by curcumin in renal epithelial cells. Biochem Biophys Res Commun 
308:950-955. 
Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, Motterlini R. 2003b. Curcumin 
activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive 
element. Biochem J 371:887-895. 
Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM. 1992. Ferritin: a 
cytoprotective antioxidant strategem of endothelium. J Biol Chem 267:18148-18153. 
Baum M, Fauth E, Fritzen S, Herrmann A, Mertes P, Rudolphi M, Spormann T, Zankl H, Eisenbrand 
G, Bertow D. 2005. Acrylamide and glycidamide: approach towards risk assessment based on 
biomarker guided dosimetry of genotoxic/mutagenic effects in human blood. Adv Exp Med Biol 
561:77-88. 
Beaudoin MS, Graham TE. 2011. Methylxanthines and human health: epidemiological and 
experimental evidence. Handb Exp Pharmacol:509-548. 
Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland EW, Newman EV. 1970. Effects of 
xanthine derivatives on lipolysis and on adenosine 3',5'-monophosphate phosphodiesterase 
activity. Mol Pharmacol 6:597-603. 
Beavo JA, Francis SH, Houslay MD. 2007. Cyclic Nucleotide Phosphodiesterases in Health and 
Disease. Boca Raton, FL. 
Beldi G, Wu Y, Sun X, Imai M, Enjyoji K, Csizmadia E, Candinas D, Erb L, Robson SC. 2008. 
Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver 
regeneration. Gastroenterology 135:1751-1760. 
Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ. 2002. The effect of 
caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney 
disease. J Am Soc Nephrol 13:2723-2729. 
Belitz H-D, Grosch W, Schieberle P. 2009. Food chemistry. 4th Edition. Heidelberg. 
Bellion P, Olk M, Will F, Dietrich H, Baum M, Eisenbrand G, Janzowski C. 2009. Formation of 
hydrogen peroxide in cell culture media by apple polyphenols and its effect on antioxidant 
biomarkers in the colon cell line HT-29. Mol Nutr Food Res 53:1226-1236. 
Bender AT, Beavo JA. 2006. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical 
use. Pharmacol Rev 58:488-520. 
References  164 
 
                          
Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli B, Autschbach F, Meuer S, 
Buchler MW, Friess H. 2005. Inhibition of heme oxygenase-1 increases responsiveness of 
pancreatic cancer cells to anticancer treatment. Clin Cancer Res 11:3790-3798. 
Beres BJ, Toth-Zsamboki E, Vargova K, Laszlo A, Masszi T, Kerecsen G, Preda I, Kiss RG. 2008. 
Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease 
patients on dual antiplatelet therapy. Thromb Haemost 100:829-838. 
Berger D, Winterhalter B, Fiebig H. 1992. Establishment and characterization of human tumor 
xenografts in thymus aplastic nude mice. Contr Oncol 42:23-46. 
Berger FI, Feld J, Bertow D, Eisenbrand G, Fricker G, Gerhardt N, Merz KH, Richling E, Baum M. 
2011. Biological effects of acrylamide after daily ingestion of various foods in comparison to 
water: a study in rats. Mol Nutr Food Res 55:387-399. 
Berridge MJ. 1985. The molecular basis of communication within the cell. Sci Am 253:142-152. 
Biaggioni I, Paul S, Puckett A, Arzubiaga C. 1991. Caffeine and theophylline as adenosine receptor 
antagonists in humans. J Pharmacol Exp Ther 258:588-593. 
Bishop-Bailey D. 2010. The platelet as a model system for the acute actions of nuclear receptors. 
Steroids 75:570-575. 
Bjellaas T, Stolen LH, Haugen M, Paulsen JE, Alexander J, Lundanes E, Becher G. 2007. Urinary 
acrylamide metabolites as biomarkers for short-term dietary exposure to acrylamide. Food 
Chem Toxicol 45:1020-1026. 
Blake MJ, Castro L, Leeder JS, Kearns GL. 2005. Ontogeny of drug metabolizing enzymes in the 
neonate. Semin Fetal Neonatal Med 10:123-138. 
Boettler U, Sommerfeld K, Volz N, Pahlke G, Teller N, Somoza V, Lang R, Hofmann T, Marko D. 
2011a. Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE)-
dependent gene expression. J Nutr Biochem 22:426-440. 
Boettler U, Volz N, Pahlke G, Teller N, Kotyczka C, Somoza V, Stiebitz H, Bytof G, Lantz I, Lang R, 
Hofmann T, Marko D. 2011b. Coffees rich in chlorogenic acid or N-methylpyridinium induce 
chemopreventive phase II-enzymes via the Nrf2/ARE pathway in vitro and in vivo. Mol Nutr 
Food Res 55:798-802. 
Boon PE, de Mul A, van der Voet H, van Donkersgoed G, Brette M, van Klaveren JD. 2005. 
Calculations of dietary exposure to acrylamide. Mutat Res 580:143-155. 
Borea PA, Varani K, Portaluppi F, Merighi S, Ongini E, Belardinelli L. 1999. Caffeine alters A2A 
adenosine receptors and their function in human platelets. Circulation 99:2499-2502. 
References  165 
 
                          
Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254. 
Busserolles J, Megias J, Terencio MC, Alcaraz MJ. 2006. Heme oxygenase-1 inhibits apoptosis in 
Caco-2 cells via activation of Akt pathway. Int J Biochem Cell Biol 38:1510-1517. 
Butcher RW, Sutherland EW. 1962. Adenosine 3',5'-phosphate in biological materials. I. Purification 
and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to 
characterize adenosine 3',5'-phosphate in human urine. J Biol Chem 237:1244-1250. 
Cantergiani E, Brevard H, Krebs Y, Feria-Morales A, Amadò R, Yeretzian C. 2001. Characterisation of 
the aroma of green Mexican coffee and identification of mouldy/earthy defect. European Food 
Research and Technology 212:648-657. 
Casal S, Oliveira MB, Alves MR, Ferreira MA. 2000. Discriminate analysis of roasted coffee varieties 
for trigonelline, nicotinic acid, and caffeine content. J Agric Food Chem 48:3420-3424. 
Castro A, Jerez MJ, Gil C, Martinez A. 2005. Cyclic nucleotide phosphodiesterases and their role in 
immunomodulatory responses: advances in the development of specific phosphodiesterase 
inhibitors. Med Res Rev 25:229-244. 
Cavin C, Marin-Kuan M, Langouet S, Bezencon C, Guignard G, Verguet C, Piguet D, Holzhauser D, 
Cornaz R, Schilter B. 2008. Induction of Nrf2-mediated cellular defenses and alteration of 
phase I activities as mechanisms of chemoprotective effects of coffee in the liver. Food Chem 
Toxicol 46:1239-1248. 
CIVO-TNO. 1999. Volatile components in food. TNO Nutrition and food research Supplement 5, 6th 
ed. 
Clark JE, Foresti R, Green CJ, Motterlini R. 2000. Dynamics of haem oxygenase-1 expression and 
bilirubin production in cellular protection against oxidative stress. Biochem J 348 Pt 3:615-619. 
Clifford MN. 2000. Chlorogenic acids and other cinnamates – nature, occurrence, dietary burden, 
absorption and metabolism. J Sci Food Agric 80:1033-1043. 
Colton T, Gosselin RE, Smith RP. 1968. The tolerance of coffee drinkers to caffeine. Clin Pharmacol 
Ther 9:31-39. 
Conlay LA, Conant JA, deBros F, Wurtman R. 1997. Caffeine alters plasma adenosine levels. Nature 
389:136. 
Corbin J, Francis S, Zoraghi R. 2006. Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil 
over sildenafil. Int J Impot Res 18:251-257. 
References  166 
 
                          
Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, Camaioni E. 2001. Adenosine 
deaminase: functional implications and different classes of inhibitors. Med Res Rev 21:105-
128. 
Cronstein BN. 2011. Adenosine receptors and fibrosis: a translational review. F1000 Biol Rep 3:21. 
Czerny M, Grosch W. 2000. Potent odorants of raw Arabica coffee. Their changes during roasting. J 
Agric Food Chem 48:868-872. 
Czerny M, Mayer F, Grosch W. 1999. Sensory study on the character impact odorants of roasted 
arabica coffee. J Agric Food Chem 47:695-699. 
Chan ES, Cronstein BN. 2002. Molecular action of methotrexate in inflammatory diseases. Arthritis 
Res 4:266-273. 
Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, Reiss AB, Pillinger MH, Chen 
JF, Schwarzschild MA, Friedman SL, Cronstein BN. 2006. Adenosine A(2A) receptors play a 
role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol 148:1144-1155. 
Chaves VE, Frasson D, Kawashita NH. 2011. Several agents and pathways regulate lipolysis in 
adipocytes. Biochimie. 
Chen C, Pung D, Leong V, Hebbar V, Shen G, Nair S, Li W, Kong AN. 2004a. Induction of detoxifying 
enzymes by garlic organosulfur compounds through transcription factor Nrf2: effect of 
chemical structure and stress signals. Free Radic Biol Med 37:1578-1590. 
Chen CY, Jang JH, Li MH, Surh YJ. 2005. Resveratrol upregulates heme oxygenase-1 expression via 
activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 331:993-
1000. 
Chen GG, Liu ZM, Vlantis AC, Tse GM, Leung BC, van Hasselt CA. 2004b. Heme oxygenase-1 
protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in 
papillary thyroid carcinoma cells. J Cell Biochem 92:1246-1256. 
Chen MC, Ye YY, Ji G, Liu JW. 2010. Hesperidin upregulates heme oxygenase-1 to attenuate 
hydrogen peroxide-induced cell damage in hepatic L02 cells. J Agric Food Chem 58:3330-
3335. 
Chen SY, Hsiao G, Hwang HR, Cheng PY, Lee YM. 2006. Tetramethylpyrazine induces heme 
oxygenase-1 expression and attenuates myocardial ischemia/reperfusion injury in rats. J 
Biomed Sci 13:731-740. 
Chen Z, Huo JR, Yang L, Zhu HY. 2011. Effect of ligustrazine on mice model of hepatic veno-
occlusive disease induced by Gynura segetum. J Gastroenterol Hepatol 26:1016-1021. 
References  167 
 
                          
Chou KH, Bell LN. 2007. Caffeine content of prepackaged national-brand and private-label carbonated 
beverages. J Food Sci 72:C337-342. 
Chou T. 1992. Wake up and smell the coffee. Caffeine, coffee, and the medical consequences. West J 
Med 157:544-553. 
Chou TC, Talalay P. 1984. Quantitative-Analysis of Dose-Effect Relationships - the Combined Effects 
of Multiple-Drugs or Enzyme-Inhibitors. Advances in Enzyme Regulation 22:27-55. 
Christensen B, Mosdol A, Retterstol L, Landaas S, Thelle DS. 2001. Abstention from filtered coffee 
reduces the concentrations of plasma homocysteine and serum cholesterol--a randomized 
controlled trial. Am J Clin Nutr 74:302-307. 
Christian MS, Brent RL. 2001. Teratogen update: evaluation of the reproductive and developmental 
risks of caffeine. Teratology 64:51-78. 
Dallas C, Gerbi A, Tenca G, Juchaux F, Bernard FX. 2008. Lipolytic effect of a polyphenolic citrus dry 
extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. 
Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE). Phytomedicine 15:783-
792. 
Davi G, Patrono C. 2007. Mechanisms of disease: Platelet activation and atherothrombosis. New 
England Journal of Medicine 357:2482-2494. 
de Roos B, Caslake MJ, Stalenhoef AF, Bedford D, Demacker PN, Katan MB, Packard CJ. 2001. The 
coffee diterpene cafestol increases plasma triacylglycerol by increasing the production rate of 
large VLDL apolipoprotein B in healthy normolipidemic subjects. Am J Clin Nutr 73:45-52. 
Dekker MJ, Gusba JE, Robinson LE, Graham TE. 2007. Glucose homeostasis remains altered by 
acute caffeine ingestion following 2 weeks of daily caffeine consumption in previously non-
caffeine-consuming males. Br J Nutr 98:556-562. 
del Castillo MD, Gordon MH, Ames JM. 2005. Peroxyl radical-scavenging activity of coffee brews. 
European Food Research and Technology 221:471-477. 
Del Rio D, Stalmach A, Calani L, Crozier A. 2010. Bioavailability of coffee chlorogenic acids and green 
tea flavan-3-ols. Nutrients 2:820-833. 
Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, Stevenson DK. 1995. Hyperbilirubinemia results 
in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med 
19:395-404. 
Deutscher-Kaffeeverband. 2011. http://www.kaffee-wirkungen.de/. 
References  168 
 
                          
Devlin TM. 2002. Textbook of biochemistry with clinical correlations (5th ed.). New York. Wiley-Liss 
Editors. 
Dhalla AK, Chisholm JW, Reaven GM, Belardinelli L. 2009. A1 adenosine receptor: role in diabetes 
and obesity. Handb Exp Pharmacol:271-295. 
Diaz-Rubio ME, Saura-Calixto F. 2007. Dietary fiber in brewed coffee. J Agric Food Chem 55:1999-
2003. 
Diaz-Rubio ME, Saura-Calixto F. 2011. Beverages have an appreciable contribution to the intake of 
soluble dietary fibre: a study in the Spanish diet. Int J Food Sci Nutr. 
Diazyme, Laboratories. 2010. Adenosine Deaminase Assay Kit. In. Poway. CA USA. 
Doerge DR, Young JF, McDaniel LP, Twaddle NC, Churchwell MI. 2005. Toxicokinetics of acrylamide 
and glycidamide in Fischer 344 rats. Toxicol Appl Pharmacol 208:199-209. 
Doi K, Akaike T, Fujii S, Tanaka S, Ikebe N, Beppu T, Shibahara S, Ogawa M, Maeda H. 1999. 
Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and 
implications for tumour growth. Br J Cancer 80:1945-1954. 
Dolezalova P, Krijt J, Chladek J, Nemcova D, Hoza J. 2005. Adenosine and methotrexate 
polyglutamate concentrations in patients with juvenile arthritis. Rheumatology (Oxford) 44:74-
79. 
Dong Q, Ginsberg HN, Erlanger BF. 2001. Overexpression of the A1 adenosine receptor in adipose 
tissue protects mice from obesity-related insulin resistance. Diabetes Obes Metab 3:360-366. 
Doroshyenko O, Fuhr U, Kunz D, Frank D, Kinzig M, Jetter A, Reith Y, Lazar A, Taubert D, 
Kirchheiner J, Baum M, Eisenbrand G, Berger FI, Bertow D, Berkessel A, Sorgel F, Schomig 
E, Tomalik-Scharte D. 2009. In vivo role of cytochrome P450 2E1 and glutathione-S-
transferase activity for acrylamide toxicokinetics in humans. Cancer Epidemiol Biomarkers 
Prev 18:433-443. 
dos Santos MD, Almeida MC, Lopes NP, de Souza GE. 2006. Evaluation of the anti-inflammatory, 
analgesic and antipyretic activities of the natural polyphenol chlorogenic acid. Biol Pharm Bull 
29:2236-2240. 
Dousa TP. 1994. Cyclic-3',5'-nucleotide phosphodiesterases in the cyclic adenosine monophosphate 
(cAMP)-mediated actions of vasopressin. Semin Nephrol 14:333-340. 
Dousa TP. 1999. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and 
pathophysiology of the kidney. Kidney Int 55:29-62. 
Droge W. 2003. Oxidative stress and aging. Adv Exp Med Biol 543:191-200. 
References  169 
 
                          
DSMZ. 2004. German Collection of Microorganisms and Cell Cultures. http://www.dsmz.de/. 
Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, Chantre P, Vandermander J. 1999. 
Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h 
energy expenditure and fat oxidation in humans. Am J Clin Nutr 70:1040-1045. 
Durante W, Christodoulides N, Cheng K, Peyton KJ, Sunahara RK, Schafer AI. 1997. cAMP induces 
heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth 
muscle. Am J Physiol 273:H317-323. 
EFSA. 2009. Technical report of EFSA prepared by Data Collection and Exposure Unit (DATEX) on 
“Monitoring of furan levels in food”.The EFSA Scientific Report. In: EFSA, editor.: European 
Food Safety Authority. 
EFSA. 2011. Panel on Dietetic Products, Nutrition and Allergies (NDA); Guidance on the scientific 
requirements for health claims related to antioxidants, oxidative damage and cardiovascular 
health. EFSA Journal 9:2474. 
Ehrenberg L, Tornqvist M. 1991. Human health risk assessment and biological reactive intermediates: 
hemoglobin binding. Adv Exp Med Biol 283:641-647. 
Eirich M. 2011. Diplom arbeit: Einfluss von Kaffeeauf die Enzymaktivität der Adenosin Desaminase 
und Plasmaharnsäure. TU Kaiserslautern, Lebesmittelchemie. Germany. 
Eisenbrand G, Schreier P. 2006. 2. Auflage. Römpp Lexikon Lebensmittelchemie. Stuttgart: Georg 
Thieme Verlag. 
Essayan DM. 2001. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108:671-680. 
Eteng MU, Eyong EU, Akpanyung EO, Agiang MA, Aremu CY. 1997. Recent advances in caffeine and 
theobromine toxicities: a review. Plant Foods Hum Nutr 51:231-243. 
Fan LH, Wang KZ, Cheng B, Wang CS, Dang XQ. 2006. Anti-apoptotic and neuroprotective effects of 
Tetramethylpyrazine following spinal cord ischemia in rabbits. BMC Neurosci 7:48. 
Fang J, Sawa T, Akaike T, Greish K, Maeda H. 2004. Enhancement of chemotherapeutic response of 
tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 109:1-
8. 
Farag NH, Whitsett TL, McKey BS, Wilson MF, Vincent AS, Everson-Rose SA, Lovallo WR. 2010. 
Caffeine and blood pressure response: sex, age, and hormonal status. J Womens Health 
(Larchmt) 19:1171-1176. 
Farah A, de Paulis T, Trugo LC, Martin PR. 2005. Effect of roasting on the formation of chlorogenic 
acid lactones in coffee. J Agric Food Chem 53:1505-1513. 
References  170 
 
                          
Farah A, de Paulis T, Moreira DP, Trugo LC, Martin PR. 2006. Chlorogenic acids and lactones in 
regular and water-decaffeinated arabica coffees. J Agric Food Chem 54:374-381. 
Farombi EO, Shrotriya S, Na HK, Kim SH, Surh YJ. 2008. Curcumin attenuates dimethylnitrosamine-
induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem 
Toxicol 46:1279-1287. 
FDA. 2011. Select Committee on GRAS Substances (SCOGS) Opinion: Caffeine. 
http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/GRA
SSubstancesSCOGSDatabase/ucm256650.htm. 
Federal Ministry of Economics and Technology, 2011. German Business Portal. http://www.german-
business-portal.info/GBP/Navigation/en/Service/new-archiv,did=370408.html. 
Feldman AM, Wagner DR, McNamara DM. 1999. AMPD1 gene mutation in congestive heart failure: 
new insights into the pathobiology of disease progression. Circulation 99:1397-1399. 
Feng R, Lu Y, Bowman LL, Qian Y, Castranova V, Ding M. 2005. Inhibition of activator protein-1, NF-
kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. 
J Biol Chem 280:27888-27895. 
Ferruzzi MG. 2010. The influence of beverage composition on delivery of phenolic compounds from 
coffee and tea. Physiol Behav 100:33-41. 
Fiebig HH, Berger DP, Dengler WA, Wallbrecher E, Winterhalter BR. 1992. Combined in vitro/in vivo 
test procedure with human tumor xenografts for new drug development. Contributions to 
oncology 42: Immunodeficient mice in oncology:321-351. Karger: Basel. 
Fischer-Posovszky P, Newell FS, Wabitsch M, Tornqvist HE. 2008. Human SGBS cells - a unique tool 
for studies of human fat cell biology. Obes Facts 1:184-189. 
Flament I, Bessiere-Thomas Y. 2002. Coffee Flavor Chemistry. England: John Wiley & Sons Editors. 
Follett JR, Suzuki YA, Lonnerdal B. 2002. High specific activity heme-Fe and its application for 
studying heme-Fe metabolism in Caco-2 cell monolayers. Am J Physiol Gastrointest Liver 
Physiol 283:G1125-1131. 
Fondevila C, Shen XD, Tsuchiyashi S, Yamashita K, Csizmadia E, Lassman C, Busuttil RW, Kupiec-
Weglinski JW, Bach FH. 2004. Biliverdin therapy protects rat livers from ischemia and 
reperfusion injury. Hepatology 40:1333-1341. 
Foresti R, Clark JE, Green CJ, Motterlini R. 1997. Thiol compounds interact with nitric oxide in 
regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and 
peroxynitrite anions. J Biol Chem 272:18411-18417. 
References  171 
 
                          
Foresti R, Hoque M, Monti D, Green CJ, Motterlini R. 2005. Differential activation of heme oxygenase-
1 by chalcones and rosolic acid in endothelial cells. J Pharmacol Exp Ther 312:686-693. 
Francis SH. 2005. Phosphodiesterase 11 (PDE11): is it a player in human testicular function? Int J 
Impot Res 17:467-468. 
Francis SH, Sekhar KR, Ke H, Corbin JD. 2011. Inhibition of cyclic nucleotide phosphodiesterases by 
methylxanthines and related compounds. Handb Exp Pharmacol:93-133. 
Fredholm BB. 2010. Adenosine receptors as drug targets. Exp Cell Res 316:1284-1288. 
Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. 2001. International Union of Pharmacology. 
XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552. 
Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. 1999. Actions of caffeine in the brain with 
special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83-133. 
Fredholm BB, Chen JF, Masino SA, Vaugeois JM. 2005. Actions of adenosine at its receptors in the 
CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 45:385-412. 
Fredholm BB, Jacobson KA. 2009. Daly and the early characterization of adenosine receptors. 
Heterocycles 79:73-83. 
Freshney R. 1994. Animal Cell Culture. A Practical Approach. Second edition. Oxford. IRL Editors. 
Fuhr U, Boettcher MI, Kinzig-Schippers M, Weyer A, Jetter A, Lazar A, Taubert D, Tomalik-Scharte D, 
Pournara P, Jakob V, Harlfinger S, Klaassen T, Berkessel A, Angerer J, Sorgel F, Schomig E. 
2006. Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal 
to improve risk assessment for acrylamide carcinogenicity. Cancer Epidemiol Biomarkers Prev 
15:266-271. 
Furchgott RF, Jothianandan D. 1991. Endothelium-dependent and -independent vasodilation involving 
cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessels 
28:52-61. 
Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A. 1997. Phosphodiesterase 
profiles of highly purified human peripheral blood leukocyte populations from normal and 
atopic individuals: a comparative study. J Allergy Clin Immunol 100:527-535. 
Ghanayem BI, McDaniel LP, Churchwell MI, Twaddle NC, Snyder R, Fennell TR, Doerge DR. 2005. 
Role of CYP2E1 in the epoxidation of acrylamide to glycidamide and formation of DNA and 
hemoglobin adducts. Toxicol Sci 88:311-318. 
References  172 
 
                          
Ghattas MH, Chuang LT, Kappas A, Abraham NG. 2002. Protective effect of HO-1 against oxidative 
stress in human hepatoma cell line (HepG2) is independent of telomerase enzyme activity. Int 
J Biochem Cell Biol 34:1619-1628. 
Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. 2003. Transcript 
profiling of human platelets using microarray and serial analysis of gene expression. Blood 
101:2285-2293. 
Gomez-Ruiz JA, Leake DS, Ames JM. 2007. In vitro antioxidant activity of coffee compounds and their 
metabolites. J Agric Food Chem 55:6962-6969. 
Gong P, Cederbaum AI, Nieto N. 2003. Increased expression of cytochrome P450 2E1 induces heme 
oxygenase-1 through ERK MAPK pathway. J Biol Chem 278:29693-29700. 
Goodman AI, Choudhury M, da Silva JL, Schwartzman ML, Abraham NG. 1997. Overexpression of 
the heme oxygenase gene in renal cell carcinoma. Proc Soc Exp Biol Med 214:54-61. 
Greenberg AS, Shen WJ, Muliro K, Patel S, Souza SC, Roth RA, Kraemer FB. 2001. Stimulation of 
lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J 
Biol Chem 276:45456-45461. 
Greenberg JA, Boozer CN, Geliebter A. 2006. Coffee, diabetes, and weight control. Am J Clin Nutr 
84:682-693. 
Greengar P, Rudolph SA, Sturteva.Jm. 1969. Enthalpy of Hydrolysis of 3' Bond of Adenosine 3',5'-
Monophosphate and Guanosine 3',5'-Monophosphate. Journal of Biological Chemistry 
244:4798-&. 
Greer F, Hudson R, Ross R, Graham T. 2001. Caffeine ingestion decreases glucose disposal during a 
hyperinsulinemic-euglycemic clamp in sedentary humans. Diabetes 50:2349-2354. 
Gresele P, Momi S, Falcinelli E. 2011. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin 
Pharmacol 72:634-646. 
Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, 
Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, 
Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, 
Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, 
Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge 
ML, Kong A, Stefansson K, Gulcher JR. 2003. The gene encoding phosphodiesterase 4D 
confers risk of ischemic stroke. Nat Genet 35:131-138. 
Grosch W. 1996. Warum riecht Kaffee so gut? Chemie in unserer Zeit. 30. Jahrg. Nr.3:126-133. 
References  173 
 
                          
Grosch W. 2001. Evaluation of the key odorants of foods by dilution experiments, aroma models and 
omission. Chem Senses 26:533-545. 
Grubben MJ, Boers GH, Blom HJ, Broekhuizen R, de Jong R, van Rijt L, de Ruijter E, Swinkels DW, 
Nagengast FM, Katan MB. 2000. Unfiltered coffee increases plasma homocysteine 
concentrations in healthy volunteers: a randomized trial. Am J Clin Nutr 71:480-484. 
Gu L, Gonzalez FJ, Kalow W, Tang BK. 1992. Biotransformation of caffeine, paraxanthine, 
theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. 
Pharmacogenetics 2:73-77. 
Guenther H, Anklam E, Wenzl T, Stadler RH. 2007. Acrylamide in coffee: review of progress in 
analysis, formation and level reduction. Food Addit Contam 24 Suppl 1:60-70. 
Gunnar S. 2010. Adenosin, Adenosinrezeptoren und adenosinrezeptoraktivierte Signalwege. 
BIOspektrum 2/04, 159-161. 
Ha HL, Shin HJ, Feitelson MA, Yu DY. 2010. Oxidative stress and antioxidants in hepatic 
pathogenesis. World J Gastroenterol 16:6035-6043. 
Halliwell B, Gutteridge JMC. 1999. Free radicals in biology and medicine (3rd ed.). Oxford University 
Press Editors. 
Hameleers PA, Van Boxtel MP, Hogervorst E, Riedel WJ, Houx PJ, Buntinx F, Jolles J. 2000. Habitual 
caffeine consumption and its relation to memory, attention, planning capacity and 
psychomotor performance across multiple age groups. Hum Psychopharmacol 15:573-581. 
Hanson MS, Stephenson AH, Bowles EA, Sridharan M, Adderley S, Sprague RS. 2008. 
Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates 
iloprost-induced increases in cAMP. Am J Physiol Heart Circ Physiol 295:H786-793. 
Hara E, Takahashi K, Tominaga T, Kumabe T, Kayama T, Suzuki H, Fujita H, Yoshimoto T, Shirato K, 
Shibahara S. 1996. Expression of heme oxygenase and inducible nitric oxide synthase mRNA 
in human brain tumors. Biochem Biophys Res Commun 224:153-158. 
Harris DC. 1991. Quantitative Chemical Analysis, Third Edition. New York: W.H. Freeman & Company 
Editors. 
Hashimoto K, Tanii H. 1985. Mutagenicity of acrylamide and its analogues in Salmonella typhimurium. 
Mutat Res 158:129-133. 
Hata K, Yamamoto Y, Nakajima A, Taura K, Yonezawa K, Uchinami H, Ikeda F, Yamaoka Y. 2003. 
Induction of heme oxygenase-1 and dilatation of hepatic sinusoids by an administration of 
pyrrolidine dithiocarbamate in rat livers. J Surg Res 115:310-317. 
References  174 
 
                          
Hawksworth G, Scheline RR. 1975. Metabolism in the rat of some pyrazine derivatives having flavour 
improtance in foods. Xenobiotica 5:389-399. 
Hayashi Y, Matsushima M, Nakamura T, Shibasaki M, Hashimoto N, Imaizumi K, Shimokata K, 
Hasegawa Y, Kawabe T. 2011. Quercetin protects against pulmonary oxidant stress via heme 
oxygenase-1 induction in lung epithelial cells. Biochem Biophys Res Commun. 
Heckman MA, Weil J, Gonzalez de Mejia E. 2010. Caffeine (1, 3, 7-trimethylxanthine) in foods: a 
comprehensive review on consumption, functionality, safety, and regulatory matters. J Food 
Sci 75:R77-87. 
Hellmer J, Arner P, Lundin A. 1989. Automatic luminometric kinetic assay of glycerol for lipolysis 
studies. Anal Biochem 177:132-137. 
Hellmuth M, Wetzler C, Nold M, Chang JH, Frank S, Pfeilschifter J, Muhl H. 2002. Expression of 
interleukin-8, heme oxygenase-1 and vascular endothelial growth factor in DLD-1 colon 
carcinoma cells exposed to pyrrolidine dithiocarbamate. Carcinogenesis 23:1273-1279. 
Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. 2010. Contribution of chlorogenic acids to the 
inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized 
decaffeinated green coffee extract. J Agric Food Chem 58:4141-4144. 
Hetzler RK, Knowlton RG, Somani SM, Brown DD, Perkins RM, 3rd. 1990. Effect of paraxanthine on 
FFA mobilization after intravenous caffeine administration in humans. J Appl Physiol 68:44-47. 
Hill M, Pereira V, Chauveau C, Zagani R, Remy S, Tesson L, Mazal D, Ubillos L, Brion R, Asghar K, 
Mashreghi MF, Kotsch K, Moffett J, Doebis C, Seifert M, Boczkowski J, Osinaga E, Anegon I. 
2005. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross 
inhibition with indoleamine 2,3-dioxygenase. FASEB J 19:1957-1968. 
Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H. 2007. Inhibition of heme oxygenase-1 by zinc 
protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int J Cancer 
120:500-505. 
Hirakawa N, Okauchi R, Miura Y, Yagasaki K. 2005. Anti-invasive activity of niacin and trigonelline 
against cancer cells. Biosci Biotechnol Biochem 69:653-658. 
Ho CT, Hwang HI, Yu TH, Zhang J. 1993. An overview of the Maillard reactions related to aroma 
generation in coffee. ASIC 15th Int. Colloq. Chem. Coffee 2:519-527. 
Hoelzl C, Knasmuller S, Wagner KH, Elbling L, Huber W, Kager N, Ferk F, Ehrlich V, Nersesyan A, 
Neubauer O, Desmarchelier A, Marin-Kuan M, Delatour T, Verguet C, Bezencon C, Besson A, 
Grathwohl D, Simic T, Kundi M, Schilter B, Cavin C. 2010. Instant coffee with high chlorogenic 
References  175 
 
                          
acid levels protects humans against oxidative damage of macromolecules. Mol Nutr Food Res 
54:1722-1733. 
Hogervorst JG, Schouten LJ, Konings EJ, Goldbohm RA, van den Brandt PA. 2007. A prospective 
study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer. 
Cancer Epidemiol Biomarkers Prev 16:2304-2313. 
Hogervorst JG, Schouten LJ, Konings EJ, Goldbohm RA, van den Brandt PA. 2008. Dietary 
acrylamide intake and the risk of renal cell, bladder, and prostate cancer. Am J Clin Nutr 
87:1428-1438. 
Holscher W, Steinhart H. 1994. Formation Pathways for Primary Roasted Coffee Aroma Compounds. 
Thermally Generated Flavors 543:206-217. 
Houessou JK, Delteil C, Camel V. 2006. Investigation of sample treatment steps for the analysis of 
polycyclic aromatic hydrocarbons in ground coffee. J Agric Food Chem 54:7413-7421. 
Houessou JK, Maloug S, Leveque AS, Delteil C, Heyd B, Camel V. 2007. Effect of roasting conditions 
on the polycyclic aromatic hydrocarbon content in ground Arabica coffee and coffee brew. J 
Agric Food Chem 55:9719-9726. 
Houslay MD, Adams DR. 2003. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate 
signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18. 
Huang XP, Song X, Wang HY, Malbon CC. 2002. Targeted expression of activated Q227L G(alpha)(s) 
in vivo. Am J Physiol Cell Physiol 283:C386-395. 
Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, Hayaishi O. 2005. 
Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 
8:858-859. 
Huber WJ, 3rd, Marohnic CC, Peters M, Alam J, Reed JR, Masters BS, Backes WL. 2009. 
Measurement of membrane-bound human heme oxygenase-1 activity using a chemically 
defined assay system. Drug Metab Dispos 37:857-864. 
Huber WW, Rossmanith W, Grusch M, Haslinger E, Prustomersky S, Peter-Vorosmarty B, Parzefall 
W, Scharf G, Schulte-Hermann R. 2008. Effects of coffee and its chemopreventive 
components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food 
Chem Toxicol 46:1230-1238. 
Hwang YP, Jeong HG. 2008. The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K 
and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-
derived oxidative stress. FEBS Lett 582:2655-2662. 
References  176 
 
                          
IARC. 1994. Monographs on the Evaluation of Carcinogen Risk toHumans: Some Industrial 
Chemicals. International Agency for Research on Cancer. 60, Lyon. 
Iba MM, Nguyen T, Fung J. 2002. CYP1A1 induction by pyridine and its metabolites in HepG2 cells. 
Arch Biochem Biophys 404:326-334. 
ICO. 2011. International Coffee Organization. http://www.ico.org/index.asp. 
ICO, International-Coffee-Organization. 2011. MONTHLY COFFEE MARKET REPORT (June 2011). 
Immenschuh S, Kietzmann T, Hinke V, Wiederhold M, Katz N, Muller-Eberhard U. 1998. The rat heme 
oxygenase-1 gene is transcriptionally induced via the protein kinase A signaling pathway in rat 
hepatocyte cultures. Mol Pharmacol 53:483-491. 
Ishikawa K, Sugawara D, Wang X, Suzuki K, Itabe H, Maruyama Y, Lusis AJ. 2001. Heme oxygenase-
1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res 88:506-512. 
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, 
Yamamoto M, Nabeshima Y. 1997. An Nrf2/small Maf heterodimer mediates the induction of 
phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys 
Res Commun 236:313-322. 
IUPAC. 1997. Compendium of Chemical Terminology., 2nd ed ed. Oxford. 
Jackson AS, Pollock ML, Ward A. 1980. Generalized equations for predicting body density of women. 
Med Sci Sports Exerc 12:175-181. 
Jackson SP, Schoenwaelder SM. 2003. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev 
Drug Discov 2:775-789. 
Jacobson KA, Gao ZG. 2006. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 
5:247-264. 
James JE. 1991. Toxicity. Caffeine and Health. London: Academic Press. Edited by J.E. James.  
 
Jarvis MJ. 1993. Does caffeine intake enhance absolute levels of cognitive performance? 
Psychopharmacology (Berl) 110:45-52. 
JECFA. 2010. JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES. Seventy-second 
meeting. Rome. http://www.who.int/foodsafety/chem/summary72_rev.pdf. 
Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM. 2005. Phosphodiesterase: overview of 
protein structures, potential therapeutic applications and recent progress in drug development. 
Cell Mol Life Sci 62:1198-1220. 
References  177 
 
                          
Johansson B, Georgiev V, Lindstrom K, Fredholm BB. 1997. A1 and A2A adenosine receptors and A1 
mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res 762:153-164. 
Johansson SM, Lindgren E, Yang JN, Herling AW, Fredholm BB. 2008. Adenosine A1 receptors 
regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. Eur J 
Pharmacol 597:92-101. 
Johnston KL, Clifford MN, Morgan LM. 2003. Coffee acutely modifies gastrointestinal hormone 
secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. 
Am J Clin Nutr 78:728-733. 
Jones JH, Bicking JB, Cragoe EJ, Jr. 1967. Pyrazine diuretics. IV. N-amidino-3-amino-6-substituted 
pyrazinecarboxamides. J Med Chem 10:899-903. 
Juan SH, Cheng TH, Lin HC, Chu YL, Lee WS. 2005. Mechanism of concentration-dependent 
induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem 
Pharmacol 69:41-48. 
Kagami K, Onda K, Oka K, Hirano T. 2008. Suppression of blood lipid concentrations by volatile 
Maillard reaction products. Nutrition 24:1159-1166. 
Kakhlon O, Cabantchik ZI. 2002. The labile iron pool: characterization, measurement, and 
participation in cellular processes(1). Free Radic Biol Med 33:1037-1046. 
Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RI. 1997. 
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin 
Pharmacol 37:693-703. 
Kaushansky K. 2008. Historical review: megakaryopoiesis and thrombopoiesis. Blood 111:981-986. 
Keijzers GB, De Galan BE, Tack CJ, Smits P. 2002. Caffeine can decrease insulin sensitivity in 
humans. Diabetes Care 25:364-369. 
Kelly KA, Havrilla CM, Brady TC, Abramo KH, Levin ED. 1998. Oxidative stress in toxicology: 
established mammalian and emerging piscine model systems. Environ Health Perspect 
106:375-384. 
Kerzendorfer C, O'Driscoll M. 2009. UVB and caffeine: inhibiting the DNA damage response to protect 
against the adverse effects of UVB. J Invest Dermatol 129:1611-1613. 
Keyse SM, Tyrrell RM. 1989. Heme oxygenase is the major 32-kDa stress protein induced in human 
skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci 
U S A 86:99-103. 
References  178 
 
                          
Kim HP, Wang X, Galbiati F, Ryter SW, Choi AM. 2004. Caveolae compartmentalization of heme 
oxygenase-1 in endothelial cells. FASEB J 18:1080-1089. 
Kim ND, Kwak MK, Kim SG. 1997. Inhibition of cytochrome P450 2E1 expression by 2-
(allylthio)pyrazine, a potential chemoprotective agent: hepatoprotective effects. Biochem 
Pharmacol 53:261-269. 
Klaasse EC, Ijzerman AP, de Grip WJ, Beukers MW. 2008. Internalization and desensitization of 
adenosine receptors. Purinergic Signal 4:21-37. 
Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. 1998. Comparative 
pharmacology of human adenosine receptor subtypes - characterization of stably transfected 
receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 357:1-9. 
Knopp SE, Bytof G, Selmar D. 2006. Influence of processing on the content of sugars in green Arabica 
coffee beans. Eur Food Res Technol 223:195-201. 
Koch HP, Jager W, Groh U, Plank G. 1992. In vitro inhibition of adenosine deaminase by flavonoids 
and related compounds. New insight into the mechanism of action of plant phenolics. Methods 
Find Exp Clin Pharmacol 14:413-417. 
Kohlmeier L. 1994. Gaps in dietary assessment methodology: meal- vs list-based methods. Am J Clin 
Nutr 59:175S-179S. 
Kovacs EM, Lejeune MP, Nijs I, Westerterp-Plantenga MS. 2004. Effects of green tea on weight 
maintenance after body-weight loss. Br J Nutr 91:431-437. 
Kuballa T, Stier S, Strichow N. 2005. Furan in Kaffee und Kaffeegetränken. Deutsche Lebensmittel-
Rundschau 101:229-235. 
Kull B, Svenningsson P, Fredholm BB. 2000. Adenosine A(2A) receptors are colocalized with and 
activate g(olf) in rat striatum. Mol Pharmacol 58:771-777. 
Kunz CE. 2000. Untersuchungen zur PDE-Ausstattung unterschiedlicher Zelllinien und Xenograft-
Tumoren sowie zum Wirkmechanismus substituierter Pteridine. Dissertation, TU 
Kaiserslautern. 
Kutty RK, Maines MD. 1981. Purification and characterization of biliverdin reductase from rat liver. J 
Biol Chem 256:3956-3962. 
Lang R, Mueller C, Hofmann T. 2006. Development of a stable isotope dilution analysis with liquid 
chromatography-tandem mass spectrometry detection for the quantitative analysis of di- and 
trihydroxybenzenes in foods and model systems. J Agric Food Chem 54:5755-5762. 
References  179 
 
                          
Lang R, Wahl A, Stark T, Hofmann T. 2011. Urinary N-methylpyridinium and trigonelline as candidate 
dietary biomarkers of coffee consumption. Mol Nutr Food Res. 55(11):1613-23. 
Lang R, Yagar EF, Eggers R, Hofmann T. 2008. Quantitative investigation of trigonelline, nicotinic 
acid, and nicotinamide in foods, urine, and plasma by means of LC-MS/MS and stable isotope 
dilution analysis. J Agric Food Chem 56:11114-11121. 
Lantz I, Ternite R, Wilkens J, Hoenicke K, Guenther H, van der Stegen GH. 2006. Studies on 
acrylamide levels in roasting, storage and brewing of coffee. Mol Nutr Food Res 50:1039-
1046. 
Lavrovsky Y, Song CS, Chatterjee B, Roy AK. 2000. Age-dependent increase of heme oxygenase-1 
gene expression in the liver mediated by NFkappaB. Mech Ageing Dev 114:49-60. 
Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, 
Heath JK, Vassart G, Parmentier M. 1997. Aggressiveness, hypoalgesia and high blood 
pressure in mice lacking the adenosine A2a receptor. Nature 388:674-678. 
Lee KJ, Jeong HG. 2007. Protective effects of kahweol and cafestol against hydrogen peroxide-
induced oxidative stress and DNA damage. Toxicol Lett 173:80-87. 
Lee SH, Sohn DH, Jin XY, Kim SW, Choi SC, Seo GS. 2007. 2',4',6'-tris(methoxymethoxy) chalcone 
protects against trinitrobenzene sulfonic acid-induced colitis and blocks tumor necrosis factor-
alpha-induced intestinal epithelial inflammation via heme oxygenase 1-dependent and 
independent pathways. Biochem Pharmacol 74:870-880. 
Lee TA, Kempthorne R, Hardy JK. 1992. Compositional Changes in Brewed Coffee as a Function of 
Brewing Time. J of Food Science 57:1417-1419. 
Li XY, He JL, Liu HT, Li WM, Yu C. 2009. Tetramethylpyrazine suppresses interleukin-8 expression in 
LPS-stimulated human umbilical vein endothelial cell by blocking ERK, p38 and nulear factor-
kappaB signaling pathways. J Ethnopharmacol 125:83-89. 
Liang HX, Belardinelli L, Ozeck MJ, Shryock JC. 2002. Tonic activity of the rat adipocyte A1-
adenosine receptor. Br J Pharmacol 135:1457-1466. 
Lin F, Girotti AW. 1998. Hemin-enhanced resistance of human leukemia cells to oxidative killing: 
antisense determination of ferritin involvement. Arch Biochem Biophys 352:51-58. 
Lindl T. 2000. Zell- und Gewebekultur. Heidelberg.Spektrum Akademischer Verlag. 
Lipworth BJ. 2005. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary 
disease. Lancet 365:167-175. 
Liu SY, Sylvester DM. 1994. Antiplatelet activity of tetramethylpyrazine. Thromb Res 75:51-62. 
References  180 
 
                          
Liu Y, Ortiz de Montellano PR. 2000. Reaction intermediates and single turnover rate constants for the 
oxidation of heme by human heme oxygenase-1. J Biol Chem 275:5297-5307. 
Liu ZM, Chen GG, Ng EK, Leung WK, Sung JJ, Chung SC. 2004. Upregulation of heme oxygenase-1 
and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene 23:503-513. 
Long LH, Kirkland D, Whitwell J, Halliwell B. 2007. Different cytotoxic and clastogenic effects of 
epigallocatechin gallate in various cell-culture media due to variable rates of its oxidation in the 
culture medium. Mutat Res 634:177-183. 
Lopez-Garcia E, van Dam RM, Rajpathak S, Willett WC, Manson JE, Hu FB. 2006a. Changes in 
caffeine intake and long-term weight change in men and women. Am J Clin Nutr 83:674-680. 
Lopez-Garcia E, van Dam RM, Willett WC, Rimm EB, Manson JE, Stampfer MJ, Rexrode KM, Hu FB. 
2006b. Coffee consumption and coronary heart disease in men and women: a prospective 
cohort study. Circulation 113:2045-2053. 
Low MY, Parker JK, Mottram DS. 2007. Mechanisms of alkylpyrazine formation in a potato model 
system containing added glycine. J Agric Food Chem 55:4087-4094. 
Lundin A, Arner P, Hellmer J. 1989. A new linear plot for standard curves in kinetic substrate assays 
extended above the Michaelis-Menten constant: application to a luminometric assay of 
glycerol. Anal Biochem 177:125-131. 
Lloyd HG, Fredholm BB. 1995. Involvement of adenosine deaminase and adenosine kinase in 
regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem Int 
26:387-395. 
Maia L, de Mendonca A. 2002. Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 
9:377-382. 
Maier HG. 1981. Kaffee. Berlin. Paul Parey Verlag 
Maines MD. 1997. The heme oxygenase system: a regulator of second messenger gases. Annu Rev 
Pharmacol Toxicol 37:517-554. 
Maines MD, Abrahamsson PA. 1996. Expression of heme oxygenase-1 (HSP32) in human prostate: 
normal, hyperplastic, and tumor tissue distribution. Urology 47:727-733. 
Mandel HG. 2002. Update on caffeine consumption, disposition and action. Food Chem Toxicol 
40:1231-1234. 
Manzano S, Williamson G. 2010. Polyphenols and phenolic acids from strawberry and apple decrease 
glucose uptake and transport by human intestinal Caco-2 cells. Mol Nutr Food Res 54:1773-
1780. 
References  181 
 
                          
Marko D, Merz KH, Kunz C, Muller A, Tarasova N, Eisenbrand G. 2002. Intracellular localization of 7-
benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine in membrane structures impeding 
the inhibition of cytosolic cyclic AMP-specific phosphodiesterase. Biochem Pharmacol 63:669-
676. 
Marko D, Pahlke G, Merz KH, Eisenbrand G. 2000. Cyclic 3',5'-nucleotide phosphodiesterases: 
potential targets for anticancer therapy. Chem Res Toxicol 13:944-948. 
Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Cuadrado A. 2004. 
Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt 
pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical 
carnosol. J Biol Chem 279:8919-8929. 
Martindale JL, Holbrook NJ. 2002. Cellular response to oxidative stress: signaling for suicide and 
survival. J Cell Physiol 192:1-15. 
Maurice DH. 1998. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic 
nucleotide phosphodiesterase activity. Selective effect of cyclic AMP. Cell Biochem Biophys 
29:35-47. 
Maurice DH, Haslam RJ. 1990. Molecular basis of the synergistic inhibition of platelet function by 
nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by 
cyclic GMP. Mol Pharmacol 37:671-681. 
Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, Jimmo 
SL. 2003. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of 
the cardiovascular system. Mol Pharmacol 64:533-546. 
Mazzafera P. 1991. Trigonelline in coffee. Phytochemistry 30:2309-2310. 
Mazzafera P. 1999. Chemical composition of defective coffee beans. Food Chemistry 64:547-554. 
McAllister SC, Hansen SG, Ruhl RA, Raggo CM, DeFilippis VR, Greenspan D, Fruh K, Moses AV. 
2004. Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression 
and activity in KSHV-infected endothelial cells. Blood 103:3465-3473. 
McCarty MF. 2005. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact 
of heavy coffee consumption on diabetes risk. Med Hypotheses 64:848-853. 
McDonagh AF. 2001. Turning green to gold. Nat Struct Biol 8:198-200. 
McDonagh AF. 2002. Lyophilic properties of protoporphyrin and bilirubin. Hepatology 36:1028-1029. 
McDonagh AF. 2010a. The biliverdin-bilirubin antioxidant cycle of cellular protection: Missing a wheel? 
Free Radic Biol Med 49:814-820. 
References  182 
 
                          
McDonagh AF. 2010b. Controversies in bilirubin biochemistry and their clinical relevance. Semin Fetal 
Neonatal Med 15:141-147. 
McNally SJ, Ross JA, James Garden O, Wigmore SJ. 2004. Optimization of the paired enzyme assay 
for heme oxygenase activity. Anal Biochem 332:398-400. 
Michelson AD. 2007. Platelets 2 Ed. Elsevier, New York. Alan D. Michelson Editor. 
Milczarska B, Foks H, Sokolowska J, Janowiec M, Zwolska Z, Andrzejczyk Z. 1999. Studies on 
pyrazine derivatives. XXXIII. Synthesis and tuberculostatic activity of 1-[1-(2-pyrazinyl)-ethyl]-
4-N-substituted thiosemicarbazide derivatives. Acta Pol Pharm 56:121-126. 
Mills C, Tlustos C, Evans R, Matthews W. 2008. Dietary acrylamide exposure estimates for the United 
Kingdom and Ireland: comparison between semiprobabilistic and probabilistic exposure 
models. J Agric Food Chem 56:6039-6045. 
Mills DC, Smith JB. 1971. The influence on platelet aggregation of drugs that affect the accumulation 
of adenosine 3':5'-cyclic monophosphate in platelets. Biochem J 121:185-196. 
Min KS, Lee HJ, Kim SH, Lee SK, Kim HR, Pae HO, Chung HT, Shin HI, Kim EC. 2008. Hydrogen 
peroxide induces heme oxygenase-1 and dentin sialophosphoprotein mRNA in human pulp 
cells. J Endod 34:983-989. 
Minamisawa M, Yoshida S, Takai N. 2004. Determination of biologically active substances in roasted 
coffees using a diode-array HPLC system. Anal Sci 20:325-328. 
Montellano PR. 2000. The mechanism of heme oxygenase. Curr Opin Chem Biol 4:221-227. 
Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, Cronstein BN. 2002. 
Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury 
via occupancy of A(2A) receptors. Am J Pathol 160:2009-2018. 
Morehouse KM, Nyman PJ, McNeal TP, Dinovi MJ, Perfetti GA. 2008. Survey of furan in heat 
processed foods by headspace gas chromatography/mass spectrometry and estimated adult 
exposure. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 25:259-264. 
Motterlini R, Foresti R, Bassi R, Green CJ. 2000. Curcumin, an antioxidant and anti-inflammatory 
agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free 
Radic Biol Med 28:1303-1312. 
Motterlini R, Foresti R, Vandegriff K, Intaglietta M, Winslow RM. 1995. Oxidative-stress response in 
vascular endothelial cells exposed to acellular hemoglobin solutions. Am J Physiol 269:H648-
655. 
References  183 
 
                          
Muller CE, Jacobson KA. 2011a. Recent developments in adenosine receptor ligands and their 
potential as novel drugs. Biochim Biophys Acta 1808:1290-1308. 
Muller CE, Jacobson KA. 2011b. Xanthines as adenosine receptor antagonists. Handb Exp 
Pharmacol:151-199. 
Muller R, Rappert S. 2010. Pyrazines: occurrence, formation and biodegradation. Appl Microbiol 
Biotechnol 85:1315-1320. 
Nakagawa M, Willner J, Cerri C, Reydel P. 1984. The effect of membrane preparation and cellular 
maturation on human erythrocyte adenylate cyclase. Biochim Biophys Acta 770:122-126. 
Nakamura T, Matsushima M, Hayashi Y, Shibasaki M, Imaizumi K, Hashimoto N, Shimokata K, 
Hasegawa Y, Kawabe T. 2011. Attenuation of transforming growth factor-beta-stimulated 
collagen production in fibroblasts by quercetin-induced heme oxygenase-1. Am J Respir Cell 
Mol Biol 44:614-620. 
Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. 2003. Effects of caffeine on 
human health. Food Addit Contam 20:1-30. 
Nenadis N, Wang LF, Tsimidou M, Zhang HY. 2004. Estimation of scavenging activity of phenolic 
compounds using the ABTS(*+) assay. J Agric Food Chem 52:4669-4674. 
Offermanns S, Simon MI. 1995. G alpha 15 and G alpha 16 couple a wide variety of receptors to 
phospholipase C. J Biol Chem 270:15175-15180. 
Olesen PT, Olsen A, Frandsen H, Frederiksen K, Overvad K, Tjonneland A. 2008. Acrylamide 
exposure and incidence of breast cancer among postmenopausal women in the Danish Diet, 
Cancer and Health Study. Int J Cancer 122:2094-2100. 
Olthof MR, Hollman PC, Buijsman MN, van Amelsvoort JM, Katan MB. 2003. Chlorogenic acid, 
quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J Nutr 
133:1806-1814. 
Olthof MR, Hollman PC, Katan MB. 2001a. Chlorogenic acid and caffeic acid are absorbed in humans. 
J Nutr 131:66-71. 
Olthof MR, Hollman PC, Zock PL, Katan MB. 2001b. Consumption of high doses of chlorogenic acid, 
present in coffee, or of black tea increases plasma total homocysteine concentrations in 
humans. Am J Clin Nutr 73:532-538. 
Olthof MR, van Dijk AE, Deacon CF, Heine RJ, van Dam RM. 2011. Acute effects of decaffeinated 
coffee and the major coffee components chlorogenic acid and trigonelline on incretin 
hormones. Nutr Metab (Lond) 8:10. 
References  184 
 
                          
Ongini E, Fredholm BB. 1996. Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 
17:364-372. 
Oosterveld A, Schols HA, Voragen AG. 2003. Effect of roasting on the carbohydrate composition of 
Coffea arabica beans Carbohydrates. Polymers 54:183-192. 
Orecchio S, Ciotti VP, Culotta L. 2009. Polycyclic aromatic hydrocarbons (PAHs) in coffee brew 
samples: analytical method by GC-MS, profile, levels and sources. Food Chem Toxicol 
47:819-826. 
Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. 2000. 
Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase 
pathway. Nat Med 6:422-428. 
Pardo Lozano R, Alvarez Garcia Y, Barral Tafalla D, Farre Albaladejo M. 2007. Cafeína: un nutriente, 
un fármaco, o una droga de abuso. Adicciones 19:225-238. 
Parmar D, Burka LT. 1993. Studies on the interaction of furan with hepatic cytochrome P-450. J 
Biochem Toxicol 8:1-9. 
Pastor N, Weinstein H, Jamison E, Brenowitz M. 2000. A detailed interpretation of OH radical 
footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-
specific binding. J Mol Biol 304:55-68. 
Paul G, Bataille F, Obermeier F, Bock J, Klebl F, Strauch U, Lochbaum D, Rummele P, Farkas S, 
Scholmerich J, Fleck M, Rogler G, Herfarth H. 2005. Analysis of intestinal haem-oxygenase-1 
(HO-1) in clinical and experimental colitis. Clin Exp Immunol 140:547-555. 
Pereira MA, Parker ED, Folsom AR. 2006. Coffee consumption and risk of type 2 diabetes mellitus: an 
11-year prospective study of 28 812 postmenopausal women. Arch Intern Med 166:1311-
1316. 
Perera V, Gross AS, McLachlan AJ. 2010. Caffeine and paraxanthine HPLC assay for CYP1A2 
phenotype assessment using saliva and plasma. Biomed Chromatogr 24:1136-1144. 
PerkinElmer, Inc. AS. 2007. LANCE® cAMP 384 Kit. Massachusetts,  USA. 
Petersen RK, Madsen L, Pedersen LM, Hallenborg P, Hagland H, Viste K, Doskeland SO, Kristiansen 
K. 2008. Cyclic AMP (cAMP)-mediated stimulation of adipocyte differentiation requires the 
synergistic action of Epac- and cAMP-dependent protein kinase-dependent processes. Mol 
Cell Biol 28:3804-3816. 
References  185 
 
                          
Petrov V, Fagard R, Lijnen P. 1998. Human erythrocytes contain Ca2+, calmodulin-dependent cyclic 
nucleotide phosphodiesterase which is involved in the hydrolysis of cGMP. Methods Find Exp 
Clin Pharmacol 20:387-393. 
Pickard S, Becker I, Merz KH, Eisenbrand G, Richling E. 2011. Quantifizierung von Alkylpyrazinen in 
Röstkaffee mittels Stabilisotopenverdünungsanalyse. Lebensmittelchemie 65. 
Pietinen P, Aro A, Tuomilehto J, Uusitalo U, Korhonen H. 1990. Consumption of boiled coffee is 
correlated with serum cholesterol in Finland. Int J Epidemiol 19:586-590. 
Plumb GW, Garcia-Conesa MT, Kroon PA, Rhodes M, Saxon R, Williamson G. 1999. Metabolism of 
chlorogenic acid by human plasma, liver, intestine and gut microflora. J Sci Food Agric 
79:390-392. 
Poch G. 1971. Assay of phosphodiesterase with radioactively labeled cyclic 3',5'-AMP as substrate. 
Naunyn Schmiedebergs Arch Pharmakol 268:272-299. 
Polte T, Abate A, Dennery PA, Schroder H. 2000. Heme oxygenase-1 is a cGMP-inducible endothelial 
protein and mediates the cytoprotective action of nitric oxide. Arterioscler Thromb Vasc Biol 
20:1209-1215. 
Porkka-Heiskanen T, Kalinchuk AV. 2011. Adenosine, energy metabolism and sleep homeostasis. 
Sleep Med Rev 15:123-135. 
Raju VS, McCoubrey WK, Jr., Maines MD. 1997. Regulation of heme oxygenase-2 by glucocorticoids 
in neonatal rat brain: characterization of a functional glucocorticoid response element. Biochim 
Biophys Acta 1351:89-104. 
Ralevic V, Burnstock G. 1998. Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492. 
Ramalakshmi K, Raghavan B. 1999. Caffeine in coffee: its removal. Why and how? Crit Rev Food Sci 
Nutr 39:441-456. 
Randall D, Burggren W, French K. 1997. Eckert Animal Physiology Mechanisms and Adaptations. 
New York. W. H. Freeman and Company. 
Ranheim T, Halvorsen B. 2005. Coffee consumption and human health--beneficial or detrimental?--
Mechanisms for effects of coffee consumption on different risk factors for cardiovascular 
disease and type 2 diabetes mellitus. Mol Nutr Food Res 49:274-284. 
Ravanelli MI, Branco LG. 2008. Role of locus coeruleus heme oxygenase-carbon monoxide-cGMP 
pathway during hypothermic response to restraint. Brain Res Bull 75:526-532. 
References  186 
 
                          
Reid PG, Watt AH, Penny WJ, Newby AC, Smith AP, Routledge PA. 1991. Plasma adenosine 
concentrations during adenosine-induced respiratory stimulation in man. Eur J Clin Pharmacol 
40:175-180. 
Renda G, Zimarino M, Antonucci I, Tatasciore A, Ruggieri B, Bucciarelli T, Prontera T, Stuppia L, De 
Caterina R. 2012. Genetic determinants of blood pressure responses to caffeine drinking. Am 
J Clin Nutr 95:241-248. 
Reneland RH, Mah S, Kammerer S, Hoyal CR, Marnellos G, Wilson SG, Sambrook PN, Spector TD, 
Nelson MR, Braun A. 2005. Association between a variation in the phosphodiesterase 4D 
gene and bone mineral density. BMC Med Genet 6:1-11. 
Rey-Salgueiro L, Garcia-Falcon MS, Martinez-Carballo E, Simal-Gandara J. 2008 Effects of toasting 
procedures on the levels of polycyclic aromatic hydrocarbons in toasted bread. Food 
Chemistry 108:607-615. 
Ribeiro JA, Sebastiao AM. 2010. Caffeine and adenosine. J Alzheimers Dis. 20 Suppl 1:S3-S15. 
Richling E, Preston C, Kavvadias D, Kahle K, Heppel C, Hummel S, Konig T, Schreier P. 2005. 
Determination of the 2H/1H and 15N/14N ratios of Alkylpyrazines from coffee beans (Coffea 
arabica L. and Coffea canephoravar. robusta) by isotope ratio mass spectrometry. J Agric 
Food Chem 53:7925-7930. 
Rodbell M. 1964. Metabolism of Isolated Fat Cells. I to VI. J Biol Chem 239:375-380. 
Rodriguez de Sotillo DV, Hadley M. 2002. Chlorogenic acid modifies plasma and liver concentrations 
of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem 13:717-726. 
Rosengren A, Dotevall A, Wilhelmsen L, Thelle D, Johansson S. 2004. Coffee and incidence of 
diabetes in Swedish women: a prospective 18-year follow-up study. J Intern Med 255:89-95. 
Ruggeri ZM. 2002. Platelets in atherothrombosis. Nat Med 8:1227-1234. 
Ryter SW, Alam J, Choi AM. 2006a. Heme oxygenase-1/carbon monoxide: from basic science to 
therapeutic applications. Physiol Rev 86:583-650. 
Ryter SW, Alam J, Choi AMK. 2006b. Heme oxygenase-1/carbon monoxide: From basic science to 
therapeutic applications. Physiol Rev 86:583-650. 
Ryter SW, Xi S, Hartsfield CL, Choi AM. 2002. Mitogen activated protein kinase (MAPK) pathway 
regulates heme oxygenase-1 gene expression by hypoxia in vascular cells. Antioxid Redox 
Signal 4:587-592. 
References  187 
 
                          
Saito H, Nishimura M, Shinano H, Makita H, Tsujino I, Shibuya E, Sato F, Miyamoto K, Kawakami Y. 
1999. Plasma concentration of adenosine during normoxia and moderate hypoxia in humans. 
Am J Respir Crit Care Med 159:1014-1018. 
Sala-Newby GB, Skladanowski AC, Newby AC. 1999. The mechanism of adenosine formation in cells. 
Cloning of cytosolic 5'-nucleotidase-I. J Biol Chem 274:17789-17793. 
Salazar-Martinez E, Willett WC, Ascherio A, Manson JE, Leitzmann MF, Stampfer MJ, Hu FB. 2004. 
Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 140:1-8. 
Sardana MK, Kappas A. 1987. Dual control mechanism for heme oxygenase: tin(IV)-protoporphyrin 
potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver. 
Proc Natl Acad Sci U S A 84:2464-2468. 
Saura C, Ciruela F, Casado V, Canela EI, Mallol J, Lluis C, Franco R. 1996. Adenosine deaminase 
interacts with A1 adenosine receptors in pig brain cortical membranes. J Neurochem 66:1675-
1682. 
Scapagnini G, Foresti R, Calabrese V, Giuffrida Stella AM, Green CJ, Motterlini R. 2002. Caffeic acid 
phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Mol Pharmacol 
61:554-561. 
Schipper HM. 2011. Heme oxygenase-1 in Alzheimer disease: a tribute to Moussa Youdim. J Neural 
Transm 118:381-387. 
Schudt C, Dent G, Rabe KF. 1996. Phosphodiesterase Inhibitors. London: Academic Press. 
Schulte G, Fredholm BB. 2003. Signalling from adenosine receptors to mitogen-activated protein 
kinases. Cell Signal 15:813-827. 
Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. 2006. Targeting adenosine A2A receptors in 
Parkinson's disease. Trends Neurosci 29:647-654. 
Schweiger M, Schreiber R, Haemmerle G, Lass A, Fledelius C, Jacobsen P, Tornqvist H, Zechner R, 
Zimmermann R. 2006. Adipose triglyceride lipase and hormone-sensitive lipase are the major 
enzymes in adipose tissue triacylglycerol catabolism. J Biol Chem 281:40236-40241. 
Selmar D, Bytof G. 2008. Das Geheimnis eines guten Kaffees. Biol. unserer Zeit 3:158-167. 
Selmar D, Bytof G, Knopp SE. 2008. The storage of green coffee (Coffea arabica): decrease of 
viability and changes of potential aroma precursors. Ann Bot 101:31-38. 
Sette C, Conti M. 1996. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the 
cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol 
Chem 271:16526-16534. 
References  188 
 
                          
Settels E, Bernauer U, Palavinskas R, Klaffke HS, Gundert-Remy U, Appel KE. 2008. Human 
CYP2E1 mediates the formation of glycidamide from acrylamide. Arch Toxicol 82:717-727. 
Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Manganiello V. 2001. Regulation and 
function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid 
Res Mol Biol 66:241-277. 
Sheu JR, Kan YC, Hung WC, Ko WC, Yen MH. 1997. Mechanisms involved in the antiplatelet activity 
of tetramethylpyrazine in human platelets. Thromb Res 88:259-270. 
Shibamoto T, Akiyama T, Sakaguchi M, Enomoto Y, Masuda H. 1979. A study of pyrazine formation. 
J. Agric. Food Chem. 27:1027-1031. 
Sim DS, Merrill-Skoloff G, Furie BC, Furie B, Flaumenhaft R. 2004. Initial accumulation of platelets 
during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels. Blood 
103:2127-2134. 
Sinues B, Saenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, Mayayo E. 1999. Five caffeine 
metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with 
urinary mutagenicity and urine flow. Cancer Epidemiol Biomarkers Prev 8:159-166. 
Siuciak JA. 2008. The role of phosphodiesterases in schizophrenia : therapeutic implications. CNS 
Drugs 22:983-993. 
Slow S, Miller WE, McGregor DO, Lee MB, Lever M, George PM, Chambers ST. 2004. Trigonelline is 
not responsible for the acute increase in plasma homocysteine following ingestion of instant 
coffee. Eur J Clin Nutr 58:1253-1256. 
Snyder FF, Lukey T. 1982. Kinetic considerations for the regulation of adenosine and deoxyadenosine 
metabolism in mouse and human tissues based on a thymocyte model. Biochimica Et 
Biophysica Acta 696:299-307. 
Somoza V, Lindenmeier M, Wenzel E, Frank O, Erbersdobler HF, Hofmann T. 2003. Activity-guided 
identification of a chemopreventive compound in coffee beverage using in vitro and in vivo 
techniques. J Agric Food Chem 51:6861-6869. 
Spriet LL, MacLean DA, Dyck DJ, Hultman E, Cederblad G, Graham TE. 1992. Caffeine ingestion and 
muscle metabolism during prolonged exercise in humans. Am J Physiol 262:E891-898. 
Spychala J. 2000. Tumor-promoting functions of adenosine. Pharmacol Ther 87:161-173. 
Stadler RH, Lineback DR. 2009. Process-Induced Food Toxicants: Occurrence, Formation, Mitigation 
& Health Risks. Wiley Editors. 
References  189 
 
                          
Stadler RH, Varga N, Hau J, Vera FA, Welti DH. 2002a. Alkylpyridiniums. 1. Formation in model 
systems via thermal degradation of trigonelline. J Agric Food Chem 50:1192-1199. 
Stadler RH, Varga N, Milo C, Schilter B, Vera FA, Welti DH. 2002b. Alkylpyridiniums. 2. Isolation and 
quantification in roasted and ground coffees. J Agric Food Chem 50:1200-1206. 
Stanley C, Brown AM, Hill SJ. 1989. Effect of isozyme-selective inhibitors of phosphodiesterase on 
histamine-stimulated cyclic AMP accumulation in guinea-pig hippocampus. J Neurochem 
52:671-676. 
Stevens CF, Wang Y. 1993. Reversal of long-term potentiation by inhibitors of haem oxygenase. 
Nature 364:147-149. 
Stolzenberg-Solomon RZ, Miller ER, 3rd, Maguire MG, Selhub J, Appel LJ. 1999. Association of 
dietary protein intake and coffee consumption with serum homocysteine concentrations in an 
older population. Am J Clin Nutr 69:467-475. 
Strober W. 1997. Current Protocols in Immunology. John Wiley & Sons, Inc.Editors. 
Stuhlmeier KM. 2000. Activation and regulation of Hsp32 and Hsp70. Eur J Biochem 267:1161-1167. 
Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H. 2000. Potent effects of 
novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide 
phosphodiesterase isozyme activity. Biochem Pharmacol 59:347-356. 
Sumner SC, Fennell TR, Moore TA, Chanas B, Gonzalez F, Ghanayem BI. 1999. Role of cytochrome 
P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. Chem Res Toxicol 
12:1110-1116. 
Sun B, Li H, Shakur Y, Hensley J, Hockman S, Kambayashi J, Manganiello VC, Liu Y. 2007. Role of 
phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-
selective knockout mice. Cell Signal 19:1765-1771. 
Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, 
Abraham NG. 2003. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic 
cancer. Angiogenesis 6:15-24. 
Sutherland EW, Rall TW. 1958. Fractionation and characterization of a cyclic adenine ribonucleotide 
formed by tissue particles. J Biol Chem 232:1077-1091. 
Suzuki A, Fujii A, Jokura H, Tokimitsu I, Hase T, Saito I. 2008. Hydroxyhydroquinone interferes with 
the chlorogenic acid-induced restoration of endothelial function in spontaneously hypertensive 
rats. Am J Hypertens 21:23-27. 
References  190 
 
                          
Suzuki K, Tanaka I, Nakanishi I, Kurematsua A, Yakumaru H, Ikota N, Ishihara H. 2006. Drastic effect 
of several caffeic acid derivatives on the induction of heme oxygenase-1 expression revealed 
by quantitative real-time RT-PCR. Biofactors 28:151-158. 
Szkudelski T, Szkudelska K, Nogowski L. 2009. Effects of adenosine A1 receptor antagonism on 
lipogenesis and lipolysis in isolated rat adipocytes. Physiol Res 58:863-871. 
Takahashi S, Takahashi Y, Ito K, Nagano T, Shibahara S, Miura T. 1999. Positive and negative 
regulation of the human heme oxygenase-1 gene expression in cultured cells. Biochim 
Biophys Acta 1447:231-235. 
Takakusa H, Masumoto H, Yukinaga H, Makino C, Nakayama S, Okazaki O, Sudo K. 2008. Covalent 
binding and tissue distribution/retention assessment of drugs associated with idiosyncratic 
drug toxicity. Drug Metab Dispos 36:1770-1779. 
Tallarida RJ. 2006. An overview of drug combination analysis with isobolograms. J Pharmacol Exp 
Ther 319:1-7. 
Tarter RE, Ammerman RT, Ott PJ. 1998. Handbook of substance abuse: neurobehavioral 
pharmacology. Plenum Press. New York. 
Tenhunen R, Marver HS, Schmid R. 1969. Microsomal heme oxygenase. Characterization of the 
enzyme. J Biol Chem 244:6388-6394. 
Tenhunen R, Marver HS, Schmid R. 1970. The enzymatic catabolism of hemoglobin: stimulation of 
microsomal heme oxygenase by hemin. J Lab Clin Med 75:410-421. 
Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. 2002. Identification of 
Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide 
microarray. Cancer Res 62:5196-5203. 
Thom E. 2007. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy 
volunteers and its effect on body mass when used long-term in overweight and obese people. 
J Int Med Res 35:900-908. 
Thompson WJ. 1991. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and 
function. Pharmacol Ther 51:13-33. 
Torisu-Itakura H, Furue M, Kuwano M, Ono M. 2000. Co-expression of thymidine phosphorylase and 
heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. Jpn J 
Cancer Res 91:906-910. 
Tullin S, Hansen BS, Ankersen M, Moller J, Von Cappelen KA, Thim L. 2000. Adenosine is an agonist 
of the growth hormone secretagogue receptor. Endocrinology 141:3397-3402. 
References  191 
 
                          
Tunnicliffe JM, Shearer J. 2008. Coffee, glucose homeostasis, and insulin resistance: physiological 
mechanisms and mediators. Appl Physiol Nutr Metab 33:1290-1300. 
Tuomilehto J, Hu G, Bidel S, Lindstrom J, Jousilahti P. 2004. Coffee consumption and risk of type 2 
diabetes mellitus among middle-aged Finnish men and women. JAMA 291:1213-1219. 
Turkseven S, Kruger A, Mingone CJ, Kaminski P, Inaba M, Rodella LF, Ikehara S, Wolin MS, 
Abraham NG. 2005. Antioxidant mechanism of heme oxygenase-1 involves an increase in 
superoxide dismutase and catalase in experimental diabetes. Am J Physiol Heart Circ Physiol 
289:H701-707. 
Tyla RW, Friedman MA, Losco PE, Fisher LC, Johnson KA, Strother DE, Wolf CH. 2000. Rat two-
generation reproduction and dominant lethal study of acrylamide in drinking water. Reprod 
Toxicol 14:385-401. 
Uc A, Britigan BE. 2003. Does heme oxygenase-1 have a role in Caco-2 cell cycle progression? Exp 
Biol Med (Maywood) 228:590-595. 
Unno M, Matsui T, Ikeda-Saito M. 2007. Structure and catalytic mechanism of heme oxygenase. Nat 
Prod Rep 24:553-570. 
Urgert R, van Vliet T, Zock PL, Katan MB. 2000. Heavy coffee consumption and plasma 
homocysteine: a randomized controlled trial in healthy volunteers. Am J Clin Nutr 72:1107-
1110. 
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. 2007. Free radicals and antioxidants in 
normal physiological functions and human disease. Int J Biochem Cell Biol 39:44-84. 
van Dam RM. 2006. Coffee and type 2 diabetes: from beans to beta-cells. Nutr Metab Cardiovasc Dis 
16:69-77. 
van Dam RM, Feskens EJ. 2002. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 
360:1477-1478. 
van Dam RM, Hu FB. 2005. Coffee consumption and risk of type 2 diabetes: a systematic review. 
JAMA 294:97-104. 
van Dam RM, Pasman WJ, Verhoef P. 2004. Effects of coffee consumption on fasting blood glucose 
and insulin concentrations: randomized controlled trials in healthy volunteers. Diabetes Care 
27:2990-2992. 
Van Nieuwenhoven MA, Brummer RM, Brouns F. 2000. Gastrointestinal function during exercise: 
comparison of water, sports drink, and sports drink with caffeine. J Appl Physiol 89:1079-1085. 
References  192 
 
                          
van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-
Yehuda S, Fong KL, Fishman P. 2004. Tolerability, pharmacokinetics and concentration-
dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy 
young men. Int J Clin Pharmacol Ther 42:534-542. 
Varani K, Portaluppi F, Gessi S, Merighi S, Ongini E, Belardinelli L, Borea PA. 2000. Dose and time 
effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and 
biochemical aspects. Circulation 102:285-289. 
Varani K, Portaluppi F, Merighi S, Ongini E, Belardinelli L, Borea PA. 1999. Caffeine alters A2A 
adenosine receptors and their function in human platelets. Circulation 99:2499-2502. 
Verhoef P, Pasman WJ, Van Vliet T, Urgert R, Katan MB. 2002. Contribution of caffeine to the 
homocysteine-raising effect of coffee: a randomized controlled trial in humans. Am J Clin Nutr 
76:1244-1248. 
Victor-Vega C, Desai A, Montesinos MC, Cronstein BN. 2002. Adenosine A2A receptor agonists 
promote more rapid wound healing than recombinant human platelet-derived growth factor 
(Becaplermin gel). Inflammation 26:19-24. 
Vollmann K, Qurishi R, Hockemeyer J, Muller CE. 2008. Synthesis and properties of a new water-
soluble prodrug of the adenosine A 2A receptor antagonist MSX-2. Molecules 13:348-359. 
Wabitsch M, Brenner RE, Melzner I, Braun M, Moller P, Heinze E, Debatin KM, Hauner H. 2001. 
Characterization of a human preadipocyte cell strain with high capacity for adipose 
differentiation. Int J Obes Relat Metab Disord 25:8-15. 
WADA. 2011. World Antidoping Agency. The 2011 prohibited list -International standard-. 
http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-
list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf. 
Wagner R, Czerny M, Bielohradsky J, Grosch W. 1999. Structure-odour-activity relationships of 
alkylpyrazines. Z Lebensm Unters Forsch A 208:308-316. 
Wang S, Lian XJ, Xu GL, Lin NN, Li Q, Zhu HS. 2008. The application with tetramethyl pyrazine for 
antithrombogenicity improvement on silk fibroin surface. Applied Surface Science 255:480-
482. 
Was H, Cichon T, Smolarczyk R, Rudnicka D, Stopa M, Chevalier C, Leger JJ, Lackowska B, Grochot 
A, Bojkowska K, Ratajska A, Kieda C, Szala S, Dulak J, Jozkowicz A. 2006. Overexpression 
of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, 
decreased survival of mice. Am J Pathol 169:2181-2198. 
References  193 
 
                          
Was H, Dulak J, Jozkowicz A. 2010. Heme oxygenase-1 in tumor biology and therapy. Curr Drug 
Targets 11:1551-1570. 
Was H, Sokolowska M, Sierpniowska A, Dominik P, Skrzypek K, Lackowska B, Pratnicki A, Grochot-
Przeczek A, Taha H, Kotlinowski J, Kozakowska M, Mazan A, Nowak W, Muchova L, Vitek L, 
Ratajska A, Dulak J, Jozkowicz A. 2011. Effects of heme oxygenase-1 on induction and 
development of chemically induced squamous cell carcinoma in mice. Free Radic Biol Med 
51:1717-1726. 
Watson S, Authi K. 1996. Platelets: A Practical Approach. New York. D. Rickwood and B.D. Hames 
Editors. 
Watson SP. 2009. Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. 
Curr Pharm Des 15:1358-1372. 
Watzek N, Bohm N, Feld J, Scherbl D, Berger F, Merz KH, Lampen A, Reemtsma T, Tannenbaum 
SR, Skipper PL, Baum M, Richling E, Eisenbrand G. 2012. N7-glycidamide-guanine DNA 
adduct formation by orally ingested acrylamide in rats: a dose-response study encompassing 
human diet-related exposure levels. Chem Res Toxicol 25:381-390. 
Weiss C, Rubach M, Lang R, Seebach E, Blumberg S, Frank O, Hofmann T, Somoza V. 2010. 
Measurement of the intracellular ph in human stomach cells: a novel approach to evaluate the 
gastric acid secretory potential of coffee beverages. J Agric Food Chem 58:1976-1985. 
WHO. 2011. World Health Organization: Diabetes. http://www.who.int/topics/diabetes_mellitus/en/. 
Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes: estimates for the 
year 2000 and projections for 2030. Diabetes Care 27:1047-1053. 
Wilks A. 2002. Heme oxygenase: evolution, structure, and mechanism. Antioxid Redox Signal 4:603-
614. 
Wilson AJ, Petracco M, Illy E. 1997. Some Preliminary Investigations of Oil Biosynthesis in the Coffee 
Fruit and Its Subsequent Re-Distribution within Green and Roasted Beans. In: ASIC. 17th 
International Colloquium on the Chemistry of Coffee. Paris. 
Wilson CN, Mustafa SJ. 2009. Adenosine receptors in health and disease. Berlin. 
Williams MS, Weiss EJ, Sabatine MS, Simon DI, Bahou WF, Becker LC, Parise LV, Dauerman HL, 
French PA, Smyth SS, Becker RC. 2010. Genetic regulation of platelet receptor expression 
and function: application in clinical practice and drug development. Arterioscler Thromb Vasc 
Biol 30:2372-2384. 
References  194 
 
                          
Williams SE, Wootton P, Mason HS, Bould J, Iles DE, Riccardi D, Peers C, Kemp PJ. 2004. 
Hemoxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel. Science 
306:2093-2097. 
Williamson G, Dionisi F, Renouf M. 2011. Flavanols from green tea and phenolic acids from coffee: 
critical quantitative evaluation of the pharmacokinetic data in humans after consumption of 
single doses of beverages. Mol Nutr Food Res 55:864-873. 
Winder WW. 1986. Effect of intravenous caffeine on liver glycogenolysis during prolonged exercise. 
Med Sci Sports Exerc 18:192-196. 
Wu CC, Chiou WF, Yen MH. 1989. A Possible Mechanism of Action of Tetramethylpyrazine on 
Vascular Smooth-Muscle in Rat Aorta. Eur J Pharmacol 169:189-195. 
Wu JN, Ho SC, Zhou C, Ling WH, Chen WQ, Wang CL, Chen YM. 2009. Coffee consumption and risk 
of coronary heart diseases: a meta-analysis of 21 prospective cohort studies. Int J Cardiol 
137:216-225. 
Wu ML, Ho YC, Lin CY, Yet SF. 2011. Heme oxygenase-1 in inflammation and cardiovascular 
disease. Am J Cardiovasc Dis 1:150-158. 
Wu X, Skog K, Jagerstad M. 1997. Trigonelline, a naturally occurring constituent of green coffee 
beans behind the mutagenic activity of roasted coffee? Mutat Res 391:171-177. 
Yanagimoto K, Ochi H, Lee KG, Shibamoto T. 2004. Antioxidative activities of fractions obtained from 
brewed coffee. J Agric Food Chem 52:592-596. 
Yang A, Palmer AA, de Wit H. 2010a. Genetics of caffeine consumption and responses to caffeine. 
Psychopharmacology (Berl) 211:245-257. 
Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K. 2010b. A 
new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 
8:817-827. 
Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, Brass LF. 2002. Signaling 
through Gi family members in platelets. Redundancy and specificity in the regulation of 
adenylyl cyclase and other effectors. J Biol Chem 277:46035-46042. 
Yasuhara A, Tanaka Y, Hengel M, Shibamoto T. 2003. Gas chromatographic investigation of 
acrylamide formation in browning model systems. J Agric Food Chem 51:3999-4003. 
Yaylayan VA, Stadler RH. 2005. Acrylamide formation in food: a mechanistic perspective. J AOAC Int 
88:262-267. 
References  195 
 
                          
Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, 
O'Donnell JM. 2005. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on 
memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology 
(Berl) 179:613-619. 
Zhang W, Lopez-Garcia E, Li TY, Hu FB, van Dam RM. 2009. Coffee consumption and risk of 
cardiovascular diseases and all-cause mortality among men with type 2 diabetes. Diabetes 
Care 32:1043-1045. 
Zhang YS, Gordon GB. 2004. A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling 
pathway. Molecular Cancer Therapeutics 3:885-893. 
Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. 2003. Tetramethylpyrazine scavenges superoxide anion 
and decreases nitric oxide production in human polymorphonuclear leukocytes. Life Sci 
72:2465-2472. 
Zhao AZ, Bornfeldt KE, Beavo JA. 1998. Leptin inhibits insulin secretion by activation of 
phosphodiesterase 3B. J Clin Invest 102:869-873. 
Zhao AZ, Huan JN, Gupta S, Pal R, Sahu A. 2002. A phosphatidylinositol 3-kinase phosphodiesterase 
3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat Neurosci 5:727-728. 
Zheng XQ, Ashihara H. 2004. Distribution, biosynthesis and function of purine and pyridine alkaloids in 
Coffea arabica seedlings. Plant Sci 166:807-813. 
Zhou J, Zhou S, Zeng S. 2011. Experimental diabetes treated with trigonelline: effect on beta cell and 
pancreatic oxidative parameters. Fundam Clin Pharmacol. Early view. 
Ziegler-Heitbrock L. 2006. Human Monocytes In Health and Disease. http://www.monocytes.de. 
Zimmermann H. 1992. 5'-Nucleotidase: molecular structure and functional aspects. Biochem J 285 
(Pt2):345-365. 
 
Acknowledgments  196 
 
                          
8. Publications 
 
Montoya, G.A., Bakuradze, T., Eisenbrand, G., Baum, M., Richling, E. (2012), Modulation 
von Adenosin-Rezeptor vermittelten Signalwegen durch Kaffeekonsum in Human-
Thrombozyten. Regional meeting of the german society of food chemist. Southwest Regional 
Association. Oral presentation. Kaiserslautern, Germany. 
 
Montoya, G.A., Baum, M., Eisenbrand, G., Richling, E. (2012), Coffee constituents as 
modulators of cAMP phosphodiesterases activity of human platelets and lung carcinoma 
cells Regional meeting of the german society of food chemist. Southwest Regional 
Association. Poster. Kaiserslautern, Germany. 
 
Montoya, G.A., Baum, M., Eisenbrand, G., Richling, E. (2011), Coffee polyphenols 
modulating the activity of cAMP phosphodiesterases activity in human platelets. The 5th 
International Conference on Polyphenols and Health, Poster, Sitges, Barcelona, Spain. 
 
Montoya, G.A., Baum, M., Eisenbrand, G., Richling, E. (2011), Modulation of cAMP-
phosphodiesterase activity by coffee constituents in human platelets and in lung carcinoma 
cells. 2nd Luxembourgish Int. Nutrition Conference „Dietary Composition, Pattern and  ealth“, 
Poster. Mondorf-les Bains, Luxemburg. Best Poster Award. 
 
Montoya, G.A., Richling, E., Eisenbrand, G., Baum, M. (2010), Modulation der cAMP-
Phosphodiesterase-Aktivität durch Kaffeeinhaltsstoffe. 39th annual meeting of the german 
society of food chemist. Poster. Stuttgart-Hohenheim, Germany. 
 
Montoya, G.A., Richling, E., Eisenbrand, G., Baum, M. (2010), Modulation der 
Hämoxygenase-Aktivität durch Kaffeeinhaltsstoffe in Caco2, HepG2 und MonoMac6 Zellen. 
38th annual meeting of the german society of food chemist. Poster. Berlin, Germany. 
 
 
 
 
 
 
 
 
 
Acknowledgments  197 
 
                          
Acknowledgments 
 
I would like to express my sincere gratitude to all colleagues and friends who supported and 
assisted me during these years.  In particular I would like to express my sincere and warmest 
appreciation to: 
 
Prof. Gerhard Eisenbrand for allowing me to make my dreams come true, for warmly 
welcoming me to Germany, and for guiding me in the world of research. Thank you for 
sharing your knowledge and your scientific ideas with me, for your never-ending scientific 
curiosity, for all your invaluable advice and for providing me the opportunity to work with a 
true scientist and a wonderful human. 
Prof. Elke Richling for adopting me into her research group and ensuring the fulfillment of 
the objectives of this work. 
The DAAD (German Academic Exchange Service) and the Universidad de Antioquia for 
believing in me and giving me the chance to be part of science in the “big leagues”. 
Tchibo for giving me the opportunity to work in an excellent interdisciplinary team and the 
great atmosphere in the meetings. Here I learned that coffee science is passion. 
Michael Habermeyer for being a wonderful friend and work colleague. Thank you for your 
unconditional and selfless help, for all your good advice and for sharing your encyclopedic 
knowledge with me. I know, germans are too serious but: “que mi Dios lo bendiga 
infinitamente” (God bless you infinitely)... 
Sandra Vatter and Melanie Esselen for always listen to me (even with my bad german), for 
their eternal patience, for caring about my well being and for all the great and supportive 
conversations in and outside the lab. 
Tamarita, thank you for your wonderful hugs, your wise advices, the Zumba evenings and 
for making me part of your family. 
Mathias Baum for his infinite peace, his open mind, for understanding the humanity outside 
of Germany and for believing in me. 
Frau Janzowski for the support and for always being nice and good to me. 
Ingrid Hemm, thank you for your eternal optimism, kindness and understanding; and for 
always being willing to help me. 
To the “chicas” Doloritas and Steffi, for being my “german sisters”, for being happy with my 
achievements and encourage me in my sad moments. Que bonito encontrarlas en mi 
camino… 
To my favorite “freundin” Hannita, for her never-ending goodness, her sincerity and all the 
good times 
Eugenie Gieser for being so funny, for the „guanábana“ y „la pendeja“….  
Acknowledgments  198 
 
                          
Dr. Schnatz (Markus Schantz) for his crazy mind and for show me "die wichtigsten 
Tradizionen und Gepflogenheiten (♪♫ das rote Pferd, Ich bin ein Gummibär!! ♪♫)”  of the 
german culture. 
Nico, Denise, Julia and Thomas for the nice support and helpfulness. 
To all other past and present members of the Eisenbrand, Schrenk, Richling and Esselen 
groups: Bülent, Christiane, Phillip, Kevin, Teresa, Lena, Annika, Andreas, Jutta, Reiner, 
Eva und Silvi for the nice working atmosphere and for sharing your great expertise in the 
lab. To my „Diplomanden“ and „Forschungspraktikanten“ 
To Silke, Helena, Robert und Jencito for being so kind with me and making me a part of 
your beautiful friendship. 
To Ludvik Napast for all the great and supportive conversations and for always finding a 
solution to my problems 
To the volunteers who participated in both studies. 
Carumix y Martumix por ser mi familia kaiserslaurteña, por sus consejos colmados de 
sabiduría, por su paciencia ilimitada y por ser “tan bonitas”.... Las quiero mucho!!! 
Luis Antelo y su familia por su apoyo en TODOS los aspectos de mi vida. 
Maria Elena, Nubia y Eliana por cruzar los dedos por mi desde la distancia y por cultivar y 
cuidar la hermosa amistad que nos une. 
Todos y cada uno de los casi 100 miembros de mi familia y especialmente a Rosalbita, 
Norita, Sofi “perfección”, Cami, Germancho, Adiela, Idalba, Olguita, Naty, Luz Dary y 
Mauricio por sus oraciones y buenas energías. 
A mis papis por su maravilloso amor, por su apoyo, optimismo y por enseñarme a verle 
siempre el lado positivo a la vida. Aún estando tan lejos del nido, nunca me he sentido 
alejada de ustedes, nuestro amor vence las barreras de la distancia y el tiempo. Los adoro!!! 
Snoopy por estar siempre ahí, darme siempre motivos para ser felíz y aguantarme en estos 
últimos meses de estrés. Gracias por ser mi enciclopedia andante, explicarme el mundo y 
sus maravillas y ser enormemente bondadoso conmigo. 
Kerito y Dianita por su apoyo incondicional desde la distancia, por hacerme partícipe de 
cada momento de sus vidas y por su amor sin fronteras. Chicos ustedes son maravillosos!! 
Les debo tiempo, juegos, alegrías y muchos helados ;-).  
A las que partieron al cielo durante la realización de este trabajo, mi abuelita Edilma y 
Mulancita, por haber iluminado mi vida y haberme dado la oportunidad de compartir sus 
últimos días. 
Heikito for being the love of my life, for his never-ending support in all situations y por 
hacerme infinitamente felíz ♥. Gracias a Margit y Walter por hacerme sentir como una hjita 
en casa. 
Y finalmente a Hugo, Paco y Luis por ser mis compañeros durante 3 hermosos años. 
Appendices  199 
 
                          
Appendices 
 
Data from Figure 5-2: Effect of PDTC, curcumin and quercetin on HO-activity in HepG2. Caco-2 and MM6 cells (12h incubation) 
* 4-5 independent experiments (triplicates) 
Standard Deviation 
PDTC Curcumin Quercetin 
HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
1.327 0.893 1.790 1.327 0.893 1.790 1.327 0.893 1.790 
1.652 3.224 2.420 1.907 1.014 0.936 0.962 0.812 0.560 
1.755 2.884 2.401 0.765 3.056 3.563 1.147 0.814 3.251 
5.005 2.225 2.982 1.547 0.121 2.402 3.211 0.650 2.500 
 
Data from Figure 5-3:  Effect of PDTC, curcumin and quercetin on HO-activity in HepG2. Caco-2 and MM6cells (24h incubation) 
  PDTC Curcumin Quercetin 
 MEAN* HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
0 µM 4.0 5.7 12.6 4.0 5.7 12.6 4.0 5.7 12.6 
10 µM 3.4 8.7 14.3 2.1 5 12.1 6.3 6.4 11.4 
100 µM 10.9 11.15 15.3 4.8 4.8 11.9 7.5 8.8 10.4 
1000 µM 39.8 30.3 17.6 5.2 5.5 12.0 10.1 12.3 10.9 
* 4-5 independent experiments (triplicates) 
  PDTC Curcumin Quercetin 
 MEAN* HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
0 µM 4.0 5.7 12.6 4.0 5.7 12.6 4.0 5.7 12.6 
10 µM 2.8 5.4 11.4 5.2 5.9 13.6 3.3 5.4 5.4 
100 µM 5.2 6.2 10.3 2.45 7.18 14.9 2.5 5.8 3.2 
1000 µM 9.8 6.3 12.6 3.64 6.3 15.2 5.6 7.3 9.9 
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Standard Deviation 
PDTC Curcumin Quercetin 
HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
1.327 0.893 1.790 1.327 0.893 1.790 1.327 0.893 1.790 
0.001 3.224 2.501 1.907 1.014 0.767 0.962 0.812 0.560 
0.755 2.884 2.401 0.079 0.173 0.849 0.315 0.467 0.988 
6.005 0.225 2.150 1.547 0.121 2.785 0.149 0.002 0.520 
 
Data from Figure 5-5:  Effect of PDTC, curcumin and quercetin on HO-activity in HepG2. Caco-2 and MM6 cells (48 h incubation) 
  PDTC Curcumin Quercetin 
 MEAN* HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
0 µM 4.0 5.7 12.6 4.0 5.7 12.6 4.0 5.7 12.6 
10 µM 3.2 8.7 11.3 17.1 19 15.1 6.3 6.4 10.4 
100 µM 8.9 7.5 10.3 8.8 9.8 11.9 2.5 6.8 9.4 
1000 µM 21.3 11.15 13.6 10.2 3.5 12 2.1 2.3 8.9 
* 4-5 independent experiments (triplicates) 
Standard Deviation 
PDTC Curcumin Quercetin 
HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
1.327 0.893 1.790 1.327 0.893 1.790 1.327 0.927 1.790 
1.632 3.224 2.501 3.987 4.315 1.542 1.857 0.932 2.560 
4.755 2.884 2.401 4.079 3.173 2.849 1.542 0.467 1.001 
3.250 2.489 4.150 2.517 2.323 1.785 1.958 2.002 3.520 
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Data from Figure 5-4: Viability of cells exposed to PDTC, curcumin and quercetin at 
37°C (24 and 48h incubation). 
  PDTC 
 MEAN* HepG2 Caco-2 MM6 
Control 100 100 100 
10 98.9 98.3 99.6 
100 93.5 90.2 95.9 
1000 90.6 85.4 90.3 
10 65.4 50.9 50.2 
100 53.2 51.7 40.8 
1000 32.2 38.2 33.9 
SD       
10 (24h) 1.987 0.988 5.155 
100 (24h) 1.855 0.820 8.862 
1000 (24h) 2.199 3.898 10.890 
10 (48h) 3.257 1.357 0.983 
100 (48h) 2.257 3.154 2.141 
1000(48h) 3.587 2.495 0.584 
  Curcumin 
  MEAN* HepG2 Caco-2 MM6 
Control 100 100 100 
10 98.9 95.1 80 
100 93.5 88.6 83.2 
1000 83.2 85.4 83.8 
10 73.2 64.5 68.6 
100 44.2 30.6 39.2 
1000 23.2 22.9 20.3 
SD       
10 (24h) 2.570 0.988 3.155 
100 (24h) 2.649 5.923 4.236 
1000 (24h) 5.549 3.898 8.955 
10 (48h) 3.459 4.274 2.419 
100 (48h) 2.983 3.219 2.574 
1000(48h) 3.954 2.275 0.887 
  Quercetin 
  HepG2 Caco-2 MM6 
Control 100 100 100 
10 80.1 78.4 89.2 
100 85.9 83.5 80.2 
1000 70.6 65.4 70.3 
10 63.3 45.9 57.2 
100 45.4 29.2 33.2 
1000 38.9 18.6 24.5 
SD       
10 (24h) 8.741 5.219 4.854 
100 (24h) 4.894 7.146 3.590 
1000 (24h) 8.237 4.897 5.190 
10 (48h) 2.544 0.983 1.549 
100 (48h) 6.875 1.366 2.302 
1000(48h) 3.257 2.545 3.824 
* 6 independent experiments (triplicates) 
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Data from Figure 5-6: Modulation of HO-activity in HepG2, Caco-2 and MM6 cells after 
24 h incubation with PDTC (0 –1000 µM with/without catalase 100 U/mL). 
 
* 5 independent experiments (triplicates) 
** Catalase-treated cells 
 
Data from Figure 5-7: Effect of NMP (N-methylpyridinium) on HO-activity in HepG2, 
Caco-2 and MM6 cells. 
* 5 independent experiments (triplicates) 
 
Data from Figure 5-8: Effect of caffeine on HO-activity in HepG2 cells 
 
 
 
 
 
 
 
 
 
 
 
* 3 independent experiments (triplicates) 
 
  PDTC (Mean*) SD 
  HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
0 µM 4.0 5.7 12.6 1.327 0.893 1.790 
0 µM + cat** 4.4 4.1 12.1 0.985 0.057 2.385 
10 µM 3.4 8.7 14.3 0.001 3.224 2.501 
10µM + cat** 5.3 7.3 15.1 0.124 1.337 0.985 
100 µM 10.9 11.2 15.3 0.755 2.884 2.401 
100 µM + cat** 9.8 7.1 14.7 0.636 0.366 1.987 
1000 µM 39.8 30.3 17.6 6.005 0.225 2.150 
1000 µM + cat** 38.1 25.2 15.9 2.569 1.269 0.895 
  NMP (Mean*) SD 
  HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
Control 4.0 5.7 12.6 1.327 0.893 1.790 
PDTC 1mM 39.8 30.3 17.6 6.005 0.225 2.150 
0.1 µM 4.6 2.6 10.6 3.181 3.538 0.250 
0.3 µM 5.6 2.5 11.7 1.668 3.805 0.121 
1 µM 6.8 7.0 12.0 2.166 0.962 0.849 
3 µM 7.6 7.0 13.7 1.429 0.767 0.173 
10 µM 9.2 10.2 13.6 1.666 1.019 3.547 
100 µM 12.6 11.4 16.8 1.729 1.907 2.785 
1000 µM 24.8 16.4 17.7 4.479 3.269 0.359 
 
Caffeine 
(Mean*)  SD 
Control 4.0 1.327 
PDTC 1mM 39.8 6.005 
0.1 µM 9.9 5.665 
0.3  µM 7.8 3.564 
1  µM 6.6 1.920 
3  µM 6.8 2.655 
10  µM 4.2 2.248 
100  µM 6.1 2.583 
1000  µM 6.5 1.703 
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Data from Figure 5-9: Effect of TMP and 2-E-3,5-DMP on HO-activity in HepG2, Caco-2 
and MM6 cells 
 
* 5 independent experiments (triplicates) 
 
Data from Figure 5-10: Effect of 2-E-3-MP and 2MP on HO-activity in HepG2 cells 
 
  
2-MP  
(Mean*) SD 
Control 4.0 1.327 
PDTC 1mM 39.8 6.005 
0.1 µM 4.53 0.520 
0.3 µM 5.27 0.842 
1 µM 4.45 0.536 
3 µM 3.89 1.862 
10 µM 5.83 1.613 
100 µM 6.94 2.502 
1000 µM 4.55 1.859 
* 5 independent experiments (triplicates) 
 
 
 
 
  TMP(Mean*) SD 
  HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
Control 4.0 5.7 12.6 1.327 0.893 1.790 
PDTC 1mM 39.8 30.3 17.6 6.005 0.225 2.150 
0.1 µM 6.5 3.8 17.6 3.367 4.331 0.482 
0.3 µM 6.7 5.6 18.0 3.186 4.298 2.346 
1 µM 9.8 9.7 16.2 0.224 0.963 4.172 
3 µM 10.8 10.3 13.6 0.886 0.671 0.218 
10 µM 5.6 10.4 15.3 1.553 0.560 0.197 
100 µM 7.8 9.1 18.3 1.120 0.812 4.319 
1000 µM 6.5 9.8 13.4 1.386 0.695 0.982 
  2-E-3,5-DMP (Mean*) SD 
  HepG2 Caco-2 MM6 HepG2 Caco-2 MM6 
Control 4.0 5.7 12.6 1.327 0.893 1.790 
PDTC 1mM 39.8 30.3 17.6 6.005 0.225 2.150 
0.1  µM 4.3 3.7 12.3 0.398 3.767 0.058 
0.3  µM 4.5 3.4 12.6 3.951 4.283 0.171 
1  µM 7.6 8.6 13.0 1.299 0.430 0.923 
3  µM 7.7 8.9 13.9 1.398 1.868 0.672 
10  µM 8.2 9.1 11.4 2.606 0.547 1.570 
100  µM 11.4 10.2 13.3 2.883 1.157 2.043 
1000  µM 11.6 11.1 11.6 1.327 3.614 1.790 
 
2-E-3-MP 
(Mean*) SD 
Control 4.0 1.327 
PDTC 1mM 39.8 6.005 
0.1 µM 6.54 1.862 
0.3 µM 6.60 1.859 
1 µM 6.45 1.613 
3 µM 6.10 0.520 
10 µM 5.83 0.536 
100 µM 5.80 0.625 
1000 µM 4.65 0.842 
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Data from Figure 5-11: Effect of AB1 and AB2 coffee extracts on HO-activity in HepG2 
cells 
 
 
(Mean*)  SD 
Control 4.0 1.327 
PDTC 1mM 39.8 6.005 
AB 1 10µg/l 7.8 0.604 
AB 1 100µg/l 10.0 0.715 
AB 1 1mg/l 9.2 0.684 
AB 1 10mg/l 12.0 1.203 
AB 1 100mg/l 15.2 1.920 
AB 2 1µg/l 8.6 0.986 
AB 2 10µg/l 10.0 1.286 
AB 2 100µg/l 10.5 1.792 
AB 2 1mg/l 14.9 2.384 
AB 2 10mg/l 13.0 2.118 
* 3 independent experiments (triplicates) 
 
 
Data from Figure 5-12: Modulation of cAMP-phosphodiesterase activity by coffee 
constituents and caffeine metabolites in LXFL529L cell lysates. 
 
 Concentration (mM) (Mean*)  SD p-value  Compound 
Control (Water) 100.0 0   
 
0.01 34.3 4.808 1.17935E-13 Rolipram 
0.1 91.7 3.374 0.069715851 
Caffeine 
0.5 79.6 8.342 9.61E-03 
1.0 68.0 9.607 4.00806E-07 
5.0 52.0 2.800 6.20199E-14 
0.1 79.6 4.009 1.24106E-24 
Teophylline 
0.5 48.7 1.511 6.66436E-12 
1.0 40.1 4.383 1.16802E-16 
5.0 22.4 0.067 1.82368E-14 
0.1 86.7 7.129 0.001984479 
Paraxanthine 
0.5 68.9 0.061 0.000768775 
1.0 58.9 6.856 1.04194E-09 
5.0 32.8 1.136 8.23519E-05 
0.1 93.5 3.047 0.070380067 
NMP 
0.5 86.4 8.007 0.05382831 
1.0 93.4 18.647 0.375962848 
5.0 97.4 19.199 0.605257644 
* 5 independent experiments (triplicates) 
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Data from Figure 5-13: Modulation of cAMP-phosphodiesterase activity by pyrazines 
in LXFL529L cell lysates. 
Concentration (mM) (Mean*)  SD Compound 
0.01 30.5 8.208 Rolipram 
0.1 100.9 7.475 
2-E-3,5-DMP 
0.5 97.2 10.782 
1.0 78.3 7.096 
5.0 49.2 9.643 
0.1 109.0 13.268 
2-MP 
0.5 103.8 8.856 
1.0 103.8 8.610 
5.0 99.4 7.219 
0.1 108.6 10.069 
2,3,5-TMP 
0.5 106.9 14.524 
1.0 98.6 9.477 
5.0 76.9 1.604 
0.1 109.4 16.799 
2,3-DMP 
0.5 104.8 15.412 
1.0 104.0 12.586 
5.0 93.0 6.155 
0.1 118.1 1.461 
2,5-DMP 
0.5 113.0 2.199 
1.0 105.9 10.728 
5.0 103.4 12.063 
0.1 82.2 0.394 
TMP 
0.5 61.8 1.924 
1.0 58.6 4.204 
5.0 44.0 7.281 
0.1 79.5 0.892 
2,3-DE-6-MP 
0.5 35.0 10.762 
1.0 30.8 10.327 
5.0 8.9 5.676 
0.1 98.2 0.876 
Pyrazine 
0.5 96.5 7.006 
1.0 94.8 8.814 
5.0 85.4 11.424 
0.1 101.6 1.700 
2-E-5-MP 
0.5 98.8 4.300 
1.0 80.4 2.419 
5.0 46.9 3.741 
0.1 109.9 2.399 
2,6-DMP 
0.5 98.8 2.777 
1.0 102.0 10.606 
5.0 75.7 5.397 
0.1 106.4 2.907 
2-Isobutyl-3-methoxyP 
0.5 51.6 0.217 
1.0 44.2 3.583 
5.0 20.0 4.449 
0.1 93.2 0.100 
2-E-3-MP  
0.5 92.1 15.269 
1.0 80.3 8.571 
5.0 69.5 5.733 
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* 4 to 5 independent experiments (triplicates) 
 
 
Data from Figure 5-14: Modulation of cAMP-phosphodiesterase activity by coffee 
extracts in LXFL529L cell lysates. 
 
 
Concentration (µg/mL) (Mean*)  SD   
Rolip. 30.5 8.200 Rolipram 
0.10 87.4 5.320 
AB1 
0.25 78.0 7.012 
0.50 58.8 1.939 
1.00 45.9 4.551 
5.00 30.1 0.929 
0.10 87.0 8.451 
AB2 
0.25 55.6 6.543 
0.50 44.0 7.137 
1.00 27.6 0.081 
5.00 15.3 7.656 
0.10 101.4 0.627 
Caffè crema  
0.25 95.6 1.843 
0.50 78.1 0.857 
1.00 69.6 2.427 
5.00 45.1 0.860 
0.10 101.1 1.237 
Caffeine reduced coffee 
0.25 91.7 1.132 
0.50 79.9 1.347 
1.00 70.1 2.448 
5.00 41.6 2.532 
0.10 100.4 1.207 
ECE 
0.25 88.9 2.331 
0.50 84.7 5.452 
1.00 54.2 11.194 
5.00 26.2 5.490 
0.10 70.6 0.489 
RCE 
0.25 91.3 2.447 
0.50 85.5 2.006 
1.00 100.9 1.540 
5.00 58.0 1.187 
* 4 to 5 independent experiments (triplicates) 
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Data from Figure 5-15: Profile of phosphodiesterase activity in human platelets lysates 
Concentration (µM) (Mean*)  SD Modulator 
10 91,4 11,442 Rolipram 
50 88,1 6,444 Rolipram 
10 38,6 2,909 Millrinone 
50 21,4 7,002 Ca
+
/CaM 
0.2 97,0 1,387 Zaprinast 
* 11 independent experiments (triplicates) 
 
Data from Figure 5-16: Modulation of cAMP-phosphodiesterase activity by coffee 
constituents and caffeine metabolites in platelet lysates 
  Concentration (mM) (Mean*)  SD p-value Compound 
0.01 38.6 2.199 7.17001E-08 Milrinone 
0.1 92.6 6.367 0.116167061 
Caffeine 
0.5 60.4 4.672 0.000522629 
1 39.7 9.081 0.001076313 
5 0.2 0.109 4.18809E-10 
0.1 80.96 9.248 0.023479704 
Teophylline 
0.5 58.74 15.399 0.02434035 
1 52.21 7.659 0.001295146 
5 27.79 9.818 0.000796972 
0.1 88.96 7.951 0.073914262 
Paraxanthine 
0.5 63.48 25.537 0.068408599 
1 63.22 4.408 0.014043106 
5 57.40 8.440 0.025672167 
0.1 98.1 2.453 0.243007458 
NMP 
0.5 98.5 2.133 0.301717985 
1 100.1 5.556 0.981927881 
5 100.3 7.438 0.948172101 
* 5 independent experiments (triplicates) 
 
Data from Figure 5-17: Modulation of cAMP-phosphodiesterase activity by pyrazines in 
platelet lysates 
  Concentration (mM) (Mean*)  SD p-value Compound 
0.01 38.6 2.910 7.17001E-08   
0.1 95.6 1.998 0.158044690 
2-Isobutyl-3-
methoxyP 
0.5 67.4 2.863 0.001276213 
1 52.6 2.031 0.001831163 
5 26.4 12.005 0.025622810 
0.1 81.8 13.882 0.320735203 
2-E-3,5 DMP  
0.5 61.7 17.361 0.015817001 
1 53.2 14.364 0.008274873 
5 28.0 10.279 0.019791668 
0.1 81.8 5.531 0.081618549 
2,3-DE-5-MP 
0.5 45.7 11.758 0.038962693 
1 30.7 14.838 0.028843090 
5 13.6 12.922 0.001660515 
0.1 93.3 0.400 0.871446791 
TMP 
0.5 80.8 0.180 0.000423986 
1 63.4 0.150 0.001226800 
5 42.8 0.200 0.001340374 
* 5 independent experiments (triplicates) 
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Data from Figure 5-18: Modulation of cAMP-phosphodiesterase activity by coffee 
extracts in platelet lysates. 
 
Concentration (µg/mL) (Mean*)  SD Compound 
Milrin. 38.6 2.910 Milrinone 
0.10 91.4 2.295 
AB1 
0.25 59.0 25.731 
0.50 50.3 8.148 
1.00 26.5 10.507 
5.00 8.5 1.586 
0.10 81.8 1.336 
AB2 
0.25 50.3 2.777 
0.50 34.2 1.427 
1.00 21.5 5.667 
5.00 2.6 0.636 
0.10 102.8 0.461 
Caffé crema 
0.25 89.9 0.106 
0.50 79.2 2.672 
1.00 64.9 0.932 
5.00 45.7 1.831 
0.10 99.0 3.357 
Caffeine reduced coffee 
0.25 85.8 1.792 
0.50 75.1 2.007 
1.00 63.8 5.942 
5.00 46.3 0.565 
0.10 86.9 0.556 
SCE 
0.25 79.9 1.076 
0.50 66.5 4.547 
1.00 57.9 3.283 
5.00 43.3 4.862 
0.10 58.4 0.032 
RCE 
0.25 46.5 3.198 
0.50 47.3 1.733 
1.00 48.5 8.340 
5.00 41.4 9.577 
* 4 to 5 independent experiments (triplicates) 
 
Data from Figure 5-19: Modulation of cAMP-phosphodiesterase activity by coffee 
polyphenols in platelet lysates. 
  Concentration (mM) (Mean*)  SD p-value Compound 
0.01 38.6 2.910 0.000134393   
0.1 64.8 16.473 0.054527628 
Chlorogenic Acid 
0.5 45.7 0.897 1.04365E-07 
1.0 35.2 7.528 7.95255E-05 
5.0 36.3 9.828 0.006396169 
0.1 57.1 2.094 3.23322E-06 
Caffeic acid 
0.5 46.6 3.904 0.001498772 
1.0 44.3 5.884 0.003050773 
5.0 34.7 1.221 1.08757E-07 
* 3 independent experiments (triplicates)
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Data from Figure 5-21: cAMP Hydrolisis activity of Rat adipocytes and SGBS cells. 
   (Mean*)  SD 
Rat Adipocytes (ground activity) 6.6 0.159 
10 µM Rolipram 3.8 1.779 
50 10 µM Rolipram 1.9 0.487 
10 µM Milrinone 6.1 0.099 
50 µM Milrinone 3.4 1.306 
SGBS Preadipocytes (ground activity) 13.3 1.520 
50 µM Rolipram 13.1 0.595 
50 µM Milrinone 2.8 1.890 
SGBS Adipocytes (Day 5) 1.6 1.005 
SGBS Adipocytes (Day 10) 1.2 0.500 
SGBS Adipocytes (Day 20) 1.4 1.000 
SGBS Adipocytes (Day 30) 1.6 0.500 
* 5 independent experiments (triplicates) 
 
Data from Figure 5-22. Modulation of cAMP-phosphodiesterase activity by coffee consumption in platelets of volunteers during the 
course of the trial. 
 
 
 
 
 
 
 
 
* Values are means of triplicate measurements 
 
Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC*  5.BC* 6.BC* 7.BC* 8.BC* 
P1 45.13 64.62 6.15 7.45 9.90 73.99 76.05 78.06 
P3 38.95 75.16 6.03 6.95         
P4 56.15 71.44 6.73 7.08 7.30 75.16 54.92 83.51 
P5 34.92 72.90 4.44 7.54 9.45 64.62 73.44 86.93 
P6 31.25 69.97 6.26 8.59 11.10 62.87 72.32 77.72 
P7 36.13 73.99 4.15 6.62 10.16 69.97 86.33 76.81 
P8 31.71 83.72 6.46 8.03 8.48 71.44 71.32 80.82 
P9 34.06 79.96 6.60 5.57 9.79 72.90 90.86 91.71 
P10 23.85 62.87 9.43 7.16 9.49 83.72 79.30 80.42 
P11 57.29 72.22             
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Data Summary 1. BE 2.BE  3. BE  4. BE  5.BE 6.BE  7.BE  8.BE  
Mean 38,9 72,7 6,3 7,2 9,5 71,8 75,6 82,0 
SD 9,250 6,641 1,509 0,856 1,141 6,482 10,845 5,150 
F-test 0,05876398   0,00025333 3,4309E-06 8,7766E-05 0,45082132 0,06408611 0,309816449 
Student´s t-test 
p-Value vs. 2.BC 6,5253E-07   2,1799E-16 2,1027E-16 0,00034514 0,78247733 0,48865774 0,003784551 
  ***   *** *** ***     ** 
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Data from Figure 5-23. Modulation of cAMP-phosphodiesterase activity by coffee 
consumption in platelets of volunteers during the course of the long term trial. 
 
Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC*  5.BC* 6.BC* 
P1 48,8 70,9 7,1 35,2 44,5 70,5 
P2 46,5 47,5 15,6 56,6 39,7 68,5 
P3 53,8 43,3 11,5 38,5 31,0 44,1 
P4 52,2 42,2 16,4 58,0 30,8 58,3 
P5 47,6 87,0 8,6 57,6 44,3 85,2 
P6 56,1 44,4 14,6 58,4 37,9 29,7 
P7 34,9 43,4 12,8 67,3 34,1 45,5 
P8 57,1 53,8 12,2 58,1 30,4 40,7 
P9 87,5 45,1 20,4 55,4 59,2 63,1 
P10 56,6 37,9 11,4 57,9 35,4 56,5 
P11 68,1 40,6 13,6 47,8 25,1 60,6 
P12 61,6 45,0 12,2 56,8 42,7 67,6 
P13 64,9 36,8 - - - - 
P14 54,5 43,7 13,7 61,3 35,7 51,2 
P15 57,4 48,4 19,9 71,4 44,6 42,9 
P17 56,8 42,5 12,8 50,7 43,4 66,7 
P18 54,3 37,8 18,9 78,3 52,3 60,8 
P19 64,1 48,4 14,8 50,3 55,2 62,7 
P20 65,2 51,2 47,0 47,8 41,6 66,3 
P21 53,0 38,7 16,1 59,3 43,2 33,0 
P22 56,8 52,9 30,2 69,2 49,5 38,1 
P23 70,2 46,5 21,7 50,3 43,0 67,9 
P24 79,3 60,0 15,3 46,4 28,8 65,0 
P25 61,2 46,8 16,1 27,8 38,2 49,4 
P26 45,6 49,6 11,5 58,5 29,2 41,3 
P27 45,8 - - - - - 
P28 71,7 50,1 15,4 38,4 45,3 40,0 
P29 58,1 35,0 12,9 59,3 26,5 49,4 
P30 58,0 47,2 29,4 62,9 27,3 56,0 
P31 49,4 46,0 10,1 80,0 7,0 58,6 
P32 52,6 55,2 12,1 20,9 38,2 74,3 
P33 72,0 42,3 8,1 53,2 34,7 59,8 
P34 66,5 45,8 11,9 51,6 32,2 77,2 
P35 93,0 41,0 - - - - 
P36 50,2 35,7 11,8 84,9 31,4 62,4 
P37 53,0 57,5 13,0 39,8 22,8 44,5 
P38 47,8 26,1 11,6 85,6 26,9 44,6 
P39 78,3 49,9 14,4 34,2 30,0 59,0 
P40 54,1 45,3 10,4 58,4 38,7 39,0 
P41 68,0 38,5 13,8 55,6 31,7 48,7 
P42 56,8 63,1 8,7 54,9 32,8 32,2 
P43 90,1 41,2 16,2 67,9 40,2 66,4 
P44 57,8 35,5 11,0 56,2 65,1 52,4 
P45 35,6 47,3 13,8 63,2 31,3 50,9 
P46 51,9 37,4 13,3 73,2 48,1 43,9 
P47 78,3 - - - - - 
P48 56,6 62,5 15,1 62,1 49,7 61,0 
P49 57,3 39,8 10,3 59,1 92,4 59,1 
P50 58,1 33,9 15,7 52,6 68,4 58,1 
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Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC*  5.BC* 6.BC* 
P51 53,3 42,7 9,5 63,1 96,9 42,0 
P52 47,7 68,3 17,9 60,3 58,5 33,0 
P53 77,5 48,5 10,5 62,7 65,2 53,0 
P54 51,9 40,0 - - - - 
P55 36,0 61,1 13,5 53,5 101,4 55,8 
P56 63,3 37,7 4,5 40,9 46,4 46,7 
P57 29,4 27,3 13,6 66,5 68,0 54,1 
P58 36,2 63,9 12,1 67,6 59,5 38,1 
P60 37,6 32,7 2,7 56,6 55,2 64,1 
P61 37,6 45,6 21,2 51,7 85,1 60,1 
P62 55,0 48,6 18,2 65,1 46,8 48,3 
P63 46,4 54,2 4,9 52,6 99,0 32,6 
P64 41,5 42,3 7,1 20,1 81,9 32,2 
P65 62,8 50,5 10,6 51,1 61,9 39,2 
P66 48,8 39,8 3,5 50,2 55,5 33,9 
P67 49,4 37,6 7,8 36,3 55,5 45,1 
P68 55,0 41,2 10,2 96,9 62,5 47,4 
P69 73,3 53,6 1,6 60,1 68,8 48,9 
P70 45,0 39,3 8,5 68,8 91,0 49,3 
P71 39,8 55,2 9,9 70,2 55,2 45,8 
P72 31,3 42,6 4,2 28,2 71,7 49,6 
P73 32,5 39,8 12,9 75,4 64,8 50,4 
P74 34,5 56,0 10,1 79,3 68,3 47,5 
P75 33,9 46,9 7,6 67,1 59,9 45,8 
P76 41,7 46,0 10,8 79,9 62,4 41,2 
P77 40,8 64,7 9,4 48,0 48,2 36,8 
P78 50,6 34,4 14,4 55,5 53,0 56,5 
P79 63,2 33,1 9,7 60,7 59,3 44,8 
P80 67,4 51,6 6,6 71,3 50,5 46,4 
P81 103,6 40,3 5,7 76,0 47,5 32,7 
P82 65,5 47,2 3,0 78,1 54,7 40,7 
P83 58,6 35,1 4,5 61,3 48,5 50,1 
P84 59,7 41,9 10,6 67,9 62,9 44,3 
P85 61,9 38,0 9,8 92,7 56,9 41,8 
P86 81,3 55,0 7,1 82,9 43,3 45,3 
P87 60,0 38,8 5,9 60,2 52,9 43,4 
P88 49,6 30,5 3,4 57,3 44,6 32,9 
P90 68,6 25,3 2,9 49,6 31,1 36,0 
P91 80,8 25,1 5,6 68,4 59,7 39,2 
P92 61,4 37,5 4,9 67,3 46,4 31,0 
* Values are means of triplicate measurements 
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Normal Distribution Test 
Anderson Darling Test auf Normalverteilung 
 
         Anzahl Werte 504 
 
Prüfgrösse AD:  4,0623 
Mittelwert: 45,40 
 
Schwellwert SW [95%]: 0,7509 
Standardabw: 20,42 
 
Signifikant keine Normalverteilung 
Sortierte Originaldaten 
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Wilcoxon test for the analysis of significances between time points (Group A) 
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Wilcoxon test for the analysis of significances between time points (Group B) 
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Mann-Withney test for the analysis of significances between groups 
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Data from Figure 5-24. Determination of the optimal HEK-293 cell number 
 
cAMP concentration Lance Signal (665nm) Mean* SD 
1,0E-06 5587 75,0 
3,0E-07 6532 298,4 
1,0E-07 8928 399,5 
3,0E-08 16030 685,9 
1,0E-08 26160 56,6 
3,0E-09 39474 1364,0 
1,0E-09 51684 1200,7 
3,0E-10 58976 33,2 
1,0E-10 60615 456,8 
3,0E-11 63763 1877,4 
1,0E-11 62907 2957,8 
0,0E+00 62462 1300,4 
         * Values are means of triplicate measurements 
 
Data from Figure 5-25. Forskolin Dose-Response of SGBS preadipocytes and 
adipocytes at the 17th day of differentiation. 
 
 
Forskolin 
concentration (M) 
Preadipocytes (6000 cells/well) Mean SD 
3,00E-04 7938 7890 7818 7882 60,399 
1,00E-04 8251 8054 7801 8035 225,580 
3,00E-05 8494 7906 8071 8157 303,287 
1,00E-05 8862 9122 7539 8508 848,903 
3,00E-06 9847 8881 9296 9341 484,593 
1,00E-06 11646 10493 10347 10829 711,586 
3,00E-07 13765 11403 12928 12699 1197,584 
1,00E-07 18366 18515 18140 18340 188,813 
3,00E-08 24201 23298 22921 23473 657,766 
1,00E-08 20493 30366 29520 29943 5472,333 
3,00E-09 34987 28186 28612 34987 3809,543 
1,00E-09 31759 31732 30152 31214 920,107 
Forskolin 
concentration (M) 
Adipocytes at 17
th
 day (6000 cells/well) Mean SD 
3,00E-04 43272 34947 55361 44527 10264,7 
1,00E-04 39612 52914 49222 47249 6866,9 
3,00E-05 62001 65612 65863 64492 2160,9 
1,00E-05 77400 77950 75767 77039 1135,4 
3,00E-06 73065 87692 90373 83710 9315,8 
1,00E-06 108230 95202 86748 96727 10821,9 
3,00E-07 96406 88941 95181 93509 4003,4 
1,00E-07 78237 91546 99351 89711 10675,9 
3,00E-08 94801 98469 101092 98121 3159,9 
1,00E-08 98302 99829 99238 99123 770,0 
3,00E-09 98999 96901 97694 97865 1059,4 
1,00E-09 96692 95625 98209 96842 1298,5 
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Data from Figure 5-26. Modulation of the cAMP concentration in SGBS cells by 
caffeine, NMP, chlorogenic acid and trigonelline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 5 independent experiments (triplicates)
Adipos Tag 17 Mean* SD F-test t-test 
Caffeine (M) 
    
1,00E-03 75,13 0,329 0,44680715 2,25339E-09 
5,00E-04 75,23 1,400 0,063823442 0,000167413 
3,00E-04 87,69 26,225 0,000194271 0,007049088 
1,00E-04 67,39 2,525 0,020528089 2,71784E-06 
5,00E-05 52,61 6,215 0,003448144 0,000308473 
3,00E-05 38,97 5,749 0,004027231 0,001046992 
1,00E-05 30,45 3,525 0,010638843 0,000641464 
5,00E-06 17,72 0,554 0,303027312 0,000351164 
3,00E-06 12,00 0,385 0,474460421 0,012391297 
1,00E-06 10,75 0,473 0,374079529 0,820635805 
0,00E+00 10,67 0,366 
  
NMP (M) 
    
1,00E-03 14,36 1,098 0,005480879 0,004939244 
5,00E-04 13,32 0,541 0,022166331 0,001315612 
3,00E-04 13,19 0,448 0,031980517 0,000801967 
1,00E-04 12,62 0,658 0,015093381 0,008795136 
5,00E-05 13,52 0,714 0,012860341 0,002745785 
3,00E-05 13,74 0,800 0,010255638 0,003133866 
1,00E-05 12,28 2,128 0,001464156 0,291659916 
5,00E-06 14,03 0,385 0,042877288 0,0001399 
3,00E-06 11,03 0,280 0,078138659 0,283752154 
1,00E-06 10,76 0,234 0,108462405 0,884927621 
0,00E+00 10,79 0,081 
  
Chlorogenic Acid (M) 
    
1,00E-03 71,38 3,842 0,182872659 0,000131529 
5,00E-04 48,73 1,031 0,243421304 6,01454E-05 
3,00E-04 29,12 3,905 0,178029259 0,003774906 
1,00E-04 14,64 3,061 0,260656196 0,062779737 
5,00E-05 9,77 4,396 0,145976895 0,721074345 
3,00E-05 11,50 2,178 0,410401461 0,161836827 
1,00E-05 10,41 1,419 0,378805079 0,267732488 
5,00E-06 8,93 1,944 0,466330973 0,883492185 
3,00E-06 9,87 1,750 0,481145244 0,465575294 
1,00E-06 10,45 2,397 0,365042677 0,368969939 
0,00E+00 8,69 1,817 
  
Trigonelline (M) 
    
1,00E-03 30,93 1,570 0,137549199 0,000178708 
5,00E-04 19,35 0,580 0,461103207 2,45277E-05 
3,00E-04 11,85 0,363 0,251122914 0,003820679 
1,00E-04 10,70 1,024 0,272885903 0,046260063 
5,00E-05 10,30 0,352 0,239111502 0,020300965 
3,00E-05 10,59 1,664 0,124425548 0,125002813 
1,00E-05 10,52 0,822 0,368069621 0,024575484 
5,00E-06 10,14 0,409 0,298371588 0,028505334 
3,00E-06 10,85 1,113 0,241032519 0,045965925 
1,00E-06 11,29 0,371 0,259486358 0,006491772 
0,00E+00 8,42 0,627 
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Data from Figure 5-27. Modulation of cAMP concentration by coffee consumption in platelets of volunteers during the course of the trial 
 
 
 
 
 
 
 
 
 
 
 
 
                               * Values are means of triplicate measurements 
 
 
 
 
Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC*  5.BC* 6.BC* 7.BC* 8.BC* 
P1 4,4 0,18 0,48 1,26 5,81 1,28 4,53 3,31 
P3 1,2 0,51 1,13 -- -- -- -- -- 
P4 2,1 0,33 0,69 1,42 4,11 1,6 4,91 4,96 
P5 1,7 0,14 1,43 1,48 3,07 1,29 5,11 4,69 
P6 1,5 0,25 0,76 1,62 3,71 1,22 4,26 3,52 
P7 1,1 0,04 0,61 0,95 4 1,71 4,81 2,72 
P8 0,9 0,1 0,69 2,35 3,83 1,46 5,29 2,62 
P9 1,1 0,33 1,18 1,39 4,24 1,04 6,34 3,59 
P10 1,6 0,18 0,48 1,52 1,93 1,17 4,06 3,02 
P11 1,3 0,20 0,24 0,44 
    
Data Summary 1. BE 2.BE  3. BE  4. BE  5.BE 6.BE  7.BE  8.BE  
Mean 1,7 0,2 0,8 1,5 3,8 1,3 4,9 3,6 
SD 1,009 0,137 0,337 0,399 1,095 0,225 0,711 0,860 
F-test 9,2352E-07   0,007145477 0,001659066 6,02206E-07 0,138985611 0,043033767 3,06832E-06 
Student´s t-test 
p-Value vs. 2.BC 0,000241188   7,22601E-05 1,97103E-07 1,56616E-08 1,18955E-07 3,13083E-14 9,92795E-09 
  ***   *** *** *** *** *** *** 
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Data from Figure 5-28. Modulation of the cAMP concentration in platelets of volunteers 
during the course of the long term trial. 
Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC*  5.BC* 6.BC* 
P1 3,51 4,34 3,36 9,83 2,38 2,29 
P2 3,40 2,64 5,78 10,13 2,84 3,01 
P3 3,78 3,64 3,26 7,13 2,95 3,04 
P4 2,29 5,10 3,40 14,35 3,72 5,77 
P5 3,25 4,05 4,30 10,45 2,29 2,53 
P6 2,43 3,49 6,10 6,51 1,37 1,44 
P7 2,73 2,64 4,31 7,37 2,44 2,34 
P8 2,31 3,36 4,79 10,57 1,94 4,99 
P9 2,96 3,41 2,92 9,51 2,45 3,72 
P10 4,69 3,67 4,61 8,20 2,24 0,74 
P11 2,85 4,41 4,02 6,09 3,16 4,54 
P12 4,41 4,38 4,33 11,36 4,34 8,14 
P13 4,25 3,53  -  -  -  - 
P14 2,58 3,91 3,95 7,24 4,02 3,34 
P15 2,92 4,49 6,03 10,15 4,18 1,73 
P17 4,59 2,06 4,54 10,43 2,43 3,93 
P18 3,89 2,81 4,37 5,88 3,56 8,18 
P19 4,91 5,01 5,44 10,50 2,36 2,21 
P20 3,54 5,91 5,39 10,83 2,27 3,68 
P21 3,94 4,73 5,22 7,31 3,63 2,34 
P22 3,47 4,85 5,11 11,05 3,55 4,26 
P23 2,82 3,69 5,46 5,66 2,56 2,46 
P24 2,51 3,07 4,47 13,85 2,61 2,87 
P25 2,63 3,98 3,34 6,10 2,87 3,23 
P26 4,22 3,29 5,26 11,11 2,77 3,54 
P27 4,69 - - - - 
 P28 3,31 3,57 3,26 7,50 2,04 2,54 
P29 4,91 3,43 8,54 10,35 3,33 3,16 
P30 3,19 3,44 4,64 8,25 3,43 2,73 
P31 4,32 1,76 3,88 7,34 2,34 3,27 
P32 5,67 3,11 2,21 7,56 1,89 3,01 
P33 2,39 2,46 5,62 11,58 1,63 2,65 
P34 6,26 4,93 4,18 17,51 1,42 2,80 
P35 4,62 3,38  - -  - - 
P36 4,29 3,57 4,58 8,57 3,22 4,25 
P37 4,68 3,82 9,78 7,16 3,60 3,23 
P38 2,80 2,49 6,52 6,04 2,84 2,08 
P39 3,39 3,73 4,56 5,45 1,76 3,60 
P40 4,34 4,65 6,09 8,02 3,09 2,53 
P41 5,29 3,89 4,34 10,97 3,21 4,05 
P42 5,14 4,12 5,48 8,71 3,24 2,39 
P43 5,10 5,91 5,04 7,09 2,97 3,23 
P44 12,09 2,60 6,11 5,35 3,39 3,20 
P45 5,96 3,44 6,64 12,54 4,31 5,86 
P46 6,03 3,83 4,91 7,47 4,19 2,35 
P47 4,63 - - - - - 
P48 5,72 5,13 5,95 6,91 2,25 4,64 
P49 6,99 3,65 5,30 6,78 2,38 4,83 
P50 3,46 2,93 7,16 7,26 3,83 3,03 
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Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC*  5.BC* 6.BC* 
P51 3,75 2,25 8,41 9,67 2,40 2,29 
P52 8,75 3,50 5,19 7,73 3,77 1,81 
P53 7,16 4,47 7,24 9,94 3,22 3,53 
P54 5,45 4,06 - - - - 
P55 3,58 4,44 4,48 11,34 1,54 5,38 
P56 5,27 2,34 4,87 7,01 1,74 3,34 
P57 5,95 3,03 4,62 8,80 1,39 2,83 
P58 3,27 5,12 3,75 9,59 0,93 2,64 
P60 3,20 2,70 2,26 9,19 1,40 2,82 
P61 4,50 1,22 3,29 10,32 3,55 2,88 
P62 7,13 2,89 3,59 18,32 2,94 3,38 
P63 0,52 2,20 4,74 15,41 0,52 1,43 
P64 5,20 2,74 3,02 2,51 1,54 1,87 
P65 6,30 2,75 1,98 7,78 1,41 2,16 
P66 3,12 2,40 9,45 8,39 1,53 2,04 
P67 4,29 3,17 3,87 8,62 1,30 2,77 
P68 1,67 2,87 3,13 5,81 0,40 2,24 
P69 2,84 2,10 3,04 9,60 1,41 1,51 
P70 4,65 3,08 4,83 8,71 1,67 3,48 
P71 5,32 1,40 4,63 9,80 1,13 2,76 
P72 3,40 3,14 2,19 8,73 2,13 3,09 
P73 1,82 3,35 2,78 10,18 1,49 3,43 
P74 6,07 1,93 1,96 6,31 1,81 2,94 
P75 6,07 2,73 2,67 10,58 0,65 3,30 
P76 3,94 3,79 4,19 11,03 1,38 2,66 
P77 2,90 2,50 3,44 7,32 1,08 2,85 
P78 8,09 2,62 4,16 11,37 1,38 1,33 
P79 2,83 2,18 3,65 7,60 0,56 3,53 
P80 3,04 2,38 3,34 7,54 0,82 2,85 
P81 3,13 3,32 3,43 11,87 1,16 2,15 
P82 3,29 3,45 3,04 12,97 1,93 2,65 
P83 4,37 4,28 3,93 7,60 0,80 3,56 
P84 5,10 3,51 2,94 9,22 1,11 1,56 
P85 2,88 2,84 3,56 11,20 1,03 2,28 
P86 4,09 3,65 4,60 4,28 2,69 2,43 
P87 6,36 3,03 5,00 14,17 1,74 2,94 
P88 3,67 3,27 2,40 10,73 1,67 2,40 
P90 2,59 1,88 1,67 7,67 1,43 1,85 
P91 3,89 2,98 2,85 7,43 1,78 1,18 
P92 3,42 1,91 2,87 8,12 1,20 1,81 
* Values are means of triplicate measurements 
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Normal Distribution Tests 
Anderson Darling Test auf Normalverteilung 
 
         Anzahl Werte 504 
 
Prüfgrösse AD:  237,0145 
Mittelwert: 4,41 
 
Schwellwert SW [95%]: 0,7509 
Standardabw: 2,77 
 
Signifikant keine Normalverteilung 
Sortierte Originaldaten 
     
 
Appendices  223 
 
                          
 
Wilcoxon test for the analysis of significances between time points (Group A) 
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Wilcoxon test for the analysis of significances between time points (Group B) 
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Mann-Withney test for the analysis of significances between groups 
 
 
 
Appendices  227 
 
                          
 
 
 
 
 
Data from Figure 5-29. Intraassay (within-day) and interassay (between-day) variation 
of the adenosine quantification in plasma samples by HPLC-ESI-MS/MS. 
 
 
 
   Mean* SD 
Ctrl 100 0,000 
24h, blood dep, RT 120 3,579 
24h, RT 103 1,254 
24h, -80°C 98 3,887 
48h, -80°C 105 4,541 
96h, -80°C 113 2,155 
144h, -80°C 127 1,117 
* 5 independent experiments (triplicates)
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Data from Figure 5-30. Modulation of cAMP concentration by coffee consumption in platelets of volunteers during the course of the trial 
 
 
 
 
 
 
 
 
 
 
 
 
                               * Values are means of triplicate measurements 
 
 
Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC*  5.BC* 6.BC* 7.BC* 8.BC* 
P1 47,7 12,7 12,5 8,1 7,2 17,0 11,8 15,0 
P3 17,3 10,1 9,5           
P4 19,6 6,1 16,1 9,3 6,0 17,6 11,2 20,0 
P5 16,6 16,3 10,0 6,1 4,0 12,2 6,1 17,2 
P6 18,0 11,8 17,0 9,3 9,3 15,1 8,9 14,6 
P7 34,8 8,2 11,2 4,6 4,0 14,6 7,3 15,3 
P8 13,9 8,4 10,8 12,5 6,6 12,9 7,8 12,9 
P9 17,6 15,7 11,5 12,1 14,7 14,5     
P10 17,6 6,4 13,6 9,2 7,5 14,8 14,3 13,8 
P11 21,1 7,2             
Data Summary 1. BE 2.BE  3. BE  4. BE  5.BE 6.BE  7.BE  8.BE  
Mean 22,43 10,30 12,47 8,89 7,41 14,90 9,62 15,53 
SD 10,54625 3,71010 2,62422 2,68946 3,43654 1,96128 2,91589 2,39021 
F-test 0,085981183 
 
0,080501819 0,204202025 0,060550928 0,067328592 0,287037581 0,14835775 
Student´s t-test 
p-Value vs. 2.BC 
0,005594817 
 
0,156567849 0,364514701 0,10691213 0,005129718 0,681503553 0,003023187 
  *** 
      
** 
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Data from Figure 5-31. Modulation of adenosine plasma concentrations after (0, 1 and 
2h) coffee consumption 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data from Figure 5-32. Modulation of adenosine plasma concentrations by coffee 
consum of volunteers during the course of the trial. 
 
Proband Nr.  1.BE  2.BE  3.BE  4.BE  5.BE 6.BE 
P1 42,0 10,8 17,8 17,4 19,4 22,3 
P2 45,8 14,3 18,5 15,3 19,0 21,0 
P3 35,9 9,7 14,0 10,4 10,4 15,3 
P4 50,4 17,0 24,0 19,8 20,6 25,8 
P5 52,0 9,4 24,4 21,0 22,7 27,8 
P6 35,4 5,0 18,3 15,4 15,5 18,6 
P7 36,1 37,7 16,0 13,6 13,3 15,7 
P9 34,3 17,9 16,5 15,0 19,8 19,0 
P10 33,6 11,1 14,3 11,2 13,0 17,2 
P30 36,7 14,8 17,1 14,7 16,2 19,5 
P46 38,5 22,3 18,0 19,7 17,7 23,0 
P47 44,7  -  -  -  - -  
P48 36,9 14,3 19,4 18,7 15,4 20,2 
P49 35,0 16,0 22,6 22,2 22,2 25,1 
P50 35,5 16,3 20,2 19,7 17,3 21,6 
P51 41,6 4,7 25,5 19,5 22,2 21,2 
P52 30,8 17,3 15,3 14,2 15,3 17,8 
P53 36,9 9,0 21,7 17,3 16,9 27,9 
P55 35,1 7,3 21,6 16,9 18,7 22,8 
P84 37,4 9,0 20,8 13,7 19,1 18,9 
 
Normal Distribution Tests 
Anderson Darling Test auf Normalverteilung 
 
         Anzahl Werte 114 
 
Prüfgrösse AD:  52,5550 
Mittelwert: 21,14 
 
Schwellwert SW [95%]: 0,7470 
Standardabw: 9,30 
 
Signifikant keine Normalverteilung 
Sortierte Originaldaten 
     
 
 
Volunteer Nr. 2. BC 0h   2. BE after 1h   2. BE after 2h 
P1 12,7 6,1 10,0 
P3 10,1 8,0 9,4 
P4 6,1 10,5 4,2 
P5 16,3 4,0 2,0 
P6 11,8 7,1 7,1 
P7 8,2 6,5 4,0 
P8 8,4 8,5 10,8 
P9 15,7 17,0 11,9 
P10 6,4 10,1 8,7 
P11 7,2 10,6 9,0 
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Wilcoxon test for the analysis of significances between time points (Group A) 
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Wilcoxon test for the analysis of significances between time points (Group B) 
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Mann-Withney test for the analysis of significances between groups 
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Data from Figure 5-33. Modulation of the adenosine deaminase activity by coffee 
consumption in plasma of volunteers during the course of the trial. 
 
Volunteer Nr. Start 1
st 
WO Coffee phase 2
nd
 WO 
P1 9,03 8,38 14,22 8,70 
P2 9,03 7,73 8,86 10,81 
P3 8,05 7,56 8,70 7,89 
P4 7,89 7,40 9,51 8,21 
P5 7,55 9,03 17,03 10,97 
P6 6,10 7,73 11,14 11,95 
P7 6,10 7,40 8,05 6,43 
P8 8,05 10,49 9,35 8,86 
P9 7,40 9,35 8,21 7,40 
P10 7,89 10,65 9,51 8,05 
P11 7,201 7,245 9,615 7,636 
P12 7,158 6,679 15,594 12,354 
P14 8,245 6,897 9,984 8,767 
P15 8,767 9,615 17,898 13,811 
P16 7,940 8,701 9,419 8,245 
P17 8,680 6,636 9,897 6,723 
P18 11,14 8,65 18,82 8,11 
P19 9,40 8,27 13,35 12,87 
P20 7,78 7,24 14,87 15,03 
P21 6,27 7,65 19,90 11,41 
P22 11,19 12,11 18,06 12,76 
P23 10,16 9,40 12,49 9,73 
P26 6,19 7,57 8,28 8,86 
P27 6,11 6,57 7,28 6,03 
P28 6,82 5,40 7,36 5,32 
P29 5,36 4,82 6,11 4,86 
P30 6,90 5,07 6,19 6,07 
P31 5,15 4,90 6,49 5,90 
P32 6,15 6,57 6,57 6,99 
P33 6,47 6,83 6,05 6,05 
P34 7,50 7,34 8,84 5,38 
P35 11,05 11,21 17,14 9,82 
Mean 7,77 7,85 11,09 8,81 
SD 1,609 1,764 4,238 2,698 
Student´s t-test 
p-Value vs. 
2.BC 
0,00026309 
 
0,000175919 0,013295476 
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Data from Figure 5-34. Modulation of plasma adenosine deaminase activity by coffee 
consumption of volunteers during the course of the long term trial. 
Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC* 5.BC* 6.BC* 
P1 6,6 5,6 3,8 5,8 10,1 5,6 
P2 10,3 8,8 5,7 9,0 10,6 8,4 
P3 4,8 6,5 7,3 5,8 5,4 4,3 
P4 8,8 11,4 9,7 10,8 7,4 6,2 
P5 6,8 22,9 41,8 10,0 12,0 7,4 
P6 7,9 7,3 8,4 8,2 10,7 8,6 
P7 7,7 7,6 8,4 5,6 5,1 5,5 
P8 10,1 7,9 9,3 7,5 6,8 5,8 
P9 8,5 6,5 6,4 6,0 24,9 4,7 
P10 8,6 10,0 6,5 8,5 10,9 6,4 
P11 8,5 9,5 6,9 6,7 6,6 7,5 
P12 8,2 9,3 7,9 7,2 9,7 5,8 
P13 7,2 7,5 - - - - 
P14 12,1 8,1 13,2 4,8 9,1 4,2 
P15 4,3 4,5 4,6 3,7 4,3 2,8 
P17 5,2 5,5 6,2 5,7 5,7 4,8 
P18 5,2 7,3 4,4 5,3 5,5 4,0 
P19 11,3 4,5 3,1 6,0 5,4 5,3 
P20 6,5 7,3 6,4 6,3 6,7 6,0 
P21 5,7 6,0 5,8 4,4 4,9 4,0 
P22 6,6 7,6 10,1 7,6 7,5 6,6 
P23 7,2 6,4 5,3 4,4 6,4 3,8 
P24 9,5 8,8 20,4 8,0 7,4 10,3 
P25 5,6 4,9 4,9 3,3 4,1 3,7 
P26 9,1 9,8 9,9 8,5 7,6 5,6 
P27 9,0 - - - - - 
P28 9,2 11,7 6,5 6,8 6,8 7,1 
P29 9,0 5,7 5,4 6,1 5,2 3,6 
P30 7,9 7,4 5,2 6,0 7,7 3,1 
P31 15,4 9,0 6,9 7,7 6,5 3,9 
P32 5,7 5,8 5,8 4,6 6,6 5,2 
P33 4,7 6,1 5,8 4,4 7,1 4,6 
P34 6,7 9,0 6,4 10,5 6,3 7,8 
P35 8,3 5,6 
    
P36 6,1 9,3 11,0 7,2 2,6 6,3 
P37 4,3 8,2 9,2 6,4 4,8 4,5 
P38 7,2 9,3 7,6 4,9 4,6 4,9 
P39 4,5 6,3 5,0 5,1 4,0 4,9 
P40 7,4 10,5 8,6 6,7 6,1 4,3 
P41 6,5 5,5 4,3 6,1 6,5 5,8 
P42 6,9 8,3 10,3 4,8 11,7 6,7 
P43 6,6 9,3 5,5 5,9 3,1 5,2 
P44 7,2 9,9 9,4 4,7 4,5 7,5 
P45 6,2 7,2 9,2 8,5 6,0 4,3 
P46 4,0 6,3 9,2 8,2 4,2 3,8 
P47 5,7 - - - - - 
P48 4,2 5,3 6,8 2,9 4,8 4,5 
P49 5,4 8,4 11,0 3,1 6,9 5,7 
P50 5,0 7,4 4,8 4,5 6,7 4,9 
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Volunteer Nr. 1. BC* 2.BC* 3. BC* 4. BC* 5.BC* 6.BC* 
P51 6,8 8,9 5,4 6,4 5,9 5,3 
P52 6,4 7,7 5,3 4,1 4,4 3,9 
P53 5,0 7,8 8,2 3,4 3,8 7,7 
P54 5,9 4,5 - - - - 
P55 9,2 8,2 6,4 10,6 10,3 4,7 
P56 4,9 6,0 5,6 4,1 5,2 4,2 
P57 4,5 6,3 9,9 6,0 4,4 4,1 
P58 5,1 4,0 11,4 3,9 6,7 4,8 
P60 6,9 5,8 8,4 4,6 6,6 5,1 
P61 4,7 6,9 5,3 6,4 5,6 3,3 
P62 6,8 6,2 6,4 4,1 5,7 5,2 
P63 5,0 7,9 8,2 4,7 6,8 5,2 
P64 7,9 8,6 15,2 5,1 6,5 6,7 
P65 8,6 9,7 5,5 10,9 9,7 8,2 
P66 6,5 9,5 16,7 6,5 7,6 5,0 
P67 6,4 12,5 12,5 7,2 7,9 6,7 
P68 5,1 7,8 7,2 5,8 7,5 5,7 
P69 6,5 9,1 10,6 13,6 6,1 6,1 
P70 5,0 7,2 9,2 5,4 4,8 4,2 
P71 6,9 9,6 6,8 3,3 4,6 5,0 
P72 5,7 8,0 11,0 4,5 4,0 5,5 
P73 5,8 7,8 4,8 4,3 6,1 6,0 
P74 7,2 9,5 8,1 5,4 7,4 5,2 
P75 7,7 8,3 8,9 5,3 6,2 4,8 
P76 6,9 7,7 7,9 5,1 3,1 4,3 
P77 9,1 11,6 8,4 4,2 4,5 5,9 
P78 5,2 9,5 10,9 13,2 6,0 4,3 
P79 5,3 8,4 10,0 6,9 4,2 4,0 
P80 12,4 6,9 7,9 4,6 4,8 3,9 
P81 8,0 7,3 10,7 4,9 6,9 4,9 
P82 4,9 5,0 10,0 7,3 6,7 4,2 
P83 5,7 9,9 9,7 3,7 5,9 7,4 
P84 5,6 4,7 8,0 5,6 4,4 6,0 
P85 6,6 8,9 13,4 4,3 3,8 5,5 
P86 7,2 8,0 7,2 3,3 10,3 6,6 
P87 6,6 10,5 9,2 5,1 5,2 4,9 
P88 7,4 7,6 7,2 4,6 4,4 5,1 
P90 7,7 9,4 9,8 5,5 6,7 6,0 
P91 5,8 4,2 4,0 8,2 6,6 4,5 
P92 7,8 8,4 5,0 3,1 5,6 4,9 
* Values are means of triplicate measurements 
 
 
 
 
 
 
 
 
Appendices  236 
 
                          
Normal Distribution Tests 
Anderson Darling Test auf Normalverteilung 
 
         Anzahl Werte 504 
 
Prüfgrösse AD:  236,5505 
Mittelwert: 6,88 
 
Schwellwert SW [95%]: 0,7509 
Standardabw: 2,99 
 
Signifikant keine Normalverteilung 
Sortierte Originaldaten 
     
 
 
 
 
 
 
Wilcoxon test for the analysis of significances between time points (Group A) 
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Wilcoxon test for the analysis of significances between time points (Group B) 
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Mann-Withney test for the analysis of significances between groups 
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